

**NUCLEIC ACIDS AND CORRESPONDING PROTEINS ENTITLED 254P1D6B  
USEFUL IN TREATMENT AND DETECTION OF CANCER**

**CROSS-REFERENCE TO RELATED APPLICATIONS**

This application is a non-provisional utility patent application that claims priority from United States provisional patent application USSN 60/442,526, filed 24-January-2003. The contents of the applications listed in this paragraph are fully incorporated by reference herein.

**STATEMENT OF RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH**

Not applicable.

**FIELD OF THE INVENTION**

The invention described herein relates to genes and their encoded proteins, termed 254P1D6B and variants thereof, expressed in certain cancers, and to diagnostic and therapeutic methods and compositions useful in the management of cancers that express 254P1D6B.

**BACKGROUND OF THE INVENTION**

Cancer is the second leading cause of human death next to coronary disease. Worldwide, millions of people die from cancer every year. In the United States alone, as reported by the American Cancer Society, cancer causes the death of well over a half-million people annually, with over 1.2 million new cases diagnosed per year. While deaths from heart disease have been declining significantly, those resulting from cancer generally are on the rise. In the early part of the next century, cancer is predicted to become the leading cause of death.

Worldwide, several cancers stand out as the leading killers. In particular, carcinomas of the lung, prostate, breast, colon, pancreas, and ovary represent the primary causes of cancer death. These and virtually all other carcinomas share a common lethal feature. With very few exceptions, metastatic disease from a carcinoma is fatal. Moreover, even for those cancer patients who initially survive their primary cancers, common experience has shown that their lives are dramatically altered. Many cancer patients experience strong anxieties driven by the awareness of the potential for recurrence or treatment failure. Many cancer patients experience physical debilitations following treatment. Furthermore, many cancer patients experience a recurrence.

Worldwide, prostate cancer is the fourth most prevalent cancer in men. In North America and Northern Europe, it is by far the most common cancer in males and is the second leading cause of cancer death in men. In the United States alone, well over 30,000 men die annually of this disease - second only to lung cancer. Despite the magnitude of these figures, there is still no effective treatment for metastatic prostate cancer. Surgical prostatectomy, radiation therapy, hormone ablation therapy, surgical castration and chemotherapy continue to be the main treatment modalities. Unfortunately, these treatments are ineffective for many and are often associated with undesirable consequences.

On the diagnostic front, the lack of a prostate tumor marker that can accurately detect early-stage, localized tumors remains a significant limitation in the diagnosis and management of this disease. Although the serum prostate specific antigen (PSA) assay has been a very useful tool, however its specificity and general utility is widely regarded as lacking in several important respects.

Progress in identifying additional specific markers for prostate cancer has been improved by the generation of prostate cancer xenografts that can recapitulate different stages of the disease in mice. The LAPC (Los Angeles Prostate

Cancer) xenografts are prostate cancer xenografts that have survived passage in severe combined immune deficient (SCID) mice and have exhibited the capacity to mimic the transition from androgen dependence to androgen independence (Klein *et al.*, 1997, Nat. Med. 3:402). More recently identified prostate cancer markers include PCTA-1 (Su *et al.*, 1996, Proc. Natl. Acad. Sci. USA 93: 7252), prostate-specific membrane (PSM) antigen (Pinto *et al.*, Clin Cancer Res 1996 Sep 2 (9): 1445-51), STEAP (Hubert, *et al.*, Proc Natl Acad Sci U S A. 1999 Dec 7; 96(25): 14523-8) and prostate stem cell antigen (PSCA) (Reiter *et al.*, 1998, Proc. Natl. Acad. Sci. USA 95: 1735).

While previously identified markers such as PSA, PSM, PCTA and PSCA have facilitated efforts to diagnose and treat prostate cancer, there is need for the identification of additional markers and therapeutic targets for prostate and related cancers in order to further improve diagnosis and therapy.

Renal cell carcinoma (RCC) accounts for approximately 3 percent of adult malignancies. Once adenomas reach a diameter of 2 to 3 cm, malignant potential exists. In the adult, the two principal malignant renal tumors are renal cell adenocarcinoma and transitional cell carcinoma of the renal pelvis or ureter. The incidence of renal cell adenocarcinoma is estimated at more than 29,000 cases in the United States, and more than 11,600 patients died of this disease in 1998. Transitional cell carcinoma is less frequent, with an incidence of approximately 500 cases per year in the United States.

Surgery has been the primary therapy for renal cell adenocarcinoma for many decades. Until recently, metastatic disease has been refractory to any systemic therapy. With recent developments in systemic therapies, particularly immunotherapies, metastatic renal cell carcinoma may be approached aggressively in appropriate patients with a possibility of durable responses. Nevertheless, there is a remaining need for effective therapies for these patients.

Of all new cases of cancer in the United States, bladder cancer represents approximately 5 percent in men (fifth most common neoplasm) and 3 percent in women (eighth most common neoplasm). The incidence is increasing slowly, concurrent with an increasing older population. In 1998, there was an estimated 54,500 cases, including 39,500 in men and 15,000 in women. The age-adjusted incidence in the United States is 32 per 100,000 for men and eight per 100,000 in women. The historic male/female ratio of 3:1 may be decreasing related to smoking patterns in women. There were an estimated 11,000 deaths from bladder cancer in 1998 (7,800 in men and 3,900 in women). Bladder cancer incidence and mortality strongly increase with age and will be an increasing problem as the population becomes more elderly.

Most bladder cancers recur in the bladder. Bladder cancer is managed with a combination of transurethral resection of the bladder (TUR) and intravesical chemotherapy or immunotherapy. The multifocal and recurrent nature of bladder cancer points out the limitations of TUR. Most muscle-invasive cancers are not cured by TUR alone. Radical cystectomy and urinary diversion is the most effective means to eliminate the cancer but carry an undeniable impact on urinary and sexual function. There continues to be a significant need for treatment modalities that are beneficial for bladder cancer patients.

An estimated 130,200 cases of colorectal cancer occurred in 2000 in the United States, including 93,800 cases of colon cancer and 36,400 of rectal cancer. Colorectal cancers are the third most common cancers in men and women. Incidence rates declined significantly during 1992-1996 (-2.1% per year). Research suggests that these declines have been due to increased screening and polyp removal, preventing progression of polyps to invasive cancers. There were an estimated 56,300 deaths (47,700 from colon cancer, 8,600 from rectal cancer) in 2000, accounting for about 11% of all U.S. cancer deaths.

At present, surgery is the most common form of therapy for colorectal cancer, and for cancers that have not spread, it is frequently curative. Chemotherapy, or chemotherapy plus radiation, is given before or after surgery to most patients whose cancer has deeply perforated the bowel wall or has spread to the lymph nodes. A permanent colostomy (creation of an abdominal opening for elimination of body wastes) is occasionally needed for colon cancer and is infrequently

required for rectal cancer. There continues to be a need for effective diagnostic and treatment modalities for colorectal cancer.

There were an estimated 164,100 new cases of lung and bronchial cancer in 2000, accounting for 14% of all U.S. cancer diagnoses. The incidence rate of lung and bronchial cancer is declining significantly in men, from a high of 86.5 per 100,000 in 1984 to 70.0 in 1996. In the 1990s, the rate of increase among women began to slow. In 1996, the incidence rate in women was 42.3 per 100,000.

Lung and bronchial cancer caused an estimated 156,900 deaths in 2000, accounting for 28% of all cancer deaths. During 1992–1996, mortality from lung cancer declined significantly among men (-1.7% per year) while rates for women were still significantly increasing (0.9% per year). Since 1987, more women have died each year of lung cancer than breast cancer, which, for over 40 years, was the major cause of cancer death in women. Decreasing lung cancer incidence and mortality rates most likely resulted from decreased smoking rates over the previous 30 years; however, decreasing smoking patterns among women lag behind those of men. Of concern, although the declines in adult tobacco use have slowed, tobacco use in youth is increasing again.

Treatment options for lung and bronchial cancer are determined by the type and stage of the cancer and include surgery, radiation therapy, and chemotherapy. For many localized cancers, surgery is usually the treatment of choice. Because the disease has usually spread by the time it is discovered, radiation therapy and chemotherapy are often needed in combination with surgery. Chemotherapy alone or combined with radiation is the treatment of choice for small cell lung cancer; on this regimen, a large percentage of patients experience remission, which in some cases is long lasting. There is however, an ongoing need for effective treatment and diagnostic approaches for lung and bronchial cancers.

An estimated 182,800 new invasive cases of breast cancer were expected to occur among women in the United States during 2000. Additionally, about 1,400 new cases of breast cancer were expected to be diagnosed in men in 2000. After increasing about 4% per year in the 1980s, breast cancer incidence rates in women have leveled off in the 1990s to about 110.6 cases per 100,000.

In the U.S. alone, there were an estimated 41,200 deaths (40,800 women, 400 men) in 2000 due to breast cancer. Breast cancer ranks second among cancer deaths in women. According to the most recent data, mortality rates declined significantly during 1992–1996 with the largest decreases in younger women, both white and black. These decreases were probably the result of earlier detection and improved treatment.

Taking into account the medical circumstances and the patient's preferences, treatment of breast cancer may involve lumpectomy (local removal of the tumor) and removal of the lymph nodes under the arm; mastectomy (surgical removal of the breast) and removal of the lymph nodes under the arm; radiation therapy; chemotherapy; or hormone therapy. Often, two or more methods are used in combination. Numerous studies have shown that, for early stage disease, long-term survival rates after lumpectomy plus radiotherapy are similar to survival rates after modified radical mastectomy. Significant advances in reconstruction techniques provide several options for breast reconstruction after mastectomy. Recently, such reconstruction has been done at the same time as the mastectomy.

Local excision of ductal carcinoma *in situ* (DCIS) with adequate amounts of surrounding normal breast tissue may prevent the local recurrence of the DCIS. Radiation to the breast and/or tamoxifen may reduce the chance of DCIS occurring in the remaining breast tissue. This is important because DCIS, if left untreated, may develop into invasive breast cancer. Nevertheless, there are serious side effects or sequelae to these treatments. There is, therefore, a need for efficacious breast cancer treatments.

There were an estimated 23,100 new cases of ovarian cancer in the United States in 2000. It accounts for 4% of all cancers among women and ranks second among gynecologic cancers. During 1992–1996, ovarian cancer incidence

rates were significantly declining. Consequent to ovarian cancer, there were an estimated 14,000 deaths in 2000. Ovarian cancer causes more deaths than any other cancer of the female reproductive system.

Surgery, radiation therapy, and chemotherapy are treatment options for ovarian cancer. Surgery usually includes the removal of one or both ovaries, the fallopian tubes (salpingo-oophorectomy), and the uterus (hysterectomy). In some very early tumors, only the involved ovary will be removed, especially in young women who wish to have children. In advanced disease, an attempt is made to remove all intra-abdominal disease to enhance the effect of chemotherapy. There continues to be an important need for effective treatment options for ovarian cancer.

There were an estimated 28,300 new cases of pancreatic cancer in the United States in 2000. Over the past 20 years, rates of pancreatic cancer have declined in men. Rates among women have remained approximately constant but may be beginning to decline. Pancreatic cancer caused an estimated 28,200 deaths in 2000 in the United States. Over the past 20 years, there has been a slight but significant decrease in mortality rates among men (about -0.9% per year) while rates have increased slightly among women.

Surgery, radiation therapy, and chemotherapy are treatment options for pancreatic cancer. These treatment options can extend survival and/or relieve symptoms in many patients but are not likely to produce a cure for most. There is a significant need for additional therapeutic and diagnostic options for pancreatic cancer.

#### SUMMARY OF THE INVENTION

The present invention relates to a gene, designated 254P1D6B, that has now been found to be over-expressed in the cancer(s) listed in Table I. Northern blot expression analysis of 254P1D6B gene expression in normal tissues shows a restricted expression pattern in adult tissues. The nucleotide (Figure 2) and amino acid (Figure 2, and Figure 3) sequences of 254P1D6B are provided. The tissue-related profile of 254P1D6B in normal adult tissues, combined with the over-expression observed in the tissues listed in Table I, shows that 254P1D6B is aberrantly over-expressed in at least some cancers, and thus serves as a useful diagnostic, prophylactic, prognostic, and/or therapeutic target for cancers of the tissue(s) such as those listed in Table I.

The invention provides polynucleotides corresponding or complementary to all or part of the 254P1D6B genes, mRNAs, and/or coding sequences, preferably in isolated form, including polynucleotides encoding 254P1D6B-related proteins and fragments of 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, or more than 25 contiguous amino acids; at least 30, 35, 40, 45, 50, 55, 60, 65, 70, 80, 85, 90, 95, 100 or more than 100 contiguous amino acids of a 254P1D6B-related protein, as well as the peptides/proteins themselves; DNA, RNA, DNA/RNA hybrids, and related molecules, polynucleotides or oligonucleotides complementary or having at least a 90% homology to the 254P1D6B genes or mRNA sequences or parts thereof, and polynucleotides or oligonucleotides that hybridize to the 254P1D6B genes, mRNAs, or to 254P1D6B-encoding polynucleotides. Also provided are means for isolating cDNAs and the genes encoding 254P1D6B. Recombinant DNA molecules containing 254P1D6B polynucleotides, cells transformed or transduced with such molecules, and host-vector systems for the expression of 254P1D6B gene products are also provided. The invention further provides antibodies that bind to 254P1D6B proteins and polypeptide fragments thereof, including polyclonal and monoclonal antibodies, murine and other mammalian antibodies, chimeric antibodies, humanized and fully human antibodies, and antibodies labeled with a detectable marker or therapeutic agent. In certain embodiments, there is a *proviso* that the entire nucleic acid sequence of Figure 2 is not encoded and/or the entire amino acid sequence of Figure 2 is not prepared. In certain embodiments, the entire nucleic acid sequence of Figure 2 is encoded and/or the entire amino acid sequence of Figure 2 is prepared, either of which are in respective human unit dose forms.

The invention further provides methods for detecting the presence and status of 254P1D6B polynucleotides and proteins in various biological samples, as well as methods for identifying cells that express 254P1D6B. A typical embodiment of

this invention provides methods for monitoring 254P1D6B gene products in a tissue or hematology sample having or suspected of having some form of growth dysregulation such as cancer.

The invention further provides various immunogenic or therapeutic compositions and strategies for treating cancers that express 254P1D6B such as cancers of tissues listed in Table I, including therapies aimed at inhibiting the transcription, translation, processing or function of 254P1D6B as well as cancer vaccines. In one aspect, the invention provides compositions, and methods comprising them, for treating a cancer that expresses 254P1D6B in a human subject wherein the composition comprises a carrier suitable for human use and a human unit dose of one or more than one agent that inhibits the production or function of 254P1D6B. Preferably, the carrier is a uniquely human carrier. In another aspect of the invention, the agent is a moiety that is immunoreactive with 254P1D6B protein. Non-limiting examples of such moieties include, but are not limited to, antibodies (such as single chain, monoclonal, polyclonal, humanized, chimeric, or human antibodies), functional equivalents thereof (whether naturally occurring or synthetic), and combinations thereof. The antibodies can be conjugated to a diagnostic or therapeutic moiety. In another aspect, the agent is a small molecule as defined herein.

In another aspect, the agent comprises one or more than one peptide which comprises a cytotoxic T lymphocyte (CTL) epitope that binds an HLA class I molecule in a human to elicit a CTL response to 254P1D6B and/or one or more than one peptide which comprises a helper T lymphocyte (HTL) epitope which binds an HLA class II molecule in a human to elicit an HTL response. The peptides of the invention may be on the same or on one or more separate polypeptide molecules. In a further aspect of the invention, the agent comprises one or more than one nucleic acid molecule that expresses one or more than one of the CTL or HTL response stimulating peptides as described above. In yet another aspect of the invention, the one or more than one nucleic acid molecule may express a moiety that is immunologically reactive with 254P1D6B as described above. The one or more than one nucleic acid molecule may also be, or encodes, a molecule that inhibits production of 254P1D6B. Non-limiting examples of such molecules include, but are not limited to, those complementary to a nucleotide sequence essential for production of 254P1D6B (e.g. antisense sequences or molecules that form a triple helix with a nucleotide double helix essential for 254P1D6B production) or a ribozyme effective to lyse 254P1D6B mRNA.

Note that to determine the starting position of any peptide set forth in Tables VIII-XXI and XXII to XLIX (collectively HLA Peptide Tables) respective to its parental protein, e.g., variant 1, variant 2, etc., reference is made to three factors: the particular variant, the length of the peptide in an HLA Peptide Table, and the Search Peptides in Table VII. Generally, a unique Search Peptide is used to obtain HLA peptides of a particular for a particular variant. The position of each Search Peptide relative to its respective parent molecule is listed in Table VII. Accordingly, if a Search Peptide begins at position "X", one must add the value "X - 1" to each position in Tables VIII-XXI and XXII to XLIX to obtain the actual position of the HLA peptides in their parental molecule. For example, if a particular Search Peptide begins at position 150 of its parental molecule, one must add 150 - 1, i.e., 149 to each HLA peptide amino acid position to calculate the position of that amino acid in the parent molecule.

One embodiment of the invention comprises an HLA peptide, that occurs at least twice in Tables VIII-XXI and XXII to XLIX collectively, or an oligonucleotide that encodes the HLA peptide. Another embodiment of the invention comprises an HLA peptide that occurs at least once in Tables VIII-XXI and at least once in tables XXII to XLIX, or an oligonucleotide that encodes the HLA peptide.

Another embodiment of the invention is antibody epitopes, which comprise a peptide regions, or an oligonucleotide encoding the peptide region, that has one two, three, four, or five of the following characteristics:

i) a peptide region of at least 5 amino acids of a particular peptide of Figure 3, in any whole number increment up to the full length of that protein in Figure 3, that includes an amino acid position having a value equal to or greater than 0.5, 0.6, 0.7, 0.8, 0.9, or having a value equal to 1.0, in the Hydrophilicity profile of Figure 5;

- ii) a peptide region of at least 5 amino acids of a particular peptide of Figure 3, in any whole number increment up to the full length of that protein in Figure 3, that includes an amino acid position having a value equal to or less than 0.5, 0.4, 0.3, 0.2, 0.1, or having a value equal to 0.0, in the Hydropathicity profile of Figure 6;
- iii) a peptide region of at least 5 amino acids of a particular peptide of Figure 3, in any whole number increment up to the full length of that protein in Figure 3, that includes an amino acid position having a value equal to or greater than 0.5, 0.6, 0.7, 0.8, 0.9, or having a value equal to 1.0, in the Percent Accessible Residues profile of Figure 7;
- iv) a peptide region of at least 5 amino acids of a particular peptide of Figure 3, in any whole number increment up to the full length of that protein in Figure 3, that includes an amino acid position having a value equal to or greater than 0.5, 0.6, 0.7, 0.8, 0.9, or having a value equal to 1.0, in the Average Flexibility profile of Figure 8; or
- v) a peptide region of at least 5 amino acids of a particular peptide of Figure 3, in any whole number increment up to the full length of that protein in Figure 3, that includes an amino acid position having a value equal to or greater than 0.5, 0.6, 0.7, 0.8, 0.9, or having a value equal to 1.0, in the Beta-turn profile of Figure 9.

#### **BRIEF DESCRIPTION OF THE FIGURES**

**Figure 1.** The 254P1D6B SSH sequence of 284 nucleotides.

**Figure 2. A)** The cDNA and amino acid sequence of 254P1D6B variant 1 (also called "254P1D6B v.1" or "254P1D6B variant 1") is shown in Figure 2A. The start methionine is underlined. The open reading frame extends from nucleic acid 512-3730 including the stop codon.

**B)** The cDNA and amino acid sequence of 254P1D6B variant 2 (also called "254P1D6B v.2") is shown in Figure 2B. The codon for the start methionine is underlined. The open reading frame extends from nucleic acid 512-3730 including the stop codon.

**C)** The cDNA and amino acid sequence of 254P1D6B variant 3 (also called "254P1D6B v.3") is shown in Figure 2C. The codon for the start methionine is underlined. The open reading frame extends from nucleic acid 739-3930 including the stop codon.

**D)** 254P1D6B v.4 through v.20, SNP variants of 254P1D6B v.1. The 254P1D6B v.4 through v.20 (also called "254P1D6B variant 4 through variant 20") proteins have 1072 amino acids. Variants 254P1D6B v.4 through v.20 are variants with single nucleotide difference from 254P1D6B v.1. 254P1D6B v.5 and v.6 proteins differ from 254P1D6B v.1 by one amino acid. 254P1D6B v.4 and v.7 through v.20 proteins code for the same protein as v.1. Though these SNP variants are shown separately, they can also occur in any combinations and in any of the transcript variants listed above in Figure 2A, Figure 2B, and Figure 2C.

#### **Figure 3.**

**A)** The amino acid sequence of 254P1D6B v.1 clone LCP-3 is shown in Figure 3A; it has 1072 amino acids.

**B)** The amino acid sequence of 254P1D6B v.2 is shown in Figure 3B; it has 1072 amino acids.

**C)** The amino acid sequence of 254P1D6B v.3 is shown in Figure 3C; it has 1063 amino acids.

**D)** The amino acid sequence of 254P1D6B v.5 is shown in Figure 3D; it has 1072 amino acids.

**E)** The amino acid sequence of 254P1D6B v.6 is shown in Figure 3E; it has 1072 amino acids.

As used herein, a reference to 254P1D6B includes all variants thereof, including those shown in Figures 2, 3, 10, 11, and 12 unless the context clearly indicates otherwise.

#### **Figure 4. Intentionally Omitted.**

**Figure 5.** Hydrophilicity amino acid profile of 254P1D6B v.1 determined by computer algorithm sequence analysis using the method of Hopp and Woods (Hopp T.P., Woods K.R., 1981. Proc. Natl. Acad. Sci. U.S.A. 78:3824-3828) accessed on the ProtScale website located on the World Wide Web at ([expasy.ch/cgi-bin/protscale.pl](http://expasy.ch/cgi-bin/protscale.pl)) through the ExPasy molecular biology server.

**Figure 6.** Hydropathicity amino acid profile of 254P1D6B v.1 determined by computer algorithm sequence analysis using the method of Kyte and Doolittle (Kyte J., Doolittle R.F., 1982. *J. Mol. Biol.* 157:105-132) accessed on the ProtScale website located on the World Wide Web at ([expasy.ch/cgi-bin/protscale.pl](http://expasy.ch/cgi-bin/protscale.pl)) through the ExPasy molecular biology server.

**Figure 7.** Percent accessible residues amino acid profile of 254P1D6B v.1 determined by computer algorithm sequence analysis using the method of Janin (Janin J., 1979 *Nature* 277:491-492) accessed on the ProtScale website located on the World Wide Web at ([expasy.ch/cgi-bin/protscale.pl](http://expasy.ch/cgi-bin/protscale.pl)) through the ExPasy molecular biology server.

**Figure 8.** Average flexibility amino acid profile of 254P1D6B v.1 determined by computer algorithm sequence analysis using the method of Bhaskaran and Ponnuswamy (Bhaskaran R., and Ponnuswamy P.K., 1988. *Int. J. Pept. Protein Res.* 32:242-255) accessed on the ProtScale website located on the World Wide Web at ([expasy.ch/cgi-bin/protscale.pl](http://expasy.ch/cgi-bin/protscale.pl)) through the ExPasy molecular biology server.

**Figure 9.** Beta-turn amino acid profile of 254P1D6B v.1 determined by computer algorithm sequence analysis using the method of Deleage and Roux (Deleage, G., Roux B. 1987 *Protein Engineering* 1:289-294) accessed on the ProtScale website located on the World Wide Web at ([expasy.ch/cgi-bin/protscale.pl](http://expasy.ch/cgi-bin/protscale.pl)) through the ExPasy molecular biology server.

**Figure 10. Structures of transcript variants of 254P1D6B.** Variant 254P1D6B v.3 was identified as a transcript variant of 254P1D6B v.1. Variant 254P1D6B v.3 extended exon 1 by 109 bp as compared to v.1 and added an exon in between exons 2 and 3 of variant v.1. Poly A tails and SNP are not shown here. Numbers in "( )" underneath the boxes correspond to those of 254P1D6B v.1. Lengths of introns and exons are not proportional.

**Figure 11. Schematic alignment of protein variants of 254P1D6B.** Protein variants correspond to nucleotide variants. Nucleotide variants 254P1D6B v.4 and v.7 through v.20 coded for the same protein as v.1. Variant v.2 coded the same protein as variant v.6. 254P1D6Bv.5 coded for a protein that differed by one amino acid from v.1. Nucleotide variant 254P1D6B v.3 was a transcript variant of v.1, as shown in Figure 10, and coded a protein that differed from v.1 in the N-terminal. SNP in v.1 could also appear in v.3. Single amino acid differences were indicated above the boxes. Black boxes represent the same sequence as 254P1D6B v.1. Numbers underneath the box correspond to 254P1D6B.

**Figure 12. Schematic alignment of SNP variants of 254P1D6B.** Variants 254P1D6B v.4 through v.20 were variants with single nucleotide differences as compared to variant v.1 (ORF: 512-3730). Though these SNP variants were shown separately, they could also occur in any combinations, (e.g., occur with 254P1D6Bv.2, and in any transcript variants that contained the base pairs, such as v.3 shown in Fig. 10. Numbers correspond to those of 254P1D6B v.1. Black box shows the same sequence as 254P1D6B v.1. SNPs are indicated above the box.

**Figure 13.** Secondary structure and transmembrane domains prediction for 254P1D6b protein variant 1.

**Figure 13A:** The secondary structures of 254P1D6b protein variant was predicted using the HNN - Hierarchical Neural Network method (NPS@: Network Protein Sequence Analysis TIBS 2000 March Vol. 25, No 3 [291]:147-150 Combet C., Blanchet C., Geourjon C. and Deléage G., [http://pbil.ibcp.fr/cgi-bin/npsa\\_automat.pl?page=npsa\\_nn.html](http://pbil.ibcp.fr/cgi-bin/npsa_automat.pl?page=npsa_nn.html)), accessed from the ExPasy molecular biology server located on the World Wide Web at [expasy.ch/tools/](http://expasy.ch/tools/). This method predicts the presence and location of alpha helices, extended strands, and random coils from the primary protein sequence. The percent of the protein variant in a given secondary structure is also listed. **Figure 13B:** Schematic representation of the probability of existence of transmembrane regions of 254P1D6b variant 1 based on the TMpred algorithm of Hofmann and Stoffel which utilizes TMBASE (K. Hofmann, W. Stoffel. TMBASE - A database of membrane spanning protein segments *Biol. Chem. Hoppe-Seyler* 374:166, 1993). **Figure 13C:** Schematic representation of the probability of the existence of transmembrane regions of 254P1D6b variant 1 based on the TMHMM algorithm of Sonnhammer, von Heijne, and Krogh (Erik L.L. Sonnhammer, Gunnar von Heijne, and Anders Krogh: A hidden Markov model for predicting transmembrane helices in

protein sequences. In Proc. of Sixth Int. Conf. on Intelligent Systems for Molecular Biology, p 175-182 Ed J. Glasgow, T. Littlejohn, F. Major, R. Lathrop, D. Sankoff, and C. Sensen Menlo Park, CA: AAAI Press, 1998). The TMpred and TMHMM algorithms are accessed from the ExPasy molecular biology server located on the World Wide Web at [expasy.ch/tools/](http://expasy.ch/tools/).

**Figure 14. Expression of 254P1D6B by RT-PCR.** First strand cDNA was prepared from vital pool 1 (liver, lung and kidney), vital pool 2 (pancreas, colon and stomach), normal lung, ovary cancer pool, lung cancer pool (**Figure 14A**), as well as from normal stomach, brain, heart, liver, spleen, skeletal muscle, testis, prostate, bladder, kidney, colon, lung and ovary cancer pool (**Figure 14B**). Normalization was performed by PCR using primers to actin and GAPDH. Semi-quantitative PCR, using primers to 254P1D6B, was performed at 26 and 30 cycles of amplification. Results show strong expression of 254P1D6B in lung cancer pool and ovary cancer pool but not in normal lung nor in vital pool 1. Low expression was detected in vital pool 2.

**Figure 15. Expression of 254P1D6B in normal tissues.** Two multiple tissue northern blots (Clontech) both with 2 ug of mRNA/lane were probed with the 254P1D6B sequence. Size standards in kilobases (kb) are indicated on the side. Results show expression of two 254P1D6B transcript, 4.4 kb and 7.5 kb primarily in brain and testis, and only the 4.4 kb transcript in placenta, but not in any other normal tissue tested.

**Figure 16. Expression of 254P1D6B in lung cancer patient specimens.** First strand cDNA was prepared from normal lung lung cancer cell line A427 and a panel of lung cancer patient specimens. Normalization was performed by PCR using primers to actin and GAPDH. Semi-quantitative PCR, using primers to 254P1D6B, was performed at 26 and 30 cycles of amplification. Results show expression of 254P1D6B in 13 out of 30 tumor specimens tested but not in normal lung. Expression was also detected in the A427 cell line.

**Figure 17. Expression of 254P1D6b in 293T cells.** **Figure 17A.** 293T cells were transfected with either an empty pCDNA 3.1 vector plasmid or pCDNA 3.1 plasmid encoding the full length cDNA of 254P1D6b. 2 days post-transfection, lysates were prepared from the transfected cells and separated by SDS-PAGE, transferred to nitrocellulose and subjected to Western blotting using an anti-His pAb (Santa Cruz Biotechnology, Santa Cruz, California) to detect the C-terminal epitope tag on the protein. An arrow indicates the band corresponding to the full length 254P1D6b protein product. An additional verified lysate containing an epitope tagged AGSX protein served as a positive control. **Figure 17B.** 293T cells were transfected with either an empty vector or the Tag5 expression vector encoding the extracellular domain (ECD) of 254P1D6 (amino acids 26-953) and subjected to SDS-PAGE and Western blotting as described above. An arrow indicates the band corresponding to the 254P1D6b ECD present in the lysates and the media from transfected cells.

## **DETAILED DESCRIPTION OF THE INVENTION**

### **Outline of Sections**

- I.) Definitions**
- II.) 254P1D6B Polynucleotides**
  - II.A.) Uses of 254P1D6B Polynucleotides**
    - II.A.1.) Monitoring of Genetic Abnormalities**
    - II.A.2.) Antisense Embodiments**
    - II.A.3.) Primers and Primer Pairs**
    - II.A.4.) Isolation of 254P1D6B-Encoding Nucleic Acid Molecules**
    - II.A.5.) Recombinant Nucleic Acid Molecules and Host-Vector Systems**
- III.) 254P1D6B-related Proteins**
  - III.A.) Motif-bearing Protein Embodiments**
  - III.B.) Expression of 254P1D6B-related Proteins**
  - III.C.) Modifications of 254P1D6B-related Proteins**

- III.D.) Uses of 254P1D6B-related Proteins
- IV.) 254P1D6B Antibodies
- V.) 254P1D6B Cellular Immune Responses
- VI.) 254P1D6B Transgenic Animals
- VII.) Methods for the Detection of 254P1D6B
- VIII.) Methods for Monitoring the Status of 254P1D6B-related Genes and Their Products
- IX.) Identification of Molecules That Interact With 254P1D6B
- X.) Therapeutic Methods and Compositions
  - X.A.) Anti-Cancer Vaccines
  - X.B.) 254P1D6B as a Target for Antibody-Based Therapy
  - X.C.) 254P1D6B as a Target for Cellular Immune Responses
    - X.C.1. Minigene Vaccines
    - X.C.2. Combinations of CTL Peptides with Helper Peptides
    - X.C.3. Combinations of CTL Peptides with T Cell Priming Agents
    - X.C.4. Vaccine Compositions Comprising DC Pulsed with CTL and/or HTL Peptides
  - X.D.) Adoptive Immunotherapy
  - X.E.) Administration of Vaccines for Therapeutic or Prophylactic Purposes
- XI.) Diagnostic and Prognostic Embodiments of 254P1D6B.
- XII.) Inhibition of 254P1D6B Protein Function
  - XII.A.) Inhibition of 254P1D6B With Intracellular Antibodies
  - XII.B.) Inhibition of 254P1D6B with Recombinant Proteins
  - XII.C.) Inhibition of 254P1D6B Transcription or Translation
  - XII.D.) General Considerations for Therapeutic Strategies
- XIII.) Identification, Characterization and Use of Modulators of 254P1D6B
- XIV.) RNAi and Therapeutic use of small interfering RNA
- XV.) KITS/Articles of Manufacture

**I.) Definitions:**

Unless otherwise defined, all terms of art, notations and other scientific terms or terminology used herein are intended to have the meanings commonly understood by those of skill in the art to which this invention pertains. In some cases, terms with commonly understood meanings are defined herein for clarity and/or for ready reference, and the inclusion of such definitions herein should not necessarily be construed to represent a substantial difference over what is generally understood in the art. Many of the techniques and procedures described or referenced herein are well understood and commonly employed using conventional methodology by those skilled in the art, such as, for example, the widely utilized molecular cloning methodologies described in Sambrook *et al.*, Molecular Cloning: A Laboratory Manual 2nd. edition (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. As appropriate, procedures involving the use of commercially available kits and reagents are generally carried out in accordance with manufacturer defined protocols and/or parameters unless otherwise noted.

The terms "advanced prostate cancer", "locally advanced prostate cancer", "advanced disease" and "locally advanced disease" mean prostate cancers that have extended through the prostate capsule, and are meant to include stage C disease under the American Urological Association (AUA) system, stage C1 - C2 disease under the Whitmore-Jewett system, and stage T3 - T4 and N+ disease under the TNM (tumor, node, metastasis) system. In general, surgery is not

recommended for patients with locally advanced disease, and these patients have substantially less favorable outcomes compared to patients having clinically localized (organ-confined) prostate cancer. Locally advanced disease is clinically identified by palpable evidence of induration beyond the lateral border of the prostate, or asymmetry or induration above the prostate base. Locally advanced prostate cancer is presently diagnosed pathologically following radical prostatectomy if the tumor invades or penetrates the prostatic capsule, extends into the surgical margin, or invades the seminal vesicles.

"Altering the native glycosylation pattern" is intended for purposes herein to mean deleting one or more carbohydrate moieties found in native sequence 254P1D6B (either by removing the underlying glycosylation site or by deleting the glycosylation by chemical and/or enzymatic means), and/or adding one or more glycosylation sites that are not present in the native sequence 254P1D6B. In addition, the phrase includes qualitative changes in the glycosylation of the native proteins, involving a change in the nature and proportions of the various carbohydrate moieties present.

The term "analog" refers to a molecule which is structurally similar or shares similar or corresponding attributes with another molecule (e.g. a 254P1D6B-related protein). For example, an analog of a 254P1D6B protein can be specifically bound by an antibody or T cell that specifically binds to 254P1D6B.

The term "antibody" is used in the broadest sense. Therefore, an "antibody" can be naturally occurring or man-made such as monoclonal antibodies produced by conventional hybridoma technology. Anti-254P1D6B antibodies comprise monoclonal and polyclonal antibodies as well as fragments containing the antigen-binding domain and/or one or more complementarity determining regions of these antibodies.

An "antibody fragment" is defined as at least a portion of the variable region of the immunoglobulin molecule that binds to its target, i.e., the antigen-binding region. In one embodiment it specifically covers single anti-254P1D6B antibodies and clones thereof (including agonist, antagonist and neutralizing antibodies) and anti-254P1D6B antibody compositions with polypeptidic specificity.

The term "codon optimized sequences" refers to nucleotide sequences that have been optimized for a particular host species by replacing any codons having a usage frequency of less than about 20%. Nucleotide sequences that have been optimized for expression in a given host species by elimination of spurious polyadenylation sequences, elimination of exon/intron splicing signals, elimination of transposon-like repeats and/or optimization of GC content in addition to codon optimization are referred to herein as an "expression enhanced sequences."

A "combinatorial library" is a collection of diverse chemical compounds generated by either chemical synthesis or biological synthesis by combining a number of chemical "building blocks" such as reagents. For example, a linear combinatorial chemical library, such as a polypeptide (e.g., mutein) library, is formed by combining a set of chemical building blocks called amino acids in every possible way for a given compound length (i.e., the number of amino acids in a polypeptide compound). Numerous chemical compounds are synthesized through such combinatorial mixing of chemical building blocks (Gallop et al., J. Med. Chem. 37(9): 1233-1251 (1994)).

Preparation and screening of combinatorial libraries is well known to those of skill in the art. Such combinatorial chemical libraries include, but are not limited to, peptide libraries (see, e.g., U.S. Patent No. 5,010,175, Furka, Pept. Prot. Res. 37:487-493 (1991), Houghton et al., Nature, 354:84-88 (1991)), peptoids (PCT Publication No WO 91/19735), encoded peptides (PCT Publication WO 93/20242), random bio- oligomers (PCT Publication WO 92/00091), benzodiazepines (U.S. Pat. No. 5,288,514), diversomers such as hydantoins, benzodiazepines and dipeptides (Hobbs et al., Proc. Nat. Acad. Sci. USA 90:6909-6913 (1993)), vinylogous polypeptides (Hagihara et al., J. Amer. Chem. Soc. 114:6568 (1992)), nonpeptidic peptidomimetics with a Beta-D-Glucose scaffolding (Hirschmann et al., J. Amer. Chem. Soc. 114:9217-9218 (1992)), analogous organic syntheses of small compound libraries (Chen et al., J. Amer. Chem. Soc. 116:2661 (1994)), oligocarbamates (Cho, et al., Science 261:1303 (1993)), and/or peptidyl phosphonates (Campbell et al., J. Org. Chem. 59:658 (1994)). See, generally, Gordon et al., J. Med. Chem. 37:1385 (1994), nucleic acid libraries (see, e.g., Stratagene,

Corp.), peptide nucleic acid libraries (see, e.g., U.S. Patent 5,539,083), antibody libraries (see, e.g., Vaughn et al., *Nature Biotechnology* 14(3): 309-314 (1996), and PCT/US96/10287), carbohydrate libraries (see, e.g., Liang et al., *Science* 274:1520-1522 (1996), and U.S. Patent No. 5,593,853), and small organic molecule libraries (see, e.g., benzodiazepines, Baum, C&EN, Jan 18, page 33 (1993); isoprenoids, U.S. Patent No. 5,569,588; thiazolidinones and metathiazanones, U.S. Patent No. 5,549,974; pyrrolidines, U.S. Patent Nos. 5,525,735 and 5,519,134; morpholino compounds, U.S. Patent No. 5,506, 337; benzodiazepines, U.S. Patent No. 5,288,514; and the like).

Devices for the preparation of combinatorial libraries are commercially available (see, e.g., 357 NIPS, 390 NIPS, Advanced Chem Tech, Louisville KY; Symphony, Rainin, Woburn, MA; 433A, Applied Biosystems, Foster City, CA; 9050, Plus, Millipore, Bedford, MA). A number of well-known robotic systems have also been developed for solution phase chemistries. These systems include automated workstations such as the automated synthesis apparatus developed by Takeda Chemical Industries, LTD. (Osaka, Japan) and many robotic systems utilizing robotic arms (Zymate H, Zymark Corporation, Hopkinton, Mass.; Orca, Hewlett-Packard, Palo Alto, Calif.), which mimic the manual synthetic operations performed by a chemist. Any of the above devices are suitable for use with the present invention. The nature and implementation of modifications to these devices (if any) so that they can operate as discussed herein will be apparent to persons skilled in the relevant art. In addition, numerous combinatorial libraries are themselves commercially available (see, e.g., ComGenex, Princeton, NJ; Asinex, Moscow, RU; Tripos, Inc., St. Louis, MO; ChemStar, Ltd, Moscow, RU; 3D Pharmaceuticals, Exton, PA; Martek Biosciences, Columbia, MD; etc.).

The term "cytotoxic agent" refers to a substance that inhibits or prevents the expression activity of cells, function of cells and/or causes destruction of cells. The term is intended to include radioactive isotopes chemotherapeutic agents, and toxins such as small molecule toxins or enzymatically active toxins of bacterial, fungal, plant or animal origin, including fragments and/or variants thereof. Examples of cytotoxic agents include, but are not limited to auristatins, auromyxins, maytansinoids, yttrium, bismuth, ricin, ricin A-chain, combrestatin, duocarmycins, dolostatins, doxorubicin, daunorubicin, taxol, cisplatin, cc1065, ethidium bromide, mitomycin, etoposide, teniposide, vincristine, vinblastine, colchicine, dihydroxy anthracin dione, actinomycin, diphtheria toxin, *Pseudomonas* exotoxin (PE) A, PE40, abrin, abrin A chain, modeccin A chain, alpha-sarcin, gelonin, mitogellin, retsstrictocin, phenomycin, enomycin, curicin, crotin, calicheamicin, *Saponaia officinalis* inhibitor, and glucocorticoid and other chemotherapeutic agents, as well as radioisotopes such as At<sup>211</sup>, I<sup>131</sup>, I<sup>125</sup>, Y<sup>90</sup>, Re<sup>186</sup>, Re<sup>188</sup>, Sm<sup>153</sup>, Bi<sup>212</sup> or <sup>213</sup>, P<sup>32</sup> and radioactive isotopes of Lu including Lu<sup>177</sup>. Antibodies may also be conjugated to an anti-cancer pro-drug activating enzyme capable of converting the pro-drug to its active form.

The "gene product" is sometimes referred to herein as a protein or mRNA. For example, a "gene product of the invention" is sometimes referred to herein as a "cancer amino acid sequence", "cancer protein", "protein of a cancer listed in Table I", a "cancer mRNA", "mRNA of a cancer listed in Table I", etc. In one embodiment, the cancer protein is encoded by a nucleic acid of Figure 2. The cancer protein can be a fragment, or alternatively, be the full-length protein to the fragment encoded by the nucleic acids of Figure 2. In one embodiment, a cancer amino acid sequence is used to determine sequence identity or similarity. In another embodiment, the sequences are naturally occurring allelic variants of a protein encoded by a nucleic acid of Figure 2. In another embodiment, the sequences are sequence variants as further described herein.

"High throughput screening" assays for the presence, absence, quantification, or other properties of particular nucleic acids or protein products are well known to those of skill in the art. Similarly, binding assays and reporter gene assays are similarly well known. Thus, e.g., U.S. Patent No. 5,559,410 discloses high throughput screening methods for proteins; U.S. Patent No. 5,585,639 discloses high throughput screening methods for nucleic acid binding (i.e., in arrays); while U.S. Patent Nos. 5,576,220 and 5,541,061 disclose high throughput methods of screening for ligand/antibody binding.

In addition, high throughput screening systems are commercially available (see, e.g., Amersham Biosciences, Piscataway, NJ; Zymark Corp., Hopkinton, MA; Air Technical Industries, Mentor, OH; Beckman Instruments, Inc. Fullerton, CA; Precision Systems, Inc., Natick, MA; etc.). These systems typically automate entire procedures, including all sample and reagent pipetting, liquid dispensing, timed incubations, and final readings of the microplate in detector(s) appropriate for the assay. These configurable systems provide high throughput and rapid start up as well as a high degree of flexibility and customization. The manufacturers of such systems provide detailed protocols for various high throughput systems. Thus, e.g., Zymark Corp. provides technical bulletins describing screening systems for detecting the modulation of gene transcription, ligand binding, and the like.

The term "homolog" refers to a molecule which exhibits homology to another molecule, by for example, having sequences of chemical residues that are the same or similar at corresponding positions.

"Human Leukocyte Antigen" or "HLA" is a human class I or class II Major Histocompatibility Complex (MHC) protein (see, e.g., Stites, *et al.*, IMMUNOLOGY, 8<sup>TH</sup> ED., Lange Publishing, Los Altos, CA (1994).

The terms "hybridize", "hybridizing", "hybridizes" and the like, used in the context of polynucleotides, are meant to refer to conventional hybridization conditions, preferably such as hybridization in 50% formamide/6XSSC/0.1% SDS/100 µg/ml ssDNA, in which temperatures for hybridization are above 37 degrees C and temperatures for washing in 0.1XSSC/0.1% SDS are above 55 degrees C.

The phrases "isolated" or "biologically pure" refer to material which is substantially or essentially free from components which normally accompany the material as it is found in its native state. Thus, isolated peptides in accordance with the invention preferably do not contain materials normally associated with the peptides in their *in situ* environment. For example, a polynucleotide is said to be "isolated" when it is substantially separated from contaminant polynucleotides that correspond or are complementary to genes other than the 254P1D6B genes or that encode polypeptides other than 254P1D6B gene product or fragments thereof. A skilled artisan can readily employ nucleic acid isolation procedures to obtain an isolated 254P1D6B polynucleotide. A protein is said to be "isolated," for example, when physical, mechanical or chemical methods are employed to remove the 254P1D6B proteins from cellular constituents that are normally associated with the protein. A skilled artisan can readily employ standard purification methods to obtain an isolated 254P1D6B protein. Alternatively, an isolated protein can be prepared by chemical means.

The term "mammal" refers to any organism classified as a mammal, including mice, rats, rabbits, dogs, cats, cows, horses and humans. In one embodiment of the invention, the mammal is a mouse. In another embodiment of the invention, the mammal is a human.

The terms "metastatic prostate cancer" and "metastatic disease" mean prostate cancers that have spread to regional lymph nodes or to distant sites, and are meant to include stage D disease under the AUA system and stage TxNxM+ under the TNM system. As is the case with locally advanced prostate cancer, surgery is generally not indicated for patients with metastatic disease, and hormonal (androgen ablation) therapy is a preferred treatment modality. Patients with metastatic prostate cancer eventually develop an androgen-refractory state within 12 to 18 months of treatment initiation. Approximately half of these androgen-refractory patients die within 6 months after developing that status. The most common site for prostate cancer metastasis is bone. Prostate cancer bone metastases are often osteoblastic rather than osteolytic (i.e., resulting in net bone formation). Bone metastases are found most frequently in the spine, followed by the femur, pelvis, rib cage, skull and humerus. Other common sites for metastasis include lymph nodes, lung, liver and brain. Metastatic prostate cancer is typically diagnosed by open or laparoscopic pelvic lymphadenectomy, whole body radionuclide scans, skeletal radiography, and/or bone lesion biopsy.

The term "modulator" or "test compound" or "drug candidate" or grammatical equivalents as used herein describe any molecule, e.g., protein, oligopeptide, small organic molecule, polysaccharide, polynucleotide, etc., to be tested for the

capacity to directly or indirectly alter the cancer phenotype or the expression of a cancer sequence, e.g., a nucleic acid or protein sequences, or effects of cancer sequences (e.g., signaling, gene expression, protein interaction, etc.) In one aspect, a modulator will neutralize the effect of a cancer protein of the invention. By "neutralize" is meant that an activity of a protein is inhibited or blocked, along with the consequent effect on the cell. In another aspect, a modulator will neutralize the effect of a gene, and its corresponding protein, of the invention by normalizing levels of said protein. In preferred embodiments, modulators alter expression profiles, or expression profile nucleic acids or proteins provided herein, or downstream effector pathways. In one embodiment, the modulator suppresses a cancer phenotype, e.g. to a normal tissue fingerprint. In another embodiment, a modulator induced a cancer phenotype. Generally, a plurality of assay mixtures is run in parallel with different agent concentrations to obtain a differential response to the various concentrations. Typically, one of these concentrations serves as a negative control, i.e., at zero concentration or below the level of detection.

Modulators, drug candidates or test compounds encompass numerous chemical classes, though typically they are organic molecules, preferably small organic compounds having a molecular weight of more than 100 and less than about 2,500 Daltons. Preferred small molecules are less than 2000, or less than 1500 or less than 1000 or less than 500 D. Candidate agents comprise functional groups necessary for structural interaction with proteins, particularly hydrogen bonding, and typically include at least an amine, carbonyl, hydroxyl or carboxyl group, preferably at least two of the functional chemical groups. The candidate agents often comprise cyclical carbon or heterocyclic structures and/or aromatic or polyaromatic structures substituted with one or more of the above functional groups. Modulators also comprise biomolecules such as peptides, saccharides, fatty acids, steroids, purines, pyrimidines, derivatives, structural analogs or combinations thereof. Particularly preferred are peptides. One class of modulators are peptides, for example of from about five to about 35 amino acids, with from about five to about 20 amino acids being preferred, and from about 7 to about 15 being particularly preferred. Preferably, the cancer modulatory protein is soluble, includes a non-transmembrane region, and/or, has an N-terminal Cys to aid in solubility. In one embodiment, the C-terminus of the fragment is kept as a free acid and the N-terminus is a free amine to aid in coupling, i.e., to cysteine. In one embodiment, a cancer protein of the invention is conjugated to an immunogenic agent as discussed herein. In one embodiment, the cancer protein is conjugated to BSA. The peptides of the invention, e.g., of preferred lengths, can be linked to each other or to other amino acids to create a longer peptide/protein. The modulatory peptides can be digests of naturally occurring proteins as is outlined above, random peptides, or "biased" random peptides. In a preferred embodiment, peptide/protein-based modulators are antibodies, and fragments thereof, as defined herein.

Modulators of cancer can also be nucleic acids. Nucleic acid modulating agents can be naturally occurring nucleic acids, random nucleic acids, or "biased" random nucleic acids. For example, digests of prokaryotic or eukaryotic genomes can be used in an approach analogous to that outlined above for proteins.

The term "monoclonal antibody" refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the antibodies comprising the population are identical except for possible naturally occurring mutations that are present in minor amounts.

A "motif", as in biological motif of a 254P1D6B-related protein, refers to any pattern of amino acids forming part of the primary sequence of a protein, that is associated with a particular function (e.g. protein-protein interaction, protein-DNA interaction, etc) or modification (e.g. that is phosphorylated, glycosylated or amidated), or localization (e.g. secretory sequence, nuclear localization sequence, etc.) or a sequence that is correlated with being immunogenic, either humorally or cellularly. A motif can be either contiguous or capable of being aligned to certain positions that are generally correlated with a certain function or property. In the context of HLA motifs, "motif" refers to the pattern of residues in a peptide of defined length, usually a peptide of from about 8 to about 13 amino acids for a class I HLA motif and from about 6 to about 25 amino acids for a class II HLA motif, which is recognized by a particular HLA molecule. Peptide motifs for HLA binding are typically

different for each protein encoded by each human HLA allele and differ in the pattern of the primary and secondary anchor residues.

A "pharmaceutical excipient" comprises a material such as an adjuvant, a carrier, pH-adjusting and buffering agents, tonicity adjusting agents, wetting agents, preservative, and the like.

"Pharmaceutically acceptable" refers to a non-toxic, inert, and/or composition that is physiologically compatible with humans or other mammals.

The term "polynucleotide" means a polymeric form of nucleotides of at least 10 bases or base pairs in length, either ribonucleotides or deoxynucleotides or a modified form of either type of nucleotide, and is meant to include single and double stranded forms of DNA and/or RNA. In the art, this term is often used interchangeably with "oligonucleotide". A polynucleotide can comprise a nucleotide sequence disclosed herein wherein thymidine (T), as shown for example in Figure 2, can also be uracil (U); this definition pertains to the differences between the chemical structures of DNA and RNA, in particular the observation that one of the four major bases in RNA is uracil (U) instead of thymidine (T).

The term "polypeptide" means a polymer of at least about 4, 5, 6, 7, or 8 amino acids. Throughout the specification, standard three letter or single letter designations for amino acids are used. In the art, this term is often used interchangeably with "peptide" or "protein".

An HLA "primary anchor residue" is an amino acid at a specific position along a peptide sequence which is understood to provide a contact point between the immunogenic peptide and the HLA molecule. One to three, usually two, primary anchor residues within a peptide of defined length generally defines a "motif" for an immunogenic peptide. These residues are understood to fit in close contact with peptide binding groove of an HLA molecule, with their side chains buried in specific pockets of the binding groove. In one embodiment, for example, the primary anchor residues for an HLA class I molecule are located at position 2 (from the amino terminal position) and at the carboxyl terminal position of a 8, 9, 10, 11, or 12 residue peptide epitope in accordance with the invention. Alternatively, in another embodiment, the primary anchor residues of a peptide binds an HLA class II molecule are spaced relative to each other, rather than to the termini of a peptide, where the peptide is generally of at least 9 amino acids in length. The primary anchor positions for each motif and supermotif are set forth in Table IV. For example, analog peptides can be created by altering the presence or absence of particular residues in the primary and/or secondary anchor positions shown in Table IV. Such analogs are used to modulate the binding affinity and/or population coverage of a peptide comprising a particular HLA motif or supermotif.

"Radioisotopes" include, but are not limited to the following (non-limiting exemplary uses are also set forth):

Examples of Medical Isotopes:

Isotope	Description of use
Actinium-225 (AC-225)	See Thorium-229 (Th-229)
Actinium-227 (AC-227)	Parent of Radium-223 (Ra-223) which is an alpha emitter used to treat metastases in the skeleton resulting from cancer (i.e., breast and prostate cancers), and cancer radioimmunotherapy
Bismuth-212 (Bi-212)	See Thorium-228 (Th-228)
Bismuth-213 (Bi-213)	See Thorium-229 (Th-229)
Cadmium-109 (Cd-109)	Cancer detection
Cobalt-60 (Co-60)	Radiation source for radiotherapy of cancer, for food irradiators, and for sterilization of medical supplies
Copper-64 (Cu-64)	A positron emitter used for cancer therapy and SPECT imaging

Copper-67 (Cu-67)	Beta/gamma emitter used in cancer radioimmunotherapy and diagnostic studies (i.e., breast and colon cancers, and lymphoma)
Dysprosium-166 (Dy-166)	Cancer radioimmunotherapy
Erbium-169 (Er-169)	Rheumatoid arthritis treatment, particularly for the small joints associated with fingers and toes
Europium-152 (Eu-152)	Radiation source for food irradiation and for sterilization of medical supplies
Europium-154 (Eu-154)	Radiation source for food irradiation and for sterilization of medical supplies
Gadolinium-153 (Gd-153)	Osteoporosis detection and nuclear medical quality assurance devices
Gold-198 (Au-198)	Implant and intracavity therapy of ovarian, prostate, and brain cancers
Holmium-166 (Ho-166)	Multiple myeloma treatment in targeted skeletal therapy, cancer radioimmunotherapy, bone marrow ablation, and rheumatoid arthritis treatment
Iodine-125 (I-125)	Osteoporosis detection, diagnostic imaging, tracer drugs, brain cancer treatment, radiolabeling, tumor imaging, mapping of receptors in the brain, interstitial radiation therapy, brachytherapy for treatment of prostate cancer, determination of glomerular filtration rate (GFR), determination of plasma volume, detection of deep vein thrombosis of the legs
Iodine-131 (I-131)	Thyroid function evaluation, thyroid disease detection, treatment of thyroid cancer as well as other non-malignant thyroid diseases (i.e., Graves disease, goiters, and hyperthyroidism), treatment of leukemia, lymphoma, and other forms of cancer (e.g., breast cancer) using radioimmunotherapy
Iridium-192 (Ir-192)	Brachytherapy, brain and spinal cord tumor treatment, treatment of blocked arteries (i.e., arteriosclerosis and restenosis), and implants for breast and prostate tumors
Lutetium-177 (Lu-177)	Cancer radioimmunotherapy and treatment of blocked arteries (i.e., arteriosclerosis and restenosis)
Molybdenum-99 (Mo-99)	Parent of Technetium-99m (Tc-99m) which is used for imaging the brain, liver, lungs, heart, and other organs. Currently, Tc-99m is the most widely used radioisotope used for diagnostic imaging of various cancers and diseases involving the brain, heart, liver, lungs; also used in detection of deep vein thrombosis of the legs
Osmium-194 (Os-194)	Cancer radioimmunotherapy
Palladium-103 (Pd-103)	Prostate cancer treatment
Platinum-195m (Pt-195m)	Studies on biodistribution and metabolism of cisplatin, a chemotherapeutic drug
Phosphorus-32 (P-32)	Polycythemia rubra vera (blood cell disease) and leukemia treatment, bone cancer diagnosis/treatment; colon, pancreatic, and liver cancer treatment; radiolabeling nucleic acids for in vitro research, diagnosis of superficial tumors, treatment of blocked arteries (i.e., arteriosclerosis and restenosis), and intracavity therapy
Phosphorus-33 (P-33)	Leukemia treatment, bone disease diagnosis/treatment, radiolabeling, and treatment of blocked arteries (i.e., arteriosclerosis and restenosis)
Radium-223 (Ra-223)	See Actinium-227 (Ac-227)
Rhenium-186 (Re-186)	Bone cancer pain relief, rheumatoid arthritis treatment, and diagnosis and treatment of lymphoma and bone, breast, colon, and liver cancers using radioimmunotherapy
Rhenium-188 (Re-188)	Cancer diagnosis and treatment using radioimmunotherapy, bone cancer pain relief, treatment of rheumatoid arthritis, and treatment of prostate cancer
Rhodium-105 (Rh-105)	Cancer radioimmunotherapy
Samarium-145	Ocular cancer treatment

(Sm-145)	
Samarium-153 (Sm-153)	Cancer radioimmunotherapy and bone cancer pain relief
Scandium-47 (Sc-47)	Cancer radioimmunotherapy and bone cancer pain relief
Selenium-75 (Se-75)	Radiotracer used in brain studies, imaging of adrenal cortex by gamma-scintigraphy, lateral locations of steroid secreting tumors, pancreatic scanning, detection of hyperactive parathyroid glands, measure rate of bile acid loss from the endogenous pool
Strontium-85 (Sr-85)	Bone cancer detection and brain scans
Strontium-89 (Sr-89)	Bone cancer pain relief, multiple myeloma treatment, and osteoblastic therapy
Technetium-99m (Tc-99m)	See Molybdenum-99 (Mo-99)
Thorium-228 (Th-228)	Parent of Bismuth-212 (Bi-212) which is an alpha emitter used in cancer radioimmunotherapy
Thorium-229 (Th-229)	Parent of Actinium-225 (Ac-225) and grandparent of Bismuth-213 (Bi-213) which are alpha emitters used in cancer radioimmunotherapy
Thulium-170 (Tm-170)	Gamma source for blood irradiators, energy source for implanted medical devices
Tin-117m (Sn-117m)	Cancer immunotherapy and bone cancer pain relief
Tungsten-188 (W-188)	Parent for Rhenium-188 (Re-188) which is used for cancer diagnostics/treatment, bone cancer pain relief, rheumatoid arthritis treatment, and treatment of blocked arteries (i.e., arteriosclerosis and restenosis)
Xenon-127 (Xe-127)	Neuroimaging of brain disorders, high resolution SPECT studies, pulmonary function tests, and cerebral blood flow studies
Ytterbium-175 (Yb-175)	Cancer radioimmunotherapy
Yttrium-90 (Y-90)	Microseeds obtained from irradiating Yttrium-89 (Y-89) for liver cancer treatment
Yttrium-91 (Y-91)	A gamma-emitting label for Yttrium-90 (Y-90) which is used for cancer radioimmunotherapy (i.e., lymphoma, breast, colon, kidney, lung, ovarian, prostate, pancreatic, and inoperable liver cancers)

By "randomized" or grammatical equivalents as herein applied to nucleic acids and proteins is meant that each nucleic acid and peptide consists of essentially random nucleotides and amino acids, respectively. These random peptides (or nucleic acids, discussed herein) can incorporate any nucleotide or amino acid at any position. The synthetic process can be designed to generate randomized proteins or nucleic acids, to allow the formation of all or most of the possible combinations over the length of the sequence, thus forming a library of randomized candidate bioactive proteinaceous agents.

In one embodiment, a library is "fully randomized," with no sequence preferences or constants at any position. In another embodiment, the library is a "biased random" library. That is, some positions within the sequence either are held constant, or are selected from a limited number of possibilities. For example, the nucleotides or amino acid residues are randomized within a defined class, e.g., of hydrophobic amino acids, hydrophilic residues, sterically biased (either small or large) residues, towards the creation of nucleic acid binding domains, the creation of cysteines, for cross-linking, prolines for SH-3 domains, serines, threonines, tyrosines or histidines for phosphorylation sites, etc., or to purines, etc.

A "recombinant" DNA or RNA molecule is a DNA or RNA molecule that has been subjected to molecular manipulation *in vitro*.

Non-limiting examples of small molecules include compounds that bind or interact with 254P1D6B, ligands including hormones, neuropeptides, chemokines, odorants, phospholipids, and functional equivalents thereof that bind and preferably inhibit 254P1D6B protein function. Such non-limiting small molecules preferably have a molecular weight of less than about 10 kDa, more preferably below about 9, about 8, about 7, about 6, about 5 or about 4 kDa. In certain embodiments, small molecules physically associate with, or bind, 254P1D6B protein; are not found in naturally occurring metabolic pathways; and/or are more soluble in aqueous than non-aqueous solutions

"Stringency" of hybridization reactions is readily determinable by one of ordinary skill in the art, and generally is an empirical calculation dependent upon probe length, washing temperature, and salt concentration. In general, longer probes require higher temperatures for proper annealing, while shorter probes need lower temperatures. Hybridization generally depends on the ability of denatured nucleic acid sequences to reanneal when complementary strands are present in an environment below their melting temperature. The higher the degree of desired homology between the probe and hybridizable sequence, the higher the relative temperature that can be used. As a result, it follows that higher relative temperatures would tend to make the reaction conditions more stringent, while lower temperatures less so. For additional details and explanation of stringency of hybridization reactions, see Ausubel *et al.*, Current Protocols in Molecular Biology, Wiley Interscience Publishers, (1995).

"Stringent conditions" or "high stringency conditions", as defined herein, are identified by, but not limited to, those that: (1) employ low ionic strength and high temperature for washing, for example 0.015 M sodium chloride/0.0015 M sodium citrate/0.1% sodium dodecyl sulfate at 50°C; (2) employ during hybridization a denaturing agent, such as formamide, for example, 50% (v/v) formamide with 0.1% bovine serum albumin/0.1% Ficoll/0.1% polyvinylpyrrolidone/50 mM sodium phosphate buffer at pH 6.5 with 750 mM sodium chloride, 75 mM sodium citrate at 42 °C; or (3) employ 50% formamide, 5 x SSC (0.75 M NaCl, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5 x Denhardt's solution, sonicated salmon sperm DNA (50 µg/ml), 0.1% SDS, and 10% dextran sulfate at 42 °C, with washes at 42°C in 0.2 x SSC (sodium chloride/sodium citrate) and 50% formamide at 55 °C, followed by a high-stringency wash consisting of 0.1 x SSC containing EDTA at 55 °C. "Moderately stringent conditions" are described by, but not limited to, those in Sambrook *et al.*, Molecular Cloning: A Laboratory Manual, New York: Cold Spring Harbor Press, 1989, and include the use of washing solution and hybridization conditions (e.g., temperature, ionic strength and %SDS) less stringent than those described above. An example of moderately stringent conditions is overnight incubation at 37°C in a solution comprising: 20% formamide, 5 x SSC (150 mM NaCl, 15 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5 x Denhardt's solution, 10% dextran sulfate, and 20 mg/mL denatured sheared salmon sperm DNA, followed by washing the filters in 1 x SSC at about 37-50°C. The skilled artisan will recognize how to adjust the temperature, ionic strength, etc. as necessary to accommodate factors such as probe length and the like.

An HLA "supermotif" is a peptide binding specificity shared by HLA molecules encoded by two or more HLA alleles. Overall phenotypic frequencies of HLA-supertypes in different ethnic populations are set forth in Table IV (F). The non-limiting constituents of various supertypes are as follows:

**A2:** A\*0201, A\*0202, A\*0203, A\*0204, A\*0205, A\*0206, A\*6802, A\*6901, A\*0207

**A3:** A3, A11, A31, A\*3301, A\*6801, A\*0301, A\*1101, A\*3101

**B7:** B7, B\*3501-03, B\*51, B\*5301, B\*5401, B\*5501, B\*5502, B\*5601, B\*6701, B\*7801, B\*0702, B\*5101, B\*5602

**B44:** B\*3701, B\*4402, B\*4403, B\*60 (B\*4001), B61 (B\*4006)

**A1:** A\*0102, A\*2604, A\*3601, A\*4301, A\*8001

**A24:** A\*24, A\*30, A\*2403, A\*2404, A\*3002, A\*3003

**B27:** B\*1401-02, B\*1503, B\*1509, B\*1510, B\*1518, B\*3801-02, B\*3901, B\*3902, B\*3903-04, B\*4801-02, B\*7301, B\*2701-08

**B58:** B\*1516, B\*1517, B\*5701, B\*5702, B58

**B62:** B\*4601, B52, B\*1501 (B62), B\*1502 (B75), B\*1513 (B77)

Calculated population coverage afforded by different HLA-supertype combinations are set forth in Table IV (G).

As used herein "to treat" or "therapeutic" and grammatically related terms, refer to any improvement of any consequence of disease, such as prolonged survival, less morbidity, and/or a lessening of side effects which are the byproducts of an alternative therapeutic modality; full eradication of disease is not required.

A "transgenic animal" (e.g., a mouse or rat) is an animal having cells that contain a transgene, which transgene was introduced into the animal or an ancestor of the animal at a prenatal, e.g., an embryonic stage. A "transgene" is a DNA that is integrated into the genome of a cell from which a transgenic animal develops.

As used herein, an HLA or cellular immune response "vaccine" is a composition that contains or encodes one or more peptides of the invention. There are numerous embodiments of such vaccines, such as a cocktail of one or more individual peptides; one or more peptides of the invention comprised by a polyepitopic peptide; or nucleic acids that encode such individual peptides or polypeptides, e.g., a minigene that encodes a polyepitopic peptide. The "one or more peptides" can include any whole unit integer from 1-150 or more, e.g., at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, or 150 or more peptides of the invention. The peptides or polypeptides can optionally be modified, such as by lipidation, addition of targeting or other sequences. HLA class I peptides of the invention can be admixed with, or linked to, HLA class II peptides, to facilitate activation of both cytotoxic T lymphocytes and helper T lymphocytes. HLA vaccines can also comprise peptide-pulsed antigen presenting cells, e.g., dendritic cells.

The term "variant" refers to a molecule that exhibits a variation from a described type or norm, such as a protein that has one or more different amino acid residues in the corresponding position(s) of a specifically described protein (e.g. the 254P1D6B protein shown in Figure 2 or Figure 3. An analog is an example of a variant protein. Splice isoforms and single nucleotide polymorphisms (SNPs) are further examples of variants.

The "254P1D6B-related proteins" of the invention include those specifically identified herein, as well as allelic variants, conservative substitution variants, analogs and homologs that can be isolated/generated and characterized without undue experimentation following the methods outlined herein or readily available in the art. Fusion proteins that combine parts of different 254P1D6B proteins or fragments thereof, as well as fusion proteins of a 254P1D6B protein and a heterologous polypeptide are also included. Such 254P1D6B proteins are collectively referred to as the 254P1D6B-related proteins, the proteins of the invention, or 254P1D6B. The term "254P1D6B-related protein" refers to a polypeptide fragment or a 254P1D6B protein sequence of 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, or more than 25 amino acids; or, at least 30, 35, 40, 45, 50, 55, 60, 65, 70, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 525, 550, 575, or 576 or more amino acids.

## **II.) 254P1D6B Polynucleotides**

One aspect of the invention provides polynucleotides corresponding or complementary to all or part of a 254P1D6B gene, mRNA, and/or coding sequence, preferably in isolated form, including polynucleotides encoding a 254P1D6B-related protein and fragments thereof, DNA, RNA, DNA/RNA hybrid, and related molecules, polynucleotides or oligonucleotides complementary to a 254P1D6B gene or mRNA sequence or a part thereof, and polynucleotides or

oligonucleotides that hybridize to a 254P1D6B gene, mRNA, or to a 254P1D6B encoding polynucleotide (collectively, "254P1D6B polynucleotides"). In all instances when referred to in this section, T can also be U in Figure 2.

Embodiments of a 254P1D6B polynucleotide include: a 254P1D6B polynucleotide having the sequence shown in Figure 2, the nucleotide sequence of 254P1D6B as shown in Figure 2 wherein T is U; at least 10 contiguous nucleotides of a polynucleotide having the sequence as shown in Figure 2; or, at least 10 contiguous nucleotides of a polynucleotide having the sequence as shown in Figure 2 where T is U. For example, embodiments of 254P1D6B nucleotides comprise, without limitation:

- (I) a polynucleotide comprising, consisting essentially of, or consisting of a sequence as shown in Figure 2, wherein T can also be U;
- (II) a polynucleotide comprising, consisting essentially of, or consisting of the sequence as shown in Figure 2A, from nucleotide residue number 512 through nucleotide residue number 3730, including the stop codon, wherein T can also be U;
- (III) a polynucleotide comprising, consisting essentially of, or consisting of the sequence as shown in Figure 2B, from nucleotide residue number 512 through nucleotide residue number 3730, including the stop codon, wherein T can also be U;
- (IV) a polynucleotide comprising, consisting essentially of, or consisting of the sequence as shown in Figure 2C, from nucleotide residue number 739 through nucleotide residue number 3930, including the a stop codon, wherein T can also be U;
- (V) a polynucleotide comprising, consisting essentially of, or consisting of the sequence as shown in Figure 2D, from nucleotide residue number 512 through nucleotide residue number 3730, including the stop codon, wherein T can also be U;
- (VI) a polynucleotide that encodes a 254P1D6B-related protein that is at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% homologous to an entire amino acid sequence shown in Figure 2A-D;
- (VII) a polynucleotide that encodes a 254P1D6B-related protein that is at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% identical to an entire amino acid sequence shown in Figure 2A-D;
- (VIII) a polynucleotide that encodes at least one peptide set forth in Tables VIII-XXI and XXII-XLIX;
- (IX) a polynucleotide that encodes a peptide region of at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a peptide of Figures 3A, 3B, 3D, and 3E in any whole number increment up to 1072 that includes at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) having a value greater than 0.5 in the Hydrophilicity profile of Figure 5;
- (X) a polynucleotide that encodes a peptide region of at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a peptide of Figure 3A, 3B, 3D, and 3E in any whole number increment up to 1072 that includes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) having a value less than 0.5 in the Hydropathicity profile of Figure 6;
- (XI) a polynucleotide that encodes a peptide region of at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a peptide of Figure 3A, 3B, 3D, and

3E in any whole number increment up to 1072 that includes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) having a value greater than 0.5 in the Percent Accessible Residues profile of Figure 7;

(XII) a polynucleotide that encodes a peptide region of at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a peptide of Figure 3A, 3B, 3D, and 3E in any whole number increment up to 1072 that includes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) having a value greater than 0.5 in the Average Flexibility profile of Figure 8;

(XIII) a polynucleotide that encodes a peptide region of at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a peptide of Figure 3A, 3B, 3D, and 3E in any whole number increment up to 1072 that includes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) having a value greater than 0.5 in the Beta-turn profile of Figure 9;

(XIV) a polynucleotide that encodes a peptide region of at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a peptide of Figure 3C in any whole number increment up to 1063 that includes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) having a value greater than 0.5 in the Hydrophilicity profile of Figure 5;

(XV) a polynucleotide that encodes a peptide region of at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a peptide of Figure 3C in any whole number increment up to 1063 that includes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) having a value less than 0.5 in the Hydropathicity profile of Figure 6;

(XVI) a polynucleotide that encodes a peptide region of at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a peptide of Figure 3C in any whole number increment up to 1063 that includes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) having a value greater than 0.5 in the Percent Accessible Residues profile of Figure 7;

(XVII) a polynucleotide that encodes a peptide region of at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a peptide of Figure 3C in any whole number increment up to 1063 that includes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) having a value greater than 0.5 in the Average Flexibility profile of Figure 8;

(XVIII) a polynucleotide that encodes a peptide region of at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a peptide of Figure 3C in any whole number increment up to 1063 that includes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) having a value greater than 0.5 in the Beta-turn profile of Figure 9;

(XIX) a polynucleotide that is fully complementary to a polynucleotide of any one of (I)-(XVIII);

- (XX) a polynucleotide that is fully complementary to a polynucleotide of any one of (I)-(XIX);
- (XXI) a peptide that is encoded by any of (I) to (XX); and;
- (XXII) a composition comprising a polynucleotide of any of (I)-(XX) or peptide of (XXI) together with a pharmaceutical excipient and/or in a human unit dose form;
- (XXIII) a method of using a polynucleotide of any (I)-(XX) or peptide of (XXI) or a composition of (XXII) in a method to modulate a cell expressing 254P1D6B;
- (XXIV) a method of using a polynucleotide of any (I)-(XX) or peptide of (XXI) or a composition of (XXII) in a method to diagnose, prophylax, prognose, or treat an individual who bears a cell expressing 254P1D6B;
- (XXV) a method of using a polynucleotide of any (I)-(XX) or peptide of (XXI) or a composition of (XXII) in a method to diagnose, prophylax, prognose, or treat an individual who bears a cell expressing 254P1D6B, said cell from a cancer of a tissue listed in Table I;
- (XXVI) a method of using a polynucleotide of any (I)-(XX) or peptide of (XXI) or a composition of (XXII) in a method to diagnose, prophylax, prognose, or treat a cancer;
- (XXVII) a method of using a polynucleotide of any (I)-(XX) or peptide of (XXI) or a composition of (XXII) in a method to diagnose, prophylax, prognose, or treat a cancer of a tissue listed in Table I; and;
- (XXVIII) a method of using a polynucleotide of any (I)-(XX) or peptide of (XXI) or a composition of (XXII) in a method to identify or characterize a modulator of a cell expressing 254P1D6B.

As used herein, a range is understood to disclose specifically all whole unit positions thereof.

Typical embodiments of the invention disclosed herein include 254P1D6B polynucleotides that encode specific portions of 254P1D6B mRNA sequences (and those which are complementary to such sequences) such as those that encode the proteins and/or fragments thereof, for example:

(a) 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 525, 550, 575, 600, 625, 650, 675, 700, 725, 750, 775, 800, 825, 850, 875, 900, 925, 950, 975, 1000, 1025, 1050, 1060, 1065, 1070, and 1072 or more contiguous amino acids of 254P1D6B variant 1; the maximal lengths relevant for other variants are: variant 2, 1072 amino acids; variant 3, 1063 amino acids; variant 5, 1072 amino acids; variant 6, 1072 amino acids, and variants 4, 7-20, 1072 amino acids.

For example, representative embodiments of the invention disclosed herein include: polynucleotides and their encoded peptides themselves encoding about amino acid 1 to about amino acid 10 of the 254P1D6B protein shown in Figure 2 or Figure 3, polynucleotides encoding about amino acid 10 to about amino acid 20 of the 254P1D6B protein shown in Figure 2 or Figure 3, polynucleotides encoding about amino acid 20 to about amino acid 30 of the 254P1D6B protein shown in Figure 2 or Figure 3, polynucleotides encoding about amino acid 30 to about amino acid 40 of the 254P1D6B protein shown in Figure 2 or Figure 3, polynucleotides encoding about amino acid 40 to about amino acid 50 of the 254P1D6B protein shown in Figure 2 or Figure 3, polynucleotides encoding about amino acid 50 to about amino acid 60 of the 254P1D6B protein shown in Figure 2 or Figure 3, polynucleotides encoding about amino acid 60 to about amino acid 70 of the 254P1D6B protein shown in Figure 2 or Figure 3, polynucleotides encoding about amino acid 70 to about amino acid 80 of the 254P1D6B protein shown in Figure 2 or Figure 3, polynucleotides encoding about amino acid 80 to about amino acid 90 of the 254P1D6B protein shown in Figure 2 or Figure 3, polynucleotides encoding about amino acid 90 to about amino acid 100 of the 254P1D6B protein shown in Figure 2 or Figure 3, in increments of about 10 amino acids, ending at the

carboxyl terminal amino acid set forth in Figure 2 or Figure 3. Accordingly, polynucleotides encoding portions of the amino acid sequence (of about 10 amino acids), of amino acids, 100 through the carboxyl terminal amino acid of the 254P1D6B protein are embodiments of the invention. Wherein it is understood that each particular amino acid position discloses that position plus or minus five amino acid residues.

Polynucleotides encoding relatively long portions of a 254P1D6B protein are also within the scope of the invention. For example, polynucleotides encoding from about amino acid 1 (or 20 or 30 or 40 etc.) to about amino acid 20, (or 30, or 40 or 50 etc.) of the 254P1D6B protein "or variant" shown in Figure 2 or Figure 3 can be generated by a variety of techniques well known in the art. These polynucleotide fragments can include any portion of the 254P1D6B sequence as shown in Figure 2.

Additional illustrative embodiments of the invention disclosed herein include 254P1D6B polynucleotide fragments encoding one or more of the biological motifs contained within a 254P1D6B protein "or variant" sequence, including one or more of the motif-bearing subsequences of a 254P1D6B protein "or variant" set forth in Tables VIII-XXI and XXII-XLIX. In another embodiment, typical polynucleotide fragments of the invention encode one or more of the regions of 254P1D6B protein or variant that exhibit homology to a known molecule. In another embodiment of the invention, typical polynucleotide fragments can encode one or more of the 254P1D6B protein or variant N-glycosylation sites, cAMP and cGMP-dependent protein kinase phosphorylation sites, casein kinase II phosphorylation sites or N-myristoylation site and amidation sites.

Note that to determine the starting position of any peptide set forth in Tables VIII-XXI and Tables XXII to XLIX (collectively HLA Peptide Tables) respective to its parental protein, e.g., variant 1, variant 2, etc., reference is made to three factors: the particular variant, the length of the peptide in an HLA Peptide Table, and the Search Peptides listed in Table VII. Generally, a unique Search Peptide is used to obtain HLA peptides for a particular variant. The position of each Search Peptide relative to its respective parent molecule is listed in Table VII. Accordingly, if a Search Peptide begins at position "X", one must add the value "X minus 1" to each position in Tables VIII-XXI and Tables XXII-IL to obtain the actual position of the HLA peptides in their parental molecule. For example if a particular Search Peptide begins at position 150 of its parental molecule, one must add 150 - 1, i.e., 149 to each HLA peptide amino acid position to calculate the position of that amino acid in the parent molecule.

## **II.A.) Uses of 254P1D6B Polynucleotides**

### **II.A.1.) Monitoring of Genetic Abnormalities**

The polynucleotides of the preceding paragraphs have a number of different specific uses. The human 254P1D6B gene maps to the chromosomal location set forth in the Example entitled "Chromosomal Mapping of 254P1D6B." For example, because the 254P1D6B gene maps to this chromosome, polynucleotides that encode different regions of the 254P1D6B proteins are used to characterize cytogenetic abnormalities of this chromosomal locale, such as abnormalities that are identified as being associated with various cancers. In certain genes, a variety of chromosomal abnormalities including rearrangements have been identified as frequent cytogenetic abnormalities in a number of different cancers (see e.g. Krajcinovic *et al.*, *Mutat. Res.* 382(3-4): 81-83 (1998); Johansson *et al.*, *Blood* 86(10): 3905-3914 (1995) and Finger *et al.*, *P.N.A.S.* 85(23): 9158-9162 (1988)). Thus, polynucleotides encoding specific regions of the 254P1D6B proteins provide new tools that can be used to delineate, with greater precision than previously possible, cytogenetic abnormalities in the chromosomal region that encodes 254P1D6B that may contribute to the malignant phenotype. In this context, these polynucleotides satisfy a need in the art for expanding the sensitivity of chromosomal screening in order to identify more subtle and less common chromosomal abnormalities (see e.g. Evans *et al.*, *Am. J. Obstet. Gynecol.* 171(4): 1055-1057 (1994)).

Furthermore, as 254P1D6B was shown to be highly expressed in prostate and other cancers, 254P1D6B polynucleotides are used in methods assessing the status of 254P1D6B gene products in normal versus cancerous tissues.

Typically, polynucleotides that encode specific regions of the 254P1D6B proteins are used to assess the presence of perturbations (such as deletions, insertions, point mutations, or alterations resulting in a loss of an antigen etc.) in specific regions of the 254P1D6B gene, such as regions containing one or more motifs. Exemplary assays include both RT-PCR assays as well as single-strand conformation polymorphism (SSCP) analysis (see, e.g., Marrogi *et al.*, *J. Cutan. Pathol.* 26(8): 369-378 (1999), both of which utilize polynucleotides encoding specific regions of a protein to examine these regions within the protein.

#### II.A.2.) Antisense Embodiments

Other specifically contemplated nucleic acid related embodiments of the invention disclosed herein are genomic DNA, cDNAs, ribozymes, and antisense molecules, as well as nucleic acid molecules based on an alternative backbone, or including alternative bases, whether derived from natural sources or synthesized, and include molecules capable of inhibiting the RNA or protein expression of 254P1D6B. For example, antisense molecules can be RNAs or other molecules, including peptide nucleic acids (PNAs) or non-nucleic acid molecules such as phosphorothioate derivatives that specifically bind DNA or RNA in a base pair-dependent manner. A skilled artisan can readily obtain these classes of nucleic acid molecules using the 254P1D6B polynucleotides and polynucleotide sequences disclosed herein.

Antisense technology entails the administration of exogenous oligonucleotides that bind to a target polynucleotide located within the cells. The term "antisense" refers to the fact that such oligonucleotides are complementary to their intracellular targets, e.g., 254P1D6B. See for example, Jack Cohen, *Oligodeoxynucleotides, Antisense Inhibitors of Gene Expression*, CRC Press, 1989; and *Synthesis* 1:1-5 (1988). The 254P1D6B antisense oligonucleotides of the present invention include derivatives such as S-oligonucleotides (phosphorothioate derivatives or S-oligos, see, Jack Cohen, *supra*), which exhibit enhanced cancer cell growth inhibitory action. S-oligos (nucleoside phosphorothioates) are isoelectronic analogs of an oligonucleotide (O-oligo) in which a nonbridging oxygen atom of the phosphate group is replaced by a sulfur atom. The S-oligos of the present invention can be prepared by treatment of the corresponding O-oligos with 3H-1,2-benzodithiol-3-one-1,1-dioxide, which is a sulfur transfer reagent. See, e.g., Iyer, R. P. *et al.*, *J. Org. Chem.* 55:4693-4698 (1990); and Iyer, R. P. *et al.*, *J. Am. Chem. Soc.* 112:1253-1254 (1990). Additional 254P1D6B antisense oligonucleotides of the present invention include morpholino antisense oligonucleotides known in the art (see, e.g., Partridge *et al.*, 1996, *Antisense & Nucleic Acid Drug Development* 6: 169-175).

The 254P1D6B antisense oligonucleotides of the present invention typically can be RNA or DNA that is complementary to and stably hybridizes with the first 100 5' codons or last 100 3' codons of a 254P1D6B genomic sequence or the corresponding mRNA. Absolute complementarity is not required, although high degrees of complementarity are preferred. Use of an oligonucleotide complementary to this region allows for the selective hybridization to 254P1D6B mRNA and not to mRNA specifying other regulatory subunits of protein kinase. In one embodiment, 254P1D6B antisense oligonucleotides of the present invention are 15 to 30-mer fragments of the antisense DNA molecule that have a sequence that hybridizes to 254P1D6B mRNA. Optionally, 254P1D6B antisense oligonucleotide is a 30-mer oligonucleotide that is complementary to a region in the first 10 5' codons or last 10 3' codons of 254P1D6B. Alternatively, the antisense molecules are modified to employ ribozymes in the inhibition of 254P1D6B expression, see, e.g., L. A. Couture & D. T. Stinchcomb; *Trends Genet* 12: 510-515 (1996).

#### II.A.3.) Primers and Primer Pairs

Further specific embodiments of these nucleotides of the invention include primers and primer pairs, which allow the specific amplification of polynucleotides of the invention or of any specific parts thereof, and probes that selectively or specifically hybridize to nucleic acid molecules of the invention or to any part thereof. Probes can be labeled with a detectable marker, such as, for example, a radioisotope, fluorescent compound, bioluminescent compound, a

chemiluminescent compound, metal chelator or enzyme. Such probes and primers are used to detect the presence of a 254P1D6B polynucleotide in a sample and as a means for detecting a cell expressing a 254P1D6B protein.

Examples of such probes include polypeptides comprising all or part of the human 254P1D6B cDNA sequence shown in Figure 2. Examples of primer pairs capable of specifically amplifying 254P1D6B mRNAs are also described in the Examples. As will be understood by the skilled artisan, a great many different primers and probes can be prepared based on the sequences provided herein and used effectively to amplify and/or detect a 254P1D6B mRNA.

The 254P1D6B polynucleotides of the invention are useful for a variety of purposes, including but not limited to their use as probes and primers for the amplification and/or detection of the 254P1D6B gene(s), mRNA(s), or fragments thereof; as reagents for the diagnosis and/or prognosis of prostate cancer and other cancers; as coding sequences capable of directing the expression of 254P1D6B polypeptides; as tools for modulating or inhibiting the expression of the 254P1D6B gene(s) and/or translation of the 254P1D6B transcript(s); and as therapeutic agents.

The present invention includes the use of any probe as described herein to identify and isolate a 254P1D6B or 254P1D6B related nucleic acid sequence from a naturally occurring source, such as humans or other mammals, as well as the isolated nucleic acid sequence *per se*, which would comprise all or most of the sequences found in the probe used.

#### **II.A.4.) Isolation of 254P1D6B-Encoding Nucleic Acid Molecules**

The 254P1D6B cDNA sequences described herein enable the isolation of other polynucleotides encoding 254P1D6B gene product(s), as well as the isolation of polynucleotides encoding 254P1D6B gene product homologs, alternatively spliced isoforms, allelic variants, and mutant forms of a 254P1D6B gene product as well as polynucleotides that encode analogs of 254P1D6B-related proteins. Various molecular cloning methods that can be employed to isolate full length cDNAs encoding a 254P1D6B gene are well known (see, for example, Sambrook, J. *et al.*, Molecular Cloning: A Laboratory Manual, 2d edition, Cold Spring Harbor Press, New York, 1989; Current Protocols in Molecular Biology. Ausubel *et al.*, Eds., Wiley and Sons, 1995). For example, lambda phage cloning methodologies can be conveniently employed, using commercially available cloning systems (e.g., Lambda ZAP Express, Stratagene). Phage clones containing 254P1D6B gene cDNAs can be identified by probing with a labeled 254P1D6B cDNA or a fragment thereof. For example, in one embodiment, a 254P1D6B cDNA (e.g., Figure 2) or a portion thereof can be synthesized and used as a probe to retrieve overlapping and full-length cDNAs corresponding to a 254P1D6B gene. A 254P1D6B gene itself can be isolated by screening genomic DNA libraries, bacterial artificial chromosome libraries (BACs), yeast artificial chromosome libraries (YACs), and the like, with 254P1D6B DNA probes or primers.

#### **II.A.5.) Recombinant Nucleic Acid Molecules and Host-Vector Systems**

The invention also provides recombinant DNA or RNA molecules containing a 254P1D6B polynucleotide, a fragment, analog or homologue thereof; including but not limited to phages; plasmids, phagemids, cosmids, YACs, BACs, as well as various viral and non-viral vectors well known in the art, and cells transformed or transfected with such recombinant DNA or RNA molecules. Methods for generating such molecules are well known (see, for example, Sambrook *et al.*, 1989, *supra*).

The invention further provides a host-vector system comprising a recombinant DNA molecule containing a 254P1D6B polynucleotide, fragment, analog or homologue thereof within a suitable prokaryotic or eukaryotic host cell. Examples of suitable eukaryotic host cells include a yeast cell, a plant cell, or an animal cell, such as a mammalian cell or an insect cell (e.g., a baculovirus-infectible cell such as an Sf9 or HighFive cell). Examples of suitable mammalian cells include various prostate cancer cell lines such as DU145 and TsuPr1, other transfectable or transducible prostate cancer cell lines, primary cells (PrEC), as well as a number of mammalian cells routinely used for the expression of recombinant proteins (e.g., COS, CHO, 293, 293T cells). More particularly, a polynucleotide comprising the coding sequence of 254P1D6B or a fragment, analog or homolog thereof can be used to generate 254P1D6B proteins or fragments thereof using any number of host-vector systems routinely used and widely known in the art.

A wide range of host-vector systems suitable for the expression of 254P1D6B proteins or fragments thereof are available, see for example, Sambrook *et al.*, 1989, *supra*; Current Protocols in Molecular Biology, 1995, *supra*). Preferred vectors for mammalian expression include but are not limited to pcDNA 3.1 myc-His-tag (Invitrogen) and the retroviral vector pSR $\alpha$ tkneo (Muller *et al.*, 1991, MCB 11:1785). Using these expression vectors, 254P1D6B can be expressed in several prostate cancer and non-prostate cell lines, including for example 293, 293T, rat-1, NIH 3T3 and TsuPr1. The host-vector systems of the invention are useful for the production of a 254P1D6B protein or fragment thereof. Such host-vector systems can be employed to study the functional properties of 254P1D6B and 254P1D6B mutations or analogs.

Recombinant human 254P1D6B protein or an analog or homolog or fragment thereof can be produced by mammalian cells transfected with a construct encoding a 254P1D6B-related nucleotide. For example, 293T cells can be transfected with an expression plasmid encoding 254P1D6B or fragment, analog or homolog thereof, a 254P1D6B-related protein is expressed in the 293T cells, and the recombinant 254P1D6B protein is isolated using standard purification methods (e.g., affinity purification using anti-254P1D6B antibodies). In another embodiment, a 254P1D6B coding sequence is subcloned into the retroviral vector pSR $\alpha$ MSVtkneo and used to infect various mammalian cell lines, such as NIH 3T3, TsuPr1, 293 and rat-1 in order to establish 254P1D6B expressing cell lines. Various other expression systems well known in the art can also be employed. Expression constructs encoding a leader peptide joined in frame to a 254P1D6B coding sequence can be used for the generation of a secreted form of recombinant 254P1D6B protein.

As discussed herein, redundancy in the genetic code permits variation in 254P1D6B gene sequences. In particular, it is known in the art that specific host species often have specific codon preferences, and thus one can adapt the disclosed sequence as preferred for a desired host. For example, preferred analog codon sequences typically have rare codons (i.e., codons having a usage frequency of less than about 20% in known sequences of the desired host) replaced with higher frequency codons. Codon preferences for a specific species are calculated, for example, by utilizing codon usage tables available on the INTERNET such as at URL [dna.affrc.go.jp/~nakamura/codon.html](http://dna.affrc.go.jp/~nakamura/codon.html).

Additional sequence modifications are known to enhance protein expression in a cellular host. These include elimination of sequences encoding spurious polyadenylation signals, exon/intron splice site signals, transposon-like repeats, and/or other such well-characterized sequences that are deleterious to gene expression. The GC content of the sequence is adjusted to levels average for a given cellular host, as calculated by reference to known genes expressed in the host cell. Where possible, the sequence is modified to avoid predicted hairpin secondary mRNA structures. Other useful modifications include the addition of a translational initiation consensus sequence at the start of the open reading frame, as described in Kozak, *Mol. Cell Biol.*, 9:5073-5080 (1989). Skilled artisans understand that the general rule that eukaryotic ribosomes initiate translation exclusively at the 5' proximal AUG codon is abrogated only under rare conditions (see, e.g., Kozak PNAS 92(7): 2662-2666, (1995) and Kozak NAR 15(20): 8125-8148 (1987)).

### **III.) 254P1D6B-related Proteins**

Another aspect of the present invention provides 254P1D6B-related proteins. Specific embodiments of 254P1D6B proteins comprise a polypeptide having all or part of the amino acid sequence of human 254P1D6B as shown in Figure 2 or Figure 3. Alternatively, embodiments of 254P1D6B proteins comprise variant, homolog or analog polypeptides that have alterations in the amino acid sequence of 254P1D6B shown in Figure 2 or Figure 3.

Embodiments of a 254P1D6B polypeptide include: a 254P1D6B polypeptide having a sequence shown in Figure 2, a peptide sequence of a 254P1D6B as shown in Figure 2 wherein T is U; at least 10 contiguous nucleotides of a polypeptide having the sequence as shown in Figure 2; or, at least 10 contiguous peptides of a polypeptide having the sequence as shown in Figure 2 where T is U. For example, embodiments of 254P1D6B peptides comprise, without limitation:

- (I) a protein comprising, consisting essentially of, or consisting of an amino acid sequence as shown in Figure 2A-D or Figure 3A-E;
- (II) a 254P1D6B-related protein that is at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% homologous to an entire amino acid sequence shown in Figure 2A-D or 3A-E;
- (III) a 254P1D6B-related protein that is at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% identical to an entire amino acid sequence shown in Figure 2A-D or 3A-E;
- (IV) a protein that comprises at least one peptide set forth in Tables VIII to XLIX, optionally with a *proviso* that it is not an entire protein of Figure 2;
- (V) a protein that comprises at least one peptide set forth in Tables VIII-XXI, collectively, which peptide is also set forth in Tables XXII to XLIX, collectively, optionally with a *proviso* that it is not an entire protein of Figure 2;
- (VI) a protein that comprises at least two peptides selected from the peptides set forth in Tables VIII-XLIX, optionally with a *proviso* that it is not an entire protein of Figure 2;
- (VII) a protein that comprises at least two peptides selected from the peptides set forth in Tables VIII to XLIX collectively, with a *proviso* that the protein is not a contiguous sequence from an amino acid sequence of Figure 2;
- (VIII) a protein that comprises at least one peptide selected from the peptides set forth in Tables VIII-XXI; and at least one peptide selected from the peptides set forth in Tables XXII to XLIX, with a *proviso* that the protein is not a contiguous sequence from an amino acid sequence of Figure 2;
- (IX) a polypeptide comprising at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a protein of Figure 3A, 3B, 3D, and 3E in any whole number increment up to 1072 respectively that includes at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) having a value greater than 0.5 in the Hydrophilicity profile of Figure 5;
- (X) a polypeptide comprising at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a protein of Figure 3A, 3B, 3D, and 3E, in any whole number increment up to 1072 respectively that includes at least at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) having a value less than 0.5 in the Hydropathicity profile of Figure 6;
- (XI) a polypeptide comprising at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a protein of Figure 3A, 3B, 3D, and 3E, in any whole number increment up to 1072 respectively that includes at least at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) having a value greater than 0.5 in the Percent Accessible Residues profile of Figure 7;
- (XII) a polypeptide comprising at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a protein of Figure 3A, 3B, 3D, and 3E, in any whole number increment up to 1072 respectively that includes at least at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) having a value greater than 0.5 in the Average Flexibility profile of Figure 8;

- (XIII) a polypeptide comprising at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, amino acids of a protein of Figure 3A, 3B, 3D, and 3E in any whole number increment up to 1072 respectively that includes at least at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) having a value greater than 0.5 in the Beta-turn profile of Figure 9;
- (XIV) a polypeptide comprising at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a protein of Figure 3C, in any whole number increment up to 1063 respectively that includes at least at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) having a value greater than 0.5 in the Hydrophilicity profile of Figure 5;
- (XV) a polypeptide comprising at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a protein of Figure 3C, in any whole number increment up to 1063 respectively that includes at least at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) having a value less than 0.5 in the Hydropathicity profile of Figure 6;
- (XVI) a polypeptide comprising at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a protein of Figure 3C, in any whole number increment up to 1063 respectively that includes at least at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) having a value greater than 0.5 in the Percent Accessible Residues profile of Figure 7;
- (XVII) a polypeptide comprising at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a protein of Figure 3C, in any whole number increment up to 1063 respectively that includes at least at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) having a value greater than 0.5 in the Average Flexibility profile of Figure 8;
- (XVIII) a polypeptide comprising at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, amino acids of a protein of Figure 3C in any whole number increment up to 1063 respectively that includes at least at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) having a value greater than 0.5 in the Beta-turn profile of Figure 9;
- (XIX) a peptide that occurs at least twice in Tables VIII-XXI and XXII to XLIX, collectively;
- (XX) a peptide that occurs at least three times in Tables VIII-XXI and XXII to XLIX, collectively;
- (XXI) a peptide that occurs at least four times in Tables VIII-XXI and XXII to XLIX, collectively;
- (XXII) a peptide that occurs at least five times in Tables VIII-XXI and XXII to XLIX, collectively;
- (XXIII) a peptide that occurs at least once in Tables VIII-XXI, and at least once in tables XXII to XLIX;
- (XXIV) a peptide that occurs at least once in Tables VIII-XXI, and at least twice in tables XXII to XLIX;
- (XXV) a peptide that occurs at least twice in Tables VIII-XXI, and at least once in tables XXII to XLIX;
- (XXVI) a peptide that occurs at least twice in Tables VIII-XXI, and at least twice in tables XXII to XLIX;

(XXVII) a peptide which comprises one two, three, four, or five of the following characteristics, or an oligonucleotide encoding such peptide:

- i) a region of at least 5 amino acids of a particular peptide of Figure 3, in any whole number increment up to the full length of that protein in Figure 3, that includes an amino acid position having a value equal to or greater than 0.5, 0.6, 0.7, 0.8, 0.9, or having a value equal to 1.0, in the Hydrophilicity profile of Figure 5;
- ii) a region of at least 5 amino acids of a particular peptide of Figure 3, in any whole number increment up to the full length of that protein in Figure 3, that includes an amino acid position having a value equal to or less than 0.5, 0.4, 0.3, 0.2, 0.1, or having a value equal to 0.0, in the Hydropathicity profile of Figure 6;
- iii) a region of at least 5 amino acids of a particular peptide of Figure 3, in any whole number increment up to the full length of that protein in Figure 3, that includes an amino acid position having a value equal to or greater than 0.5, 0.6, 0.7, 0.8, 0.9, or having a value equal to 1.0, in the Percent Accessible Residues profile of Figure 7;
- iv) a region of at least 5 amino acids of a particular peptide of Figure 3, in any whole number increment up to the full length of that protein in Figure 3, that includes an amino acid position having a value equal to or greater than 0.5, 0.6, 0.7, 0.8, 0.9, or having a value equal to 1.0, in the Average Flexibility profile of Figure 8; or,
- v) a region of at least 5 amino acids of a particular peptide of Figure 3, in any whole number increment up to the full length of that protein in Figure 3, that includes an amino acid position having a value equal to or greater than 0.5, 0.6, 0.7, 0.8, 0.9, or having a value equal to 1.0, in the Beta-turn profile of Figure 9;

(XXVIII) a composition comprising a peptide of (I)-(XXVII) or an antibody or binding region thereof together with a pharmaceutical excipient and/or in a human unit dose form.

(XXIX) a method of using a peptide of (I)-(XXVII), or an antibody or binding region thereof or a composition of (XXVIII) in a method to modulate a cell expressing 254P1D6B;

(XXX) a method of using a peptide of (I)-(XXVII) or an antibody or binding region thereof or a composition of (XXVIII) in a method to diagnose, prophylax, prognose, or treat an individual who bears a cell expressing 254P1D6B;

(XXXI) a method of using a peptide of (I)-(XXVII) or an antibody or binding region thereof or a composition of (XXVIII) in a method to diagnose, prophylax, prognose, or treat an individual who bears a cell expressing 254P1D6B, said cell from a cancer of a tissue listed in Table I;

(XXXII) a method of using a peptide of (I)-(XXVII) or an antibody or binding region thereof or a composition of (XXVIII) in a method to diagnose, prophylax, prognose, or treat a cancer;

(XXXIII) a method of using a peptide of (I)-(XXVII) or an antibody or binding region thereof or a composition of (XXVIII) in a method to diagnose, prophylax, prognose, or treat a cancer of a tissue listed in Table I; and;

(XXXIV) a method of using a peptide of (I)-(XXVII) or an antibody or binding region thereof or a composition of (XXVIII) in a method to identify or characterize a modulator of a cell expressing 254P1D6B

As used herein, a range is understood to specifically disclose all whole unit positions thereof.

Typical embodiments of the invention disclosed herein include 254P1D6B polynucleotides that encode specific portions of 254P1D6B mRNA sequences (and those which are complementary to such sequences) such as those that encode the proteins and/or fragments thereof, for example:

(a) 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 525, 550, 575, 600, 625, 650, 675, 700, 725, 750, 775, 800, 825, 850, 875, 900, 925, 950, 975, 1000, 1025, 1050, 1060, 1070 and 1072 or more contiguous amino acids of 254P1D6B variant 1; the maximal lengths relevant for other variants are: variant 2, 1072 amino acids; variant 3, 1063 amino acids, variant 5, 1072 amino acids, variant 6, 1072 amino acids, and variants 4, 7-20, 1072 amino acids. .

In general, naturally occurring allelic variants of human 254P1D6B share a high degree of structural identity and homology (e.g., 90% or more homology). Typically, allelic variants of a 254P1D6B protein contain conservative amino acid substitutions within the 254P1D6B sequences described herein or contain a substitution of an amino acid from a corresponding position in a homologue of 254P1D6B. One class of 254P1D6B allelic variants are proteins that share a high degree of homology with at least a small region of a particular 254P1D6B amino acid sequence, but further contain a radical departure from the sequence, such as a non-conservative substitution, truncation, insertion or frame shift. In comparisons of protein sequences, the terms, similarity, identity, and homology each have a distinct meaning as appreciated in the field of genetics. Moreover, orthology and paralogy can be important concepts describing the relationship of members of a given protein family in one organism to the members of the same family in other organisms.

Amino acid abbreviations are provided in Table II. Conservative amino acid substitutions can frequently be made in a protein without altering either the conformation or the function of the protein. Proteins of the invention can comprise 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 conservative substitutions. Such changes include substituting any of isoleucine (I), valine (V), and leucine (L) for any other of these hydrophobic amino acids; aspartic acid (D) for glutamic acid (E) and vice versa; glutamine (Q) for asparagine (N) and vice versa; and serine (S) for threonine (T) and vice versa. Other substitutions can also be considered conservative, depending on the environment of the particular amino acid and its role in the three-dimensional structure of the protein. For example, glycine (G) and alanine (A) can frequently be interchangeable, as can alanine (A) and valine (V). Methionine (M), which is relatively hydrophobic, can frequently be interchanged with leucine and isoleucine, and sometimes with valine. Lysine (K) and arginine (R) are frequently interchangeable in locations in which the significant feature of the amino acid residue is its charge and the differing pK's of these two amino acid residues are not significant. Still other changes can be considered "conservative" in particular environments (see, e.g. Table III herein; pages 13-15 "Biochemistry" 2<sup>nd</sup> ED. Lubert Stryer ed (Stanford University); Henikoff *et al.*, PNAS 1992 Vol 89 10915-10919; Lei *et al.*, J Biol Chem 1995 May 19; 270(20):11882-6).

Embodiments of the invention disclosed herein include a wide variety of art-accepted variants or analogs of 254P1D6B proteins such as polypeptides having amino acid insertions, deletions and substitutions. 254P1D6B variants can be made using methods known in the art such as site-directed mutagenesis, alanine scanning, and PCR mutagenesis. Site-directed mutagenesis (Carter *et al.*, *Nucl. Acids Res.*, 13:4331 (1986); Zoller *et al.*, *Nucl. Acids Res.*, 10:6487 (1987)), cassette mutagenesis (Wells *et al.*, *Gene*, 34:315 (1985)), restriction selection mutagenesis (Wells *et al.*, *Philos. Trans. R. Soc. London SerA*, 317:415 (1986)) or other known techniques can be performed on the cloned DNA to produce the 254P1D6B variant DNA.

Scanning amino acid analysis can also be employed to identify one or more amino acids along a contiguous sequence that is involved in a specific biological activity such as a protein-protein interaction. Among the preferred scanning amino acids are relatively small, neutral amino acids. Such amino acids include alanine, glycine, serine, and cysteine. Alanine is typically a preferred scanning amino acid among this group because it eliminates the side-chain beyond the beta-carbon and is less likely to alter the main-chain conformation of the variant. Alanine is also typically preferred because it is the most common amino acid. Further, it is frequently found in both buried and exposed positions (Creighton, *The Proteins*,

(W.H. Freeman & Co., N.Y.); Chothia, J. Mol. Biol., 150:1 (1976)). If alanine substitution does not yield adequate amounts of variant, an isosteric amino acid can be used.

As defined herein, 254P1D6B variants, analogs or homologs, have the distinguishing attribute of having at least one epitope that is "cross reactive" with a 254P1D6B protein having an amino acid sequence of Figure 3. As used in this sentence, "cross reactive" means that an antibody or T cell that specifically binds to a 254P1D6B variant also specifically binds to a 254P1D6B protein having an amino acid sequence set forth in Figure 3. A polypeptide ceases to be a variant of a protein shown in Figure 3, when it no longer contains any epitope capable of being recognized by an antibody or T cell that specifically binds to the starting 254P1D6B protein. Those skilled in the art understand that antibodies that recognize proteins bind to epitopes of varying size, and a grouping of the order of about four or five amino acids, contiguous or not, is regarded as a typical number of amino acids in a minimal epitope. See, e.g., Nair *et al.*, J. Immunol 2000 165(12): 6949-6955; Hebbes *et al.*, Mol Immunol (1989) 26(9):865-73; Schwartz *et al.*, J Immunol (1985) 135(4):2598-608.

Other classes of 254P1D6B-related protein variants share 70%, 75%, 80%, 85% or 90% or more similarity with an amino acid sequence of Figure 3, or a fragment thereof. Another specific class of 254P1D6B protein variants or analogs comprises one or more of the 254P1D6B biological motifs described herein or presently known in the art. Thus, encompassed by the present invention are analogs of 254P1D6B fragments (nucleic or amino acid) that have altered functional (e.g. immunogenic) properties relative to the starting fragment. It is to be appreciated that motifs now or which become part of the art are to be applied to the nucleic or amino acid sequences of Figure 2 or Figure 3.

As discussed herein, embodiments of the claimed invention include polypeptides containing less than the full amino acid sequence of a 254P1D6B protein shown in Figure 2 or Figure 3. For example, representative embodiments of the invention comprise peptides/proteins having any 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or more contiguous amino acids of a 254P1D6B protein shown in Figure 2 or Figure 3.

Moreover, representative embodiments of the invention disclosed herein include polypeptides consisting of about amino acid 1 to about amino acid 10 of a 254P1D6B protein shown in Figure 2 or Figure 3, polypeptides consisting of about amino acid 10 to about amino acid 20 of a 254P1D6B protein shown in Figure 2 or Figure 3, polypeptides consisting of about amino acid 20 to about amino acid 30 of a 254P1D6B protein shown in Figure 2 or Figure 3, polypeptides consisting of about amino acid 30 to about amino acid 40 of a 254P1D6B protein shown in Figure 2 or Figure 3, polypeptides consisting of about amino acid 40 to about amino acid 50 of a 254P1D6B protein shown in Figure 2 or Figure 3, polypeptides consisting of about amino acid 50 to about amino acid 60 of a 254P1D6B protein shown in Figure 2 or Figure 3, polypeptides consisting of about amino acid 60 to about amino acid 70 of a 254P1D6B protein shown in Figure 2 or Figure 3, polypeptides consisting of about amino acid 70 to about amino acid 80 of a 254P1D6B protein shown in Figure 2 or Figure 3, polypeptides consisting of about amino acid 80 to about amino acid 90 of a 254P1D6B protein shown in Figure 2 or Figure 3, polypeptides consisting of about amino acid 90 to about amino acid 100 of a 254P1D6B protein shown in Figure 2 or Figure 3, etc. throughout the entirety of a 254P1D6B amino acid sequence. Moreover, polypeptides consisting of about amino acid 1 (or 20 or 30 or 40 etc.) to about amino acid 20, (or 130, or 140 or 150 etc.) of a 254P1D6B protein shown in Figure 2 or Figure 3 are embodiments of the invention. It is to be appreciated that the starting and stopping positions in this paragraph refer to the specified position as well as that position plus or minus 5 residues.

254P1D6B-related proteins are generated using standard peptide synthesis technology or using chemical cleavage methods well known in the art. Alternatively, recombinant methods can be used to generate nucleic acid molecules that encode a 254P1D6B-related protein. In one embodiment, nucleic acid molecules provide a means to generate defined fragments of a 254P1D6B protein (or variants, homologs or analogs thereof).

### **III.A.) Motif-bearing Protein Embodiments**

Additional illustrative embodiments of the invention disclosed herein include 254P1D6B polypeptides comprising the amino acid residues of one or more of the biological motifs contained within a 254P1D6B polypeptide sequence set forth in Figure 2 or Figure 3. Various motifs are known in the art, and a protein can be evaluated for the presence of such motifs by a number of publicly available Internet sites (see, e.g., URL addresses: pfam.wustl.edu/; searchlauncher.bcm.tmc.edu/seq-search/struc-predict.html; psort.ims.u-tokyo.ac.jp/; cbs.dtu.dk/; ebi.ac.uk/interpro/scan.html; expasy.ch/tools/scnpsit1.html; Epimatrix™ and Epimer™, Brown University, brown.edu/Research/TB-HIV\_Lab/epimatrix/epimatrix.html; and BIMAS, bimas.dcrf.nih.gov/).

Motif bearing subsequences of all 254P1D6B variant proteins are set forth and identified in Tables VIII-XXI and XXII-XLIX.

Table V sets forth several frequently occurring motifs based on pfam searches (see URL address pfam.wustl.edu/). The columns of Table V list (1) motif name abbreviation, (2) percent identity found amongst the different member of the motif family, (3) motif name or description and (4) most common function; location information is included if the motif is relevant for location.

Polypeptides comprising one or more of the 254P1D6B motifs discussed above are useful in elucidating the specific characteristics of a malignant phenotype in view of the observation that the 254P1D6B motifs discussed above are associated with growth dysregulation and because 254P1D6B is overexpressed in certain cancers (See, e.g., Table I). Casein kinase II, cAMP and camp-dependent protein kinase, and Protein Kinase C, for example, are enzymes known to be associated with the development of the malignant phenotype (see e.g. Chen *et al.*, Lab Invest., 78(2): 165-174 (1998); Gaiddon *et al.*, Endocrinology 136(10): 4331-4338 (1995); Hall *et al.*, Nucleic Acids Research 24(6): 1119-1126 (1996); Peterziel *et al.*, Oncogene 18(46): 6322-6329 (1999) and O'Brian, Oncol. Rep. 5(2): 305-309 (1998)). Moreover, both glycosylation and myristoylation are protein modifications also associated with cancer and cancer progression (see e.g. Dennis *et al.*, Biochem. Biophys. Acta 1473(1):21-34 (1999); Raju *et al.*, Exp. Cell Res. 235(1): 145-154 (1997)). Amidation is another protein modification also associated with cancer and cancer progression (see e.g. Treston *et al.*, J. Natl. Cancer Inst. Monogr. (13): 169-175 (1992)).

In another embodiment, proteins of the invention comprise one or more of the immunoreactive epitopes identified in accordance with art-accepted methods, such as the peptides set forth in Tables VIII-XXI and XXII-XLIX. CTL epitopes can be determined using specific algorithms to identify peptides within a 254P1D6B protein that are capable of optimally binding to specified HLA alleles (e.g., Table IV; Epimatrix™ and Epimer™, Brown University, URL brown.edu/Research/TB-HIV\_Lab/epimatrix/epimatrix.html; and BIMAS, URL bimas.dcrf.nih.gov/.) Moreover, processes for identifying peptides that have sufficient binding affinity for HLA molecules and which are correlated with being immunogenic epitopes, are well known in the art, and are carried out without undue experimentation. In addition, processes for identifying peptides that are immunogenic epitopes, are well known in the art, and are carried out without undue experimentation either *in vitro* or *in vivo*.

Also known in the art are principles for creating analogs of such epitopes in order to modulate immunogenicity. For example, one begins with an epitope that bears a CTL or HTL motif (see, e.g., the HLA Class I and HLA Class II motifs/supermotifs of Table IV). The epitope is analoged by substituting out an amino acid at one of the specified positions, and replacing it with another amino acid specified for that position. For example, on the basis of residues defined in Table IV, one can substitute out a deleterious residue in favor of any other residue, such as a preferred residue; substitute a less-preferred residue with a preferred residue; or substitute an originally-occurring preferred residue with another preferred residue. Substitutions can occur at primary anchor positions or at other positions in a peptide; see, e.g., Table IV.

A variety of references reflect the art regarding the identification and generation of epitopes in a protein of interest as well as analogs thereof. See, for example, WO 97/33602 to Chesnut *et al.*; Sette, Immunogenetics 1999 50(3-4): 201-212; Sette *et al.*, J. Immunol. 2001 166(2): 1389-1397; Sidney *et al.*, Hum. Immunol. 1997 58(1): 12-20; Kondo *et al.*,

Immunogenetics 1997 45(4): 249-258; Sidney *et al.*, J. Immunol. 1996 157(8): 3480-90; and Falk *et al.*, Nature 351: 290-6 (1991); Hunt *et al.*, Science 255:1261-3 (1992); Parker *et al.*, J. Immunol. 149:3580-7 (1992); Parker *et al.*, J. Immunol. 152:163-75 (1994); Kast *et al.*, 1994 152(8): 3904-12; Borrás-Cuesta *et al.*, Hum. Immunol. 2000 61(3): 266-278; Alexander *et al.*, J. Immunol. 2000 164(3): 1625-1633; Alexander *et al.*, PMID: 7895164, UI: 95202582; O'Sullivan *et al.*, J. Immunol. 1991 147(8): 2663-2669; Alexander *et al.*, Immunity 1994 1(9): 751-761 and Alexander *et al.*, Immunol. Res. 1998 18(2): 79-92.

Related embodiments of the invention include polypeptides comprising combinations of the different motifs set forth in Table VI, and/or, one or more of the predicted CTL epitopes of Tables VIII-XXI and XXII-XLIX, and/or, one or more of the predicted HTL epitopes of Tables XLVI-XLIX, and/or, one or more of the T cell binding motifs known in the art. Preferred embodiments contain no insertions, deletions or substitutions either within the motifs or within the intervening sequences of the polypeptides. In addition, embodiments which include a number of either N-terminal and/or C-terminal amino acid residues on either side of these motifs may be desirable (to, for example, include a greater portion of the polypeptide architecture in which the motif is located). Typically, the number of N-terminal and/or C-terminal amino acid residues on either side of a motif is between about 1 to about 100 amino acid residues, preferably 5 to about 50 amino acid residues.

254P1D6B-related proteins are embodied in many forms, preferably in isolated form. A purified 254P1D6B protein molecule will be substantially free of other proteins or molecules that impair the binding of 254P1D6B to antibody, T cell or other ligand. The nature and degree of isolation and purification will depend on the intended use. Embodiments of a 254P1D6B-related proteins include purified 254P1D6B-related proteins and functional, soluble 254P1D6B-related proteins. In one embodiment, a functional, soluble 254P1D6B protein or fragment thereof retains the ability to be bound by antibody, T cell or other ligand.

The invention also provides 254P1D6B proteins comprising biologically active fragments of a 254P1D6B amino acid sequence shown in Figure 2 or Figure 3. Such proteins exhibit properties of the starting 254P1D6B protein, such as the ability to elicit the generation of antibodies that specifically bind an epitope associated with the starting 254P1D6B protein; to be bound by such antibodies; to elicit the activation of HTL or CTL; and/or, to be recognized by HTL or CTL that also specifically bind to the starting protein.

254P1D6B-related polypeptides that contain particularly interesting structures can be predicted and/or identified using various analytical techniques well known in the art, including, for example, the methods of Chou-Fasman, Garnier-Robson, Kyte-Doolittle, Eisenberg, Karplus-Schultz or Jameson-Wolf analysis, or based on immunogenicity. Fragments that contain such structures are particularly useful in generating subunit-specific anti-254P1D6B antibodies or T cells or in identifying cellular factors that bind to 254P1D6B. For example, hydrophilicity profiles can be generated, and immunogenic peptide fragments identified, using the method of Hopp, T.P. and Woods, K.R., 1981, Proc. Natl. Acad. Sci. U.S.A. 78:3824-3828. Hydrophobicity profiles can be generated, and immunogenic peptide fragments identified, using the method of Kyte, J. and Doolittle, R.F., 1982, J. Mol. Biol. 157:105-132. Percent (%) Accessible Residues profiles can be generated, and immunogenic peptide fragments identified, using the method of Janin J., 1979, Nature 277:491-492. Average Flexibility profiles can be generated, and immunogenic peptide fragments identified, using the method of Bhaskaran R., Ponnuswamy P.K., 1988, Int. J. Pept. Protein Res. 32:242-255. Beta-turn profiles can be generated, and immunogenic peptide fragments identified, using the method of Deleage, G., Roux B., 1987, Protein Engineering 1:289-294.

CTL epitopes can be determined using specific algorithms to identify peptides within a 254P1D6B protein that are capable of optimally binding to specified HLA alleles (e.g., by using the SYFPEITHI site at World Wide Web URL [syfpeithi.bmi-heidelberg.com/](http://syfpeithi.bmi-heidelberg.com/); the listings in Table IV(A)-(E); Epimatrix™ and Epimer™, Brown University, URL ([brown.edu/Research/TB-HIV\\_Lab/epimatrix/epimatrix.html](http://brown.edu/Research/TB-HIV_Lab/epimatrix/epimatrix.html)); and BIMAS, URL [bimas.dcrf.nih.gov/](http://bimas.dcrf.nih.gov/)). Illustrating this, peptide epitopes from 254P1D6B that are presented in the context of human MHC Class I molecules, e.g., HLA-A1, A2, A3, A11, A24, B7 and B35 were predicted

(see, e.g., Tables VIII-XXI, XXII-XLIX). Specifically, the complete amino acid sequence of the 254P1D6B protein and relevant portions of other variants, i.e., for HLA Class I predictions 9 flanking residues on either side of a point mutation or exon junction, and for HLA Class II predictions 14 flanking residues on either side of a point mutation or exon junction corresponding to that variant, were entered into the HLA Peptide Motif Search algorithm found in the Bioinformatics and Molecular Analysis Section (BIMAS) web site listed above; in addition to the site SYFPEITHI, at URL [syfpeithi.bmi-heidelberg.com/](http://syfpeithi.bmi-heidelberg.com/).

The HLA peptide motif search algorithm was developed by Dr. Ken Parker based on binding of specific peptide sequences in the groove of HLA Class I molecules, in particular HLA-A2 (see, e.g., Falk *et al.*, *Nature* 351: 290-6 (1991); Hunt *et al.*, *Science* 255:1261-3 (1992); Parker *et al.*, *J. Immunol.* 149:3580-7 (1992); Parker *et al.*, *J. Immunol.* 152:163-75 (1994)). This algorithm allows location and ranking of 8-mer, 9-mer, and 10-mer peptides from a complete protein sequence for predicted binding to HLA-A2 as well as numerous other HLA Class I molecules. Many HLA class I binding peptides are 8-, 9-, 10 or 11-mers. For example, for Class I HLA-A2, the epitopes preferably contain a leucine (L) or methionine (M) at position 2 and a valine (V) or leucine (L) at the C-terminus (see, e.g., Parker *et al.*, *J. Immunol.* 149:3580-7 (1992)). Selected results of 254P1D6B predicted binding peptides are shown in Tables VIII-XXI and XXII-XLIX herein. In Tables VIII-XXI and XXII-XLVII, selected candidates, 9-mers and 10-mers, for each family member are shown along with their location, the amino acid sequence of each specific peptide, and an estimated binding score. In Tables XLVI-XLIX, selected candidates, 15-mers, for each family member are shown along with their location, the amino acid sequence of each specific peptide, and an estimated binding score. The binding score corresponds to the estimated half time of dissociation of complexes containing the peptide at 37°C at pH 6.5. Peptides with the highest binding score are predicted to be the most tightly bound to HLA Class I on the cell surface for the greatest period of time and thus represent the best immunogenic targets for T-cell recognition.

Actual binding of peptides to an HLA allele can be evaluated by stabilization of HLA expression on the antigen-processing defective cell line T2 (see, e.g., Xue *et al.*, *Prostate* 30:73-8 (1997) and Peshwa *et al.*, *Prostate* 36:129-38 (1998)). Immunogenicity of specific peptides can be evaluated *in vitro* by stimulation of CD8+ cytotoxic T lymphocytes (CTL) in the presence of antigen presenting cells such as dendritic cells.

It is to be appreciated that every epitope predicted by the BIMAS site, Epimer™ and Epimatrix™ sites, or specified by the HLA class I or class II motifs available in the art or which become part of the art such as set forth in Table IV (or determined using World Wide Web site URL [syfpeithi.bmi-heidelberg.com/](http://syfpeithi.bmi-heidelberg.com/), or BIMAS, [bimas.dcrt.nih.gov/](http://bimas.dcrt.nih.gov/)) are to be "applied" to a 254P1D6B protein in accordance with the invention. As used in this context "applied" means that a 254P1D6B protein is evaluated, e.g., visually or by computer-based patterns finding methods, as appreciated by those of skill in the relevant art. Every subsequence of a 254P1D6B protein of 8, 9, 10, or 11 amino acid residues that bears an HLA Class I motif, or a subsequence of 9 or more amino acid residues that bear an HLA Class II motif are within the scope of the invention.

### **III.B.) Expression of 254P1D6B-related Proteins**

In an embodiment described in the examples that follow, 254P1D6B can be conveniently expressed in cells (such as 293T cells) transfected with a commercially available expression vector such as a CMV-driven expression vector encoding 254P1D6B with a C-terminal 6XHis and MYC tag (pcDNA3.1/mycHIS, Invitrogen or Tag5, GenHunter Corporation, Nashville TN). The Tag5 vector provides an IgGK secretion signal that can be used to facilitate the production of a secreted 254P1D6B protein in transfected cells. The secreted HIS-tagged 254P1D6B in the culture media can be purified, e.g., using a nickel column using standard techniques.

### **III.C.) Modifications of 254P1D6B-related Proteins**

Modifications of 254P1D6B-related proteins such as covalent modifications are included within the scope of this invention. One type of covalent modification includes reacting targeted amino acid residues of a 254P1D6B polypeptide with an organic derivatizing agent that is capable of reacting with selected side chains or the N- or C- terminal residues of a 254P1D6B protein. Another type of covalent modification of a 254P1D6B polypeptide included within the scope of this invention comprises altering the native glycosylation pattern of a protein of the invention. Another type of covalent modification of 254P1D6B comprises linking a 254P1D6B polypeptide to one of a variety of nonproteinaceous polymers, e.g., polyethylene glycol (PEG), polypropylene glycol, or polyoxyalkylenes, in the manner set forth in U.S. Patent Nos. 4,640,835; 4,496,689; 4,301,144; 4,670,417; 4,791,192 or 4,179,337.

The 254P1D6B-related proteins of the present invention can also be modified to form a chimeric molecule comprising 254P1D6B fused to another, heterologous polypeptide or amino acid sequence. Such a chimeric molecule can be synthesized chemically or recombinantly. A chimeric molecule can have a protein of the invention fused to another tumor-associated antigen or fragment thereof. Alternatively, a protein in accordance with the invention can comprise a fusion of fragments of a 254P1D6B sequence (amino or nucleic acid) such that a molecule is created that is not, through its length, directly homologous to the amino or nucleic acid sequences shown in Figure 2 or Figure 3. Such a chimeric molecule can comprise multiples of the same subsequence of 254P1D6B. A chimeric molecule can comprise a fusion of a 254P1D6B-related protein with a polyhistidine epitope tag, which provides an epitope to which immobilized nickel can selectively bind, with cytokines or with growth factors. The epitope tag is generally placed at the amino- or carboxyl- terminus of a 254P1D6B protein. In an alternative embodiment, the chimeric molecule can comprise a fusion of a 254P1D6B-related protein with an immunoglobulin or a particular region of an immunoglobulin. For a bivalent form of the chimeric molecule (also referred to as an "immunoadhesin"), such a fusion could be to the Fc region of an IgG molecule. The Ig fusions preferably include the substitution of a soluble (transmembrane domain deleted or inactivated) form of a 254P1D6B polypeptide in place of at least one variable region within an Ig molecule. In a preferred embodiment, the immunoglobulin fusion includes the hinge, CH2 and CH3, or the hinge, CH1, CH2 and CH3 regions of an IgG1 molecule. For the production of immunoglobulin fusions see, e.g., U.S. Patent No. 5,428,130 issued June 27, 1995.

### **III.D.) Uses of 254P1D6B-related Proteins**

The proteins of the invention have a number of different specific uses. As 254P1D6B is highly expressed in prostate and other cancers, 254P1D6B-related proteins are used in methods that assess the status of 254P1D6B gene products in normal versus cancerous tissues, thereby elucidating the malignant phenotype. Typically, polypeptides from specific regions of a 254P1D6B protein are used to assess the presence of perturbations (such as deletions, insertions, point mutations etc.) in those regions (such as regions containing one or more motifs). Exemplary assays utilize antibodies or T cells targeting 254P1D6B-related proteins comprising the amino acid residues of one or more of the biological motifs contained within a 254P1D6B polypeptide sequence in order to evaluate the characteristics of this region in normal versus cancerous tissues or to elicit an immune response to the epitope. Alternatively, 254P1D6B-related proteins that contain the amino acid residues of one or more of the biological motifs in a 254P1D6B protein are used to screen for factors that interact with that region of 254P1D6B.

254P1D6B protein fragments/subsequences are particularly useful in generating and characterizing domain-specific antibodies (e.g., antibodies recognizing an extracellular or intracellular epitope of a 254P1D6B protein), for identifying agents or cellular factors that bind to 254P1D6B or a particular structural domain thereof, and in various therapeutic and diagnostic contexts, including but not limited to diagnostic assays, cancer vaccines and methods of preparing such vaccines.

Proteins encoded by the 254P1D6B genes, or by analogs, homologs or fragments thereof, have a variety of uses, including but not limited to generating antibodies and in methods for identifying ligands and other agents and cellular

constituents that bind to a 254P1D6B gene product. Antibodies raised against a 254P1D6B protein or fragment thereof are useful in diagnostic and prognostic assays, and imaging methodologies in the management of human cancers characterized by expression of 254P1D6B protein, such as those listed in Table I. Such antibodies can be expressed intracellularly and used in methods of treating patients with such cancers. 254P1D6B-related nucleic acids or proteins are also used in generating HTL or CTL responses.

Various immunological assays useful for the detection of 254P1D6B proteins are used, including but not limited to various types of radioimmunoassays, enzyme-linked immunosorbent assays (ELISA), enzyme-linked immunofluorescent assays (ELIFA), immunocytochemical methods, and the like. Antibodies can be labeled and used as immunological imaging reagents capable of detecting 254P1D6B-expressing cells (e.g., in radioscintigraphic imaging methods). 254P1D6B proteins are also particularly useful in generating cancer vaccines, as further described herein.

#### **IV.) 254P1D6B Antibodies**

Another aspect of the invention provides antibodies that bind to 254P1D6B-related proteins. Preferred antibodies specifically bind to a 254P1D6B-related protein and do not bind (or bind weakly) to peptides or proteins that are not 254P1D6B-related proteins under physiological conditions. In this context, examples of physiological conditions include: 1) phosphate buffered saline; 2) Tris-buffered saline containing 25mM Tris and 150 mM NaCl; or normal saline (0.9% NaCl); 4) animal serum such as human serum; or, 5) a combination of any of 1) through 4); these reactions preferably taking place at pH 7.5, alternatively in a range of pH 7.0 to 8.0, or alternatively in a range of pH 6.5 to 8.5; also, these reactions taking place at a temperature between 4°C to 37°C. For example, antibodies that bind 254P1D6B can bind 254P1D6B-related proteins such as the homologs or analogs thereof.

254P1D6B antibodies of the invention are particularly useful in cancer (see, e.g., Table I) diagnostic and prognostic assays, and imaging methodologies. Similarly, such antibodies are useful in the treatment, diagnosis, and/or prognosis of other cancers, to the extent 254P1D6B is also expressed or overexpressed in these other cancers. Moreover, intracellularly expressed antibodies (e.g., single chain antibodies) are therapeutically useful in treating cancers in which the expression of 254P1D6B is involved, such as advanced or metastatic prostate cancers.

The invention also provides various immunological assays useful for the detection and quantification of 254P1D6B and mutant 254P1D6B-related proteins. Such assays comprise one or more 254P1D6B antibodies capable of recognizing and binding a 254P1D6B-related protein, as appropriate. These assays are performed within various immunological assay formats well known in the art, including but not limited to various types of radioimmunoassays, enzyme-linked immunosorbent assays (ELISA), enzyme-linked immunofluorescent assays (ELIFA), and the like.

Immunological non-antibody assays of the invention also comprise T cell immunogenicity assays (inhibitory or stimulatory) as well as major histocompatibility complex (MHC) binding assays.

In addition, immunological imaging methods capable of detecting prostate cancer and other cancers expressing 254P1D6B are also provided by the invention, including but not limited to radioscintigraphic imaging methods using labeled 254P1D6B antibodies. Such assays are clinically useful in the detection, monitoring, and prognosis of 254P1D6B expressing cancers such as prostate cancer.

254P1D6B antibodies are also used in methods for purifying a 254P1D6B-related protein and for isolating 254P1D6B homologues and related molecules. For example, a method of purifying a 254P1D6B-related protein comprises incubating a 254P1D6B antibody, which has been coupled to a solid matrix, with a lysate or other solution containing a 254P1D6B-related protein under conditions that permit the 254P1D6B antibody to bind to the 254P1D6B-related protein; washing the solid matrix to eliminate impurities; and eluting the 254P1D6B-related protein from the coupled antibody. Other uses of 254P1D6B antibodies in accordance with the invention include generating anti-idiotypic antibodies that mimic a 254P1D6B protein.

Various methods for the preparation of antibodies are well known in the art. For example, antibodies can be prepared by immunizing a suitable mammalian host using a 254P1D6B-related protein, peptide, or fragment, in isolated or immunoconjugated form (Antibodies: A Laboratory Manual, CSH Press, Eds., Harlow, and Lane (1988); Harlow, Antibodies, Cold Spring Harbor Press, NY (1989)). In addition, fusion proteins of 254P1D6B can also be used, such as a 254P1D6B GST-fusion protein. In a particular embodiment, a GST fusion protein comprising all or most of the amino acid sequence of Figure 2 or Figure 3 is produced, then used as an immunogen to generate appropriate antibodies. In another embodiment, a 254P1D6B-related protein is synthesized and used as an immunogen.

In addition, naked DNA immunization techniques known in the art are used (with or without purified 254P1D6B-related protein or 254P1D6B expressing cells) to generate an immune response to the encoded immunogen (for review, see Donnelly *et al.*, 1997, *Ann. Rev. Immunol.* 15: 617-648).

The amino acid sequence of a 254P1D6B protein as shown in Figure 2 or Figure 3 can be analyzed to select specific regions of the 254P1D6B protein for generating antibodies. For example, hydrophobicity and hydrophilicity analyses of a 254P1D6B amino acid sequence are used to identify hydrophilic regions in the 254P1D6B structure. Regions of a 254P1D6B protein that show immunogenic structure, as well as other regions and domains, can readily be identified using various other methods known in the art, such as Chou-Fasman, Garnier-Robson, Kyte-Doolittle, Eisenberg, Karplus-Schultz or Jameson-Wolf analysis. Hydrophilicity profiles can be generated using the method of Hopp, T.P. and Woods, K.R., 1981, *Proc. Natl. Acad. Sci. U.S.A.* 78:3824-3828. Hydrophobicity profiles can be generated using the method of Kyte, J. and Doolittle, R.F., 1982, *J. Mol. Biol.* 157:105-132. Percent (%) Accessible Residues profiles can be generated using the method of Janin J., 1979, *Nature* 277:491-492. Average Flexibility profiles can be generated using the method of Bhaskaran R., Ponnuswamy P.K., 1988, *Int. J. Pept. Protein Res.* 32:242-255. Beta-turn profiles can be generated using the method of Deleage, G., Roux B., 1987, *Protein Engineering* 1:289-294. Thus, each region identified by any of these programs or methods is within the scope of the present invention. Methods for the generation of 254P1D6B antibodies are further illustrated by way of the examples provided herein. Methods for preparing a protein or polypeptide for use as an immunogen are well known in the art. Also well known in the art are methods for preparing immunogenic conjugates of a protein with a carrier, such as BSA, KLH or other carrier protein. In some circumstances, direct conjugation using, for example, carbodiimide reagents are used; in other instances linking reagents such as those supplied by Pierce Chemical Co., Rockford, IL, are effective. Administration of a 254P1D6B immunogen is often conducted by injection over a suitable time period and with use of a suitable adjuvant, as is understood in the art. During the immunization schedule, titers of antibodies can be taken to determine adequacy of antibody formation.

254P1D6B monoclonal antibodies can be produced by various means well known in the art. For example, immortalized cell lines that secrete a desired monoclonal antibody are prepared using the standard hybridoma technology of Kohler and Milstein or modifications that immortalize antibody-producing B cells, as is generally known. Immortalized cell lines that secrete the desired antibodies are screened by immunoassay in which the antigen is a 254P1D6B-related protein. When the appropriate immortalized cell culture is identified, the cells can be expanded and antibodies produced either from *in vitro* cultures or from ascites fluid.

The antibodies or fragments of the invention can also be produced, by recombinant means. Regions that bind specifically to the desired regions of a 254P1D6B protein can also be produced in the context of chimeric or complementarity-determining region (CDR) grafted antibodies of multiple species origin. Humanized or human 254P1D6B antibodies can also be produced, and are preferred for use in therapeutic contexts. Methods for humanizing murine and other non-human antibodies, by substituting one or more of the non-human antibody CDRs for corresponding human antibody sequences, are well known (see for example, Jones *et al.*, 1986, *Nature* 321: 522-525; Riechmann *et al.*, 1988, *Nature* 332: 323-327; Verhoeyen *et al.*, 1988, *Science* 239: 1534-1536). See also, Carter *et al.*, 1993, *Proc. Natl. Acad. Sci. USA* 89: 4285 and Sims *et al.*, 1993, *J. Immunol.* 151: 2296.

Methods for producing fully human monoclonal antibodies include phage display and transgenic methods (for review, see Vaughan *et al.*, 1998, *Nature Biotechnology* 16: 535-539). Fully human 254P1D6B monoclonal antibodies can be generated using cloning technologies employing large human Ig gene combinatorial libraries (i.e., phage display) (Griffiths and Hoogenboom, Building an *in vitro* immune system: human antibodies from phage display libraries. In: *Protein Engineering of Antibody Molecules for Prophylactic and Therapeutic Applications in Man*, Clark, M. (Ed.), Nottingham Academic, pp 45-64 (1993); Burton and Barbas, Human Antibodies from combinatorial libraries. *Id.*, pp 65-82). Fully human 254P1D6B monoclonal antibodies can also be produced using transgenic mice engineered to contain human immunoglobulin gene loci as described in PCT Patent Application WO98/24893, Kucherlapati and Jakobovits *et al.*, published December 3, 1997 (see also, Jakobovits, 1998, *Exp. Opin. Invest. Drugs* 7(4): 607-614; U.S. patents 6,162,963 issued 19 December 2000; 6,150,584 issued 12 November 2000; and, 6,114,598 issued 5 September 2000). This method avoids the *in vitro* manipulation required with phage display technology and efficiently produces high affinity authentic human antibodies.

Reactivity of 254P1D6B antibodies with a 254P1D6B-related protein can be established by a number of well known means, including Western blot, immunoprecipitation, ELISA, and FACS analyses using, as appropriate, 254P1D6B-related proteins, 254P1D6B-expressing cells or extracts thereof. A 254P1D6B antibody or fragment thereof can be labeled with a detectable marker or conjugated to a second molecule. Suitable detectable markers include, but are not limited to, a radioisotope, a fluorescent compound, a bioluminescent compound, chemiluminescent compound, a metal chelator or an enzyme. Further, bi-specific antibodies specific for two or more 254P1D6B epitopes are generated using methods generally known in the art. Homodimeric antibodies can also be generated by cross-linking techniques known in the art (e.g., Wolff *et al.*, *Cancer Res.* 53: 2560-2565).

#### V.) 254P1D6B Cellular Immune Responses

The mechanism by which T cells recognize antigens has been delineated. Efficacious peptide epitope vaccine compositions of the invention induce a therapeutic or prophylactic immune responses in very broad segments of the world-wide population. For an understanding of the value and efficacy of compositions of the invention that induce cellular immune responses, a brief review of immunology-related technology is provided.

A complex of an HLA molecule and a peptidic antigen acts as the ligand recognized by HLA-restricted T cells (Buus, S. *et al.*, *Cell* 47:1071, 1986; Babbitt, B. P. *et al.*, *Nature* 317:359, 1985; Townsend, A. and Bodmer, H., *Annu. Rev. Immunol.* 7:601, 1989; Germain, R. N., *Annu. Rev. Immunol.* 11:403, 1993). Through the study of single amino acid substituted antigen analogs and the sequencing of endogenously bound, naturally processed peptides, critical residues that correspond to motifs required for specific binding to HLA antigen molecules have been identified and are set forth in Table IV (see also, e.g., Southwood, *et al.*, *J. Immunol.* 160:3363, 1998; Rammensee, *et al.*, *Immunogenetics* 41:178, 1995; Rammensee *et al.*, SYFPEITHI, access via World Wide Web at URL (134.2.96.221/scripts.hlaserver.dll/home.htm); Sette, A. and Sidney, J. *Curr. Opin. Immunol.* 10:478, 1998; Engelhard, V. H., *Curr. Opin. Immunol.* 6:13, 1994; Sette, A. and Grey, H. M., *Curr. Opin. Immunol.* 4:79, 1992; Sinigaglia, F. and Hammer, J. *Curr. Biol.* 6:52, 1994; Ruppert *et al.*, *Cell* 74:929-937, 1993; Kondo *et al.*, *J. Immunol.* 155:4307-4312, 1995; Sidney *et al.*, *J. Immunol.* 157:3480-3490, 1996; Sidney *et al.*, *Human Immunol.* 45:79-93, 1996; Sette, A. and Sidney, J. *Immunogenetics* 1999 Nov; 50(3-4):201-12, Review).

Furthermore, x-ray crystallographic analyses of HLA-peptide complexes have revealed pockets within the peptide binding cleft/groove of HLA molecules which accommodate, in an allele-specific mode, residues borne by peptide ligands; these residues in turn determine the HLA binding capacity of the peptides in which they are present. (See, e.g., Madden, D.R. *Annu. Rev. Immunol.* 13:587, 1995; Smith, *et al.*, *Immunity* 4:203, 1996; Fremont *et al.*, *Immunity* 8:305, 1998; Stern *et al.*, *Structure* 2:245, 1994; Jones, E.Y. *Curr. Opin. Immunol.* 9:75, 1997; Brown, J. H. *et al.*, *Nature* 364:33, 1993; Guo, H. C. *et al.*, *Proc. Natl. Acad. Sci. USA* 90:8053, 1993; Guo, H. C. *et al.*, *Nature* 360:364, 1992; Silver, M. L. *et al.*, *Nature* 360:367,

1992; Matsumura, M. *et al.*, *Science* 257:927, 1992; Madden *et al.*, *Cell* 70:1035, 1992; Fremont, D. H. *et al.*, *Science* 257:919, 1992; Saper, M. A., Bjorkman, P. J. and Wiley, D. C., *J. Mol. Biol.* 219:277, 1991.)

Accordingly, the definition of class I and class II allele-specific HLA binding motifs, or class I or class II supermotifs allows identification of regions within a protein that are correlated with binding to particular HLA antigen(s).

Thus, by a process of HLA motif identification, candidates for epitope-based vaccines have been identified; such candidates can be further evaluated by HLA-peptide binding assays to determine binding affinity and/or the time period of association of the epitope and its corresponding HLA molecule. Additional confirmatory work can be performed to select, amongst these vaccine candidates, epitopes with preferred characteristics in terms of population coverage, and/or immunogenicity.

Various strategies can be utilized to evaluate cellular immunogenicity, including:

- 1) Evaluation of primary T cell cultures from normal individuals (see, e.g., Wentworth, P. A. *et al.*, *Mol. Immunol.* 32:603, 1995; Celis, E. *et al.*, *Proc. Natl. Acad. Sci. USA* 91:2105, 1994; Tsai, V. *et al.*, *J. Immunol.* 158:1796, 1997; Kawashima, I. *et al.*, *Human Immunol.* 59:1, 1998). This procedure involves the stimulation of peripheral blood lymphocytes (PBL) from normal subjects with a test peptide in the presence of antigen presenting cells *in vitro* over a period of several weeks. T cells specific for the peptide become activated during this time and are detected using, e.g., a lymphokine- or <sup>51</sup>Cr-release assay involving peptide sensitized target cells.
- 2) Immunization of HLA transgenic mice (see, e.g., Wentworth, P. A. *et al.*, *J. Immunol.* 26:97, 1996; Wentworth, P. A. *et al.*, *Int. Immunol.* 8:651, 1996; Alexander, J. *et al.*, *J. Immunol.* 159:4753, 1997). For example, in such methods peptides in incomplete Freund's adjuvant are administered subcutaneously to HLA transgenic mice. Several weeks following immunization, splenocytes are removed and cultured *in vitro* in the presence of test peptide for approximately one week. Peptide-specific T cells are detected using, e.g., a <sup>51</sup>Cr-release assay involving peptide sensitized target cells and target cells expressing endogenously generated antigen.
- 3) Demonstration of recall T cell responses from immune individuals who have been either effectively vaccinated and/or from chronically ill patients (see, e.g., Rehmann, B. *et al.*, *J. Exp. Med.* 181:1047, 1995; Doolan, D. L. *et al.*, *Immunity* 7:97, 1997; Bertoni, R. *et al.*, *J. Clin. Invest.* 100:503, 1997; Threlkeld, S. C. *et al.*, *J. Immunol.* 159:1648, 1997; Diepolder, H. M. *et al.*, *J. Virol.* 71:6011, 1997). Accordingly, recall responses are detected by culturing PBL from subjects that have been exposed to the antigen due to disease and thus have generated an immune response "naturally", or from patients who were vaccinated against the antigen. PBL from subjects are cultured *in vitro* for 1-2 weeks in the presence of test peptide plus antigen presenting cells (APC) to allow activation of "memory" T cells, as compared to "naive" T cells. At the end of the culture period, T cell activity is detected using assays including <sup>51</sup>Cr release involving peptide-sensitized targets, T cell proliferation, or lymphokine release.

#### **VI.) 254P1D6B Transgenic Animals**

Nucleic acids that encode a 254P1D6B-related protein can also be used to generate either transgenic animals or "knock out" animals that, in turn, are useful in the development and screening of therapeutically useful reagents. In accordance with established techniques, cDNA encoding 254P1D6B can be used to clone genomic DNA that encodes 254P1D6B. The cloned genomic sequences can then be used to generate transgenic animals containing cells that express DNA that encode 254P1D6B. Methods for generating transgenic animals, particularly animals such as mice or rats, have become conventional in the art and are described, for example, in U.S. Patent Nos. 4,736,866 issued 12 April 1988, and 4,870,009 issued 26 September 1989. Typically, particular cells would be targeted for 254P1D6B transgene incorporation with tissue-specific enhancers.

Transgenic animals that include a copy of a transgene encoding 254P1D6B can be used to examine the effect of increased expression of DNA that encodes 254P1D6B. Such animals can be used as tester animals for reagents thought to confer protection from, for example, pathological conditions associated with its overexpression. In accordance with this aspect of the invention, an animal is treated with a reagent and a reduced incidence of a pathological condition, compared to untreated animals that bear the transgene, would indicate a potential therapeutic intervention for the pathological condition.

Alternatively, non-human homologues of 254P1D6B can be used to construct a 254P1D6B "knock out" animal that has a defective or altered gene encoding 254P1D6B as a result of homologous recombination between the endogenous gene encoding 254P1D6B and altered genomic DNA encoding 254P1D6B introduced into an embryonic cell of the animal. For example, cDNA that encodes 254P1D6B can be used to clone genomic DNA encoding 254P1D6B in accordance with established techniques. A portion of the genomic DNA encoding 254P1D6B can be deleted or replaced with another gene, such as a gene encoding a selectable marker that can be used to monitor integration. Typically, several kilobases of unaltered flanking DNA (both at the 5' and 3' ends) are included in the vector (see, e.g., Thomas and Capecchi, *Cell*, 51:503 (1987) for a description of homologous recombination vectors). The vector is introduced into an embryonic stem cell line (e.g., by electroporation) and cells in which the introduced DNA has homologously recombined with the endogenous DNA are selected (see, e.g., Li *et al.*, *Cell*, 69:915 (1992)). The selected cells are then injected into a blastocyst of an animal (e.g., a mouse or rat) to form aggregation chimeras (see, e.g., Bradley, in *Teratocarcinomas and Embryonic Stem Cells: A Practical Approach*, E. J. Robertson, ed. (IRL, Oxford, 1987), pp. 113-152). A chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal, and the embryo brought to term to create a "knock out" animal. Progeny harboring the homologously recombined DNA in their germ cells can be identified by standard techniques and used to breed animals in which all cells of the animal contain the homologously recombined DNA. Knock out animals can be characterized, for example, for their ability to defend against certain pathological conditions or for their development of pathological conditions due to absence of a 254P1D6B polypeptide.

#### **VII.) Methods for the Detection of 254P1D6B**

Another aspect of the present invention relates to methods for detecting 254P1D6B polynucleotides and 254P1D6B-related proteins, as well as methods for identifying a cell that expresses 254P1D6B. The expression profile of 254P1D6B makes it a diagnostic marker for metastasized disease. Accordingly, the status of 254P1D6B gene products provides information useful for predicting a variety of factors including susceptibility to advanced stage disease, rate of progression, and/or tumor aggressiveness. As discussed in detail herein, the status of 254P1D6B gene products in patient samples can be analyzed by a variety of protocols that are well known in the art including immunohistochemical analysis, the variety of Northern blotting techniques including *in situ* hybridization, RT-PCR analysis (for example on laser capture micro-dissected samples), Western blot analysis and tissue array analysis.

More particularly, the invention provides assays for the detection of 254P1D6B polynucleotides in a biological sample, such as serum, bone, prostate, and other tissues, urine, semen, cell preparations, and the like. Detectable 254P1D6B polynucleotides include, for example, a 254P1D6B gene or fragment thereof, 254P1D6B mRNA, alternative splice variant 254P1D6B mRNAs, and recombinant DNA or RNA molecules that contain a 254P1D6B polynucleotide. A number of methods for amplifying and/or detecting the presence of 254P1D6B polynucleotides are well known in the art and can be employed in the practice of this aspect of the invention.

In one embodiment, a method for detecting a 254P1D6B mRNA in a biological sample comprises producing cDNA from the sample by reverse transcription using at least one primer; amplifying the cDNA so produced using a 254P1D6B polynucleotides as sense and antisense primers to amplify 254P1D6B cDNAs therein; and detecting the presence of the amplified 254P1D6B cDNA. Optionally, the sequence of the amplified 254P1D6B cDNA can be determined.

In another embodiment, a method of detecting a 254P1D6B gene in a biological sample comprises first isolating genomic DNA from the sample; amplifying the isolated genomic DNA using 254P1D6B polynucleotides as sense and antisense primers; and detecting the presence of the amplified 254P1D6B gene. Any number of appropriate sense and antisense probe combinations can be designed from a 254P1D6B nucleotide sequence (see, e.g., Figure 2) and used for this purpose.

The invention also provides assays for detecting the presence of a 254P1D6B protein in a tissue or other biological sample such as serum, semen, bone, prostate, urine, cell preparations, and the like. Methods for detecting a 254P1D6B-related protein are also well known and include, for example, immunoprecipitation, immunohistochemical analysis, Western blot analysis, molecular binding assays, ELISA, ELIFA and the like. For example, a method of detecting the presence of a 254P1D6B-related protein in a biological sample comprises first contacting the sample with a 254P1D6B antibody, a 254P1D6B-reactive fragment thereof, or a recombinant protein containing an antigen-binding region of a 254P1D6B antibody; and then detecting the binding of 254P1D6B-related protein in the sample.

Methods for identifying a cell that expresses 254P1D6B are also within the scope of the invention. In one embodiment, an assay for identifying a cell that expresses a 254P1D6B gene comprises detecting the presence of 254P1D6B mRNA in the cell. Methods for the detection of particular mRNAs in cells are well known and include, for example, hybridization assays using complementary DNA probes (such as *in situ* hybridization using labeled 254P1D6B riboprobes, Northern blot and related techniques) and various nucleic acid amplification assays (such as RT-PCR using complementary primers specific for 254P1D6B, and other amplification type detection methods, such as, for example, branched DNA, SISBA, TMA and the like). Alternatively, an assay for identifying a cell that expresses a 254P1D6B gene comprises detecting the presence of 254P1D6B-related protein in the cell or secreted by the cell. Various methods for the detection of proteins are well known in the art and are employed for the detection of 254P1D6B-related proteins and cells that express 254P1D6B-related proteins.

254P1D6B expression analysis is also useful as a tool for identifying and evaluating agents that modulate 254P1D6B gene expression. For example, 254P1D6B expression is significantly upregulated in prostate cancer, and is expressed in cancers of the tissues listed in Table I. Identification of a molecule or biological agent that inhibits 254P1D6B expression or over-expression in cancer cells is of therapeutic value. For example, such an agent can be identified by using a screen that quantifies 254P1D6B expression by RT-PCR, nucleic acid hybridization or antibody binding.

#### **VIII.) Methods for Monitoring the Status of 254P1D6B-related Genes and Their Products**

Oncogenesis is known to be a multistep process where cellular growth becomes progressively dysregulated and cells progress from a normal physiological state to precancerous and then cancerous states (see, e.g., Alers *et al.*, Lab Invest. 77(5): 437-438 (1997) and Isaacs *et al.*, Cancer Surv. 23: 19-32 (1995)). In this context, examining a biological sample for evidence of dysregulated cell growth (such as aberrant 254P1D6B expression in cancers) allows for early detection of such aberrant physiology, before a pathologic state such as cancer has progressed to a stage that therapeutic options are more limited and or the prognosis is worse. In such examinations, the status of 254P1D6B in a biological sample of interest can be compared, for example, to the status of 254P1D6B in a corresponding normal sample (e.g. a sample from that individual or alternatively another individual that is not affected by a pathology). An alteration in the status of 254P1D6B in the biological sample (as compared to the normal sample) provides evidence of dysregulated cellular growth. In addition to using a biological sample that is not affected by a pathology as a normal sample, one can also use a predetermined normative value such as a predetermined normal level of mRNA expression (see, e.g., Grever *et al.*, J. Comp. Neurol. 1996 Dec 9; 376(2): 306-14 and U.S. Patent No. 5,837,501) to compare 254P1D6B status in a sample.

The term "status" in this context is used according to its art accepted meaning and refers to the condition or state of a gene and its products. Typically, skilled artisans use a number of parameters to evaluate the condition or state of a gene and its

products. These include, but are not limited to the location of expressed gene products (including the location of 254P1D6B expressing cells) as well as the level, and biological activity of expressed gene products (such as 254P1D6B mRNA, polynucleotides and polypeptides). Typically, an alteration in the status of 254P1D6B comprises a change in the location of 254P1D6B and/or 254P1D6B expressing cells and/or an increase in 254P1D6B mRNA and/or protein expression.

254P1D6B status in a sample can be analyzed by a number of means well known in the art, including without limitation, immunohistochemical analysis, *in situ* hybridization, RT-PCR analysis on laser capture micro-dissected samples, Western blot analysis, and tissue array analysis. Typical protocols for evaluating the status of a 254P1D6B gene and gene products are found, for example in Ausubel *et al.* eds., 1995, Current Protocols In Molecular Biology, Units 2 (Northern Blotting), 4 (Southern Blotting), 15 (Immunoblotting) and 18 (PCR Analysis). Thus, the status of 254P1D6B in a biological sample is evaluated by various methods utilized by skilled artisans including, but not limited to genomic Southern analysis (to examine, for example perturbations in a 254P1D6B gene), Northern analysis and/or PCR analysis of 254P1D6B mRNA (to examine, for example alterations in the polynucleotide sequences or expression levels of 254P1D6B mRNAs), and, Western and/or immunohistochemical analysis (to examine, for example alterations in polypeptide sequences, alterations in polypeptide localization within a sample, alterations in expression levels of 254P1D6B proteins and/or associations of 254P1D6B proteins with polypeptide binding partners). Detectable 254P1D6B polynucleotides include, for example, a 254P1D6B gene or fragment thereof, 254P1D6B mRNA, alternative splice variants, 254P1D6B mRNAs, and recombinant DNA or RNA molecules containing a 254P1D6B polynucleotide.

The expression profile of 254P1D6B makes it a diagnostic marker for local and/or metastasized disease, and provides information on the growth or oncogenic potential of a biological sample. In particular, the status of 254P1D6B provides information useful for predicting susceptibility to particular disease stages, progression, and/or tumor aggressiveness. The invention provides methods and assays for determining 254P1D6B status and diagnosing cancers that express 254P1D6B, such as cancers of the tissues listed in Table I. For example, because 254P1D6B mRNA is so highly expressed in prostate and other cancers relative to normal prostate tissue, assays that evaluate the levels of 254P1D6B mRNA transcripts or proteins in a biological sample can be used to diagnose a disease associated with 254P1D6B dysregulation, and can provide prognostic information useful in defining appropriate therapeutic options.

The expression status of 254P1D6B provides information including the presence, stage and location of dysplastic, precancerous and cancerous cells, predicting susceptibility to various stages of disease, and/or for gauging tumor aggressiveness. Moreover, the expression profile makes it useful as an imaging reagent for metastasized disease. Consequently, an aspect of the invention is directed to the various molecular prognostic and diagnostic methods for examining the status of 254P1D6B in biological samples such as those from individuals suffering from, or suspected of suffering from a pathology characterized by dysregulated cellular growth, such as cancer.

As described above, the status of 254P1D6B in a biological sample can be examined by a number of well-known procedures in the art. For example, the status of 254P1D6B in a biological sample taken from a specific location in the body can be examined by evaluating the sample for the presence or absence of 254P1D6B expressing cells (e.g. those that express 254P1D6B mRNAs or proteins). This examination can provide evidence of dysregulated cellular growth, for example, when 254P1D6B-expressing cells are found in a biological sample that does not normally contain such cells (such as a lymph node), because such alterations in the status of 254P1D6B in a biological sample are often associated with dysregulated cellular growth. Specifically, one indicator of dysregulated cellular growth is the metastases of cancer cells from an organ of origin (such as the prostate) to a different area of the body (such as a lymph node). In this context, evidence of dysregulated cellular growth is important for example because occult lymph node metastases can be detected in a substantial proportion of patients with prostate cancer, and such metastases are associated with known predictors of

disease progression (see, e.g., Murphy *et al.*, Prostate 42(4): 315-317 (2000); Su *et al.*, Semin. Surg. Oncol. 18(1): 17-28 (2000) and Freeman *et al.*, J Urol 1995 Aug 154(2 Pt 1):474-8).

In one aspect, the invention provides methods for monitoring 254P1D6B gene products by determining the status of 254P1D6B gene products expressed by cells from an individual suspected of having a disease associated with dysregulated cell growth (such as hyperplasia or cancer) and then comparing the status so determined to the status of 254P1D6B gene products in a corresponding normal sample. The presence of aberrant 254P1D6B gene products in the test sample relative to the normal sample provides an indication of the presence of dysregulated cell growth within the cells of the individual.

In another aspect, the invention provides assays useful in determining the presence of cancer in an individual, comprising detecting a significant increase in 254P1D6B mRNA or protein expression in a test cell or tissue sample relative to expression levels in the corresponding normal cell or tissue. The presence of 254P1D6B mRNA can, for example, be evaluated in tissues including but not limited to those listed in Table I. The presence of significant 254P1D6B expression in any of these tissues is useful to indicate the emergence, presence and/or severity of a cancer, since the corresponding normal tissues do not express 254P1D6B mRNA or express it at lower levels.

In a related embodiment, 254P1D6B status is determined at the protein level rather than at the nucleic acid level. For example, such a method comprises determining the level of 254P1D6B protein expressed by cells in a test tissue sample and comparing the level so determined to the level of 254P1D6B expressed in a corresponding normal sample. In one embodiment, the presence of 254P1D6B protein is evaluated, for example, using immunohistochemical methods. 254P1D6B antibodies or binding partners capable of detecting 254P1D6B protein expression are used in a variety of assay formats well known in the art for this purpose.

In a further embodiment, one can evaluate the status of 254P1D6B nucleotide and amino acid sequences in a biological sample in order to identify perturbations in the structure of these molecules. These perturbations can include insertions, deletions, substitutions and the like. Such evaluations are useful because perturbations in the nucleotide and amino acid sequences are observed in a large number of proteins associated with a growth dysregulated phenotype (see, e.g., Marrogi *et al.*, 1999, J. Cutan. Pathol. 26(8):369-378). For example, a mutation in the sequence of 254P1D6B may be indicative of the presence or promotion of a tumor. Such assays therefore have diagnostic and predictive value where a mutation in 254P1D6B indicates a potential loss of function or increase in tumor growth.

A wide variety of assays for observing perturbations in nucleotide and amino acid sequences are well known in the art. For example, the size and structure of nucleic acid or amino acid sequences of 254P1D6B gene products are observed by the Northern, Southern, Western, PCR and DNA sequencing protocols discussed herein. In addition, other methods for observing perturbations in nucleotide and amino acid sequences such as single strand conformation polymorphism analysis are well known in the art (see, e.g., U.S. Patent Nos. 5,382,510 issued 7 September 1999, and 5,952,170 issued 17 January 1995).

Additionally, one can examine the methylation status of a 254P1D6B gene in a biological sample. Aberrant demethylation and/or hypermethylation of CpG islands in gene 5' regulatory regions frequently occurs in immortalized and transformed cells, and can result in altered expression of various genes. For example, promoter hypermethylation of the pi-class glutathione S-transferase (a protein expressed in normal prostate but not expressed in >90% of prostate carcinomas) appears to permanently silence transcription of this gene and is the most frequently detected genomic alteration in prostate carcinomas (De Marzo *et al.*, Am. J. Pathol. 155(6): 1985-1992 (1999)). In addition, this alteration is present in at least 70% of cases of high-grade prostatic intraepithelial neoplasia (PIN) (Brooks *et al.*, Cancer Epidemiol. Biomarkers Prev., 1998, 7:531-536). In another example, expression of the LAGE-I tumor specific gene (which is not expressed in normal prostate but is expressed in 25-50% of prostate cancers) is induced by deoxy-azacytidine in lymphoblastoid cells, suggesting that tumoral expression is due to demethylation (Lethe *et al.*, Int. J. Cancer 76(6): 903-908 (1998)). A variety of assays for

examining methylation status of a gene are well known in the art. For example, one can utilize, in Southern hybridization approaches, methylation-sensitive restriction enzymes that cannot cleave sequences that contain methylated CpG sites to assess the methylation status of CpG islands. In addition, MSP (methylation specific PCR) can rapidly profile the methylation status of all the CpG sites present in a CpG island of a given gene. This procedure involves initial modification of DNA by sodium bisulfite (which will convert all unmethylated cytosines to uracil) followed by amplification using primers specific for methylated versus unmethylated DNA. Protocols involving methylation interference can also be found for example in *Current Protocols In Molecular Biology*, Unit 12, Frederick M. Ausubel *et al.* eds., 1995.

Gene amplification is an additional method for assessing the status of 254P1D6B. Gene amplification is measured in a sample directly, for example, by conventional Southern blotting or Northern blotting to quantitate the transcription of mRNA (Thomas, 1980, *Proc. Natl. Acad. Sci. USA*, 77:5201-5205), dot blotting (DNA analysis), or *in situ* hybridization, using an appropriately labeled probe, based on the sequences provided herein. Alternatively, antibodies are employed that recognize specific duplexes, including DNA duplexes, RNA duplexes, and DNA-RNA hybrid duplexes or DNA-protein duplexes. The antibodies in turn are labeled and the assay carried out where the duplex is bound to a surface, so that upon the formation of duplex on the surface, the presence of antibody bound to the duplex can be detected.

Biopsied tissue or peripheral blood can be conveniently assayed for the presence of cancer cells using for example, Northern, dot blot or RT-PCR analysis to detect 254P1D6B expression. The presence of RT-PCR amplifiable 254P1D6B mRNA provides an indication of the presence of cancer. RT-PCR assays are well known in the art. RT-PCR detection assays for tumor cells in peripheral blood are currently being evaluated for use in the diagnosis and management of a number of human solid tumors. In the prostate cancer field, these include RT-PCR assays for the detection of cells expressing PSA and PSM (Verkaik *et al.*, 1997, *Urol. Res.* 25:373-384; Ghossein *et al.*, 1995, *J. Clin. Oncol.* 13:1195-2000; Heston *et al.*, 1995, *Clin. Chem.* 41:1687-1688).

A further aspect of the invention is an assessment of the susceptibility that an individual has for developing cancer. In one embodiment, a method for predicting susceptibility to cancer comprises detecting 254P1D6B mRNA or 254P1D6B protein in a tissue sample, its presence indicating susceptibility to cancer, wherein the degree of 254P1D6B mRNA expression correlates to the degree of susceptibility. In a specific embodiment, the presence of 254P1D6B in prostate or other tissue is examined, with the presence of 254P1D6B in the sample providing an indication of prostate cancer susceptibility (or the emergence or existence of a prostate tumor). Similarly, one can evaluate the integrity 254P1D6B nucleotide and amino acid sequences in a biological sample, in order to identify perturbations in the structure of these molecules such as insertions, deletions, substitutions and the like. The presence of one or more perturbations in 254P1D6B gene products in the sample is an indication of cancer susceptibility (or the emergence or existence of a tumor).

The invention also comprises methods for gauging tumor aggressiveness. In one embodiment, a method for gauging aggressiveness of a tumor comprises determining the level of 254P1D6B mRNA or 254P1D6B protein expressed by tumor cells, comparing the level so determined to the level of 254P1D6B mRNA or 254P1D6B protein expressed in a corresponding normal tissue taken from the same individual or a normal tissue reference sample, wherein the degree of 254P1D6B mRNA or 254P1D6B protein expression in the tumor sample relative to the normal sample indicates the degree of aggressiveness. In a specific embodiment, aggressiveness of a tumor is evaluated by determining the extent to which 254P1D6B is expressed in the tumor cells, with higher expression levels indicating more aggressive tumors. Another embodiment is the evaluation of the integrity of 254P1D6B nucleotide and amino acid sequences in a biological sample, in order to identify perturbations in the structure of these molecules such as insertions, deletions, substitutions and the like. The presence of one or more perturbations indicates more aggressive tumors.

Another embodiment of the invention is directed to methods for observing the progression of a malignancy in an individual over time. In one embodiment, methods for observing the progression of a malignancy in an individual over time

comprise determining the level of 254P1D6B mRNA or 254P1D6B protein expressed by cells in a sample of the tumor, comparing the level so determined to the level of 254P1D6B mRNA or 254P1D6B protein expressed in an equivalent tissue sample taken from the same individual at a different time, wherein the degree of 254P1D6B mRNA or 254P1D6B protein expression in the tumor sample over time provides information on the progression of the cancer. In a specific embodiment, the progression of a cancer is evaluated by determining 254P1D6B expression in the tumor cells over time, where increased expression over time indicates a progression of the cancer. Also, one can evaluate the integrity 254P1D6B nucleotide and amino acid sequences in a biological sample in order to identify perturbations in the structure of these molecules such as insertions, deletions, substitutions and the like, where the presence of one or more perturbations indicates a progression of the cancer.

The above diagnostic approaches can be combined with any one of a wide variety of prognostic and diagnostic protocols known in the art. For example, another embodiment of the invention is directed to methods for observing a coincidence between the expression of 254P1D6B gene and 254P1D6B gene products (or perturbations in 254P1D6B gene and 254P1D6B gene products) and a factor that is associated with malignancy, as a means for diagnosing and prognosticating the status of a tissue sample. A wide variety of factors associated with malignancy can be utilized, such as the expression of genes associated with malignancy (e.g. PSA, PSCA and PSM expression for prostate cancer etc.) as well as gross cytological observations (see, e.g., Bocking *et al.*, 1984, *Anal. Quant. Cytol.* 6(2):74-88; Epstein, 1995, *Hum. Pathol.* 26(2):223-9; Thorson *et al.*, 1998, *Mod. Pathol.* 11(6):543-51; Baisden *et al.*, 1999, *Am. J. Surg. Pathol.* 23(8):918-24). Methods for observing a coincidence between the expression of 254P1D6B gene and 254P1D6B gene products (or perturbations in 254P1D6B gene and 254P1D6B gene products) and another factor that is associated with malignancy are useful, for example, because the presence of a set of specific factors that coincide with disease provides information crucial for diagnosing and prognosticating the status of a tissue sample.

In one embodiment, methods for observing a coincidence between the expression of 254P1D6B gene and 254P1D6B gene products (or perturbations in 254P1D6B gene and 254P1D6B gene products) and another factor associated with malignancy entails detecting the overexpression of 254P1D6B mRNA or protein in a tissue sample, detecting the overexpression of PSA mRNA or protein in a tissue sample (or PSCA or PSM expression), and observing a coincidence of 254P1D6B mRNA or protein and PSA mRNA or protein overexpression (or PSCA or PSM expression). In a specific embodiment, the expression of 254P1D6B and PSA mRNA in prostate tissue is examined, where the coincidence of 254P1D6B and PSA mRNA overexpression in the sample indicates the existence of prostate cancer, prostate cancer susceptibility or the emergence or status of a prostate tumor.

Methods for detecting and quantifying the expression of 254P1D6B mRNA or protein are described herein, and standard nucleic acid and protein detection and quantification technologies are well known in the art. Standard methods for the detection and quantification of 254P1D6B mRNA include *in situ* hybridization using labeled 254P1D6B riboprobes, Northern blot and related techniques using 254P1D6B polynucleotide probes, RT-PCR analysis using primers specific for 254P1D6B, and other amplification type detection methods, such as, for example, branched DNA, SISBA, TMA and the like. In a specific embodiment, semi-quantitative RT-PCR is used to detect and quantify 254P1D6B mRNA expression. Any number of primers capable of amplifying 254P1D6B can be used for this purpose, including but not limited to the various primer sets specifically described herein. In a specific embodiment, polyclonal or monoclonal antibodies specifically reactive with the wild-type 254P1D6B protein can be used in an immunohistochemical assay of biopsied tissue.

#### **IX.) Identification of Molecules That Interact With 254P1D6B**

The 254P1D6B protein and nucleic acid sequences disclosed herein allow a skilled artisan to identify proteins, small molecules and other agents that interact with 254P1D6B, as well as pathways activated by 254P1D6B via any one of a variety of art accepted protocols. For example, one can utilize one of the so-called interaction trap systems (also referred to as the "two-hybrid assay"). In such systems, molecules interact and reconstitute a transcription factor which directs expression of a reporter gene, whereupon the expression of the reporter gene is assayed. Other systems identify protein-

protein interactions *in vivo* through reconstitution of a eukaryotic transcriptional activator, see, e.g., U.S. Patent Nos. 5,955,280 issued 21 September 1999, 5,925,523 issued 20 July 1999, 5,846,722 issued 8 December 1998 and 6,004,746 issued 21 December 1999. Algorithms are also available in the art for genome-based predictions of protein function (see, e.g., Marcotte, *et al.*, *Nature* 402: 4 November 1999, 83-86).

Alternatively one can screen peptide libraries to identify molecules that interact with 254P1D6B protein sequences. In such methods, peptides that bind to 254P1D6B are identified by screening libraries that encode a random or controlled collection of amino acids. Peptides encoded by the libraries are expressed as fusion proteins of bacteriophage coat proteins, the bacteriophage particles are then screened against the 254P1D6B protein(s).

Accordingly, peptides having a wide variety of uses, such as therapeutic, prognostic or diagnostic reagents, are thus identified without any prior information on the structure of the expected ligand or receptor molecule. Typical peptide libraries and screening methods that can be used to identify molecules that interact with 254P1D6B protein sequences are disclosed for example in U.S. Patent Nos. 5,723,286 issued 3 March 1998 and 5,733,731 issued 31 March 1998.

Alternatively, cell lines that express 254P1D6B are used to identify protein-protein interactions mediated by 254P1D6B. Such interactions can be examined using immunoprecipitation techniques (see, e.g., Hamilton B.J., *et al.* *Biochem. Biophys. Res. Commun.* 1999, 261:646-51). 254P1D6B protein can be immunoprecipitated from 254P1D6B-expressing cell lines using anti-254P1D6B antibodies. Alternatively, antibodies against His-tag can be used in a cell line engineered to express fusions of 254P1D6B and a His-tag (vectors mentioned above). The immunoprecipitated complex can be examined for protein association by procedures such as Western blotting, <sup>35</sup>S-methionine labeling of proteins, protein microsequencing, silver staining and two-dimensional gel electrophoresis.

Small molecules and ligands that interact with 254P1D6B can be identified through related embodiments of such screening assays. For example, small molecules can be identified that interfere with protein function, including molecules that interfere with 254P1D6B's ability to mediate phosphorylation and de-phosphorylation, interaction with DNA or RNA molecules as an indication of regulation of cell cycles, second messenger signaling or tumorigenesis. Similarly, small molecules that modulate 254P1D6B-related ion channel, protein pump, or cell communication functions are identified and used to treat patients that have a cancer that expresses 254P1D6B (see, e.g., Hille, B., *Ionic Channels of Excitable Membranes* 2<sup>nd</sup> Ed., Sinauer Assoc., Sunderland, MA, 1992). Moreover, ligands that regulate 254P1D6B function can be identified based on their ability to bind 254P1D6B and activate a reporter construct. Typical methods are discussed for example in U.S. Patent No. 5,928,868 issued 27 July 1999, and include methods for forming hybrid ligands in which at least one ligand is a small molecule. In an illustrative embodiment, cells engineered to express a fusion protein of 254P1D6B and a DNA-binding protein are used to co-express a fusion protein of a hybrid ligand/small molecule and a cDNA library transcriptional activator protein. The cells further contain a reporter gene, the expression of which is conditioned on the proximity of the first and second fusion proteins to each other, an event that occurs only if the hybrid ligand binds to target sites on both hybrid proteins. Those cells that express the reporter gene are selected and the unknown small molecule or the unknown ligand is identified. This method provides a means of identifying modulators, which activate or inhibit 254P1D6B.

An embodiment of this invention comprises a method of screening for a molecule that interacts with a 254P1D6B amino acid sequence shown in Figure 2 or Figure 3, comprising the steps of contacting a population of molecules with a 254P1D6B amino acid sequence, allowing the population of molecules and the 254P1D6B amino acid sequence to interact under conditions that facilitate an interaction, determining the presence of a molecule that interacts with the 254P1D6B amino acid sequence, and then separating molecules that do not interact with the 254P1D6B amino acid sequence from molecules that do. In a specific embodiment, the method further comprises purifying, characterizing and identifying a molecule that interacts with the 254P1D6B amino acid sequence. The identified molecule can be used to modulate a

function performed by 254P1D6B. In a preferred embodiment, the 254P1D6B amino acid sequence is contacted with a library of peptides.

#### **X.) Therapeutic Methods and Compositions**

The identification of 254P1D6B as a protein that is normally expressed in a restricted set of tissues, but which is also expressed in cancers such as those listed in Table I, opens a number of therapeutic approaches to the treatment of such cancers.

Of note, targeted antitumor therapies have been useful even when the targeted protein is expressed on normal tissues, even vital normal organ tissues. A vital organ is one that is necessary to sustain life, such as the heart or colon. A non-vital organ is one that can be removed whereupon the individual is still able to survive. Examples of non-vital organs are ovary, breast, and prostate.

For example, Herceptin® is an FDA approved pharmaceutical that has as its active ingredient an antibody which is immunoreactive with the protein variously known as HER2, HER2/neu, and erb-b-2. It is marketed by Genentech and has been a commercially successful antitumor agent. Herceptin sales reached almost \$400 million in 2002. Herceptin is a treatment for HER2 positive metastatic breast cancer. However, the expression of HER2 is not limited to such tumors. The same protein is expressed in a number of normal tissues. In particular, it is known that HER2/neu is present in normal kidney and heart, thus these tissues are present in all human recipients of Herceptin. The presence of HER2/neu in normal kidney is also confirmed by Latif, Z., et al., *B.J.U. International* (2002) 89:5-9. As shown in this article (which evaluated whether renal cell carcinoma should be a preferred indication for anti-HER2 antibodies such as Herceptin) both protein and mRNA are produced in benign renal tissues. Notably, HER2/neu protein was strongly overexpressed in benign renal tissue. Despite the fact that HER2/neu is expressed in such vital tissues as heart and kidney, Herceptin is a very useful, FDA approved, and commercially successful drug. The effect of Herceptin on cardiac tissue, i.e., "cardiotoxicity," has merely been a side effect to treatment. When patients were treated with Herceptin alone, significant cardiotoxicity occurred in a very low percentage of patients.

Of particular note, although kidney tissue is indicated to exhibit normal expression, possibly even higher expression than cardiac tissue, kidney has no appreciable Herceptin side effect whatsoever. Moreover, of the diverse array of normal tissues in which HER2 is expressed, there is very little occurrence of any side effect. Only cardiac tissue has manifested any appreciable side effect at all. A tissue such as kidney, where HER2/neu expression is especially notable, has not been the basis for any side effect.

Furthermore, favorable therapeutic effects have been found for antitumor therapies that target epidermal growth factor receptor (EGFR). EGFR is also expressed in numerous normal tissues. There have been very limited side effects in normal tissues following use of anti-EGFR therapeutics.

Thus, expression of a target protein in normal tissue, even vital normal tissue, does not defeat the utility of a targeting agent for the protein as a therapeutic for certain tumors in which the protein is also overexpressed.

Accordingly, therapeutic approaches that inhibit the activity of a 254P1D6B protein are useful for patients suffering from a cancer that expresses 254P1D6B. These therapeutic approaches generally fall into two classes. One class comprises various methods for inhibiting the binding or association of a 254P1D6B protein with its binding partner or with other proteins. Another class comprises a variety of methods for inhibiting the transcription of a 254P1D6B gene or translation of 254P1D6B mRNA.

#### **X.A.) Anti-Cancer Vaccines**

The invention provides cancer vaccines comprising a 254P1D6B-related protein or 254P1D6B-related nucleic acid. In view of the expression of 254P1D6B, cancer vaccines prevent and/or treat 254P1D6B-expressing cancers with minimal or no effects on non-target tissues. The use of a tumor antigen in a vaccine that generates humoral and/or cell-mediated immune responses as anti-cancer therapy is well known in the art and has been employed in prostate cancer using human PSMA and rodent PAP immunogens (Hodge *et al.*, 1995, *Int. J. Cancer* 63:231-237; Fong *et al.*, 1997, *J. Immunol.* 159:3113-3117).

Such methods can be readily practiced by employing a 254P1D6B-related protein, or a 254P1D6B-encoding nucleic acid molecule and recombinant vectors capable of expressing and presenting the 254P1D6B immunogen (which typically comprises a number of antibody or T cell epitopes). Skilled artisans understand that a wide variety of vaccine systems for delivery of immunoreactive epitopes are known in the art (see, e.g., Heryln *et al.*, *Ann Med* 1999 Feb 31(1):66-78; Maruyama *et al.*, *Cancer Immunol Immunother* 2000 Jun 49(3):123-32). Briefly, such methods of generating an immune response (e.g. humoral and/or cell-mediated) in a mammal, comprise the steps of: exposing the mammal's immune system to an immunoreactive epitope (e.g. an epitope present in a 254P1D6B protein shown in Figure 3 or analog or homolog thereof) so that the mammal generates an immune response that is specific for that epitope (e.g. generates antibodies that specifically recognize that epitope). In a preferred method, a 254P1D6B immunogen contains a biological motif, see e.g., Tables VIII-XXI and XXII-XLIX, or a peptide of a size range from 254P1D6B indicated in Figure 5, Figure 6, Figure 7, Figure 8, and Figure 9.

The entire 254P1D6B protein, immunogenic regions or epitopes thereof can be combined and delivered by various means. Such vaccine compositions can include, for example, lipopeptides (e.g., Vitiello, A. *et al.*, *J. Clin. Invest.* 95:341, 1995), peptide compositions encapsulated in poly(DL-lactide-co-glycolide) ("PLG") microspheres (see, e.g., Eldridge, *et al.*, *Molec. Immunol.* 28:287-294, 1991; Alonso *et al.*, *Vaccine* 12:299-306, 1994; Jones *et al.*, *Vaccine* 13:675-681, 1995), peptide compositions contained in immune stimulating complexes (ISCOMS) (see, e.g., Takahashi *et al.*, *Nature* 344:873-875, 1990; Hu *et al.*, *Clin Exp Immunol.* 113:235-243, 1998), multiple antigen peptide systems (MAPs) (see e.g., Tam, J. P., *Proc. Natl. Acad. Sci. U.S.A.* 85:5409-5413, 1988; Tam, J.P., *J. Immunol. Methods* 196:17-32, 1996), peptides formulated as multivalent peptides; peptides for use in ballistic delivery systems, typically crystallized peptides, viral delivery vectors (Perkus, M. E. *et al.*, In: *Concepts in vaccine development*, Kaufmann, S. H. E., ed., p. 379, 1996; Chakrabarti, S. *et al.*, *Nature* 320:535, 1986; Hu, S. L. *et al.*, *Nature* 320:537, 1986; Kieny, M.-P. *et al.*, *AIDS Bio/Technology* 4:790, 1986; Top, F. H. *et al.*, *J. Infect. Dis.* 124:148, 1971; Chanda, P. K. *et al.*, *Virology* 175:535, 1990), particles of viral or synthetic origin (e.g., Kofler, N. *et al.*, *J. Immunol. Methods.* 192:25, 1996; Eldridge, J. H. *et al.*, *Sem. Hematol.* 30:16, 1993; Falo, L. D., Jr. *et al.*, *Nature Med.* 7:649, 1995), adjuvants (Warren, H. S., Vogel, F. R., and Chedid, L. A. *Annu. Rev. Immunol.* 4:369, 1986; Gupta, R. K. *et al.*, *Vaccine* 11:293, 1993), liposomes (Reddy, R. *et al.*, *J. Immunol.* 148:1585, 1992; Rock, K. L., *Immunol. Today* 17:131, 1996), or, naked or particle absorbed cDNA (Ulmer, J. B. *et al.*, *Science* 259:1745, 1993; Robinson, H. L., Hunt, L. A., and Webster, R. G., *Vaccine* 11:957, 1993; Shiver, J. W. *et al.*, In: *Concepts in vaccine development*, Kaufmann, S. H. E., ed., p. 423, 1996; Cease, K. B., and Berzofsky, J. A., *Annu. Rev. Immunol.* 12:923, 1994 and Eldridge, J. H. *et al.*, *Sem. Hematol.* 30:16, 1993). Toxin-targeted delivery technologies, also known as receptor mediated targeting, such as those of Avant Immunotherapeutics, Inc. (Needham, Massachusetts) may also be used.

In patients with 254P1D6B-associated cancer, the vaccine compositions of the invention can also be used in conjunction with other treatments used for cancer, e.g., surgery, chemotherapy, drug therapies, radiation therapies, etc. including use in combination with immune adjuvants such as IL-2, IL-12, GM-CSF, and the like.

#### Cellular Vaccines:

CTL epitopes can be determined using specific algorithms to identify peptides within 254P1D6B protein that bind corresponding HLA alleles (see e.g., Table IV; Epimer™ and Epimatrix™, Brown University (URL [brown.edu/Research/TB-HIV\\_Lab/epimatrix/epimatrix.html](http://brown.edu/Research/TB-HIV_Lab/epimatrix/epimatrix.html)); and, BIMAS, (URL [bimas.dcrn.nih.gov/](http://bimas.dcrn.nih.gov/); SYFPEITHI at URL [syfpeithi.bmi-heidelberg.com/](http://syfpeithi.bmi-heidelberg.com/)).

In a preferred embodiment, a 254P1D6B immunogen contains one or more amino acid sequences identified using techniques well known in the art, such as the sequences shown in Tables VIII-XXI and XXII-XLIX or a peptide of 8, 9, 10 or 11 amino acids specified by an HLA Class I motif/supermotif (e.g., Table IV (A), Table IV (D), or Table IV (E)) and/or a peptide of at least 9 amino acids that comprises an HLA Class II motif/supermotif (e.g., Table IV (B) or Table IV (C)). As is appreciated in the art, the HLA Class I binding groove is essentially closed ended so that peptides of only a particular size range can fit into the groove and be bound, generally HLA Class I epitopes are 8, 9, 10, or 11 amino acids long. In contrast, the HLA Class II binding groove is essentially open ended; therefore a peptide of about 9 or more amino acids can be bound by an HLA Class II molecule. Due to the binding groove differences between HLA Class I and II, HLA Class I motifs are length specific, i.e., position two of a Class I motif is the second amino acid in an amino to carboxyl direction of the peptide. The amino acid positions in a Class II motif are relative only to each other, not the overall peptide, i.e., additional amino acids can be attached to the amino and/or carboxyl termini of a motif-bearing sequence. HLA Class II epitopes are often 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 amino acids long, or longer than 25 amino acids.

#### Antibody-based Vaccines

A wide variety of methods for generating an immune response in a mammal are known in the art (for example as the first step in the generation of hybridomas). Methods of generating an immune response in a mammal comprise exposing the mammal's immune system to an immunogenic epitope on a protein (e.g. a 254P1D6B protein) so that an immune response is generated. A typical embodiment consists of a method for generating an immune response to 254P1D6B in a host, by contacting the host with a sufficient amount of at least one 254P1D6B B cell or cytotoxic T-cell epitope or analog thereof; and at least one periodic interval thereafter re-contacting the host with the 254P1D6B B cell or cytotoxic T-cell epitope or analog thereof. A specific embodiment consists of a method of generating an immune response against a 254P1D6B-related protein or a man-made multiepitopic peptide comprising: administering 254P1D6B immunogen (e.g. a 254P1D6B protein or a peptide fragment thereof, a 254P1D6B fusion protein or analog etc.) in a vaccine preparation to a human or another mammal. Typically, such vaccine preparations further contain a suitable adjuvant (see, e.g., U.S. Patent No. 6,146,635) or a universal helper epitope such as a PADRE™ peptide (Epimmune Inc., San Diego, CA; see, e.g., Alexander *et al.*, J. Immunol. 2000 164(3); 164(3): 1625-1633; Alexander *et al.*, Immunity 1994 1(9): 751-761 and Alexander *et al.*, Immunol. Res. 1998 18(2): 79-92). An alternative method comprises generating an immune response in an individual against a 254P1D6B immunogen by: administering *in vivo* to muscle or skin of the individual's body a DNA molecule that comprises a DNA sequence that encodes a 254P1D6B immunogen, the DNA sequence operatively linked to regulatory sequences which control the expression of the DNA sequence; wherein the DNA molecule is taken up by cells, the DNA sequence is expressed in the cells and an immune response is generated against the immunogen (see, e.g., U.S. Patent No. 5,962,428). Optionally a genetic vaccine facilitator such as anionic lipids; saponins; lectins; estrogenic compounds; hydroxylated lower alkyls; dimethyl sulfoxide; and urea is also administered. In addition, an antiidiotypic antibody can be administered that mimics 254P1D6B, in order to generate a response to the target antigen.

#### Nucleic Acid Vaccines:

Vaccine compositions of the invention include nucleic acid-mediated modalities. DNA or RNA that encode protein(s) of the invention can be administered to a patient. Genetic immunization methods can be employed to generate prophylactic or therapeutic humoral and cellular immune responses directed against cancer cells expressing 254P1D6B. Constructs comprising DNA encoding a 254P1D6B-related protein/immunogen and appropriate regulatory sequences can be injected directly into muscle or skin of an individual, such that the cells of the muscle or skin take-up the construct and express the encoded 254P1D6B protein/immunogen. Alternatively, a vaccine comprises a 254P1D6B-related protein. Expression of the 254P1D6B-related protein immunogen results in the generation of prophylactic or therapeutic humoral and cellular immunity against cells that bear a 254P1D6B protein. Various prophylactic and therapeutic genetic immunization

techniques known in the art can be used (for review, see information and references published at Internet address genweb.com). Nucleic acid-based delivery is described, for instance, in Wolff *et al.*, *Science* 247:1465 (1990) as well as U.S. Patent Nos. 5,580,859; 5,589,466; 5,804,566; 5,739,118; 5,736,524; 5,679,647; WO 98/04720. Examples of DNA-based delivery technologies include "naked DNA", facilitated (bupivacaine, polymers, peptide-mediated) delivery, cationic lipid complexes, and particle-mediated ("gene gun") or pressure-mediated delivery (see, e.g., U.S. Patent No. 5,922,687).

For therapeutic or prophylactic immunization purposes, proteins of the invention can be expressed via viral or bacterial vectors. Various viral gene delivery systems that can be used in the practice of the invention include, but are not limited to, vaccinia, fowlpox, canarypox, adenovirus, influenza, poliovirus, adeno-associated virus, lentivirus, and sindbis virus (see, e.g., Restifo, 1996, *Curr. Opin. Immunol.* 8:658-663; Tsang *et al.* *J. Natl. Cancer Inst.* 87:982-990 (1995)). Non-viral delivery systems can also be employed by introducing naked DNA encoding a 254P1D6B-related protein into the patient (e.g., intramuscularly or intradermally) to induce an anti-tumor response.

Vaccinia virus is used, for example, as a vector to express nucleotide sequences that encode the peptides of the invention. Upon introduction into a host, the recombinant vaccinia virus expresses the protein immunogenic peptide, and thereby elicits a host immune response. Vaccinia vectors and methods useful in immunization protocols are described in, e.g., U.S. Patent No. 4,722,848. Another vector is BCG (Bacille Calmette Guerin). BCG vectors are described in Stover *et al.*, *Nature* 351:456-460 (1991). A wide variety of other vectors useful for therapeutic administration or immunization of the peptides of the invention, e.g. adeno and adeno-associated virus vectors, retroviral vectors, *Salmonella typhi* vectors, detoxified anthrax toxin vectors, and the like, will be apparent to those skilled in the art from the description herein.

Thus, gene delivery systems are used to deliver a 254P1D6B-related nucleic acid molecule. In one embodiment, the full-length human 254P1D6B cDNA is employed. In another embodiment, 254P1D6B nucleic acid molecules encoding specific cytotoxic T lymphocyte (CTL) and/or antibody epitopes are employed.

#### Ex Vivo Vaccines

Various *ex vivo* strategies can also be employed to generate an immune response. One approach involves the use of antigen presenting cells (APCs) such as dendritic cells (DC) to present 254P1D6B antigen to a patient's immune system. Dendritic cells express MHC class I and II molecules, B7 co-stimulator, and IL-12, and are thus highly specialized antigen presenting cells. In prostate cancer, autologous dendritic cells pulsed with peptides of the prostate-specific membrane antigen (PSMA) are being used in a Phase I clinical trial to stimulate prostate cancer patients' immune systems (Tjoa *et al.*, 1996, *Prostate* 28:65-69; Murphy *et al.*, 1996, *Prostate* 29:371-380). Thus, dendritic cells can be used to present 254P1D6B peptides to T cells in the context of MHC class I or II molecules. In one embodiment, autologous dendritic cells are pulsed with 254P1D6B peptides capable of binding to MHC class I and/or class II molecules. In another embodiment, dendritic cells are pulsed with the complete 254P1D6B protein. Yet another embodiment involves engineering the overexpression of a 254P1D6B gene in dendritic cells using various implementing vectors known in the art, such as adenovirus (Arthur *et al.*, 1997, *Cancer Gene Ther.* 4:17-25), retrovirus (Henderson *et al.*, 1996, *Cancer Res.* 56:3763-3770), lentivirus, adeno-associated virus, DNA transfection (Ribas *et al.*, 1997, *Cancer Res.* 57:2865-2869), or tumor-derived RNA transfection (Ashley *et al.*, 1997, *J. Exp. Med.* 186:1177-1182). Cells that express 254P1D6B can also be engineered to express immune modulators, such as GM-CSF, and used as immunizing agents.

#### X.B.) 254P1D6B as a Target for Antibody-based Therapy

254P1D6B is an attractive target for antibody-based therapeutic strategies. A number of antibody strategies are known in the art for targeting both extracellular and intracellular molecules (see, e.g., complement and ADCC mediated killing as well as the use of intrabodies). Because 254P1D6B is expressed by cancer cells of various lineages relative to corresponding normal cells, systemic administration of 254P1D6B-immunoreactive compositions are prepared that exhibit

excellent sensitivity without toxic, non-specific and/or non-target effects caused by binding of the immunoreactive composition to non-target organs and tissues. Antibodies specifically reactive with domains of 254P1D6B are useful to treat 254P1D6B-expressing cancers systemically, either as conjugates with a toxin or therapeutic agent, or as naked antibodies capable of inhibiting cell proliferation or function.

254P1D6B antibodies can be introduced into a patient such that the antibody binds to 254P1D6B and modulates a function, such as an interaction with a binding partner, and consequently mediates destruction of the tumor cells and/or inhibits the growth of the tumor cells. Mechanisms by which such antibodies exert a therapeutic effect can include complement-mediated cytotoxicity, antibody-dependent cellular cytotoxicity, modulation of the physiological function of 254P1D6B, inhibition of ligand binding or signal transduction pathways, modulation of tumor cell differentiation, alteration of tumor angiogenesis factor profiles, and/or apoptosis.

Those skilled in the art understand that antibodies can be used to specifically target and bind immunogenic molecules such as an immunogenic region of a 254P1D6B sequence shown in Figure 2 or Figure 3. In addition, skilled artisans understand that it is routine to conjugate antibodies to cytotoxic agents (see, e.g., Slevers *et al.* Blood 93:11 3678-3684 (June 1, 1999)). When cytotoxic and/or therapeutic agents are delivered directly to cells, such as by conjugating them to antibodies specific for a molecule expressed by that cell (e.g. 254P1D6B), the cytotoxic agent will exert its known biological effect (i.e. cytotoxicity) on those cells.

A wide variety of compositions and methods for using antibody-cytotoxic agent conjugates to kill cells are known in the art. In the context of cancers, typical methods entail administering to an animal having a tumor a biologically effective amount of a conjugate comprising a selected cytotoxic and/or therapeutic agent linked to a targeting agent (e.g. an anti-254P1D6B antibody) that binds to a marker (e.g. 254P1D6B) expressed, accessible to binding or localized on the cell surfaces. A typical embodiment is a method of delivering a cytotoxic and/or therapeutic agent to a cell expressing 254P1D6B, comprising conjugating the cytotoxic agent to an antibody that immunospecifically binds to a 254P1D6B epitope, and, exposing the cell to the antibody-agent conjugate. Another illustrative embodiment is a method of treating an individual suspected of suffering from metastasized cancer, comprising a step of administering parenterally to said individual a pharmaceutical composition comprising a therapeutically effective amount of an antibody conjugated to a cytotoxic and/or therapeutic agent.

Cancer immunotherapy using anti-254P1D6B antibodies can be done in accordance with various approaches that have been successfully employed in the treatment of other types of cancer, including but not limited to colon cancer (Arlen *et al.*, 1998, Crit. Rev. Immunol. 18:133-138), multiple myeloma (Ozaki *et al.*, 1997, Blood 90:3179-3186, Tsunenari *et al.*, 1997, Blood 90:2437-2444), gastric cancer (Kasprzyk *et al.*, 1992, Cancer Res. 52:2771-2776), B-cell lymphoma (Funakoshi *et al.*, 1996, J. Immunother. Emphasis Tumor Immunol. 19:93-101), leukemia (Zhong *et al.*, 1996, Leuk. Res. 20:581-589), colorectal cancer (Moun *et al.*, 1994, Cancer Res. 54:6160-6166; Velders *et al.*, 1995, Cancer Res. 55:4398-4403), and breast cancer (Shepard *et al.*, 1991, J. Clin. Immunol. 11:117-127). Some therapeutic approaches involve conjugation of naked antibody to a toxin or radioisotope, such as the conjugation of Y<sup>91</sup> or I<sup>131</sup> to anti-CD20 antibodies (e.g., Zevalin™, IDEC Pharmaceuticals Corp. or Bexxar™, Coulter Pharmaceuticals), while others involve co-administration of antibodies and other therapeutic agents, such as Herceptin™ (trastuzumab) with paclitaxel (Genentech, Inc.). The antibodies can be conjugated to a therapeutic agent. To treat prostate cancer, for example, 254P1D6B antibodies can be administered in conjunction with radiation, chemotherapy or hormone ablation. Also, antibodies can be conjugated to a toxin such as calicheamicin (e.g., Mylotarg™, Wyeth-Ayerst, Madison, NJ, a recombinant humanized IgG<sub>4</sub> kappa antibody conjugated to antitumor antibiotic calicheamicin) or a maytansinoid (e.g., taxane-based Tumor-Activated Prodrug, TAP, platform, ImmunoGen, Cambridge, MA, also see e.g., US Patent 5,416,064).

Although 254P1D6B antibody therapy is useful for all stages of cancer, antibody therapy can be particularly appropriate in advanced or metastatic cancers. Treatment with the antibody therapy of the invention is indicated for patients who have received one or more rounds of chemotherapy. Alternatively, antibody therapy of the invention is combined with a chemotherapeutic or radiation regimen for patients who have not received chemotherapeutic treatment. Additionally, antibody therapy can enable the use of reduced dosages of concomitant chemotherapy, particularly for patients who do not tolerate the toxicity of the chemotherapeutic agent very well. Fan et al. (Cancer Res. 53:4637-4642, 1993), Prewett et al. (International J. of Onco. 9:217-224, 1996), and Hancock et al. (Cancer Res. 51:4575-4580, 1991) describe the use of various antibodies together with chemotherapeutic agents.

Although 254P1D6B antibody therapy is useful for all stages of cancer, antibody therapy can be particularly appropriate in advanced or metastatic cancers. Treatment with the antibody therapy of the invention is indicated for patients who have received one or more rounds of chemotherapy. Alternatively, antibody therapy of the invention is combined with a chemotherapeutic or radiation regimen for patients who have not received chemotherapeutic treatment. Additionally, antibody therapy can enable the use of reduced dosages of concomitant chemotherapy, particularly for patients who do not tolerate the toxicity of the chemotherapeutic agent very well.

Cancer patients can be evaluated for the presence and level of 254P1D6B expression, preferably using immunohistochemical assessments of tumor tissue, quantitative 254P1D6B imaging, or other techniques that reliably indicate the presence and degree of 254P1D6B expression. Immunohistochemical analysis of tumor biopsies or surgical specimens is preferred for this purpose. Methods for immunohistochemical analysis of tumor tissues are well known in the art.

Anti-254P1D6B monoclonal antibodies that treat prostate and other cancers include those that initiate a potent immune response against the tumor or those that are directly cytotoxic. In this regard, anti-254P1D6B monoclonal antibodies (mAbs) can elicit tumor cell lysis by either complement-mediated or antibody-dependent cell cytotoxicity (ADCC) mechanisms, both of which require an intact Fc portion of the immunoglobulin molecule for interaction with effector cell Fc receptor sites on complement proteins. In addition, anti-254P1D6B mAbs that exert a direct biological effect on tumor growth are useful to treat cancers that express 254P1D6B. Mechanisms by which directly cytotoxic mAbs act include: inhibition of cell growth, modulation of cellular differentiation, modulation of tumor angiogenesis factor profiles, and the induction of apoptosis. The mechanism(s) by which a particular anti-254P1D6B mAb exerts an anti-tumor effect is evaluated using any number of *in vitro* assays that evaluate cell death such as ADCC, ADMMC, complement-mediated cell lysis, and so forth, as is generally known in the art.

In some patients, the use of murine or other non-human monoclonal antibodies, or human/mouse chimeric mAbs can induce moderate to strong immune responses against the non-human antibody. This can result in clearance of the antibody from circulation and reduced efficacy. In the most severe cases, such an immune response can lead to the extensive formation of immune complexes which, potentially, can cause renal failure. Accordingly, preferred monoclonal antibodies used in the therapeutic methods of the invention are those that are either fully human or humanized and that bind specifically to the target 254P1D6B antigen with high affinity but exhibit low or no antigenicity in the patient.

Therapeutic methods of the invention contemplate the administration of single anti-254P1D6B mAbs as well as combinations, or cocktails, of different mAbs. Such mAb cocktails can have certain advantages inasmuch as they contain mAbs that target different epitopes, exploit different effector mechanisms or combine directly cytotoxic mAbs with mAbs that rely on immune effector functionality. Such mAbs in combination can exhibit synergistic therapeutic effects. In addition, anti-254P1D6B mAbs can be administered concomitantly with other therapeutic modalities, including but not limited to various chemotherapeutic agents, androgen-blockers, immune modulators (e.g., IL-2, GM-CSF), surgery or radiation. The anti-

254P1D6B mAbs are administered in their "naked" or unconjugated form, or can have a therapeutic agent(s) conjugated to them.

Anti-254P1D6B antibody formulations are administered via any route capable of delivering the antibodies to a tumor cell. Routes of administration include, but are not limited to, intravenous, intraperitoneal, intramuscular, intratumor, intradermal, and the like. Treatment generally involves repeated administration of the anti-254P1D6B antibody preparation, via an acceptable route of administration such as intravenous injection (IV), typically at a dose in the range of about 0.1, .2, .3, .4, .5, .6, .7, .8, .9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, or 25 mg/kg body weight. In general, doses in the range of 10-1000 mg mAb per week are effective and well tolerated.

Based on clinical experience with the Herceptin™ mAb in the treatment of metastatic breast cancer, an initial loading dose of approximately 4 mg/kg patient body weight IV, followed by weekly doses of about 2 mg/kg IV of the anti-254P1D6B mAb preparation represents an acceptable dosing regimen. Preferably, the initial loading dose is administered as a 90-minute or longer infusion. The periodic maintenance dose is administered as a 30 minute or longer infusion, provided the initial dose was well tolerated. As appreciated by those of skill in the art, various factors can influence the ideal dose regimen in a particular case. Such factors include, for example, the binding affinity and half life of the Ab or mAbs used, the degree of 254P1D6B expression in the patient, the extent of circulating shed 254P1D6B antigen, the desired steady-state antibody concentration level, frequency of treatment, and the influence of chemotherapeutic or other agents used in combination with the treatment method of the invention, as well as the health status of a particular patient.

Optionally, patients should be evaluated for the levels of 254P1D6B in a given sample (e.g. the levels of circulating 254P1D6B antigen and/or 254P1D6B expressing cells) in order to assist in the determination of the most effective dosing regimen, etc. Such evaluations are also used for monitoring purposes throughout therapy, and are useful to gauge therapeutic success in combination with the evaluation of other parameters (for example, urine cytology and/or ImmunoCyt levels in bladder cancer therapy, or by analogy, serum PSA levels in prostate cancer therapy).

Anti-idiotypic anti-254P1D6B antibodies can also be used in anti-cancer therapy as a vaccine for inducing an immune response to cells expressing a 254P1D6B-related protein. In particular, the generation of anti-idiotypic antibodies is well known in the art; this methodology can readily be adapted to generate anti-idiotypic anti-254P1D6B antibodies that mimic an epitope on a 254P1D6B-related protein (see, for example, Wagner *et al.*, 1997, Hybridoma 16: 33-40; Foon *et al.*, 1995, J. Clin. Invest. 96:334-342; Herlyn *et al.*, 1996, Cancer Immunol. Immunother. 43:65-76). Such an anti-idiotypic antibody can be used in cancer vaccine strategies.

#### **X.C.) 254P1D6B as a Target for Cellular Immune Responses**

Vaccines and methods of preparing vaccines that contain an immunogenically effective amount of one or more HLA-binding peptides as described herein are further embodiments of the invention. Furthermore, vaccines in accordance with the invention encompass compositions of one or more of the claimed peptides. A peptide can be present in a vaccine individually. Alternatively, the peptide can exist as a homopolymer comprising multiple copies of the same peptide, or as a heteropolymer of various peptides. Polymers have the advantage of increased immunological reaction and, where different peptide epitopes are used to make up the polymer, the additional ability to induce antibodies and/or CTLs that react with different antigenic determinants of the pathogenic organism or tumor-related peptide targeted for an immune response. The composition can be a naturally occurring region of an antigen or can be prepared, e.g., recombinantly or by chemical synthesis.

Carriers that can be used with vaccines of the invention are well known in the art, and include, e.g., thyroglobulin, albumins such as human serum albumin, tetanus toxoid, polyamino acids such as poly L-lysine, poly L-glutamic acid, influenza, hepatitis B virus core protein, and the like. The vaccines can contain a physiologically tolerable (*i.e.*, acceptable)

diluent such as water, or saline, preferably phosphate buffered saline. The vaccines also typically include an adjuvant. Adjuvants such as incomplete Freund's adjuvant, aluminum phosphate, aluminum hydroxide, or alum are examples of materials well known in the art. Additionally, as disclosed herein, CTL responses can be primed by conjugating peptides of the invention to lipids, such as tripalmitoyl-S-glycerylcysteinylserine (P<sub>3</sub>CSS). Moreover, an adjuvant such as a synthetic cytosine-phosphorothiolated-guanine-containing (CpG) oligonucleotides has been found to increase CTL responses 10- to 100-fold. (see, e.g. Davila and Celis, J. Immunol. 165:539-547 (2000))

Upon immunization with a peptide composition in accordance with the invention, via injection, aerosol, oral, transdermal, transmucosal, intrapleural, intrathecal, or other suitable routes, the immune system of the host responds to the vaccine by producing large amounts of CTLs and/or HTLs specific for the desired antigen. Consequently, the host becomes at least partially immune to later development of cells that express or overexpress 254P1D6B antigen, or derives at least some therapeutic benefit when the antigen was tumor-associated.

In some embodiments, it may be desirable to combine the class I peptide components with components that induce or facilitate neutralizing antibody and or helper T cell responses directed to the target antigen. A preferred embodiment of such a composition comprises class I and class II epitopes in accordance with the invention. An alternative embodiment of such a composition comprises a class I and/or class II epitope in accordance with the invention, along with a cross reactive HTL epitope such as PADRE™ (Epimmune, San Diego, CA) molecule (described e.g., in U.S. Patent Number 5,736,142).

A vaccine of the invention can also include antigen-presenting cells (APC), such as dendritic cells (DC), as a vehicle to present peptides of the invention. Vaccine compositions can be created *in vitro*, following dendritic cell mobilization and harvesting, whereby loading of dendritic cells occurs *in vitro*. For example, dendritic cells are transfected, e.g., with a minigene in accordance with the invention, or are pulsed with peptides. The dendritic cell can then be administered to a patient to elicit immune responses *in vivo*. Vaccine compositions, either DNA- or peptide-based, can also be administered *in vivo* in combination with dendritic cell mobilization whereby loading of dendritic cells occurs *in vivo*.

Preferably, the following principles are utilized when selecting an array of epitopes for inclusion in a polypeptidic composition for use in a vaccine, or for selecting discrete epitopes to be included in a vaccine and/or to be encoded by nucleic acids such as a minigene. It is preferred that each of the following principles be balanced in order to make the selection. The multiple epitopes to be incorporated in a given vaccine composition may be, but need not be, contiguous in sequence in the native antigen from which the epitopes are derived.

1.) Epitopes are selected which, upon administration, mimic immune responses that have been observed to be correlated with tumor clearance. For HLA Class I this includes 3-4 epitopes that come from at least one tumor associated antigen (TAA). For HLA Class II a similar rationale is employed; again 3-4 epitopes are selected from at least one TAA (see, e.g., Rosenberg *et al.*, *Science* 278:1447-1450). Epitopes from one TAA may be used in combination with epitopes from one or more additional TAAs to produce a vaccine that targets tumors with varying expression patterns of frequently-expressed TAAs.

2.) Epitopes are selected that have the requisite binding affinity established to be correlated with immunogenicity: for HLA Class I an IC<sub>50</sub> of 500 nM or less, often 200 nM or less; and for Class II an IC<sub>50</sub> of 1000 nM or less.

3.) Sufficient supermotif bearing-peptides, or a sufficient array of allele-specific motif-bearing peptides, are selected to give broad population coverage. For example, it is preferable to have at least 80% population coverage. A Monte Carlo analysis, a statistical evaluation known in the art, can be employed to assess the breadth, or redundancy of, population coverage.

4.) When selecting epitopes from cancer-related antigens it is often useful to select analogs because the patient may have developed tolerance to the native epitope.

5.) Of particular relevance are epitopes referred to as "nested epitopes." Nested epitopes occur where at least two epitopes overlap in a given peptide sequence. A nested peptide sequence can comprise B cell, HLA class I and/or HLA class II epitopes. When providing nested epitopes, a general objective is to provide the greatest number of epitopes per sequence. Thus, an aspect is to avoid providing a peptide that is any longer than the amino terminus of the amino terminal epitope and the carboxyl terminus of the carboxyl terminal epitope in the peptide. When providing a multi-epitopic sequence, such as a sequence comprising nested epitopes, it is generally important to screen the sequence in order to insure that it does not have pathological or other deleterious biological properties.

6.) If a polyepitopic protein is created, or when creating a minigene, an objective is to generate the smallest peptide that encompasses the epitopes of interest. This principle is similar, if not the same as that employed when selecting a peptide comprising nested epitopes. However, with an artificial polyepitopic peptide, the size minimization objective is balanced against the need to integrate any spacer sequences between epitopes in the polyepitopic protein. Spacer amino acid residues can, for example, be introduced to avoid junctional epitopes (an epitope recognized by the immune system, not present in the target antigen, and only created by the man-made juxtaposition of epitopes), or to facilitate cleavage between epitopes and thereby enhance epitope presentation. Junctional epitopes are generally to be avoided because the recipient may generate an immune response to that non-native epitope. Of particular concern is a junctional epitope that is a "dominant epitope." A dominant epitope may lead to such a zealous response that immune responses to other epitopes are diminished or suppressed.

7.) Where the sequences of multiple variants of the same target protein are present, potential peptide epitopes can also be selected on the basis of their conservancy. For example, a criterion for conservancy may define that the entire sequence of an HLA class I binding peptide or the entire 9-mer core of a class II binding peptide be conserved in a designated percentage of the sequences evaluated for a specific protein antigen.

#### X.C.1. Minigene Vaccines

A number of different approaches are available which allow simultaneous delivery of multiple epitopes. Nucleic acids encoding the peptides of the invention are a particularly useful embodiment of the invention. Epitopes for inclusion in a minigene are preferably selected according to the guidelines set forth in the previous section. A preferred means of administering nucleic acids encoding the peptides of the invention uses minigene constructs encoding a peptide comprising one or multiple epitopes of the invention.

The use of multi-epitope minigenes is described below and in, Ishioka *et al.*, *J. Immunol.* 162:3915-3925, 1999; An, L. and Whitton, J. L., *J. Virol.* 71:2292, 1997; Thomson, S. A. *et al.*, *J. Immunol.* 157:822, 1996; Whitton, J. L. *et al.*, *J. Virol.* 67:348, 1993; Hanke, R. *et al.*, *Vaccine* 16:426, 1998. For example, a multi-epitope DNA plasmid encoding supermotif- and/or motif-bearing epitopes derived 254P1D6B, the PADRE® universal helper T cell epitope or multiple HTL epitopes from 254P1D6B (see e.g., Tables VIII-XXI and XXII to XLIX), and an endoplasmic reticulum-translocating signal sequence can be engineered. A vaccine may also comprise epitopes that are derived from other TAAs.

The immunogenicity of a multi-epitopic minigene can be confirmed in transgenic mice to evaluate the magnitude of CTL induction responses against the epitopes tested. Further, the immunogenicity of DNA-encoded epitopes *in vivo* can be correlated with the *in vitro* responses of specific CTL lines against target cells transfected with the DNA plasmid. Thus, these experiments can show that the minigene serves to both: 1.) generate a CTL response and 2.) that the induced CTLs recognized cells expressing the encoded epitopes.

For example, to create a DNA sequence encoding the selected epitopes (minigene) for expression in human cells, the amino acid sequences of the epitopes may be reverse translated. A human codon usage table can be used to guide the codon choice for each amino acid. These epitope-encoding DNA sequences may be directly adjoined, so that when translated, a continuous polypeptide sequence is created. To optimize expression and/or immunogenicity, additional

elements can be incorporated into the minigene design. Examples of amino acid sequences that can be reverse translated and included in the minigene sequence include: HLA class I epitopes, HLA class II epitopes, antibody epitopes, a ubiquitination signal sequence, and/or an endoplasmic reticulum targeting signal. In addition, HLA presentation of CTL and HTL epitopes may be improved by including synthetic (e.g. poly-alanine) or naturally-occurring flanking sequences adjacent to the CTL or HTL epitopes; these larger peptides comprising the epitope(s) are within the scope of the invention.

The minigene sequence may be converted to DNA by assembling oligonucleotides that encode the plus and minus strands of the minigene. Overlapping oligonucleotides (30-100 bases long) may be synthesized, phosphorylated, purified and annealed under appropriate conditions using well known techniques. The ends of the oligonucleotides can be joined, for example, using T4 DNA ligase. This synthetic minigene, encoding the epitope polypeptide, can then be cloned into a desired expression vector.

Standard regulatory sequences well known to those of skill in the art are preferably included in the vector to ensure expression in the target cells. Several vector elements are desirable: a promoter with a down-stream cloning site for minigene insertion; a polyadenylation signal for efficient transcription termination; an *E. coli* origin of replication; and an *E. coli* selectable marker (e.g. ampicillin or kanamycin resistance). Numerous promoters can be used for this purpose, e.g., the human cytomegalovirus (hCMV) promoter. See, e.g., U.S. Patent Nos. 5,580,859 and 5,589,466 for other suitable promoter sequences.

Additional vector modifications may be desired to optimize minigene expression and immunogenicity. In some cases, introns are required for efficient gene expression, and one or more synthetic or naturally-occurring introns could be incorporated into the transcribed region of the minigene. The inclusion of mRNA stabilization sequences and sequences for replication in mammalian cells may also be considered for increasing minigene expression.

Once an expression vector is selected, the minigene is cloned into the polylinker region downstream of the promoter. This plasmid is transformed into an appropriate *E. coli* strain, and DNA is prepared using standard techniques. The orientation and DNA sequence of the minigene, as well as all other elements included in the vector, are confirmed using restriction mapping and DNA sequence analysis. Bacterial cells harboring the correct plasmid can be stored as a master cell bank and a working cell bank.

In addition, immunostimulatory sequences (ISSs or CpGs) appear to play a role in the immunogenicity of DNA vaccines. These sequences may be included in the vector, outside the minigene coding sequence, if desired to enhance immunogenicity.

In some embodiments, a bi-cistronic expression vector which allows production of both the minigene-encoded epitopes and a second protein (included to enhance or decrease immunogenicity) can be used. Examples of proteins or polypeptides that could beneficially enhance the immune response if co-expressed include cytokines (e.g., IL-2, IL-12, GM-CSF), cytokine-inducing molecules (e.g., LelF), costimulatory molecules, or for HTL responses, pan-DR binding proteins (PADRE™, Epimmune, San Diego, CA). Helper (HTL) epitopes can be joined to intracellular targeting signals and expressed separately from expressed CTL epitopes; this allows direction of the HTL epitopes to a cell compartment different than that of the CTL epitopes. If required, this could facilitate more efficient entry of HTL epitopes into the HLA class II pathway, thereby improving HTL induction. In contrast to HTL or CTL induction, specifically decreasing the immune response by co-expression of immunosuppressive molecules (e.g. TGF- $\beta$ ) may be beneficial in certain diseases.

Therapeutic quantities of plasmid DNA can be produced for example, by fermentation in *E. coli*, followed by purification. Aliquots from the working cell bank are used to inoculate growth medium, and grown to saturation in shaker flasks or a bioreactor according to well-known techniques. Plasmid DNA can be purified using standard bioseparation technologies such as solid phase anion-exchange resins supplied by QIAGEN, Inc. (Valencia, California). If required, supercoiled DNA can be isolated from the open circular and linear forms using gel electrophoresis or other methods.

Purified plasmid DNA can be prepared for injection using a variety of formulations. The simplest of these is reconstitution of lyophilized DNA in sterile phosphate-buffer saline (PBS). This approach, known as "naked DNA," is currently being used for intramuscular (IM) administration in clinical trials. To maximize the immunotherapeutic effects of minigene DNA vaccines, an alternative method for formulating purified plasmid DNA may be desirable. A variety of methods have been described, and new techniques may become available. Cationic lipids, glycolipids, and fusogenic liposomes can also be used in the formulation (see, e.g., as described by WO 93/24640; Mannino & Gould-Fogerite, *BioTechniques* 6(7): 682 (1988); U.S. Pat No. 5,279,833; WO 91/06309; and Felgner, *et al.*, *Proc. Nat'l Acad. Sci. USA* 84:7413 (1987). In addition, peptides and compounds referred to collectively as protective, interactive, non-condensing compounds (PINC) could also be complexed to purified plasmid DNA to influence variables such as stability, intramuscular dispersion, or trafficking to specific organs or cell types.

Target cell sensitization can be used as a functional assay for expression and HLA class I presentation of minigene-encoded CTL epitopes. For example, the plasmid DNA is introduced into a mammalian cell line that is suitable as a target for standard CTL chromium release assays. The transfection method used will be dependent on the final formulation. Electroporation can be used for "naked" DNA, whereas cationic lipids allow direct *in vitro* transfection. A plasmid expressing green fluorescent protein (GFP) can be co-transfected to allow enrichment of transfected cells using fluorescence activated cell sorting (FACS). These cells are then chromium-51 ( $^{51}\text{Cr}$ ) labeled and used as target cells for epitope-specific CTL lines; cytotoxicity, detected by  $^{51}\text{Cr}$  release, indicates both production of, and HLA presentation of, minigene-encoded CTL epitopes. Expression of HTL epitopes may be evaluated in an analogous manner using assays to assess HTL activity.

*In vivo* immunogenicity is a second approach for functional testing of minigene DNA formulations. Transgenic mice expressing appropriate human HLA proteins are immunized with the DNA product. The dose and route of administration are formulation dependent (e.g., IM for DNA in PBS, intraperitoneal (i.p.) for lipid-complexed DNA). Twenty-one days after immunization, splenocytes are harvested and restimulated for one week in the presence of peptides encoding each epitope being tested. Thereafter, for CTL effector cells, assays are conducted for cytotoxicity of peptide-loaded,  $^{51}\text{Cr}$ -labeled target cells using standard techniques. Lysis of target cells that were sensitized by HLA loaded with peptide epitopes, corresponding to minigene-encoded epitopes, demonstrates DNA vaccine function for *in vivo* induction of CTLs. Immunogenicity of HTL epitopes is confirmed in transgenic mice in an analogous manner.

Alternatively, the nucleic acids can be administered using ballistic delivery as described, for instance, in U.S. Patent No. 5,204,253. Using this technique, particles comprised solely of DNA are administered. In a further alternative embodiment, DNA can be adhered to particles, such as gold particles.

Minigenes can also be delivered using other bacterial or viral delivery systems well known in the art, e.g., an expression construct encoding epitopes of the invention can be incorporated into a viral vector such as vaccinia.

#### **X.C.2. Combinations of CTL Peptides with Helper Peptides**

Vaccine compositions comprising CTL peptides of the invention can be modified, e.g., analogized, to provide desired attributes, such as improved serum half life, broadened population coverage or enhanced immunogenicity.

For instance, the ability of a peptide to induce CTL activity can be enhanced by linking the peptide to a sequence which contains at least one epitope that is capable of inducing a T helper cell response. Although a CTL peptide can be directly linked to a T helper peptide, often CTL epitope/HTL epitope conjugates are linked by a spacer molecule. The spacer is typically comprised of relatively small, neutral molecules, such as amino acids or amino acid mimetics, which are substantially uncharged under physiological conditions. The spacers are typically selected from, e.g., Ala, Gly, or other neutral spacers of nonpolar amino acids or neutral polar amino acids. It will be understood that the optionally present spacer need not be comprised of the same residues and thus may be a hetero- or homo-oligomer. When present, the spacer will

usually be at least one or two residues, more usually three to six residues and sometimes 10 or more residues. The CTL peptide epitope can be linked to the T helper peptide epitope either directly or via a spacer either at the amino or carboxy terminus of the CTL peptide. The amino terminus of either the immunogenic peptide or the T helper peptide may be acylated.

In certain embodiments, the T helper peptide is one that is recognized by T helper cells present in a majority of a genetically diverse population. This can be accomplished by selecting peptides that bind to many, most, or all of the HLA class II molecules. Examples of such amino acid bind many HLA Class II molecules include sequences from antigens such as *tetanus toxoid* at positions 830-843 QYIKANSKFIGITE; (SEQ ID NO: 13), *Plasmodium falciparum* circumsporozoite (CS) protein at positions 378-398 DIEKKIAKMEKASSVFNVNS; (SEQ ID NO: 14), and *Streptococcus* 18kD protein at positions 116-131 GAVDSILGGVATYGAA; (SEQ ID NO: 15). Other examples include peptides bearing a DR 1-4-7 supermotif, or either of the DR3 motifs.

Alternatively, it is possible to prepare synthetic peptides capable of stimulating T helper lymphocytes, in a loosely HLA-restricted fashion, using amino acid sequences not found in nature (see, e.g., PCT publication WO 95/07707). These synthetic compounds called Pan-DR-binding epitopes (e.g., PADRE™, Epimmune, Inc., San Diego, CA) are designed, most preferably, to bind most HLA-DR (human HLA class II) molecules. For instance, a *pan-DR-binding epitope* peptide having the formula: xKXVAAWTLKAAx (SEQ ID NO: 16), where "X" is either cyclohexylalanine, phenylalanine, or tyrosine, and a is either D-alanine or L-alanine, has been found to bind to most HLA-DR alleles, and to stimulate the response of T helper lymphocytes from most individuals, regardless of their HLA type. An alternative of a pan-DR binding epitope comprises all "L" natural amino acids and can be provided in the form of nucleic acids that encode the epitope.

HTL peptide epitopes can also be modified to alter their biological properties. For example, they can be modified to include D-amino acids to increase their resistance to proteases and thus extend their serum half life, or they can be conjugated to other molecules such as lipids, proteins, carbohydrates, and the like to increase their biological activity. For example, a T helper peptide can be conjugated to one or more palmitic acid chains at either the amino or carboxyl termini.

### **X.C.3. Combinations of CTL Peptides with T Cell Priming Agents**

In some embodiments it may be desirable to include in the pharmaceutical compositions of the invention at least one component which primes B lymphocytes or T lymphocytes. Lipids have been identified as agents capable of priming CTL *in vivo*. For example, palmitic acid residues can be attached to the  $\epsilon$ - and  $\alpha$ - amino groups of a lysine residue and then linked, e.g., via one or more linking residues such as Gly, Gly-Gly-, Ser, Ser-Ser, or the like, to an immunogenic peptide. The lipidated peptide can then be administered either directly in a micelle or particle, incorporated into a liposome, or emulsified in an adjuvant, e.g., incomplete Freund's adjuvant. In a preferred embodiment, a particularly effective immunogenic composition comprises palmitic acid attached to  $\epsilon$ - and  $\alpha$ - amino groups of Lys, which is attached via linkage, e.g., Ser-Ser, to the amino terminus of the immunogenic peptide.

As another example of lipid priming of CTL responses, *E. coli* lipoproteins, such as tripalmitoyl-S-glycerylcysteinylserine (P<sub>3</sub>CSS) can be used to prime virus specific CTL when covalently attached to an appropriate peptide (see, e.g., Deres, *et al.*, *Nature* 342:561, 1989). Peptides of the invention can be coupled to P<sub>3</sub>CSS, for example, and the lipopeptide administered to an individual to prime specifically an immune response to the target antigen. Moreover, because the induction of neutralizing antibodies can also be primed with P<sub>3</sub>CSS-conjugated epitopes, two such compositions can be combined to more effectively elicit both humoral and cell-mediated responses.

### **X.C.4. Vaccine Compositions Comprising DC Pulsed with CTL and/or HTL Peptides**

An embodiment of a vaccine composition in accordance with the invention comprises *ex vivo* administration of a cocktail of epitope-bearing peptides to PBMC, or isolated DC therefrom, from the patient's blood. A pharmaceutical to facilitate harvesting of DC can be used, such as Progenipoietin™ (Pharmacia-Monsanto, St. Louis, MO) or GM-CSF/IL-4.

After pulsing the DC with peptides and prior to reinfusion into patients, the DC are washed to remove unbound peptides. In this embodiment, a vaccine comprises peptide-pulsed DCs which present the pulsed peptide epitopes complexed with HLA molecules on their surfaces.

The DC can be pulsed *ex vivo* with a cocktail of peptides, some of which stimulate CTL responses to 254P1D6B. Optionally, a helper T cell (HTL) peptide, such as a natural or artificial loosely restricted HLA Class II peptide, can be included to facilitate the CTL response. Thus, a vaccine in accordance with the invention is used to treat a cancer which expresses or overexpresses 254P1D6B.

#### **X.D. Adoptive Immunotherapy**

Antigenic 254P1D6B-related peptides are used to elicit a CTL and/or HTL response *ex vivo*, as well. The resulting CTL or HTL cells, can be used to treat tumors in patients that do not respond to other conventional forms of therapy, or will not respond to a therapeutic vaccine peptide or nucleic acid in accordance with the invention. *Ex vivo* CTL or HTL responses to a particular antigen are induced by incubating in tissue culture the patient's, or genetically compatible, CTL or HTL precursor cells together with a source of antigen-presenting cells (APC), such as dendritic cells, and the appropriate immunogenic peptide. After an appropriate incubation time (typically about 7-28 days), in which the precursor cells are activated and expanded into effector cells, the cells are infused back into the patient, where they will destroy (CTL) or facilitate destruction (HTL) of their specific target cell (e.g., a tumor cell). Transfected dendritic cells may also be used as antigen presenting cells.

#### **X.E. Administration of Vaccines for Therapeutic or Prophylactic Purposes**

Pharmaceutical and vaccine compositions of the invention are typically used to treat and/or prevent a cancer that expresses or overexpresses 254P1D6B. In therapeutic applications, peptide and/or nucleic acid compositions are administered to a patient in an amount sufficient to elicit an effective B cell, CTL and/or HTL response to the antigen and to cure or at least partially arrest or slow symptoms and/or complications. An amount adequate to accomplish this is defined as "therapeutically effective dose." Amounts effective for this use will depend on, e.g., the particular composition administered, the manner of administration, the stage and severity of the disease being treated, the weight and general state of health of the patient, and the judgment of the prescribing physician.

For pharmaceutical compositions, the immunogenic peptides of the invention, or DNA encoding them, are generally administered to an individual already bearing a tumor that expresses 254P1D6B. The peptides or DNA encoding them can be administered individually or as fusions of one or more peptide sequences. Patients can be treated with the immunogenic peptides separately or in conjunction with other treatments, such as surgery, as appropriate.

For therapeutic use, administration should generally begin at the first diagnosis of 254P1D6B-associated cancer. This is followed by boosting doses until at least symptoms are substantially abated and for a period thereafter. The embodiment of the vaccine composition (*i.e.*, including, but not limited to embodiments such as peptide cocktails, polypeptidic polypeptides, minigenes, or TAA-specific CTLs or pulsed dendritic cells) delivered to the patient may vary according to the stage of the disease or the patient's health status. For example, in a patient with a tumor that expresses 254P1D6B, a vaccine comprising 254P1D6B-specific CTL may be more efficacious in killing tumor cells in patient with advanced disease than alternative embodiments.

It is generally important to provide an amount of the peptide epitope delivered by a mode of administration sufficient to stimulate effectively a cytotoxic T cell response; compositions which stimulate helper T cell responses can also be given in accordance with this embodiment of the invention.

The dosage for an initial therapeutic immunization generally occurs in a unit dosage range where the lower value is about 1, 5, 50, 500, or 1,000  $\mu\text{g}$  and the higher value is about 10,000; 20,000; 30,000; or 50,000  $\mu\text{g}$ . Dosage values for a human typically range from about 500  $\mu\text{g}$  to about 50,000  $\mu\text{g}$  per 70 kilogram patient. Boosting dosages of between about 1.0  $\mu\text{g}$  to about 50,000  $\mu\text{g}$  of peptide pursuant to a boosting regimen over weeks to months may be administered depending upon the patient's response and condition as determined by measuring the specific activity of CTL and HTL obtained from the patient's blood. Administration should continue until at least clinical symptoms or laboratory tests indicate that the neoplasia, has been eliminated or reduced and for a period thereafter. The dosages, routes of administration, and dose schedules are adjusted in accordance with methodologies known in the art.

In certain embodiments, the peptides and compositions of the present invention are employed in serious disease states, that is, life-threatening or potentially life threatening situations. In such cases, as a result of the minimal amounts of extraneous substances and the relative nontoxic nature of the peptides in preferred compositions of the invention, it is possible and may be felt desirable by the treating physician to administer substantial excesses of these peptide compositions relative to these stated dosage amounts.

The vaccine compositions of the invention can also be used purely as prophylactic agents. Generally the dosage for an initial prophylactic immunization generally occurs in a unit dosage range where the lower value is about 1, 5, 50, 500, or 1000  $\mu\text{g}$  and the higher value is about 10,000; 20,000; 30,000; or 50,000  $\mu\text{g}$ . Dosage values for a human typically range from about 500  $\mu\text{g}$  to about 50,000  $\mu\text{g}$  per 70 kilogram patient. This is followed by boosting dosages of between about 1.0  $\mu\text{g}$  to about 50,000  $\mu\text{g}$  of peptide administered at defined intervals from about four weeks to six months after the initial administration of vaccine. The immunogenicity of the vaccine can be assessed by measuring the specific activity of CTL and HTL obtained from a sample of the patient's blood.

The pharmaceutical compositions for therapeutic treatment are intended for parenteral, topical, oral, nasal, intrathecal, or local (e.g. as a cream or topical ointment) administration. Preferably, the pharmaceutical compositions are administered parentally, e.g., intravenously, subcutaneously, intradermally, or intramuscularly. Thus, the invention provides compositions for parenteral administration which comprise a solution of the immunogenic peptides dissolved or suspended in an acceptable carrier, preferably an aqueous carrier.

A variety of aqueous carriers may be used, e.g., water, buffered water, 0.8% saline, 0.3% glycine, hyaluronic acid and the like. These compositions may be sterilized by conventional, well-known sterilization techniques, or may be sterile filtered. The resulting aqueous solutions may be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterile solution prior to administration.

The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions, such as pH-adjusting and buffering agents, tonicity adjusting agents, wetting agents, preservatives, and the like, for example, sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, sorbitan monolaurate, triethanolamine oleate, etc.

The concentration of peptides of the invention in the pharmaceutical formulations can vary widely, *i.e.*, from less than about 0.1%, usually at or at least about 2% to as much as 20% to 50% or more by weight, and will be selected primarily by fluid volumes, viscosities, etc., in accordance with the particular mode of administration selected.

A human unit dose form of a composition is typically included in a pharmaceutical composition that comprises a human unit dose of an acceptable carrier, in one embodiment an aqueous carrier, and is administered in a volume/quantity that is known by those of skill in the art to be used for administration of such compositions to humans (see, e.g., Remington's Pharmaceutical Sciences, 17<sup>th</sup> Edition, A. Gennaro, Editor, Mack Publishing Co., Easton, Pennsylvania, 1985). For example a peptide dose for initial immunization can be from about 1 to about 50,000  $\mu\text{g}$ , generally 100-5,000  $\mu\text{g}$ , for a 70 kg patient. For example, for nucleic acids an initial immunization may be performed using an expression vector in the form of naked

nucleic acid administered IM (or SC or ID) in the amounts of 0.5-5 mg at multiple sites. The nucleic acid (0.1 to 1000  $\mu$ g) can also be administered using a gene gun. Following an incubation period of 3-4 weeks, a booster dose is then administered. The booster can be recombinant fowlpox virus administered at a dose of  $5 \cdot 10^7$  to  $5 \cdot 10^9$  pfu.

For antibodies, a treatment generally involves repeated administration of the anti-254P1D6B antibody preparation, via an acceptable route of administration such as intravenous injection (IV), typically at a dose in the range of about 0.1 to about 10 mg/kg body weight. In general, doses in the range of 10-500 mg mAb per week are effective and well tolerated. Moreover, an initial loading dose of approximately 4 mg/kg patient body weight IV, followed by weekly doses of about 2 mg/kg IV of the anti- 254P1D6B mAb preparation represents an acceptable dosing regimen. As appreciated by those of skill in the art, various factors can influence the ideal dose in a particular case. Such factors include, for example, half life of a composition, the binding affinity of an Ab, the immunogenicity of a substance, the degree of 254P1D6B expression in the patient, the extent of circulating shed 254P1D6B antigen, the desired steady-state concentration level, frequency of treatment, and the influence of chemotherapeutic or other agents used in combination with the treatment method of the invention, as well as the health status of a particular patient. Non-limiting preferred human unit doses are, for example, 500 $\mu$ g - 1mg, 1mg - 50mg, 50mg - 100mg, 100mg - 200mg, 200mg - 300mg, 400mg - 500mg, 500mg - 600mg, 600mg - 700mg, 700mg - 800mg, 800mg - 900mg, 900mg - 1g, or 1mg - 700mg. In certain embodiments, the dose is in a range of 2-5 mg/kg body weight, e.g., with follow on weekly doses of 1-3 mg/kg; 0.5mg, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10mg/kg body weight followed, e.g., in two, three or four weeks by weekly doses; 0.5 - 10mg/kg body weight, e.g., followed in two, three or four weeks by weekly doses; 225, 250, 275, 300, 325, 350, 375, 400mg m<sup>2</sup> of body area weekly; 1-600mg m<sup>2</sup> of body area weekly; 225-400mg m<sup>2</sup> of body area weekly; these doses can be followed by weekly doses for 2, 3, 4, 5, 6, 7, 8, 9, 19, 11, 12 or more weeks.

In one embodiment, human unit dose forms of polynucleotides comprise a suitable dosage range or effective amount that provides any therapeutic effect. As appreciated by one of ordinary skill in the art a therapeutic effect depends on a number of factors, including the sequence of the polynucleotide, molecular weight of the polynucleotide and route of administration. Dosages are generally selected by the physician or other health care professional in accordance with a variety of parameters known in the art, such as severity of symptoms, history of the patient and the like. Generally, for a polynucleotide of about 20 bases, a dosage range may be selected from, for example, an independently selected lower limit such as about 0.1, 0.25, 0.5, 1, 2, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400 or 500 mg/kg up to an independently selected upper limit, greater than the lower limit, of about 60, 80, 100, 200, 300, 400, 500, 750, 1000, 1500, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000 or 10,000 mg/kg. For example, a dose may be about any of the following: 0.1 to 100 mg/kg, 0.1 to 50 mg/kg, 0.1 to 25 mg/kg, 0.1 to 10 mg/kg, 1 to 500 mg/kg, 100 to 400 mg/kg, 200 to 300 mg/kg, 1 to 100 mg/kg, 100 to 200 mg/kg, 300 to 400 mg/kg, 400 to 500 mg/kg, 500 to 1000 mg/kg, 500 to 5000 mg/kg, or 500 to 10,000 mg/kg. Generally, parenteral routes of administration may require higher doses of polynucleotide compared to more direct application to the nucleotide to diseased tissue, as do polynucleotides of increasing length.

In one embodiment, human unit dose forms of T-cells comprise a suitable dosage range or effective amount that provides any therapeutic effect. As appreciated by one of ordinary skill in the art, a therapeutic effect depends on a number of factors. Dosages are generally selected by the physician or other health care professional in accordance with a variety of parameters known in the art, such as severity of symptoms, history of the patient and the like. A dose may be about  $10^4$  cells to about  $10^6$  cells, about  $10^6$  cells to about  $10^8$  cells, about  $10^8$  to about  $10^{11}$  cells, or about  $10^8$  to about  $5 \times 10^{10}$  cells. A dose may also be about  $10^6$  cells/m<sup>2</sup> to about  $10^{10}$  cells/m<sup>2</sup>, or about  $10^6$  cells/m<sup>2</sup> to about  $10^8$  cells/m<sup>2</sup>.

Proteins(s) of the invention, and/or nucleic acids encoding the protein(s), can also be administered via liposomes, which may also serve to: 1) target the proteins(s) to a particular tissue, such as lymphoid tissue; 2) to target selectively to diseased cells; or, 3) to increase the half-life of the peptide composition. Liposomes include emulsions, foams, micelles,

insoluble monolayers, liquid crystals, phospholipid dispersions, lamellar layers and the like. In these preparations, the peptide to be delivered is incorporated as part of a liposome, alone or in conjunction with a molecule which binds to a receptor prevalent among lymphoid cells, such as monoclonal antibodies which bind to the CD45 antigen, or with other therapeutic or immunogenic compositions. Thus, liposomes either filled or decorated with a desired peptide of the invention can be directed to the site of lymphoid cells, where the liposomes then deliver the peptide compositions. Liposomes for use in accordance with the invention are formed from standard vesicle-forming lipids, which generally include neutral and negatively charged phospholipids and a sterol, such as cholesterol. The selection of lipids is generally guided by consideration of, e.g., liposome size, acid lability and stability of the liposomes in the blood stream. A variety of methods are available for preparing liposomes, as described in, e.g., Szoka, *et al.*, *Ann. Rev. Biophys. Bioeng.* 9:467 (1980), and U.S. Patent Nos. 4,235,871, 4,501,728, 4,837,028, and 5,019,369.

For targeting cells of the immune system, a ligand to be incorporated into the liposome can include, e.g., antibodies or fragments thereof specific for cell surface determinants of the desired immune system cells. A liposome suspension containing a peptide may be administered intravenously, locally, topically, *etc.* in a dose which varies according to, *inter alia*, the manner of administration, the peptide being delivered, and the stage of the disease being treated.

For solid compositions, conventional nontoxic solid carriers may be used which include, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, magnesium carbonate, and the like. For oral administration, a pharmaceutically acceptable nontoxic composition is formed by incorporating any of the normally employed excipients, such as those carriers previously listed, and generally 10-95% of active ingredient, that is, one or more peptides of the invention, and more preferably at a concentration of 25%-75%.

For aerosol administration, immunogenic peptides are preferably supplied in finely divided form along with a surfactant and propellant. Typical percentages of peptides are about 0.01%-20% by weight, preferably about 1%-10%. The surfactant must, of course, be nontoxic, and preferably soluble in the propellant. Representative of such agents are the esters or partial esters of fatty acids containing from about 6 to 22 carbon atoms, such as caproic, octanoic, lauric, palmitic, stearic, linoleic, linolenic, olesteric and oleic acids with an aliphatic polyhydric alcohol or its cyclic anhydride. Mixed esters, such as mixed or natural glycerides may be employed. The surfactant may constitute about 0.1%-20% by weight of the composition, preferably about 0.25-5%. The balance of the composition is ordinarily propellant. A carrier can also be included, as desired, as with, e.g., lecithin for intranasal delivery.

#### XI.) Diagnostic and Prognostic Embodiments of 254P1D6B.

As disclosed herein, 254P1D6B polynucleotides; polypeptides, reactive cytotoxic T cells (CTL), reactive helper T cells (HTL) and anti-polypeptide antibodies are used in well known diagnostic, prognostic and therapeutic assays that examine conditions associated with dysregulated cell growth such as cancer, in particular the cancers listed in Table I (see, e.g., both its specific pattern of tissue expression as well as its overexpression in certain cancers as described for example in the Example entitled "Expression analysis of 254P1D6B in normal tissues, and patient specimens").

254P1D6B can be analogized to a prostate associated antigen PSA, the archetypal marker that has been used by medical practitioners for years to identify and monitor the presence of prostate cancer (see, e.g., Merrill *et al.*, *J. Urol.* 163(2): 503-5120 (2000); Polascik *et al.*, *J. Urol.* Aug; 162(2):293-306 (1999) and Fortier *et al.*, *J. Nat. Cancer Inst.* 91(19): 1635-1640(1999)). A variety of other diagnostic markers are also used in similar contexts including p53 and K-ras (see, e.g., Tulchinsky *et al.*, *Int J Mol Med* 1999 Jul 4(1):99-102 and Minimoto *et al.*, *Cancer Detect Prev* 2000;24(1):1-12). Therefore, this disclosure of 254P1D6B polynucleotides and polypeptides (as well as 254P1D6B polynucleotide probes and anti-254P1D6B antibodies used to identify the presence of these molecules) and their properties allows skilled artisans to utilize

these molecules in methods that are analogous to those used, for example, in a variety of diagnostic assays directed to examining conditions associated with cancer.

Typical embodiments of diagnostic methods which utilize the 254P1D6B polynucleotides, polypeptides, reactive T cells and antibodies are analogous to those methods from well-established diagnostic assays, which employ, e.g., PSA polynucleotides, polypeptides, reactive T cells and antibodies. For example, just as PSA polynucleotides are used as probes (for example in Northern analysis, see, e.g., Sharief *et al.*, *Biochem. Mol. Biol. Int.* 33(3):567-74(1994)) and primers (for example in PCR analysis, see, e.g., Okegawa *et al.*, *J. Urol.* 163(4): 1189-1190 (2000)) to observe the presence and/or the level of PSA mRNAs in methods of monitoring PSA overexpression or the metastasis of prostate cancers, the 254P1D6B polynucleotides described herein can be utilized in the same way to detect 254P1D6B overexpression or the metastasis of prostate and other cancers expressing this gene. Alternatively, just as PSA polypeptides are used to generate antibodies specific for PSA which can then be used to observe the presence and/or the level of PSA proteins in methods to monitor PSA protein overexpression (see, e.g., Stephan *et al.*, *Urology* 55(4):560-3 (2000)) or the metastasis of prostate cells (see, e.g., Alanen *et al.*, *Pathol. Res. Pract.* 192(3):233-7 (1996)), the 254P1D6B polypeptides described herein can be utilized to generate antibodies for use in detecting 254P1D6B overexpression or the metastasis of prostate cells and cells of other cancers expressing this gene.

Specifically, because metastases involves the movement of cancer cells from an organ of origin (such as the lung or prostate gland etc.) to a different area of the body (such as a lymph node), assays which examine a biological sample for the presence of cells expressing 254P1D6B polynucleotides and/or polypeptides can be used to provide evidence of metastasis. For example, when a biological sample from tissue that does not normally contain 254P1D6B-expressing cells (lymph node) is found to contain 254P1D6B-expressing cells such as the 254P1D6B expression seen in LAPC4 and LAPC9, xenografts isolated from lymph node and bone metastasis, respectively, this finding is indicative of metastasis.

Alternatively 254P1D6B polynucleotides and/or polypeptides can be used to provide evidence of cancer, for example, when cells in a biological sample that do not normally express 254P1D6B or express 254P1D6B at a different level are found to express 254P1D6B or have an increased expression of 254P1D6B (see, e.g., the 254P1D6B expression in the cancers listed in Table I and in patient samples etc. shown in the accompanying Figures). In such assays, artisans may further wish to generate supplementary evidence of metastasis by testing the biological sample for the presence of a second tissue restricted marker (in addition to 254P1D6B) such as PSA, PSCA etc. (see, e.g., Alanen *et al.*, *Pathol. Res. Pract.* 192(3): 233-237 (1996)).

The use of immunohistochemistry to identify the presence of a 254P1D6B polypeptide within a tissue section can indicate an altered state of certain cells within that tissue. It is well understood in the art that the ability of an antibody to localize to a polypeptide that is expressed in cancer cells is a way of diagnosing presence of disease, disease stage, progression and/or tumor aggressiveness. Such an antibody can also detect an altered distribution of the polypeptide within the cancer cells, as compared to corresponding non-malignant tissue.

The 254P1D6B polypeptide and immunogenic compositions are also useful in view of the phenomena of altered subcellular protein localization in disease states. Alteration of cells from normal to diseased state causes changes in cellular morphology and is often associated with changes in subcellular protein localization/distribution. For example, cell membrane proteins that are expressed in a polarized manner in normal cells can be altered in disease, resulting in distribution of the protein in a non-polar manner over the whole cell surface.

The phenomenon of altered subcellular protein localization in a disease state has been demonstrated with MUC1 and Her2 protein expression by use of immunohistochemical means. Normal epithelial cells have a typical apical distribution of MUC1, in addition to some supranuclear localization of the glycoprotein, whereas malignant lesions often demonstrate an apolar staining pattern (Diaz *et al.*, *The Breast Journal*, 7; 40-45 (2001); Zhang *et al.*, *Clinical Cancer Research*, 4; 2669-2676

(1998): Cao, *et al*, The Journal of Histochemistry and Cytochemistry, 45: 1547-1557 (1997)). In addition, normal breast epithelium is either negative for Her2 protein or exhibits only a basolateral distribution whereas malignant cells can express the protein over the whole cell surface (De Potter, *et al*, International Journal of Cancer, 44: 969-974 (1989); McCormick, *et al*, 117: 935-943 (2002)). Alternatively, distribution of the protein may be altered from a surface only localization to include diffuse cytoplasmic expression in the diseased state. Such an example can be seen with MUC1 (Diaz, *et al*, The Breast Journal, 7: 40-45 (2001)).

Alteration in the localization/distribution of a protein in the cell, as detected by immunohistochemical methods, can also provide valuable information concerning the favorability of certain treatment modalities. This last point is illustrated by a situation where a protein may be intracellular in normal tissue, but cell surface in malignant cells; the cell surface location makes the cells favorably amenable to antibody-based diagnostic and treatment regimens. When such an alteration of protein localization occurs for 254P1D6B, the 254P1D6B protein and immune responses related thereto are very useful. Accordingly, the ability to determine whether alteration of subcellular protein localization occurred for 24P4C12 make the 254P1D6B protein and immune responses related thereto very useful. Use of the 254P1D6B compositions allows those skilled in the art to make important diagnostic and therapeutic decisions.

Immunohistochemical reagents specific to 254P1D6B are also useful to detect metastases of tumors expressing 254P1D6B when the polypeptide appears in tissues where 254P1D6B is not normally produced.

Thus, 254P1D6B polypeptides and antibodies resulting from immune responses thereto are useful in a variety of important contexts such as diagnostic, prognostic, preventative and/or therapeutic purposes known to those skilled in the art.

Just as PSA polynucleotide fragments and polynucleotide variants are employed by skilled artisans for use in methods of monitoring PSA, 254P1D6B polynucleotide fragments and polynucleotide variants are used in an analogous manner. In particular, typical PSA polynucleotides used in methods of monitoring PSA are probes or primers which consist of fragments of the PSA cDNA sequence. Illustrating this, primers used to PCR amplify a PSA polynucleotide must include less than the whole PSA sequence to function in the polymerase chain reaction. In the context of such PCR reactions, skilled artisans generally create a variety of different polynucleotide fragments that can be used as primers in order to amplify different portions of a polynucleotide of interest or to optimize amplification reactions (see, e.g., Caetano-Anolles, G. Biotechniques 25(3): 472-476, 478-480 (1998); Robertson *et al*, Methods Mol. Biol. 98:121-154 (1998)). An additional illustration of the use of such fragments is provided in the Example entitled "Expression analysis of 254P1D6B in normal tissues, and patient specimens," where a 254P1D6B polynucleotide fragment is used as a probe to show the expression of 254P1D6B RNAs in cancer cells. In addition, variant polynucleotide sequences are typically used as primers and probes for the corresponding mRNAs in PCR and Northern analyses (see, e.g., Sawai *et al*, Fetal Diagn. Ther. 1996 Nov-Dec 11(6):407-13 and Current Protocols In Molecular Biology, Volume 2, Unit 2, Frederick M. Ausubel *et al*. eds., 1995)). Polynucleotide fragments and variants are useful in this context where they are capable of binding to a target polynucleotide sequence (e.g., a 254P1D6B polynucleotide shown in Figure 2 or variant thereof) under conditions of high stringency.

Furthermore, PSA polypeptides which contain an epitope that can be recognized by an antibody or T cell that specifically binds to that epitope are used in methods of monitoring PSA. 254P1D6B polypeptide fragments and polypeptide analogs or variants can also be used in an analogous manner. This practice of using polypeptide fragments or polypeptide variants to generate antibodies (such as anti-PSA antibodies or T cells) is typical in the art with a wide variety of systems such as fusion proteins being used by practitioners (see, e.g., Current Protocols In Molecular Biology, Volume 2, Unit 16, Frederick M. Ausubel *et al*. eds., 1995). In this context, each epitope(s) functions to provide the architecture with which an antibody or T cell is reactive. Typically, skilled artisans create a variety of different polypeptide fragments that can be used in order to generate immune responses specific for different portions of a polypeptide of interest (see, e.g., U.S. Patent No. 5,840,501 and U.S. Patent No. 5,939,533). For example it may be preferable to utilize a polypeptide comprising one of the

254P1D6B biological motifs discussed herein or a motif-bearing subsequence which is readily identified by one of skill in the art based on motifs available in the art. Polypeptide fragments, variants or analogs are typically useful in this context as long as they comprise an epitope capable of generating an antibody or T cell specific for a target polypeptide sequence (e.g. a 254P1D6B polypeptide shown in Figure 3).

As shown herein, the 254P1D6B polynucleotides and polypeptides (as well as the 254P1D6B polynucleotide probes and anti-254P1D6B antibodies or T cells used to identify the presence of these molecules) exhibit specific properties that make them useful in diagnosing cancers such as those listed in Table I. Diagnostic assays that measure the presence of 254P1D6B gene products, in order to evaluate the presence or onset of a disease condition described herein, such as prostate cancer, are used to identify patients for preventive measures or further monitoring, as has been done so successfully with PSA. Moreover, these materials satisfy a need in the art for molecules having similar or complementary characteristics to PSA in situations where, for example, a definite diagnosis of metastasis of prostatic origin cannot be made on the basis of a test for PSA alone (see, e.g., Alanen *et al.*, *Pathol. Res. Pract.* 192(3): 233-237 (1996)), and consequently, materials such as 254P1D6B polynucleotides and polypeptides (as well as the 254P1D6B polynucleotide probes and anti-254P1D6B antibodies used to identify the presence of these molecules) need to be employed to confirm a metastases of prostatic origin.

Finally, in addition to their use in diagnostic assays, the 254P1D6B polynucleotides disclosed herein have a number of other utilities such as their use in the identification of oncogenetic associated chromosomal abnormalities in the chromosomal region to which the 254P1D6B gene maps (see the Example entitled "Chromosomal Mapping of 254P1D6B" below). Moreover, in addition to their use in diagnostic assays, the 254P1D6B-related proteins and polynucleotides disclosed herein have other utilities such as their use in the forensic analysis of tissues of unknown origin (see, e.g., Takahama K *Forensic Sci Int* 1996 Jun 28;80(1-2): 63-9).

Additionally, 254P1D6B-related proteins or polynucleotides of the invention can be used to treat a pathologic condition characterized by the over-expression of 254P1D6B. For example, the amino acid or nucleic acid sequence of Figure 2 or Figure 3, or fragments of either, can be used to generate an immune response to a 254P1D6B antigen. Antibodies or other molecules that react with 254P1D6B can be used to modulate the function of this molecule, and thereby provide a therapeutic benefit.

## **XII.) Inhibition of 254P1D6B Protein Function**

The invention includes various methods and compositions for inhibiting the binding of 254P1D6B to its binding partner or its association with other protein(s) as well as methods for inhibiting 254P1D6B function.

### **XII.A.) Inhibition of 254P1D6B With Intracellular Antibodies**

In one approach, a recombinant vector that encodes single chain antibodies that specifically bind to 254P1D6B are introduced into 254P1D6B expressing cells via gene transfer technologies. Accordingly, the encoded single chain anti-254P1D6B antibody is expressed intracellularly, binds to 254P1D6B protein, and thereby inhibits its function. Methods for engineering such intracellular single chain antibodies are well known. Such intracellular antibodies, also known as "intrabodies", are specifically targeted to a particular compartment within the cell, providing control over where the inhibitory activity of the treatment is focused. This technology has been successfully applied in the art (for review, see Richardson and Marasco, 1995, *TIBTECH* vol. 13). Intrabodies have been shown to virtually eliminate the expression of otherwise abundant cell surface receptors (see, e.g., Richardson *et al.*, 1995, *Proc. Natl. Acad. Sci. USA* 92: 3137-3141; Beerli *et al.*, 1994, *J. Biol. Chem.* 269: 23931-23936; Deshane *et al.*, 1994, *Gene Ther.* 1: 332-337).

Single chain antibodies comprise the variable domains of the heavy and light chain joined by a flexible linker polypeptide, and are expressed as a single polypeptide. Optionally, single chain antibodies are expressed as a single chain variable region fragment joined to the light chain constant region. Well-known intracellular trafficking signals are engineered into recombinant polynucleotide vectors encoding such single chain antibodies in order to target precisely the intrabody to the desired intracellular compartment. For example, intrabodies targeted to the endoplasmic reticulum (ER) are engineered to incorporate a leader peptide and, optionally, a C-terminal ER retention signal, such as the KDEL amino acid motif. Intrabodies intended to exert activity in the nucleus are engineered to include a nuclear localization signal. Lipid moieties are joined to intrabodies in order to tether the intrabody to the cytosolic side of the plasma membrane. Intrabodies can also be targeted to exert function in the cytosol. For example, cytosolic intrabodies are used to sequester factors within the cytosol, thereby preventing them from being transported to their natural cellular destination.

In one embodiment, intrabodies are used to capture 254P1D6B in the nucleus, thereby preventing its activity within the nucleus. Nuclear targeting signals are engineered into such 254P1D6B intrabodies in order to achieve the desired targeting. Such 254P1D6B intrabodies are designed to bind specifically to a particular 254P1D6B domain. In another embodiment, cytosolic intrabodies that specifically bind to a 254P1D6B protein are used to prevent 254P1D6B from gaining access to the nucleus, thereby preventing it from exerting any biological activity within the nucleus (e.g., preventing 254P1D6B from forming transcription complexes with other factors).

In order to specifically direct the expression of such intrabodies to particular cells, the transcription of the intrabody is placed under the regulatory control of an appropriate tumor-specific promoter and/or enhancer. In order to target intrabody expression specifically to prostate, for example, the PSA promoter and/or promoter/enhancer can be utilized (See, for example, U.S. Patent No. 5,919,652 issued 6 July 1999).

#### **XII.B.) Inhibition of 254P1D6B with Recombinant Proteins**

In another approach, recombinant molecules bind to 254P1D6B and thereby inhibit 254P1D6B function. For example, these recombinant molecules prevent or inhibit 254P1D6B from accessing/binding to its binding partner(s) or associating with other protein(s). Such recombinant molecules can, for example, contain the reactive part(s) of a 254P1D6B specific antibody molecule. In a particular embodiment, the 254P1D6B binding domain of a 254P1D6B binding partner is engineered into a dimeric fusion protein, whereby the fusion protein comprises two 254P1D6B ligand binding domains linked to the Fc portion of a human IgG, such as human IgG1. Such IgG portion can contain, for example, the C<sub>H</sub>2 and C<sub>H</sub>3 domains and the hinge region, but not the C<sub>H</sub>1 domain. Such dimeric fusion proteins are administered in soluble form to patients suffering from a cancer associated with the expression of 254P1D6B, whereby the dimeric fusion protein specifically binds to 254P1D6B and blocks 254P1D6B interaction with a binding partner. Such dimeric fusion proteins are further combined into multimeric proteins using known antibody linking technologies.

#### **XII.C.) Inhibition of 254P1D6B Transcription or Translation**

The present invention also comprises various methods and compositions for inhibiting the transcription of the 254P1D6B gene. Similarly, the invention also provides methods and compositions for inhibiting the translation of 254P1D6B mRNA into protein.

In one approach, a method of inhibiting the transcription of the 254P1D6B gene comprises contacting the 254P1D6B gene with a 254P1D6B antisense polynucleotide. In another approach, a method of inhibiting 254P1D6B mRNA translation comprises contacting a 254P1D6B mRNA with an antisense polynucleotide. In another approach, a 254P1D6B specific ribozyme is used to cleave a 254P1D6B message, thereby inhibiting translation. Such antisense and ribozyme based methods can also be directed to the regulatory regions of the 254P1D6B gene, such as 254P1D6B promoter and/or

enhancer elements. Similarly, proteins capable of inhibiting a 254P1D6B gene transcription factor are used to inhibit 254P1D6B mRNA transcription. The various polynucleotides and compositions useful in the aforementioned methods have been described above. The use of antisense and ribozyme molecules to inhibit transcription and translation is well known in the art.

Other factors that inhibit the transcription of 254P1D6B by interfering with 254P1D6B transcriptional activation are also useful to treat cancers expressing 254P1D6B. Similarly, factors that interfere with 254P1D6B processing are useful to treat cancers that express 254P1D6B. Cancer treatment methods utilizing such factors are also within the scope of the invention.

#### **XII.D.) General Considerations for Therapeutic Strategies**

Gene transfer and gene therapy technologies can be used to deliver therapeutic polynucleotide molecules to tumor cells synthesizing 254P1D6B (i.e., antisense, ribozyme, polynucleotides encoding intrabodies and other 254P1D6B inhibitory molecules). A number of gene therapy approaches are known in the art. Recombinant vectors encoding 254P1D6B antisense polynucleotides, ribozymes, factors capable of interfering with 254P1D6B transcription, and so forth, can be delivered to target tumor cells using such gene therapy approaches.

The above therapeutic approaches can be combined with any one of a wide variety of surgical, chemotherapy or radiation therapy regimens. The therapeutic approaches of the invention can enable the use of reduced dosages of chemotherapy (or other therapies) and/or less frequent administration, an advantage for all patients and particularly for those that do not tolerate the toxicity of the chemotherapeutic agent well.

The anti-tumor activity of a particular composition (e.g., antisense, ribozyme, intrabody), or a combination of such compositions, can be evaluated using various *in vitro* and *in vivo* assay systems. *In vitro* assays that evaluate therapeutic activity include cell growth assays, soft agar assays and other assays indicative of tumor promoting activity, binding assays capable of determining the extent to which a therapeutic composition will inhibit the binding of 254P1D6B to a binding partner, etc.

*In vivo*, the effect of a 254P1D6B therapeutic composition can be evaluated in a suitable animal model. For example, xenogenic prostate cancer models can be used, wherein human prostate cancer explants or passaged xenograft tissues are introduced into immune compromised animals, such as nude or SCID mice (Klein *et al.*, 1997, Nature Medicine 3: 402-408). For example, PCT Patent Application WO98/16628 and U.S. Patent 6,107,540 describe various xenograft models of human prostate cancer capable of recapitulating the development of primary tumors, micrometastasis, and the formation of osteoblastic metastases characteristic of late stage disease. Efficacy can be predicted using assays that measure inhibition of tumor formation, tumor regression or metastasis, and the like.

*In vivo* assays that evaluate the promotion of apoptosis are useful in evaluating therapeutic compositions. In one embodiment, xenografts from tumor bearing mice treated with the therapeutic composition can be examined for the presence of apoptotic foci and compared to untreated control xenograft-bearing mice. The extent to which apoptotic foci are found in the tumors of the treated mice provides an indication of the therapeutic efficacy of the composition.

The therapeutic compositions used in the practice of the foregoing methods can be formulated into pharmaceutical compositions comprising a carrier suitable for the desired delivery method. Suitable carriers include any material that when combined with the therapeutic composition retains the anti-tumor function of the therapeutic composition and is generally non-reactive with the patient's immune system. Examples include, but are not limited to, any of a number of standard pharmaceutical carriers such as sterile phosphate buffered saline solutions, bacteriostatic water, and the like (see, generally, Remington's Pharmaceutical Sciences 16<sup>th</sup> Edition, A. Osal., Ed., 1980).

Therapeutic formulations can be solubilized and administered via any route capable of delivering the therapeutic composition to the tumor site. Potentially effective routes of administration include, but are not limited to, intravenous,

parenteral, intraperitoneal, intramuscular, intratumor, intradermal, intraorgan, orthotopic, and the like. A preferred formulation for intravenous injection comprises the therapeutic composition in a solution of preserved bacteriostatic water, sterile unpreserved water, and/or diluted in polyvinylchloride or polyethylene bags containing 0.9% sterile Sodium Chloride for Injection, USP. Therapeutic protein preparations can be lyophilized and stored as sterile powders, preferably under vacuum, and then reconstituted in bacteriostatic water (containing for example, benzyl alcohol preservative) or in sterile water prior to injection.

Dosages and administration protocols for the treatment of cancers using the foregoing methods will vary with the method and the target cancer, and will generally depend on a number of other factors appreciated in the art.

### **XIII.) Identification, Characterization and Use of Modulators of 254P1D6B**

#### **Methods to Identify and Use Modulators**

In one embodiment, screening is performed to identify modulators that induce or suppress a particular expression profile, suppress or induce specific pathways, preferably generating the associated phenotype thereby. In another embodiment, having identified differentially expressed genes important in a particular state; screens are performed to identify modulators that alter expression of individual genes, either increase or decrease. In another embodiment, screening is performed to identify modulators that alter a biological function of the expression product of a differentially expressed gene. Again, having identified the importance of a gene in a particular state, screens are performed to identify agents that bind and/or modulate the biological activity of the gene product.

In addition, screens are done for genes that are induced in response to a candidate agent. After identifying a modulator (one that suppresses a cancer expression pattern leading to a normal expression pattern, or a modulator of a cancer gene that leads to expression of the gene as in normal tissue) a screen is performed to identify genes that are specifically modulated in response to the agent. Comparing expression profiles between normal tissue and agent-treated cancer tissue reveals genes that are not expressed in normal tissue or cancer tissue, but are expressed in agent treated tissue, and vice versa. These agent-specific sequences are identified and used by methods described herein for cancer genes or proteins. In particular these sequences and the proteins they encode are used in marking or identifying agent-treated cells. In addition, antibodies are raised against the agent-induced proteins and used to target novel therapeutics to the treated cancer tissue sample.

#### **Modulator-related Identification and Screening Assays:**

##### **Gene Expression-related Assays**

Proteins, nucleic acids, and antibodies of the invention are used in screening assays. The cancer-associated proteins, antibodies, nucleic acids, modified proteins and cells containing these sequences are used in screening assays, such as evaluating the effect of drug candidates on a "gene expression profile," expression profile of polypeptides or alteration of biological function. In one embodiment, the expression profiles are used, preferably in conjunction with high throughput screening techniques to allow monitoring for expression profile genes after treatment with a candidate agent (e.g., Davis, GF, et al, J Biol Screen 7:69 (2002); Zlokarnik, et al., Science 279:84-8 (1998); Heid, Genome Res 6:986-94, 1996).

The cancer proteins, antibodies, nucleic acids, modified proteins and cells containing the native or modified cancer proteins or genes are used in screening assays. That is, the present invention comprises methods for screening for compositions which modulate the cancer phenotype or a physiological function of a cancer protein of the invention. This is done on a gene itself or by evaluating the effect of drug candidates on a "gene expression profile" or biological function. In

one embodiment, expression profiles are used, preferably in conjunction with high throughput screening techniques to allow monitoring after treatment with a candidate agent, see Zlokam, *supra*.

A variety of assays are executed directed to the genes and proteins of the invention. Assays are run on an individual nucleic acid or protein level. That is, having identified a particular gene as up regulated in cancer, test compounds are screened for the ability to modulate gene expression or for binding to the cancer protein of the invention. "Modulation" in this context includes an increase or a decrease in gene expression. The preferred amount of modulation will depend on the original change of the gene expression in normal versus tissue undergoing cancer, with changes of at least 10%, preferably 50%, more preferably 100-300%, and in some embodiments 300-1000% or greater. Thus, if a gene exhibits a 4-fold increase in cancer tissue compared to normal tissue, a decrease of about four-fold is often desired; similarly, a 10-fold decrease in cancer tissue compared to normal tissue a target value of a 10-fold increase in expression by the test compound is often desired. Modulators that exacerbate the type of gene expression seen in cancer are also useful, e.g., as an upregulated target in further analyses.

The amount of gene expression is monitored using nucleic acid probes and the quantification of gene expression levels, or, alternatively, a gene product itself is monitored, e.g., through the use of antibodies to the cancer protein and standard immunoassays. Proteomics and separation techniques also allow for quantification of expression.

#### Expression Monitoring to Identify Compounds that Modify Gene Expression

In one embodiment, gene expression monitoring, i.e., an expression profile, is monitored simultaneously for a number of entities. Such profiles will typically involve one or more of the genes of Figure 2. In this embodiment, e.g., cancer nucleic acid probes are attached to biochips to detect and quantify cancer sequences in a particular cell. Alternatively, PCR can be used. Thus, a series, e.g., wells of a microtiter plate, can be used with dispensed primers in desired wells. A PCR reaction can then be performed and analyzed for each well.

Expression monitoring is performed to identify compounds that modify the expression of one or more cancer-associated sequences, e.g., a polynucleotide sequence set out in Figure 2. Generally, a test modulator is added to the cells prior to analysis. Moreover, screens are also provided to identify agents that modulate cancer, modulate cancer proteins of the invention, bind to a cancer protein of the invention, or interfere with the binding of a cancer protein of the invention and an antibody or other binding partner.

In one embodiment, high throughput screening methods involve providing a library containing a large number of potential therapeutic compounds (candidate compounds). Such "combinatorial chemical libraries" are then screened in one or more assays to identify those library members (particular chemical species or subclasses) that display a desired characteristic activity. The compounds thus identified can serve as conventional "lead compounds," as compounds for screening, or as therapeutics.

In certain embodiments, combinatorial libraries of potential modulators are screened for an ability to bind to a cancer polypeptide or to modulate activity. Conventionally, new chemical entities with useful properties are generated by identifying a chemical compound (called a "lead compound") with some desirable property or activity, e.g., inhibiting activity, creating variants of the lead compound, and evaluating the property and activity of those variant compounds. Often, high throughput screening (HTS) methods are employed for such an analysis.

As noted above, gene expression monitoring is conveniently used to test candidate modulators (e.g., protein, nucleic acid or small molecule). After the candidate agent has been added and the cells allowed to incubate for a period, the sample containing a target sequence to be analyzed is, e.g., added to a biochip.

If required, the target sequence is prepared using known techniques. For example, a sample is treated to lyse the cells, using known lysis buffers, electroporation, etc., with purification and/or amplification such as PCR performed as

appropriate. For example, an in vitro transcription with labels covalently attached to the nucleotides is performed. Generally, the nucleic acids are labeled with biotin-FITC or PE, or with cy3 or cy5.

The target sequence can be labeled with, e.g., a fluorescent, a chemiluminescent, a chemical, or a radioactive signal, to provide a means of detecting the target sequence's specific binding to a probe. The label also can be an enzyme, such as alkaline phosphatase or horseradish peroxidase, which when provided with an appropriate substrate produces a product that is detected. Alternatively, the label is a labeled compound or small molecule, such as an enzyme inhibitor, that binds but is not catalyzed or altered by the enzyme. The label also can be a moiety or compound, such as, an epitope tag or biotin which specifically binds to streptavidin. For the example of biotin, the streptavidin is labeled as described above, thereby, providing a detectable signal for the bound target sequence. Unbound labeled streptavidin is typically removed prior to analysis.

As will be appreciated by those in the art, these assays can be direct hybridization assays or can comprise "sandwich assays", which include the use of multiple probes, as is generally outlined in U.S. Patent Nos. 5, 681,702; 5,597,909; 5,545,730; 5,594,117; 5,591,584; 5,571,670; 5,580,731; 5,571,670; 5,591,584; 5,624,802; 5,635,352; 5,594,118; 5,359,100; 5,124, 246; and 5,681,697. In this embodiment, in general, the target nucleic acid is prepared as outlined above, and then added to the biochip comprising a plurality of nucleic acid probes, under conditions that allow the formation of a hybridization complex.

A variety of hybridization conditions are used in the present invention, including high, moderate and low stringency conditions as outlined above. The assays are generally run under stringency conditions which allow formation of the label probe hybridization complex only in the presence of target. Stringency can be controlled by altering a step parameter that is a thermodynamic variable, including, but not limited to, temperature, formamide concentration, salt concentration, chaotropic salt concentration pH, organic solvent concentration, etc. These parameters may also be used to control non-specific binding, as is generally outlined in U.S. Patent No. 5,681,697. Thus, it can be desirable to perform certain steps at higher stringency conditions to reduce non-specific binding.

The reactions outlined herein can be accomplished in a variety of ways. Components of the reaction can be added simultaneously, or sequentially, in different orders, with preferred embodiments outlined below. In addition, the reaction may include a variety of other reagents. These include salts, buffers, neutral proteins, e.g. albumin, detergents, etc. which can be used to facilitate optimal hybridization and detection, and/or reduce nonspecific or background interactions. Reagents that otherwise improve the efficiency of the assay, such as protease inhibitors, nuclease inhibitors, anti-microbial agents, etc., may also be used as appropriate, depending on the sample preparation methods and purity of the target. The assay data are analyzed to determine the expression levels of individual genes, and changes in expression levels as between states, forming a gene expression profile.

#### Biological Activity-related Assays

The invention provides methods identify or screen for a compound that modulates the activity of a cancer-related gene or protein of the invention. The methods comprise adding a test compound, as defined above, to a cell comprising a cancer protein of the invention. The cells contain a recombinant nucleic acid that encodes a cancer protein of the invention. In another embodiment, a library of candidate agents is tested on a plurality of cells.

In one aspect, the assays are evaluated in the presence or absence or previous or subsequent exposure of physiological signals, e.g. hormones, antibodies, peptides, antigens, cytokines, growth factors, action potentials, pharmacological agents including chemotherapeutics, radiation, carcinogenics, or other cells (i.e., cell-cell contacts). In another example, the determinations are made at different stages of the cell cycle process. In this way, compounds that modulate genes or proteins of the invention are identified. Compounds with pharmacological activity are able to enhance or

interfere with the activity of the cancer protein of the invention. Once identified, similar structures are evaluated to identify critical structural features of the compound.

In one embodiment, a method of modulating (e.g., inhibiting) cancer cell division is provided; the method comprises administration of a cancer modulator. In another embodiment, a method of modulating (e.g., inhibiting) cancer is provided; the method comprises administration of a cancer modulator. In a further embodiment, methods of treating cells or individuals with cancer are provided; the method comprises administration of a cancer modulator.

In one embodiment, a method for modulating the status of a cell that expresses a gene of the invention is provided. As used herein status comprises such art-accepted parameters such as growth, proliferation, survival, function, apoptosis, senescence, location, enzymatic activity, signal transduction, etc. of a cell. In one embodiment, a cancer inhibitor is an antibody as discussed above. In another embodiment, the cancer inhibitor is an antisense molecule. A variety of cell growth, proliferation, and metastasis assays are known to those of skill in the art, as described herein.

#### High Throughput Screening to Identify Modulators

The assays to identify suitable modulators are amenable to high throughput screening. Preferred assays thus detect enhancement or inhibition of cancer gene transcription, inhibition or enhancement of polypeptide expression, and inhibition or enhancement of polypeptide activity.

In one embodiment, modulators evaluated in high throughput screening methods are proteins, often naturally occurring proteins or fragments of naturally occurring proteins. Thus, e.g., cellular extracts containing proteins, or random or directed digests of proteinaceous cellular extracts, are used. In this way, libraries of proteins are made for screening in the methods of the invention. Particularly preferred in this embodiment are libraries of bacterial, fungal, viral, and mammalian proteins, with the latter being preferred, and human proteins being especially preferred. Particularly useful test compound will be directed to the class of proteins to which the target belongs, e.g., substrates for enzymes, or ligands and receptors.

#### Use of Soft Agar Growth and Colony Formation to Identify and Characterize Modulators

Normal cells require a solid substrate to attach and grow. When cells are transformed, they lose this phenotype and grow detached from the substrate. For example, transformed cells can grow in stirred suspension culture or suspended in semi-solid media, such as semi-solid or soft agar. The transformed cells, when transfected with tumor suppressor genes, can regenerate normal phenotype and once again require a solid substrate to attach to and grow. Soft agar growth or colony formation in assays are used to identify modulators of cancer sequences, which when expressed in host cells, inhibit abnormal cellular proliferation and transformation. A modulator reduces or eliminates the host cells' ability to grow suspended in solid or semisolid media, such as agar.

Techniques for soft agar growth or colony formation in suspension assays are described in Freshney, *Culture of Animal Cells a Manual of Basic Technique* (3rd ed., 1994). See also, the methods section of Garkavtsev et al. (1996), *supra*.

#### Evaluation of Contact Inhibition and Growth Density Limitation to Identify and Characterize Modulators

Normal cells typically grow in a flat and organized pattern in cell culture until they touch other cells. When the cells touch one another, they are contact inhibited and stop growing. Transformed cells, however, are not contact inhibited and continue to grow to high densities in disorganized foci. Thus, transformed cells grow to a higher saturation density than corresponding normal cells. This is detected morphologically by the formation of a disoriented monolayer of cells or cells in foci. Alternatively, labeling index with (<sup>3</sup>H)-thymidine at saturation density is used to measure density limitation of growth, similarly an MTT or Alamar blue assay will reveal proliferation capacity of cells and the ability of modulators to affect same. See Freshney (1994), *supra*. Transformed cells, when transfected with tumor suppressor genes, can regenerate a normal phenotype and become contact inhibited and would grow to a lower density.

In this assay, labeling index with  $^3\text{H}$ -thymidine at saturation density is a preferred method of measuring density limitation of growth. Transformed host cells are transfected with a cancer-associated sequence and are grown for 24 hours at saturation density in non-limiting medium conditions. The percentage of cells labeling with  $(^3\text{H})$ -thymidine is determined by incorporated cpm.

Contact independent growth is used to identify modulators of cancer sequences, which had led to abnormal cellular proliferation and transformation. A modulator reduces or eliminates contact independent growth, and returns the cells to a normal phenotype.

#### Evaluation of Growth Factor or Serum Dependence to Identify and Characterize Modulators

Transformed cells have lower serum dependence than their normal counterparts (see, e.g., Temin, J. Natl. Cancer Inst. 37:167-175 (1966); Eagle et al., J. Exp. Med 131:836-879 (1970)); Freshney, *supra*. This is in part due to release of various growth factors by the transformed cells. The degree of growth factor or serum dependence of transformed host cells can be compared with that of control. For example, growth factor or serum dependence of a cell is monitored in methods to identify and characterize compounds that modulate cancer-associated sequences of the invention.

#### Use of Tumor-specific Marker Levels to Identify and Characterize Modulators

Tumor cells release an increased amount of certain factors (hereinafter "tumor specific markers") than their normal counterparts. For example, plasminogen activator (PA) is released from human glioma at a higher level than from normal brain cells (see, e.g., Gullino, Angiogenesis, Tumor Vascularization, and Potential Interference with Tumor Growth, *in* Biological Responses in Cancer, pp. 178-184 (Mihich (ed.) 1985)). Similarly, Tumor Angiogenesis Factor (TAF) is released at a higher level in tumor cells than their normal counterparts. See, e.g., Folkman, Angiogenesis and Cancer, *Sem Cancer Biol.* (1992)), while bFGF is released from endothelial tumors (Ensoli, B et al).

Various techniques which measure the release of these factors are described in Freshney (1994), *supra*. Also, see, Unkless et al., J. Biol. Chem. 249:4295-4305 (1974); Strickland & Beers, J. Biol. Chem. 251:5694-5702 (1976); Whur et al., Br. J. Cancer 42:305 312 (1980); Gullino, Angiogenesis, Tumor Vascularization, and Potential Interference with Tumor Growth, *in* Biological Responses in Cancer, pp. 178-184 (Mihich (ed.) 1985); Freshney, *Anticancer Res.* 5:111-130 (1985). For example, tumor specific marker levels are monitored in methods to identify and characterize compounds that modulate cancer-associated sequences of the invention.

#### Invasiveness into Matrigel to Identify and Characterize Modulators

The degree of invasiveness into Matrigel or an extracellular matrix constituent can be used as an assay to identify and characterize compounds that modulate cancer associated sequences. Tumor cells exhibit a positive correlation between malignancy and invasiveness of cells into Matrigel or some other extracellular matrix constituent. In this assay, tumorigenic cells are typically used as host cells. Expression of a tumor suppressor gene in these host cells would decrease invasiveness of the host cells. Techniques described in Cancer Res. 1999; 59:6010; Freshney (1994), *supra*, can be used. Briefly, the level of invasion of host cells is measured by using filters coated with Matrigel or some other extracellular matrix constituent. Penetration into the gel, or through to the distal side of the filter, is rated as invasiveness, and rated histologically by number of cells and distance moved, or by prelabeling the cells with  $^{125}\text{I}$  and counting the radioactivity on the distal side of the filter or bottom of the dish. See, e.g., Freshney (1984), *supra*.

#### Evaluation of Tumor Growth *In Vivo* to Identify and Characterize Modulators

Effects of cancer-associated sequences on cell growth are tested in transgenic or immune-suppressed organisms. Transgenic organisms are prepared in a variety of art-accepted ways. For example, knock-out transgenic organisms, e.g., mammals such as mice, are made, in which a cancer gene is disrupted or in which a cancer gene is inserted. Knock-out transgenic mice are made by insertion of a marker gene or other heterologous gene into the endogenous cancer gene site in the mouse genome via homologous recombination. Such mice can also be made by substituting the endogenous cancer

gene with a mutated version of the cancer gene, or by mutating the endogenous cancer gene, e.g., by exposure to carcinogens.

To prepare transgenic chimeric animals, e.g., mice, a DNA construct is introduced into the nuclei of embryonic stem cells. Cells containing the newly engineered genetic lesion are injected into a host mouse embryo, which is re-implanted into a recipient female. Some of these embryos develop into chimeric mice that possess germ cells some of which are derived from the mutant cell line. Therefore, by breeding the chimeric mice it is possible to obtain a new line of mice containing the introduced genetic lesion (see, e.g., Capecchi et al., *Science* 244:1288 (1989)). Chimeric mice can be derived according to US Patent 6,365,797, issued 2 April 2002; US Patent 6,107,540 issued 22 August 2000; Hogan et al., *Manipulating the Mouse Embryo: A laboratory Manual*, Cold Spring Harbor Laboratory (1988) and *Teratocarcinomas and Embryonic Stem Cells: A Practical Approach*, Robertson, ed., IRL Press, Washington, D.C., (1987).

Alternatively, various immune-suppressed or immune-deficient host animals can be used. For example, a genetically athymic "nude" mouse (see, e.g., Giovanella et al., *J. Natl. Cancer Inst.* 52:921 (1974)), a SCID mouse, a thymectomized mouse, or an irradiated mouse (see, e.g., Bradley et al., *Br. J. Cancer* 38:263 (1978); Selby et al., *Br. J. Cancer* 41:52 (1980)) can be used as a host. Transplantable tumor cells (typically about  $10^6$  cells) injected into isogenic hosts produce invasive tumors in a high proportion of cases, while normal cells of similar origin will not. In hosts which developed invasive tumors, cells expressing cancer-associated sequences are injected subcutaneously or orthotopically. Mice are then separated into groups, including control groups and treated experimental groups) e.g. treated with a modulator). After a suitable length of time, preferably 4-8 weeks, tumor growth is measured (e.g., by volume or by its two largest dimensions, or weight) and compared to the control. Tumors that have statistically significant reduction (using, e.g., Student's T test) are said to have inhibited growth.

#### In Vitro Assays to Identify and Characterize Modulators

Assays to identify compounds with modulating activity can be performed in vitro. For example, a cancer polypeptide is first contacted with a potential modulator and incubated for a suitable amount of time, e.g., from 0.5 to 48 hours. In one embodiment, the cancer polypeptide levels are determined in vitro by measuring the level of protein or mRNA. The level of protein is measured using immunoassays such as Western blotting, ELISA and the like with an antibody that selectively binds to the cancer polypeptide or a fragment thereof. For measurement of mRNA, amplification, e.g., using PCR, LCR, or hybridization assays, e.g., Northern hybridization, RNase protection, dot blotting, are preferred. The level of protein or mRNA is detected using directly or indirectly labeled detection agents, e.g., fluorescently or radioactively labeled nucleic acids, radioactively or enzymatically labeled antibodies, and the like, as described herein.

Alternatively, a reporter gene system can be devised using a cancer protein promoter operably linked to a reporter gene such as luciferase, green fluorescent protein, CAT, or P-gal. The reporter construct is typically transfected into a cell. After treatment with a potential modulator, the amount of reporter gene transcription, translation, or activity is measured according to standard techniques known to those of skill in the art (Davis GF, *supra*; Gonzalez, J. & Negulescu, P. *Curr. Opin. Biotechnol.* 1998: 9:624).

As outlined above, in vitro screens are done on individual genes and gene products. That is, having identified a particular differentially expressed gene as important in a particular state, screening of modulators of the expression of the gene or the gene product itself is performed.

In one embodiment, screening for modulators of expression of specific gene(s) is performed. Typically, the expression of only one or a few genes is evaluated. In another embodiment, screens are designed to first find compounds that bind to differentially expressed proteins. These compounds are then evaluated for the ability to modulate differentially

expressed activity. Moreover, once initial candidate compounds are identified, variants can be further screened to better evaluate structure activity relationships.

#### Binding Assays to Identify and Characterize Modulators

In binding assays in accordance with the invention, a purified or isolated gene product of the invention is generally used. For example, antibodies are generated to a protein of the invention, and immunoassays are run to determine the amount and/or location of protein. Alternatively, cells comprising the cancer proteins are used in the assays.

Thus, the methods comprise combining a cancer protein of the invention and a candidate compound such as a ligand, and determining the binding of the compound to the cancer protein of the invention. Preferred embodiments utilize the human cancer protein; animal models of human disease of can also be developed and used. Also, other analogous mammalian proteins also can be used as appreciated by those of skill in the art. Moreover, in some embodiments variant or derivative cancer proteins are used.

Generally, the cancer protein of the invention, or the ligand, is non-diffusibly bound to an insoluble support. The support can, e.g., be one having isolated sample receiving areas (a microtiter plate, an array, etc.). The insoluble supports can be made of any composition to which the compositions can be bound, is readily separated from soluble material, and is otherwise compatible with the overall method of screening. The surface of such supports can be solid or porous and of any convenient shape.

Examples of suitable insoluble supports include microtiter plates, arrays, membranes and beads. These are typically made of glass, plastic (e.g., polystyrene), polysaccharide, nylon, nitrocellulose, or Teflon™, etc. Microtiter plates and arrays are especially convenient because a large number of assays can be carried out simultaneously, using small amounts of reagents and samples. The particular manner of binding of the composition to the support is not crucial so long as it is compatible with the reagents and overall methods of the invention, maintains the activity of the composition and is nondiffusible. Preferred methods of binding include the use of antibodies which do not sterically block either the ligand binding site or activation sequence when attaching the protein to the support, direct binding to "sticky" or ionic supports, chemical crosslinking, the synthesis of the protein or agent on the surface, etc. Following binding of the protein or ligand/binding agent to the support, excess unbound material is removed by washing. The sample receiving areas may then be blocked through incubation with bovine serum albumin (BSA), casein or other innocuous protein or other moiety.

Once a cancer protein of the invention is bound to the support, and a test compound is added to the assay. Alternatively, the candidate binding agent is bound to the support and the cancer protein of the invention is then added. Binding agents include specific antibodies, non-natural binding agents identified in screens of chemical libraries, peptide analogs, etc.

Of particular interest are assays to identify agents that have a low toxicity for human cells. A wide variety of assays can be used for this purpose, including proliferation assays, cAMP assays, labeled *in vitro* protein-protein binding assays, electrophoretic mobility shift assays, immunoassays for protein binding, functional assays (phosphorylation assays, etc.) and the like.

A determination of binding of the test compound (ligand, binding agent, modulator, etc.) to a cancer protein of the invention can be done in a number of ways. The test compound can be labeled, and binding determined directly, e.g., by attaching all or a portion of the cancer protein of the invention to a solid support, adding a labeled candidate compound (e.g., a fluorescent label), washing off excess reagent, and determining whether the label is present on the solid support. Various blocking and washing steps can be utilized as appropriate.

In certain embodiments, only one of the components is labeled, e.g., a protein of the invention or ligands labeled. Alternatively, more than one component is labeled with different labels, e.g.,  $I^{125}$ , for the proteins and a fluorophore for the compound. Proximity reagents, e.g., quenching or energy transfer reagents are also useful.

#### Competitive Binding to Identify and Characterize Modulators

In one embodiment, the binding of the "test compound" is determined by competitive binding assay with a "competitor." The competitor is a binding moiety that binds to the target molecule (e.g., a cancer protein of the invention). Competitors include compounds such as antibodies, peptides, binding partners, ligands, etc. Under certain circumstances, the competitive binding between the test compound and the competitor displaces the test compound. In one embodiment, the test compound is labeled. Either the test compound, the competitor, or both, is added to the protein for a time sufficient to allow binding. Incubations are performed at a temperature that facilitates optimal activity, typically between four and 40°C. Incubation periods are typically optimized, e.g., to facilitate rapid high throughput screening; typically between zero and one hour will be sufficient. Excess reagent is generally removed or washed away. The second component is then added, and the presence or absence of the labeled component is followed, to indicate binding.

In one embodiment, the competitor is added first, followed by the test compound. Displacement of the competitor is an indication that the test compound is binding to the cancer protein and thus is capable of binding to, and potentially modulating, the activity of the cancer protein. In this embodiment, either component can be labeled. Thus, e.g., if the competitor is labeled, the presence of label in the post-test compound wash solution indicates displacement by the test compound. Alternatively, if the test compound is labeled, the presence of the label on the support indicates displacement.

In an alternative embodiment, the test compound is added first, with incubation and washing, followed by the competitor. The absence of binding by the competitor indicates that the test compound binds to the cancer protein with higher affinity than the competitor. Thus, if the test compound is labeled, the presence of the label on the support, coupled with a lack of competitor binding, indicates that the test compound binds to and thus potentially modulates the cancer protein of the invention.

Accordingly, the competitive binding methods comprise differential screening to identify agents that are capable of modulating the activity of the cancer proteins of the invention. In this embodiment, the methods comprise combining a cancer protein and a competitor in a first sample. A second sample comprises a test compound, the cancer protein, and a competitor. The binding of the competitor is determined for both samples, and a change, or difference in binding between the two samples indicates the presence of an agent capable of binding to the cancer protein and potentially modulating its activity. That is, if the binding of the competitor is different in the second sample relative to the first sample, the agent is capable of binding to the cancer protein.

Alternatively, differential screening is used to identify drug candidates that bind to the native cancer protein, but cannot bind to modified cancer proteins. For example the structure of the cancer protein is modeled and used in rational drug design to synthesize agents that interact with that site, agents which generally do not bind to site-modified proteins. Moreover, such drug candidates that affect the activity of a native cancer protein are also identified by screening drugs for the ability to either enhance or reduce the activity of such proteins.

Positive controls and negative controls can be used in the assays. Preferably control and test samples are performed in at least triplicate to obtain statistically significant results. Incubation of all samples occurs for a time sufficient to allow for the binding of the agent to the protein. Following incubation, samples are washed free of non-specifically bound material and the amount of bound, generally labeled agent determined. For example, where a radiolabel is employed, the samples can be counted in a scintillation counter to determine the amount of bound compound.

A variety of other reagents can be included in the screening assays. These include reagents like salts, neutral proteins, e.g. albumin, detergents, etc. which are used to facilitate optimal protein-protein binding and/or reduce non-specific or background interactions. Also reagents that otherwise improve the efficiency of the assay, such as protease inhibitors, nuclease inhibitors, anti-microbial agents, etc., can be used. The mixture of components is added in an order that provides for the requisite binding.

#### Use of Polynucleotides to Down-regulate or Inhibit a Protein of the Invention.

Polynucleotide modulators of cancer can be introduced into a cell containing the target nucleotide sequence by formation of a conjugate with a ligand-binding molecule, as described in WO 91/04753. Suitable ligand-binding molecules include, but are not limited to, cell surface receptors, growth factors, other cytokines, or other ligands that bind to cell surface receptors. Preferably, conjugation of the ligand binding molecule does not substantially interfere with the ability of the ligand binding molecule to bind to its corresponding molecule or receptor, or block entry of the sense or antisense oligonucleotide or its conjugated version into the cell. Alternatively, a polynucleotide modulator of cancer can be introduced into a cell containing the target nucleic acid sequence, e.g., by formation of a polynucleotide-lipid complex, as described in WO 90/10448. It is understood that the use of antisense molecules or knock out and knock in models may also be used in screening assays as discussed above, in addition to methods of treatment.

#### Inhibitory and Antisense Nucleotides

In certain embodiments, the activity of a cancer-associated protein is down-regulated, or entirely inhibited, by the use of antisense polynucleotide or inhibitory small nuclear RNA (snRNA), i.e., a nucleic acid complementary to, and which can preferably hybridize specifically to, a coding mRNA nucleic acid sequence, e.g., a cancer protein of the invention, mRNA, or a subsequence thereof. Binding of the antisense polynucleotide to the mRNA reduces the translation and/or stability of the mRNA.

In the context of this invention, antisense polynucleotides can comprise naturally occurring nucleotides, or synthetic species formed from naturally occurring subunits or their close homologs. Antisense polynucleotides may also have altered sugar moieties or inter-sugar linkages. Exemplary among these are the phosphorothioate and other sulfur containing species which are known for use in the art. Analogs are comprised by this invention so long as they function effectively to hybridize with nucleotides of the invention. See, e.g., Isis Pharmaceuticals, Carlsbad, CA; Sequitor, Inc., Natick, MA.

Such antisense polynucleotides can readily be synthesized using recombinant means, or can be synthesized in vitro. Equipment for such synthesis is sold by several vendors, including Applied Biosystems. The preparation of other oligonucleotides such as phosphorothioates and alkylated derivatives is also well known to those of skill in the art.

Antisense molecules as used herein include antisense or sense oligonucleotides. Sense oligonucleotides can, e.g., be employed to block transcription by binding to the anti-sense strand. The antisense and sense oligonucleotide comprise a single stranded nucleic acid sequence (either RNA or DNA) capable of binding to target mRNA (sense) or DNA (antisense) sequences for cancer molecules. Antisense or sense oligonucleotides, according to the present invention, comprise a fragment generally at least about 12 nucleotides, preferably from about 12 to 30 nucleotides. The ability to derive an antisense or a sense oligonucleotide, based upon a cDNA sequence encoding a given protein is described in, e.g., Stein & Cohen (Cancer Res. 48:2659 (1988) and van der Krol et al. (BioTechniques 6:958 (1988)).

#### Ribozymes

In addition to antisense polynucleotides, ribozymes can be used to target and inhibit transcription of cancer-associated nucleotide sequences. A ribozyme is an RNA molecule that catalytically cleaves other RNA molecules. Different kinds of ribozymes have been described, including group I ribozymes, hammerhead ribozymes, hairpin ribozymes, RNase P,

and axhead ribozymes (see, e.g., Castanotto et al., *Adv. in Pharmacology* 25: 289-317 (1994) for a general review of the properties of different ribozymes).

The general features of hairpin ribozymes are described, e.g., in Hampel et al., *Nucl. Acids Res.* 18:299-304 (1990); European Patent Publication No. 0360257; U.S. Patent No. 5,254,678. Methods of preparing are well known to those of skill in the art (see, e.g., WO 94/26877; Ojwang et al., *Proc. Natl. Acad. Sci. USA* 90:6340-6344 (1993); Yamada et al., *Human Gene Therapy* 1:39-45 (1994); Leavitt et al., *Proc. Natl. Acad. Sci. USA* 92:699-703 (1995); Leavitt et al., *Human Gene Therapy* 5: 1151-120 (1994); and Yamada et al., *Virology* 205: 121-126 (1994)).

#### Use of Modulators in Phenotypic Screening

In one embodiment, a test compound is administered to a population of cancer cells, which have an associated cancer expression profile. By "administration" or "contacting" herein is meant that the modulator is added to the cells in such a manner as to allow the modulator to act upon the cell, whether by uptake and intracellular action, or by action at the cell surface. In some embodiments, a nucleic acid encoding a proteinaceous agent (i.e., a peptide) is put into a viral construct such as an adenoviral or retroviral construct, and added to the cell, such that expression of the peptide agent is accomplished, e.g., PCT US97/01019. Regulatable gene therapy systems can also be used. Once the modulator has been administered to the cells, the cells are washed if desired and are allowed to incubate under preferably physiological conditions for some period. The cells are then harvested and a new gene expression profile is generated. Thus, e.g., cancer tissue is screened for agents that modulate, e.g., induce or suppress, the cancer phenotype. A change in at least one gene, preferably many, of the expression profile indicates that the agent has an effect on cancer activity. Similarly, altering a biological function or a signaling pathway is indicative of modulator activity. By defining such a signature for the cancer phenotype, screens for new drugs that alter the phenotype are devised. With this approach, the drug target need not be known and need not be represented in the original gene/protein expression screening platform, nor does the level of transcript for the target protein need to change. The modulator inhibiting function will serve as a surrogate marker.

As outlined above, screens are done to assess genes or gene products. That is, having identified a particular differentially expressed gene as important in a particular state, screening of modulators of either the expression of the gene or the gene product itself is performed.

#### Use of Modulators to Affect Peptides of the Invention

Measurements of cancer polypeptide activity, or of the cancer phenotype are performed using a variety of assays. For example, the effects of modulators upon the function of a cancer polypeptide(s) are measured by examining parameters described above. A physiological change that affects activity is used to assess the influence of a test compound on the polypeptides of this invention. When the functional outcomes are determined using intact cells or animals, a variety of effects can be assessed such as, in the case of a cancer associated with solid tumors, tumor growth, tumor metastasis, neovascularization, hormone release, transcriptional changes to both known and uncharacterized genetic markers (e.g., by Northern blots), changes in cell metabolism such as cell growth or pH changes, and changes in intracellular second messengers such as cGNIP.

#### Methods of Identifying Characterizing Cancer-associated Sequences

Expression of various gene sequences is correlated with cancer. Accordingly, disorders based on mutant or variant cancer genes are determined. In one embodiment, the invention provides methods for identifying cells containing variant cancer genes, e.g., determining the presence of, all or part, the sequence of at least one endogenous cancer gene in a cell. This is accomplished using any number of sequencing techniques. The invention comprises methods of identifying

the cancer genotype of an individual, e.g., determining all or part of the sequence of at least one gene of the invention in the individual. This is generally done in at least one tissue of the individual, e.g., a tissue set forth in Table I, and may include the evaluation of a number of tissues or different samples of the same tissue. The method may include comparing the sequence of the sequenced gene to a known cancer gene, i.e., a wild-type gene to determine the presence of family members, homologies, mutations or variants. The sequence of all or part of the gene can then be compared to the sequence of a known cancer gene to determine if any differences exist. This is done using any number of known homology programs, such as BLAST, Bestfit, etc. The presence of a difference in the sequence between the cancer gene of the patient and the known cancer gene correlates with a disease state or a propensity for a disease state, as outlined herein.

In a preferred embodiment, the cancer genes are used as probes to determine the number of copies of the cancer gene in the genome. The cancer genes are used as probes to determine the chromosomal localization of the cancer genes. Information such as chromosomal localization finds use in providing a diagnosis or prognosis in particular when chromosomal abnormalities such as translocations, and the like are identified in the cancer gene locus.

#### **XIV.) RNAi and Therapeutic use of small interfering RNA (siRNAs)**

The present invention is also directed towards siRNA oligonucleotides, particularly double stranded RNAs encompassing at least a fragment of the 254P1D6B coding region or 5' UTR regions, or complement, or any antisense oligonucleotide specific to the 254P1D6B sequence. In one embodiment such oligonucleotides are used to elucidate a function of 254P1D6B, or are used to screen for or evaluate modulators of 254P1D6B function or expression. In another embodiment, gene expression of 254P1D6B is reduced by using siRNA transfection and results in significantly diminished proliferative capacity of transformed cancer cells that endogenously express the antigen; cells treated with specific 254P1D6B siRNAs show reduced survival as measured, e.g., by a metabolic readout of cell viability, correlating to the reduced proliferative capacity. Thus, 254P1D6B siRNA compositions comprise siRNA (double stranded RNA) that correspond to the nucleic acid ORF sequence of the 254P1D6B protein or subsequences thereof; these subsequences are generally 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or more than 35 contiguous RNA nucleotides in length and contain sequences that are complementary and non-complementary to at least a portion of the mRNA coding sequence. In a preferred embodiment, the subsequences are 19-25 nucleotides in length, most preferably 21-23 nucleotides in length.

RNA interference is a novel approach to silencing genes *in vitro* and *in vivo*, thus small double stranded RNAs (siRNAs) are valuable therapeutic agents. The power of siRNAs to silence specific gene activities has now been brought to animal models of disease and is used in humans as well. For example, hydrodynamic infusion of a solution of siRNA into a mouse with a siRNA against a particular target has been proven to be therapeutically effective.

The pioneering work by Song *et al.* indicates that one type of entirely natural nucleic acid, small interfering RNAs (siRNAs), served as therapeutic agents even without further chemical modification (Song, E., et al. "RNA interference targeting Fas protects mice from fulminant hepatitis" *Nat. Med.* 9(3): 347-51(2003)). This work provided the first *in vivo* evidence that infusion of siRNAs into an animal could alleviate disease. In that case, the authors gave mice injections of siRNA designed to silence the FAS protein (a cell death receptor that when over-activated during inflammatory response induces hepatocytes and other cells to die). The next day, the animals were given an antibody specific to Fas. Control mice died of acute liver failure within a few days, while over 80% of the siRNA-treated mice remained free from serious disease and survived. About 80% to 90% of their liver cells incorporated the naked siRNA oligonucleotides. Furthermore, the RNA molecules functioned for 10 days before losing effect after 3 weeks.

For use in human therapy, siRNA is delivered by efficient systems that induce long-lasting RNAi activity. A major caveat for clinical use is delivering siRNAs to the appropriate cells. Hepatocytes seem to be particularly receptive to

exogenous RNA. Today, targets located in the liver are attractive because liver is an organ that can be readily targeted by nucleic acid molecules and viral vectors. However, other tissue and organs targets are preferred as well.

Formulations of siRNAs with compounds that promote transit across cell membranes are used to improve administration of siRNAs in therapy. Chemically modified synthetic siRNA, that are resistant to nucleases and have serum stability have concomitant enhanced duration of RNAi effects, are an additional embodiment.

Thus, siRNA technology is a therapeutic for human malignancy by delivery of siRNA molecules directed to 254P1D6B to individuals with the cancers, such as those listed in Table 1. Such administration of siRNAs leads to reduced growth of cancer cells expressing 254P1D6B, and provides an anti-tumor therapy, lessening the morbidity and/or mortality associated with malignancy.

The effectiveness of this modality of gene product knockdown is significant when measured *in vitro* or *in vivo*. Effectiveness *in vitro* is readily demonstrable through application of siRNAs to cells in culture (as described above) or to aliquots of cancer patient biopsies when *in vitro* methods are used to detect the reduced expression of 254P1D6B protein.

#### **XV.) Kits/Articles of Manufacture**

For use in the laboratory, prognostic, prophylactic, diagnostic and therapeutic applications described herein, kits are within the scope of the invention. Such kits can comprise a carrier, package, or container that is compartmentalized to receive one or more containers such as vials, tubes, and the like, each of the container(s) comprising one of the separate elements to be used in the method, along with a label or insert comprising instructions for use, such as a use described herein. For example, the container(s) can comprise a probe that is or can be detectably labeled. Such probe can be an antibody or polynucleotide specific for a protein or a gene or message of the invention, respectively. Where the method utilizes nucleic acid hybridization to detect the target nucleic acid, the kit can also have containers containing nucleotide(s) for amplification of the target nucleic acid sequence. Kits can comprise a container comprising a reporter, such as a biotin-binding protein, such as avidin or streptavidin, bound to a reporter molecule, such as an enzymatic, fluorescent, or radioisotope label; such a reporter can be used with, e.g., a nucleic acid or antibody. The kit can include all or part of the amino acid sequences in Figure 2 or Figure 3 or analogs thereof, or a nucleic acid molecule that encodes such amino acid sequences.

The kit of the invention will typically comprise the container described above and one or more other containers associated therewith that comprise materials desirable from a commercial and user standpoint, including buffers, diluents, filters, needles, syringes; carrier, package, container, vial and/or tube labels listing contents and/or instructions for use, and package inserts with instructions for use.

A label can be present on or with the container to indicate that the composition is used for a specific therapy or non-therapeutic application, such as a prognostic, prophylactic, diagnostic or laboratory application, and can also indicate directions for either *in vivo* or *in vitro* use, such as those described herein. Directions and or other information can also be included on an insert(s) or label(s) which is included with or on the kit. The label can be on or associated with the container. A label can be on a container when letters, numbers or other characters forming the label are molded or etched into the container itself; a label can be associated with a container when it is present within a receptacle or carrier that also holds the container, e.g., as a package insert. The label can indicate that the composition is used for diagnosing, treating, prophylaxing or prognosing a condition, such as a neoplasia of a tissue set forth in Table I.

The terms "kit" and "article of manufacture" can be used as synonyms.

In another embodiment of the invention, an article(s) of manufacture containing compositions, such as amino acid sequence(s), small molecule(s), nucleic acid sequence(s), and/or antibody(s), e.g., materials useful for the diagnosis, prognosis, prophylaxis and/or treatment of neoplasias of tissues such as those set forth in Table I is provided. The article of

manufacture typically comprises at least one container and at least one label. Suitable containers include, for example, bottles, vials, syringes, and test tubes. The containers can be formed from a variety of materials such as glass, metal or plastic. The container can hold amino acid sequence(s), small molecule(s), nucleic acid sequence(s), cell population(s) and/or antibody(s). In one embodiment, the container holds a polynucleotide for use in examining the mRNA expression profile of a cell, together with reagents used for this purpose. In another embodiment a container comprises an antibody, binding fragment thereof or specific binding protein for use in evaluating protein expression of 282P1G3 in cells and tissues, or for relevant laboratory, prognostic, diagnostic, prophylactic and therapeutic purposes; indications and/or directions for such uses can be included on or with such container, as can reagents and other compositions or tools used for these purposes. In another embodiment, a container comprises materials for eliciting a cellular or humoral immune response, together with associated indications and/or directions. In another embodiment, a container comprises materials for adoptive immunotherapy, such as cytotoxic T cells (CTL) or helper T cells (HTL), together with associated indications and/or directions; reagents and other compositions or tools used for such purpose can also be included.

The container can alternatively hold a composition that is effective for treating, diagnosis, prognosing or prophylaxing a condition and can have a sterile access port (for example the container can be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle). The active agents in the composition can be an antibody capable of specifically binding 282P1G3 and modulating the function of 282P1G3.

The article of manufacture can further comprise a second container comprising a pharmaceutically-acceptable buffer, such as phosphate-buffered saline, Ringer's solution and/or dextrose solution. It can further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, stirrers, needles, syringes, and/or package inserts with indications and/or instructions for use.

#### **EXAMPLES:**

Various aspects of the invention are further described and illustrated by way of the several examples that follow, none of which is intended to limit the scope of the invention.

#### **Example 1: SSH-Generated Isolation of cDNA Fragment of the 254P1D6B Gene**

To isolate genes that are over-expressed in prostate cancer we used the Suppression Subtractive Hybridization (SSH) procedure using cDNA derived from prostate cancer xenograft tissues. LAPC-9AD xenograft was obtained from Dr. Charles Sawyers (UCLA) and was generated as described (Klein et al., 1997, Nature Med. 3:402-408; Craft et al., 1999, Cancer Res. 59:5030-5036). LAPC-9AD<sup>2</sup> was generated from LAPC-9AD xenograft by growing LAPC-9AD xenograft tissues within a piece of human bone implanted in SCID mice. Tumors were then harvested and subsequently passaged subcutaneously into other SCID animals to generate LAPC-9AD<sup>2</sup>.

The 254P1D6B SSH cDNA of 284 bp is listed in Figure 1. The full length 254P1D6B variant 1 and variants 2-20, cDNAs and ORFs are described in Figure 2 with the protein sequences listed in Figure 3.

#### **Materials and Methods**

##### **RNA Isolation:**

Tumor tissues were homogenized in Trizol reagent (Life Technologies, Gibco BRL) using 10 ml/ g tissue or 10 ml/ 10<sup>8</sup> cells to isolate total RNA. Poly A RNA was purified from total RNA using Qiagen's Oligotex mRNA Mini and Midi kits. Total and mRNA were quantified by spectrophotometric analysis (O.D. 260/280 nm) and analyzed by gel electrophoresis.

##### **Oligonucleotides:**

The following HPLC purified oligonucleotides were used.

DPNCDN (cDNA synthesis primer):5'TTTTGATCAAGCTT<sub>30</sub>3' (SEQ ID NO: 17)Adaptor 1:

5'CTAATACGACTCACTATAGGGCTCGAGCGGCCGCCCGGCAG3' (SEQ ID NO: 18)

3'GGCCCGTCCTAG5' (SEQ ID NO: 19)

Adaptor 2:

5'GTAATACGACTCACTATAGGGCAGCGTGGTCGCGGCCGAG3' (SEQ ID NO: 20)

3'CGGCTCCTAG5' (SEQ ID NO: 21)

PCR primer 1:

5'CTAATACGACTCACTATAGGGC3' (SEQ ID NO: 22)

Nested primer (NP)1:

5'TCGAGCGGCCGCCCGGCAGGA3' (SEQ ID NO: 23)

Nested primer (NP)2:

5'AGCGTGGTCGCGGCCGAGGA3' (SEQ ID NO: 24)

Suppression Subtractive Hybridization:

Suppression Subtractive Hybridization (SSH) was used to identify cDNAs corresponding to genes that may be differentially expressed in prostate cancer. The SSH reaction utilized cDNA from prostate cancer xenograft LAPC-9AD<sup>2</sup>. The gene 254P1D6B was derived from a prostate cancer xenograft LAPC-9AD<sup>2</sup> minus prostate cancer xenograft LAPC-9AD tissues. The SSH DNA sequence (Figure 1) was identified.

The cDNA derived from prostate cancer xenograft LAPC-9AD tissue was used as the source of the "driver" cDNA, while the cDNA from prostate cancer xenograft LAPC-9AD<sup>2</sup> was used as the source of the "tester" cDNA. Double stranded cDNAs corresponding to tester and driver cDNAs were synthesized from 2 µg of poly(A)<sup>+</sup> RNA isolated from the relevant tissue, as described above, using CLONTECH's PCR-Select cDNA Subtraction Kit and 1 ng of oligonucleotide DPNCDN as primer. First- and second-strand synthesis were carried out as described in the Kit's user manual protocol (CLONTECH Protocol No. PT1117-1, Catalog No. K1804-1). The resulting cDNA was digested with Dpn II for 3 hrs at 37°C. Digested cDNA was extracted with phenol/chloroform (1:1) and ethanol precipitated.

Tester cDNA was generated by diluting 1 µl of Dpn II digested cDNA from the relevant tissue source (see above) (400 ng) in 5 µl of water. The diluted cDNA (2 µl, 160 ng) was then ligated to 2 µl of Adaptor 1 and Adaptor 2 (10 µM), in separate ligation reactions, in a total volume of 10 µl at 16°C overnight, using 400 u of T4 DNA ligase (CLONTECH). Ligation was terminated with 1 µl of 0.2 M EDTA and heating at 72°C for 5 min.

The first hybridization was performed by adding 1.5 µl (600 ng) of driver cDNA to each of two tubes containing 1.5 µl (20 ng) Adaptor 1- and Adaptor 2- ligated tester cDNA. In a final volume of 4 µl, the samples were overlaid with mineral oil, denatured in an MJ Research thermal cycler at 98°C for 1.5 minutes, and then were allowed to hybridize for 8 hrs at 68°C. The two hybridizations were then mixed together with an additional 1 µl of fresh denatured driver cDNA and were

allowed to hybridize overnight at 68°C. The second hybridization was then diluted in 200 µl of 20 mM Hepes, pH 8.3, 50 mM NaCl, 0.2 mM EDTA, heated at 70°C for 7 min. and stored at -20°C.

#### PCR Amplification, Cloning and Sequencing of Gene Fragments Generated from SSH:

To amplify gene fragments resulting from SSH reactions, two PCR amplifications were performed. In the primary PCR reaction 1 µl of the diluted final hybridization mix was added to 1 µl of PCR primer 1 (10 µM), 0.5 µl dNTP mix (10 µM), 2.5 µl 10 x reaction buffer (CLONTECH) and 0.5 µl 50 x Advantage cDNA polymerase Mix (CLONTECH) in a final volume of 25 µl. PCR 1 was conducted using the following conditions: 75°C for 5 min., 94°C for 25 sec., then 27 cycles of 94°C for 10 sec, 66°C for 30 sec, 72°C for 1.5 min. Five separate primary PCR reactions were performed for each experiment. The products were pooled and diluted 1:10 with water. For the secondary PCR reaction, 1 µl from the pooled and diluted primary PCR reaction was added to the same reaction mix as used for PCR 1, except that primers NP1 and NP2 (10 µM) were used instead of PCR primer 1. PCR 2 was performed using 10-12 cycles of 94°C for 10 sec, 68°C for 30 sec, and 72°C for 1.5 minutes. The PCR products were analyzed using 2% agarose gel electrophoresis.

The PCR products were inserted into pCR2.1 using the T/A vector cloning kit (Invitrogen). Transformed *E. coli* were subjected to blue/white and ampicillin selection. White colonies were picked and arrayed into 96 well plates and were grown in liquid culture overnight. To identify inserts, PCR amplification was performed on 1 ml of bacterial culture using the conditions of PCR1 and NP1 and NP2 as primers. PCR products were analyzed using 2% agarose gel electrophoresis.

Bacterial clones were stored in 20% glycerol in a 96 well format. Plasmid DNA was prepared, sequenced, and subjected to nucleic acid homology searches of the GenBank, dBest, and NCI-CGAP databases.

#### RT-PCR Expression Analysis:

First strand cDNAs can be generated from 1 µg of mRNA with oligo (dT)12-18 priming using the Gibco-BRL Superscript Preamplification system. The manufacturer's protocol was used which included an incubation for 50 min at 42°C with reverse transcriptase followed by RNase H treatment at 37°C for 20 min. After completing the reaction, the volume can be increased to 200 µl with water prior to normalization. First strand cDNAs from 16 different normal human tissues can be obtained from Clontech.

Normalization of the first strand cDNAs from multiple tissues was performed by using the primers 5'atatgccgcgctcgtcgtcgacaa3' (SEQ ID NO: 25) and 5'agccacacgcagctcattgtagaagg 3' (SEQ ID NO: 26) to amplify β-actin. First strand cDNA (5 µl) were amplified in a total volume of 50 µl containing 0.4 µM primers, 0.2 µM each dNTPs, 1XPCR buffer (Clontech, 10 mM Tris-HCL, 1.5 mM MgCl<sub>2</sub>, 50 mM KCl, pH8.3) and 1X KlenTaq DNA polymerase (Clontech). Five µl of the PCR reaction can be removed at 18, 20, and 22 cycles and used for agarose gel electrophoresis. PCR was performed using an MJ Research thermal cycler under the following conditions: Initial denaturation can be at 94°C for 15 sec, followed by a 18, 20, and 22 cycles of 94°C for 15, 65°C for 2 min, 72°C for 5 sec. A final extension at 72°C was carried out for 2 min. After agarose gel electrophoresis, the band intensities of the 283 bp β-actin bands from multiple tissues were compared by visual inspection. Dilution factors for the first strand cDNAs were calculated to result in equal β-actin band intensities in all tissues after 22 cycles of PCR. Three rounds of normalization can be required to achieve equal band intensities in all tissues after 22 cycles of PCR.

To determine expression levels of the 254P1D6B gene, 5 µl of normalized first strand cDNA were analyzed by PCR using 26, and 30 cycles of amplification. Semi-quantitative expression analysis can be achieved by comparing the PCR products at cycle numbers that give light band intensities.

A typical RT-PCR expression analysis is shown in Figures 14(a) and 14(b). First strand cDNA was prepared from vital pool 1 (liver, lung and kidney), vital pool 2 (pancreas, colon and stomach), normal lung ovary cancer pool, lung cancer pool (Figure 14A), as well as from normal stomach, brain, heart, liver, spleen, skeletal muscle, testis, prostate, bladder, kidney, colon, lung and ovary cancer pool (Figure 14B). Normalization was performed by PCR using primers to actin and GAPDH. Semi-quantitative PCR, using primers to 254P1D6B, was performed at 26 and 30 cycles of amplification. Results show strong expression of 254P1D6B in lung cancer pool and ovary cancer pool but not in normal lung nor in vital pool 1. Low expression was detected in vital pool 2.

#### **Example 2: Isolation of Full Length 254P1D6B encoding DNA**

To isolate genes that are involved in prostate cancer, an experiment was conducted using the prostate cancer xenograft LAPC-9AD<sup>2</sup>. The gene 254P1D6B was derived from a subtraction consisting of a prostate cancer xenograft LAPC-9AD<sup>2</sup> minus prostate cancer xenograft LAPC-9AD. The SSH DNA sequence (Figure 1) was designated 254P1D6B. Variants of 254P1D6B were identified (Figures 2 and 3).

#### **Example 3: Chromosomal Mapping of 254P1D6B**

Chromosomal localization can implicate genes in disease pathogenesis. Several chromosome mapping approaches are available including fluorescent *in situ* hybridization (FISH), human/hamster radiation hybrid (RH) panels (Walter et al., 1994; Nature Genetics 7:22; Research Genetics, Huntsville AL), human-rodent somatic cell hybrid panels such as is available from the Cornell Institute (Camden, New Jersey), and genomic viewers utilizing BLAST homologies to sequenced and mapped genomic clones (NCBI, Bethesda, Maryland).

254P1D6B maps to chromosome 6p22 using 254P1D6B sequence and the NCBI BLAST tool: located on the world wide web at: ([ncbi.nlm.nih.gov/genome/seq/page.cgi?F=HsBlast.html&&ORG=Hs](http://ncbi.nlm.nih.gov/genome/seq/page.cgi?F=HsBlast.html&&ORG=Hs)).

#### **Example 4: Expression Analysis of 254P1D6B in Normal Tissues and Patient Specimens**

Figures 14(a) and 14(b) shows expression of 254P1D6B by RT-PCR. First strand cDNA was prepared from vital pool 1 (liver, lung and kidney), vital pool 2 (pancreas, colon and stomach), normal lung ovary cancer pool, lung cancer pool (Figure 14A), as well as from normal stomach, brain, heart, liver, spleen, skeletal muscle, testis, prostate, bladder, kidney, colon, lung and ovary cancer pool (Figure 14B). Normalization was performed by PCR using primers to actin and GAPDH. Semi-quantitative PCR, using primers to 254P1D6B, was performed at 26 and 30 cycles of amplification. Results show strong expression of 254P1D6B in lung cancer pool and ovary cancer pool but not in normal lung nor in vital pool 1. Low expression was detected in vital pool 2.

Figure 15 shows expression of 254P1D6B in normal tissues. Two multiple tissue northern blots (Clontech) both with 2 µg of mRNA/lane were probed with the 254P1D6B sequence. Size standards in kilobases (kb) are indicated on the side. Results show expression of two 254P1D6B transcript, 4.4 kb and 7.5 kb primarily in brain and testis, and only the 4.4 kb transcript in placenta, but not in any other normal tissue tested.

Figure 16 shows expression of 254P1D6B in lung cancer patient specimens. First strand cDNA was prepared from normal lung cancer cell line A427 and a panel of lung cancer patient specimens. Normalization was performed by PCR using primers to actin and GAPDH. Semi-quantitative PCR, using primers to 254P1D6B, was performed at 26 and 30 cycles of amplification. Results show expression of 254P1D6B in 13 out of 30 tumor specimens tested but not in normal lung. Expression was also detected in the A427 cell line.

#### **Example 5: Splice Variants of 254P1D6B**

As used herein, the term variant or comprises Transcript variants and Single Nucleotide Polymorphisms (SNPs). Transcript variants are variants of mature mRNA from the same gene which arise by alternative transcription or alternative splicing. Alternative transcripts are transcripts from the same gene but start transcription at different points. Splice variants are mRNA variants spliced differently from the same transcript. In eukaryotes, when a multi-exon gene is transcribed from genomic DNA, the initial RNA is spliced to produce functional mRNA, which has only exons and is used for translation into an amino acid sequence. Accordingly, a given gene can have zero to many alternative transcripts and each transcript can have zero to many splice variants. Each transcript variant has a unique exon makeup, and can have different coding and/or non-coding (5' or 3' end) portions, from the original transcript. Transcript variants can code for the same, similar or different proteins with the same or a similar function or can encode proteins with different functions, and can be expressed in the same tissue at the same time, or in different tissues at the same time, or in the same tissue at different times, or in different tissues at different times. Proteins encoded by transcript variants can have similar or different subcellular or extracellular localizations, e.g., secreted versus intracellular.

Transcript variants are identified by a variety of art-accepted methods. For example, alternative transcripts and splice variants are identified by full-length cloning experiments, or by use of full-length transcript and EST sequences. First, all human ESTs were grouped into clusters which show direct or indirect identity with each other. Second, ESTs in the same cluster were further grouped into sub-clusters and assembled into a consensus sequence. The original gene sequence is compared to the consensus sequence(s) or other full-length sequences. Each consensus sequence is a potential splice variant for that gene. Even when a variant is identified that is not yet a full-length clone, that portion of the variant is very useful as a research tool, e.g., for antigen generation and for further cloning of the full-length splice variant, using techniques known to those skilled in the art.

Moreover, computer programs are available to those skilled in the art that identify transcript variants based on genomic sequences. Genomic-based transcript variant identification programs include FgenesH (A. Salamov and V. Solovyev, "Ab initio gene finding in Drosophila genomic DNA," *Genome Research*. 2000 April; 10(4):516-22); Grail (URL [compbio.oml.gov/Grail-bin/EmptyGrailForm](http://compbio.oml.gov/Grail-bin/EmptyGrailForm)) and GenScan (URL [genes.mit.edu/GENSCAN.html](http://genes.mit.edu/GENSCAN.html)). For a general discussion of splice variant identification protocols see, e.g., Southan, C., A genomic perspective on human proteases, *FEBS Lett.* 2001 Jun 8; 498(2-3):214-8; de Souza, S.J., *et al.*, Identification of human chromosome 22 transcribed sequences with ORF expressed sequence tags, *Proc. Natl. Acad. Sci U S A*. 2000 Nov 7; 97(23):12690-3.

To further confirm the parameters of a transcript variant, a variety of techniques are available in the art, such as full-length cloning, proteomic validation, PCR-based validation, and 5' RACE validation, etc. (see e.g., Proteomic Validation: Brännan, S.O., *et al.*, Albumin banks peninsula: a new termination variant characterized by electrospray mass spectrometry, *Biochem Biophys Acta*. 1999 Aug 17; 1433(1-2):321-6; Ferranti P, *et al.*, Differential splicing of pre-messenger RNA produces multiple forms of mature caprine alpha(s1)-casein, *Eur J Biochem*. 1997 Oct 1; 249(1):1-7. For PCR-based Validation: Wellmann S, *et al.*, Specific reverse transcription-PCR quantification of vascular endothelial growth factor (VEGF) splice variants by LightCycler technology, *Clin Chem*. 2001 Apr; 47(4):654-60; Jia, H.P., *et al.*, Discovery of new human beta-defensins using a genomics-based approach, *Gene*. 2001 Jan 24; 263(1-2):211-8. For PCR-based and 5' RACE Validation: Brigle, K.E., *et al.*, Organization of the murine reduced folate carrier gene and identification of variant splice forms, *Biochem Biophys Acta*. 1997 Aug 7; 1353(2): 191-8).

It is known in the art that genomic regions are modulated in cancers. When the genomic region to which a gene maps is modulated in a particular cancer, the alternative transcripts or splice variants of the gene are modulated as well. Disclosed herein is that 254P1D6B has a particular expression profile related to cancer (See, e.g., Table I). Alternative transcripts and splice variants of 254P1D6B are also be involved in cancers in the same or different tissues, thus serving as tumor-associated markers/antigens.

Using the full-length gene and EST sequences, one additional transcript variant was identified, designated as 254P1D6B v.3. The boundaries of exons in the original transcript, 254P1D6B v.1 are shown in Table LI. The structures of the transcript variants are shown in Figure 10. Variant 254P1D6B v.3 extended exon 1 of v.1 by 109 base pairs and added an exon in between exons 2 and 3 of v.1.

Table LII shows nucleotide sequence of the transcript variant. Table LIII shows the alignment of the transcript variant with nucleic acid sequence of 254P1D6B v.1. Table LIV lays out amino acid translation of the transcript variant for the identified reading frame orientation. Table LV displays alignments of the amino acid sequence encoded by the splice variant with that of 254P1D6B v.1.

#### **Example 6: Single Nucleotide Polymorphisms of 254P1D6B**

A Single Nucleotide Polymorphism (SNP) is a single base pair variation in a nucleotide sequence at a specific location. At any given point of the genome, there are four possible nucleotide base pairs: A/T, C/G, G/C and T/A. Genotype refers to the specific base pair sequence of one or more locations in the genome of an individual. Haplotype refers to the base pair sequence of more than one location on the same DNA molecule (or the same chromosome in higher organisms), often in the context of one gene or in the context of several tightly linked genes. SNPs that occur on a cDNA are called cSNPs. These cSNPs may change amino acids of the protein encoded by the gene and thus change the functions of the protein. Some SNPs cause inherited diseases; others contribute to quantitative variations in phenotype and reactions to environmental factors including diet and drugs among individuals. Therefore, SNPs and/or combinations of alleles (called haplotypes) have many applications, including diagnosis of inherited diseases, determination of drug reactions and dosage, identification of genes responsible for diseases, and analysis of the genetic relationship between individuals (P. Nowotny, J. M. Kwon and A. M. Goate, "SNP analysis to dissect human traits," *Curr. Opin. Neurobiol.* 2001 Oct; 11(5):637-641; M. Pirmohamed and B. K. Park, "Genetic susceptibility to adverse drug reactions," *Trends Pharmacol. Sci.* 2001 Jun; 22(6):298-305; J. H. Riley, C. J. Allan, E. Lai and A. Roses, "The use of single nucleotide polymorphisms in the isolation of common disease genes," *Pharmacogenomics*. 2000 Feb; 1(1):39-47; R. Judson, J. C. Stephens and A. Windemuth, "The predictive power of haplotypes in clinical response," *Pharmacogenomics*. 2000 Feb; 1(1):15-26).

SNPs are identified by a variety of art-accepted methods (P. Bean, "The promising voyage of SNP target discovery," *Am. Clin. Lab.* 2001 Oct-Nov; 20(9):18-20; K. M. Weiss, "In search of human variation," *Genome Res.* 1998 Jul; 8(7):691-697; M. M. She, "Enabling large-scale pharmacogenetic studies by high-throughput mutation detection and genotyping technologies," *Clin. Chem.* 2001 Feb; 47(2):164-172). For example, SNPs are identified by sequencing DNA fragments that show polymorphism by gel-based methods such as restriction fragment length polymorphism (RFLP) and denaturing gradient gel electrophoresis (DGGE). They can also be discovered by direct sequencing of DNA samples pooled from different individuals or by comparing sequences from different DNA samples. With the rapid accumulation of sequence data in public and private databases, one can discover SNPs by comparing sequences using computer programs (Z. Gu, L. Hillier and P. Y. Kwok, "Single nucleotide polymorphism hunting in cyberspace," *Hum. Mutat.* 1998; 12(4):221-225). SNPs can be verified and genotype or haplotype of an individual can be determined by a variety of methods including direct sequencing and high throughput microarrays (P. Y. Kwok, "Methods for genotyping single nucleotide polymorphisms," *Annu. Rev. Genomics Hum. Genet.* 2001; 2:235-258; M. Kokoris, K. Dix, K. Moynihan, J. Mathis, B. Erwin, P. Grass, B. Hines and A. Dueterhoeft, "High-throughput SNP genotyping with the Masscode system," *Mol. Diagn.* 2000 Dec; 5(4):329-340).

Using the methods described above, seventeen SNPs were identified in the original transcript, 254P1D6B v.1, at positions 286 (C/G), 935 (C/A), 980 (T/G), 2347 (G/A), 3762 (C/T), 3772 (A/G), 3955 (C/T), 4096 (C/T), 4415 (G/A), 4519 (G/A), 4539 (A/G), 4614 (G/T), 5184 (G/C), 5528 (T/G), 5641 (G/A), 6221 (T/C) and 6223 (G/A). The transcripts or proteins with alternative alleles were designated as variants 254P1D6B v.4 through v.20, respectively. Figure 12 shows the

schematic alignment of the SNP variants. Figure 11 shows the schematic alignment of protein variants, corresponding to nucleotide variants. Nucleotide variants that code for the same amino acid sequence as variant 1 are not shown in Figure 11. These alleles of the SNPs, though shown separately here, can occur in different combinations (haplotypes, such as v.2) and in any one of the transcript variants (such as 254P1D6B v.3) that contains the sequence context of the SNPs.

#### **Example 7: Production of Recombinant 254P1D6B in Prokaryotic Systems**

To express recombinant 254P1D6b and 254P1D6b variants in prokaryotic cells, the full or partial length 254P1D6B and 254P1D6B variant cDNA sequences are cloned into any one of a variety of expression vectors known in the art. One or more of the following regions of 254P1D6B variants are expressed: the full length sequence presented in Figures 2 and 3, or any 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or more contiguous amino acids from 254P1D6B, variants, or analogs thereof.

##### **A. *In vitro* transcription and translation constructs:**

**pCRII:** To generate 254P1D6B sense and anti-sense RNA probes for RNA *in situ* investigations, pCRII constructs (Invitrogen, Carlsbad CA) are generated encoding either all or fragments of the 254P1D6B cDNA. The pCRII vector has Sp6 and T7 promoters flanking the insert to drive the transcription of 254P1D6B RNA for use as probes in RNA *in situ* hybridization experiments. These probes are used to analyze the cell and tissue expression of 254P1D6B at the RNA level. Transcribed 254P1D6B RNA representing the cDNA amino acid coding region of the 254P1D6B gene is used in *in vitro* translation systems such as the Tn<sup>TM</sup> Coupled Reticulolysate System (Promega, Corp., Madison, WI) to synthesize 254P1D6B protein.

##### **B. Bacterial Constructs:**

**pGEX Constructs:** To generate recombinant 254P1D6B proteins in bacteria that are fused to the Glutathione S-transferase (GST) protein, all or parts of the 254P1D6B cDNA protein coding sequence are cloned into the pGEX family of GST-fusion vectors (Amersham Pharmacia Biotech, Piscataway, NJ). These constructs allow controlled expression of recombinant 254P1D6B protein sequences with GST fused at the amino-terminus and a six histidine epitope (6X His) at the carboxyl-terminus. The GST and 6X His tags permit purification of the recombinant fusion protein from induced bacteria with the appropriate affinity matrix and allow recognition of the fusion protein with anti-GST and anti-His antibodies. The 6X His tag is generated by adding 6 histidine codons to the cloning primer at the 3' end, e.g., of the open reading frame (ORF). A proteolytic cleavage site, such as the PreScission<sup>TM</sup> recognition site in pGEX-6P-1, may be employed such that it permits cleavage of the GST tag from 254P1D6B-related protein. The ampicillin resistance gene and pBR322 origin permits selection and maintenance of the pGEX plasmids in *E. coli*.

**pMAL Constructs:** To generate, in bacteria, recombinant 254P1D6B proteins that are fused to maltose-binding protein (MBP), all or parts of the 254P1D6B cDNA protein coding sequence are fused to the MBP gene by cloning into the pMAL-c2X and pMAL-p2X vectors (New England Biolabs, Beverly, MA). These constructs allow controlled expression of recombinant 254P1D6B protein sequences with MBP fused at the amino-terminus and a 6X His epitope tag at the carboxyl-terminus. The MBP and 6X His tags permit purification of the recombinant protein from induced bacteria with the appropriate affinity matrix and allow recognition of the fusion protein with anti-MBP and anti-His antibodies. The 6X His epitope tag is generated by adding 6 histidine codons to the 3' cloning primer. A Factor Xa recognition site permits cleavage of the pMAL tag from 254P1D6B. The pMAL-c2X and pMAL-p2X vectors are optimized to express the recombinant protein in the cytoplasm or periplasm respectively. Periplasm expression enhances folding of proteins with disulfide bonds.

**pET Constructs:** To express 254P1D6B in bacterial cells, all or parts of the 254P1D6B cDNA protein coding sequence are cloned into the pET family of vectors (Novagen, Madison, WI). These vectors allow tightly controlled expression of recombinant 254P1D6B protein in bacteria with and without fusion to proteins that enhance solubility, such as

NusA and thioredoxin (Trx), and epitope tags, such as 6X His and S-Tag™ that aid purification and detection of the recombinant protein. For example, constructs are made utilizing pET NusA fusion system 43.1 such that regions of the 254P1D6B protein are expressed as amino-terminal fusions to NusA.

#### C. Yeast Constructs:

**pESC Constructs:** To express 254P1D6B in the yeast species *Saccharomyces cerevisiae* for generation of recombinant protein and functional studies, all or parts of the 254P1D6B cDNA protein coding sequence are cloned into the pESC family of vectors each of which contain 1 of 4 selectable markers, HIS3, TRP1, LEU2, and URA3 (Stratagene, La Jolla, CA). These vectors allow controlled expression from the same plasmid of up to 2 different genes or cloned sequences containing either Flag™ or Myc epitope tags in the same yeast cell. This system is useful to confirm protein-protein interactions of 254P1D6B. In addition, expression in yeast yields similar post-translational modifications, such as glycosylations and phosphorylations that are found when expressed in eukaryotic cells.

**pESP Constructs:** To express 254P1D6B in the yeast species *Saccharomyces pombe*, all or parts of the 254P1D6B cDNA protein coding sequence are cloned into the pESP family of vectors. These vectors allow controlled high level of expression of a 254P1D6B protein sequence that is fused at either the amino terminus or at the carboxyl terminus to GST which aids purification of the recombinant protein. A Flag™ epitope tag allows detection of the recombinant protein with anti-Flag™ antibody.

### **Example 8: Production of Recombinant 254P1D6B in Higher Eukaryotic Systems**

#### **A. Mammalian Constructs:**

To express recombinant 254P1D6B in eukaryotic cells, the full or partial length 254P1D6B cDNA sequences were cloned into any one of a variety of expression vectors known in the art. One or more of the following regions of 254P1D6B were expressed in these constructs, amino acids 1 to 1072, or any 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or more contiguous amino acids from 254P1D6B v.1, v.2, v.5, and v.6; amino acids 1 to 1063 of v.3; or any 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or more contiguous amino acids from 254P1D6B variants, or analogs thereof.

The constructs can be transfected into any one of a wide variety of mammalian cells such as 293T cells. Transfected 293T cell lysates can be probed with the anti-254P1D6B polyclonal serum, described herein.

**pcDNA4/HisMax Constructs:** To express 254P1D6B in mammalian cells, a 254P1D6B ORF, or portions thereof, of 254P1D6B are cloned into pcDNA4/HisMax Version A (Invitrogen, Carlsbad, CA). Protein expression is driven from the cytomegalovirus (CMV) promoter and the SP16 translational enhancer. The recombinant protein has Xpress™ and six histidine (6X His) epitopes fused to the amino-terminus. The pcDNA4/HisMax vector also contains the bovine growth hormone (BGH) polyadenylation signal and transcription termination sequence to enhance mRNA stability along with the SV40 origin for episomal replication and simple vector rescue in cell lines expressing the large T antigen. The Zeocin resistance gene allows for selection of mammalian cells expressing the protein and the ampicillin resistance gene and ColE1 origin permits selection and maintenance of the plasmid in *E. coli*.

**pcDNA3.1/MycHis Constructs:** To express 254P1D6B in mammalian cells, a 254P1D6B ORF, or portions thereof, of 254P1D6B with a consensus Kozak translation initiation site was cloned into pcDNA3.1/MycHis Version A (Invitrogen, Carlsbad, CA). Protein expression was driven from the cytomegalovirus (CMV) promoter. The recombinant proteins have the myc epitope and 6X His epitope fused to the carboxyl-terminus. The pcDNA3.1/MycHis vector also contains the bovine growth hormone (BGH) polyadenylation signal and transcription termination sequence to enhance mRNA stability, along with the SV40 origin for episomal replication and simple vector rescue in cell lines expressing the large

T antigen. The Neomycin resistance gene can be used, as it allows for selection of mammalian cells expressing the protein and the ampicillin resistance gene and ColE1 origin permits selection and maintenance of the plasmid in *E. coli*.

The complete ORF of 254P1D6B v.2 was cloned into the pcDNA3.1/MyHis construct to generate 254P1D6B.pcDNA3.1/MyHis. Figure 17A shows expression of 254P1D6B.pcDNA3.1/MyHis following transfection into 293T cells. 293T cells were transfected with either 254P1D6B.pcDNA3.1/MyHis or pcDNA3.1/MyHis vector control. Forty hours later, cell lysates were collected. Samples were run on an SDS-PAGE acrylamide gel, blotted and stained with anti-his antibody. The blot was developed using the ECL chemiluminescence kit and visualized by autoradiography. Results show expression of 254P1D6B from the 254P1D6B.pcDNA3.1/MyHis construct in the lysates of transfected cells.

**pcDNA3.1/CT-GFP-TOPO Construct:** To express 254P1D6B in mammalian cells and to allow detection of the recombinant proteins using fluorescence, a 254P1D6B ORF, or portions thereof, with a consensus Kozak translation initiation site are cloned into pcDNA3.1/CT-GFP-TOPO (Invitrogen, CA). Protein expression is driven from the cytomegalovirus (CMV) promoter. The recombinant proteins have the Green Fluorescent Protein (GFP) fused to the carboxyl-terminus facilitating non-invasive, *in vivo* detection and cell biology studies. The pcDNA3.1CT-GFP-TOPO vector also contains the bovine growth hormone (BGH) polyadenylation signal and transcription termination sequence to enhance mRNA stability along with the SV40 origin for episomal replication and simple vector rescue in cell lines expressing the large T antigen. The Neomycin resistance gene allows for selection of mammalian cells that express the protein and the ampicillin resistance gene and ColE1 origin permits selection and maintenance of the plasmid in *E. coli*. Additional constructs with an amino-terminal GFP fusion are made in pcDNA3.1/NT-GFP-TOPO spanning the entire length of a 254P1D6B protein.

**PAPtag:** A 254P1D6B ORF, or portions thereof, is cloned into pAPtag-5 (GenHunter Corp. Nashville, TN). This construct generates an alkaline phosphatase fusion at the carboxyl-terminus of a 254P1D6B protein while fusing the IgGκ signal sequence to the amino-terminus. Constructs are also generated in which alkaline phosphatase with an amino-terminal IgGκ signal sequence is fused to the amino-terminus of a 254P1D6B protein. The resulting recombinant 254P1D6B proteins are optimized for secretion into the media of transfected mammalian cells and can be used to identify proteins such as ligands or receptors that interact with 254P1D6B proteins. Protein expression is driven from the CMV promoter and the recombinant proteins also contain myc and 6X His epitopes fused at the carboxyl-terminus that facilitates detection and purification. The Zeocin resistance gene present in the vector allows for selection of mammalian cells expressing the recombinant protein and the ampicillin resistance gene permits selection of the plasmid in *E. coli*.

**pTag5:** A 254P1D6B ORF, or portions thereof, were cloned into pTag-5. This vector is similar to pAPtag but without the alkaline phosphatase fusion. This construct generates 254P1D6B protein with an amino-terminal IgGκ signal sequence and myc and 6X His epitope tags at the carboxyl-terminus that facilitate detection and affinity purification. The resulting recombinant 254P1D6B protein is optimized for secretion into the media of transfected mammalian cells, and is used as immunogen or ligand to identify proteins such as ligands or receptors that interact with the 254P1D6B proteins. Protein expression is driven from the CMV promoter. The Zeocin resistance gene present in the vector allows for selection of mammalian cells expressing the protein, and the ampicillin resistance gene permits selection of the plasmid in *E. coli*.

The extracellular domain, amino acids 26-953, of 254P1D6B v.1 was cloned into the pTag5 construct to generate 254P1D6B.pTag5. Figure 17B shows expression and secretion of the extracellular domain of 254P1D6B following 254P1D6B.pTag5 vector transfection into 293T cells. 293T cells were transfected with 254P1D6B.pTag5 construct. Forty hours later, supernatant as well as cell lysates were collected. Samples were run on an SDS-PAGE acrylamide gel, blotted and stained with anti-his antibody. The blot was developed using the ECL chemiluminescence kit and visualized by autoradiography. Results show expression and secretion of 254P1D6B from the 254P1D6B.pTag5 transfected cells.

**PsecFc:** A 254P1D6B ORF, or portions thereof, is also cloned into psecFc. The psecFc vector was assembled by cloning the human immunoglobulin G1 (IgG) Fc (hinge, CH2, CH3 regions) into pSecTag2 (Invitrogen, California). This

construct generates an IgG1 Fc fusion at the carboxyl-terminus of the 254P1D6B proteins, while fusing the IgGK signal sequence to N-terminus. 254P1D6B fusions utilizing the murine IgG1 Fc region are also used. The resulting recombinant 254P1D6B proteins are optimized for secretion into the media of transfected mammalian cells, and can be used as immunogens or to identify proteins such as ligands or receptors that interact with 254P1D6B protein. Protein expression is driven from the CMV promoter. The hygromycin resistance gene present in the vector allows for selection of mammalian cells that express the recombinant protein, and the ampicillin resistance gene permits selection of the plasmid in *E. coli*.

**pSR $\alpha$  Constructs:** To generate mammalian cell lines that express 254P1D6B constitutively, 254P1D6B ORF, or portions thereof, of 254P1D6B were cloned into pSR $\alpha$  constructs. Amphotropic and ecotropic retroviruses were generated by transfection of pSR $\alpha$  constructs into the 293T-10A1 packaging line or co-transfection of pSR $\alpha$  and a helper plasmid (containing deleted packaging sequences) into the 293 cells, respectively. The retrovirus is used to infect a variety of mammalian cell lines, resulting in the integration of the cloned gene, 254P1D6B, into the host cell-lines. Protein expression is driven from a long terminal repeat (LTR). The Neomycin resistance gene present in the vector allows for selection of mammalian cells that express the protein, and the ampicillin resistance gene and ColE1 origin permit selection and maintenance of the plasmid in *E. coli*. The retroviral vectors can thereafter be used for infection and generation of various cell lines using, for example, PC3, NIH 3T3, TsuPr1, 293 or rat-1 cells.

Additional pSR $\alpha$  constructs are made that fuse an epitope tag such as the FLAG<sup>TM</sup> tag to the carboxyl-terminus of 254P1D6B sequences to allow detection using anti-Flag antibodies. For example, the FLAG<sup>TM</sup> sequence 5' gattacaaggat gacgacgataag 3' (SEQ ID NO: 27) is added to cloning primer at the 3' end of the ORF. Additional pSR $\alpha$  constructs are made to produce both amino-terminal and carboxyl-terminal GFP and myc/6X His fusion proteins of the full-length 254P1D6B proteins.

**Additional Viral Vectors:** Additional constructs are made for viral-mediated delivery and expression of 254P1D6B. High virus titer leading to high level expression of 254P1D6B is achieved in viral delivery systems such as adenoviral vectors and herpes amplicon vectors. A 254P1D6B coding sequences or fragments thereof are amplified by PCR and subcloned into the AdEasy shuttle vector (Stratagene). Recombination and virus packaging are performed according to the manufacturer's instructions to generate adenoviral vectors. Alternatively, 254P1D6B coding sequences or fragments thereof are cloned into the HSV-1 vector (Imgenex) to generate herpes viral vectors. The viral vectors are thereafter used for infection of various cell lines such as PC3, NIH 3T3, 293 or rat-1 cells.

**Regulated Expression Systems:** To control expression of 254P1D6B in mammalian cells, coding sequences of 254P1D6B, or portions thereof, are cloned into regulated mammalian expression systems such as the T-Rex System (Invitrogen), the GeneSwitch System (Invitrogen) and the tightly-regulated Ecdysone System (Stratagene). These systems allow the study of the temporal and concentration dependent effects of recombinant 254P1D6B. These vectors are thereafter used to control expression of 254P1D6B in various cell lines such as PC3, NIH 3T3, 293 or rat-1 cells.

## **B. Baculovirus Expression Systems**

To generate recombinant 254P1D6B proteins in a baculovirus expression system, 254P1D6B ORF, or portions thereof, are cloned into the baculovirus transfer vector pBlueBac 4.5 (Invitrogen), which provides a His-tag at the N-terminus. Specifically, pBlueBac-254P1D6B is co-transfected with helper plasmid pBac-N-Blue (Invitrogen) into SF9 (*Spodoptera frugiperda*) insect cells to generate recombinant baculovirus (see Invitrogen instruction manual for details). Baculovirus is then collected from cell supernatant and purified by plaque assay.

Recombinant 254P1D6B protein is then generated by infection of HighFive insect cells (Invitrogen) with purified baculovirus. Recombinant 254P1D6B protein can be detected using anti-254P1D6B or anti-His-tag antibody. 254P1D6B protein can be purified and used in various cell-based assays or as immunogen to generate polyclonal and monoclonal antibodies specific for 254P1D6B.

### **Example 9: Antigenicity Profiles and Secondary Structure**

Figure 5, Figure 6, Figure 7, Figure 8, and Figure 9 depict graphically five amino acid profiles of 254P1D6B variant 1, each assessment available by accessing the ProtScale website located on the World Wide Web at ([expasy.ch/cgi-bin/protscale.pl](http://expasy.ch/cgi-bin/protscale.pl)) on the ExPasy molecular biology server.

These profiles: Figure 5, Hydrophilicity, (Hopp T.P., Woods K.R., 1981. *Proc. Natl. Acad. Sci. U.S.A.* 78:3824-3828); Figure 6, Hydropathicity, (Kyte J., Doolittle R.F., 1982. *J. Mol. Biol.* 157:105-132); Figure 7, Percentage Accessible Residues (Janin J., 1979 *Nature* 277:491-492); Figure 8, Average Flexibility, (Bhaskaran R., and Ponnuswamy P.K., 1988. *Int. J. Pept. Protein Res.* 32:242-255); Figure 9, Beta-turn (Deleage, G., Roux B. 1987 *Protein Engineering* 1:289-294); and optionally others available in the art, such as on the ProtScale website, were used to identify antigenic regions of each of the 254P1D6B variant proteins. Each of the above amino acid profiles of 254P1D6B variants were generated using the following ProtScale parameters for analysis: 1) A window size of 9; 2) 100% weight of the window edges compared to the window center; and, 3) amino acid profile values normalized to lie between 0 and 1.

Hydrophilicity (Figure 5), Hydropathicity (Figure 6) and Percentage Accessible Residues (Figure 7) profiles were used to determine stretches of hydrophilic amino acids (i.e., values greater than 0.5 on the Hydrophilicity and Percentage Accessible Residues profile, and values less than 0.5 on the Hydropathicity profile). Such regions are likely to be exposed to the aqueous environment, be present on the surface of the protein, and thus available for immune recognition, such as by antibodies.

Average Flexibility (Figure 8) and Beta-turn (Figure 9) profiles determine stretches of amino acids (i.e., values greater than 0.5 on the Beta-turn profile and the Average Flexibility profile) that are not constrained in secondary structures such as beta sheets and alpha helices. Such regions are also more likely to be exposed on the protein and thus accessible to immune recognition, such as by antibodies.

Antigenic sequences of the 254P1D6B variant proteins indicated, e.g., by the profiles set forth in Figure 5, Figure 6, Figure 7, Figure 8, and/or Figure 9 are used to prepare immunogens, either peptides or nucleic acids that encode them, to generate therapeutic and diagnostic anti-254P1D6B antibodies. The immunogen can be any 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50 or more than 50 contiguous amino acids, or the corresponding nucleic acids that encode them, from the 254P1D6B protein variants listed in Figures 2 and 3. In particular, peptide immunogens of the invention can comprise, a peptide region of at least 5 amino acids of Figures 2 and 3 in any whole number increment that includes an amino acid position having a value greater than 0.5 in the Hydrophilicity profiles of Figure 5; a peptide region of at least 5 amino acids of Figures 2 and 3 in any whole number increment that includes an amino acid position having a value less than 0.5 in the Hydropathicity profile of Figures 6; a peptide region of at least 5 amino acids of Figures 2 and 3 in any whole number increment that includes an amino acid position having a value greater than 0.5 in the Percent Accessible Residues profiles of Figure 7; a peptide region of at least 5 amino acids of Figures 2 and 3 in any whole number increment that includes an amino acid position having a value greater than 0.5 in the Average Flexibility profiles on Figure 8; and, a peptide region of at least 5 amino acids of Figures 2 and 3 in any whole number increment that includes an amino acid position having a value greater than 0.5 in the Beta-turn profile of Figures 9. Peptide immunogens of the invention can also comprise nucleic acids that encode any of the foregoing.

All immunogens of the invention, peptide or nucleic acid, can be embodied in human unit dose form, or comprised by a composition that includes a pharmaceutical excipient compatible with human physiology.

The secondary structure of 254P1D6B protein variant 1, namely the predicted presence and location of alpha helices, extended strands, and random coils, are predicted from the primary amino acid sequence using the HNN - Hierarchical Neural Network method (NPS@: Network Protein Sequence Analysis TIBS 2000 March Vol. 25, No 3 [291]:147-

150 Combet C., Blanchet C., Geourjon C. and Deléage G., [http://pbil.ibcp.fr/cgi-bin/npsa\\_automat.pl?page=npsa\\_nn.html](http://pbil.ibcp.fr/cgi-bin/npsa_automat.pl?page=npsa_nn.html)), accessed from the ExPasy molecular biology server located on the World Wide Web at ([expasy.ch/tools/](http://expasy.ch/tools/)). The analysis indicates that 254P1D6B variant 1 is composed of 18.19% alpha helix, 24.81% extended strand, and 57.00% random coil (Figure 13A).

Analysis for the potential presence of transmembrane domains in the 254P1D6B variant protein 1 was carried out using a variety of transmembrane prediction algorithms accessed from the ExPasy molecular biology server located on the World Wide Web at ([expasy.ch/tools/](http://expasy.ch/tools/)). Shown graphically in figure 13B is the result of analysis of variant 1 using the TMpred program and in figure 13C results using the TMHMM program. Both the TMpred program and the TMHMM program predict the presence of 1 transmembrane domain. Analyses of the variants using other structural prediction programs are summarized in Table VI.

#### **Example 10: Generation of 254P1D6B Polyclonal Antibodies**

Polyclonal antibodies can be raised in a mammal, for example, by one or more injections of an immunizing agent and, if desired, an adjuvant. Typically, the immunizing agent and/or adjuvant will be injected in the mammal by multiple subcutaneous or intraperitoneal injections. In addition to immunizing with a full length 254P1D6B protein variant, computer algorithms are employed in design of immunogens that, based on amino acid sequence analysis contain characteristics of being antigenic and available for recognition by the immune system of the immunized host (see the Example entitled "Antigenicity Profiles and Secondary Structures"). Such regions would be predicted to be hydrophilic, flexible, in beta-turn conformations, and be exposed on the surface of the protein (see, e.g., Figure 5, Figure 6, Figure 7, Figure 8, or Figure 9 for amino acid profiles that indicate such regions of 254P1D6B protein variant 1).

For example, recombinant bacterial fusion proteins or peptides containing hydrophilic, flexible, beta-turn regions of 254P1D6B protein variants are used as antigens to generate polyclonal antibodies in New Zealand White rabbits or monoclonal antibodies as described in the Example entitled "Generation of 254P1D6B Monoclonal Antibodies (mAbs)". For example, in 254P1D6B variant 1, such regions include, but are not limited to, amino acids 21-32, amino acids 82-96, amino acids 147-182, amino acids 242-270, amino acids 618-638, amino acids 791-818, and amino acids 980-1072. It is useful to conjugate the immunizing agent to a protein known to be immunogenic in the mammal being immunized. Examples of such immunogenic proteins include, but are not limited to, keyhole limpet hemocyanin (KLH), serum albumin, bovine thyroglobulin, and soybean trypsin inhibitor. In one embodiment, a peptide encoding amino acids 147-182 of 254P1D6B variant 1 was conjugated to KLH and used to immunize a rabbit. Alternatively the immunizing agent may include all or portions of the 254P1D6B variant proteins, analogs or fusion proteins thereof. For example, the 254P1D6B variant 1 amino acid sequence can be fused using recombinant DNA techniques to any one of a variety of fusion protein partners that are well known in the art, such as glutathione-S-transferase (GST) and HIS tagged fusion proteins. In another embodiment, amino acids 980-1072 of 254P1D6B variant 1 is fused to GST using recombinant techniques and the pGEX expression vector, expressed, purified and used to immunize a rabbit. Such fusion proteins are purified from induced bacteria using the appropriate affinity matrix.

Other recombinant bacterial fusion proteins that may be employed include maltose binding protein, LacZ, thioredoxin, NusA, or an immunoglobulin constant region (see the section entitled "Production of 254P1D6B in Prokaryotic Systems" and Current Protocols In Molecular Biology, Volume 2, Unit 16, Frederick M. Ausubel et al. eds., 1995; Linsley, P.S., Brady, W., Urnes, M., Grosmaire, L., Damle, N., and Ledbetter, L. (1991) J. Exp. Med. 174, 561-566).

In addition to bacterial derived fusion proteins, mammalian expressed protein antigens are also used. These antigens are expressed from mammalian expression vectors such as the Tag5 and Fc-fusion vectors (see the section entitled "Production of Recombinant 254P1D6B in Eukaryotic Systems"), and retains post-translational modifications such as glycosylations found in native protein. In one embodiment, amino acids 26-953 of 254P1D6B variant 1 was cloned into the

Tag5 mammalian secretion vector, and expressed in 293T cells (Figure 17). The recombinant protein is purified by metal chelate chromatography from tissue culture supernatants of 293T cells stably expressing the recombinant vector. The purified Tag5 254P1D6B protein is then used as immunogen.

During the immunization protocol, it is useful to mix or emulsify the antigen in adjuvants that enhance the immune response of the host animal. Examples of adjuvants include, but are not limited to, complete Freund's adjuvant (CFA) and MPL-TDM adjuvant (monophosphoryl Lipid A, synthetic trehalose dicorynomycolate).

In a typical protocol, rabbits are initially immunized subcutaneously with up to 200 µg, typically 100-200 µg, of fusion protein or peptide conjugated to KLH mixed in complete Freund's adjuvant (CFA). Rabbits are then injected subcutaneously every two weeks with up to 200 µg, typically 100-200 µg, of the immunogen in incomplete Freund's adjuvant (IFA). Test bleeds are taken approximately 7-10 days following each immunization and used to monitor the titer of the antiserum by ELISA.

To test reactivity and specificity of immune serum, such as the rabbit serum derived from immunization with the GST-fusion of 254P1D6B variant 1 protein, the full-length 254P1D6B variant 1 cDNA is cloned into pCDNA 3.1 myc-his expression vector (Invitrogen, see the Example entitled "Production of Recombinant 254P1D6B in Eukaryotic Systems"). After transfection of the constructs into 293T cells, cell lysates are probed with the anti-254P1D6B serum and with anti-His antibody (Santa Cruz Biotechnologies, Santa Cruz, CA) to determine specific reactivity to denatured 254P1D6B protein using the Western blot technique (Figure 17). In addition, the immune serum is tested by fluorescence microscopy, flow cytometry and immunoprecipitation against 293T and other recombinant 254P1D6B-expressing cells to determine specific recognition of native protein. Western blot, immunoprecipitation, fluorescent microscopy, and flow cytometric techniques using cells that endogenously express 254P1D6B are also carried out to test reactivity and specificity.

Anti-serum from rabbits immunized with 254P1D6B variant fusion proteins, such as GST and MBP fusion proteins, are purified by depletion of antibodies reactive to the fusion partner sequence by passage over an affinity column containing the fusion partner either alone or in the context of an irrelevant fusion protein. For example, antiserum derived from a GST-254P1D6B variant 1 fusion protein is first purified by passage over a column of GST protein covalently coupled to AffiGel matrix (BioRad, Hercules, Calif.). The antiserum is then affinity purified by passage over a column composed of a MBP-254P1D6B fusion protein covalently coupled to Affigel matrix. The serum is then further purified by protein G affinity chromatography to isolate the IgG fraction. Sera from other His-tagged antigens and peptide immunized rabbits as well as fusion partner depleted sera are affinity purified by passage over a column matrix composed of the original protein immunogen or free peptide.

#### **Example 11: Generation of 254P1D6B Monoclonal Antibodies (mAbs)**

In one embodiment, therapeutic mAbs to 254P1D6B variants comprise those that react with epitopes specific for each variant protein or specific to sequences in common between the variants that would disrupt or modulate the biological function of the 254P1D6B variants, for example those that would disrupt the interaction with ligands and binding partners. Immunogens for generation of such mAbs include those designed to encode or contain the entire 254P1D6B protein variant sequence, regions predicted to contain functional motifs, and regions of the 254P1D6B protein variants predicted to be antigenic from computer analysis of the amino acid sequence (see, e.g., Figure 5, Figure 6, Figure 7, Figure 8, or Figure 9, and the Example entitled "Antigenicity Profiles and Secondary Structures"). Immunogens include peptides, recombinant bacterial proteins, and mammalian expressed Tag 5 proteins and human and murine IgG FC fusion proteins. In addition, cells engineered to express high levels of a respective 254P1D6B variant, such as 293T-254P1D6B variant 1 or 300.19-254P1D6B variant 1 murine Pre-B cells, are used to immunize mice.

To generate mAbs to a 254P1D6B variant, mice are first immunized intraperitoneally (IP) with, typically, 10-50 µg of protein immunogen or 10<sup>7</sup> 254P1D6B-expressing cells mixed in complete Freund's adjuvant. Mice are then subsequently immunized IP every 2-4 weeks with, typically, 10-50 µg of protein immunogen or 10<sup>7</sup> cells mixed in incomplete Freund's adjuvant. Alternatively, MPL-TDM adjuvant is used in immunizations. In addition to the above protein and cell-based immunization strategies, a DNA-based immunization protocol is employed in which a mammalian expression vector encoding a 254P1D6B variant sequence is used to immunize mice by direct injection of the plasmid DNA. For example, amino acids 26-953 of 254P1D6B of variant 1 is cloned into the Tag5 mammalian secretion vector and the recombinant vector will then be used as immunogen. In another example the same amino acids are cloned into an Fc-fusion secretion vector in which the 254P1D6B variant 1 sequence is fused at the amino-terminus to an IgK leader sequence and at the carboxyl-terminus to the coding sequence of the human or murine IgG Fc region. This recombinant vector is then used as immunogen. The plasmid immunization protocols are used in combination with purified proteins expressed from the same vector and with cells expressing the respective 254P1D6B variant.

Alternatively, mice may be immunized directly into their footpads. In this case, 10-50 µg of protein immunogen or 10<sup>7</sup> 254P1D6B-expressing cells are injected sub-cutaneously into the footpad of each hind leg. The first immunization is given with Titermax (Sigma™) as an adjuvant and subsequent injections are given with Alum-gel in conjunction with CpG oligonucleotide sequences with the exception of the final injection which is given with PBS. Injections are given twice weekly (every three to four days) for a period of 4 weeks and mice are sacrificed 3-4 days after the final injection, at which point lymph nodes immediately draining from the footpad are harvested and the B-cells are collected for use as antibody producing fusion partners.

During the immunization protocol, test bleeds are taken 7-10 days following an injection to monitor titer and specificity of the immune response. Once appropriate reactivity and specificity is obtained as determined by ELISA, Western blotting, immunoprecipitation, fluorescence microscopy, and flow cytometric analyses, fusion and hybridoma generation is then carried out with established procedures well known in the art (see, e.g., Harlow and Lane, 1988).

In one embodiment for generating 254P1D6B monoclonal antibodies, a GST-fusion of variant 1 antigen encoding amino acids 21-182 is expressed and purified from bacteria. Balb C mice are initially immunized intraperitoneally with 25 µg of the GST-254P1D6B variant 1 protein mixed in complete Freund's adjuvant. Mice are subsequently immunized every two weeks with 25 µg of the antigen mixed in incomplete Freund's adjuvant for a total of three immunizations. ELISA using the GST-fusion antigen and a cleavage product from which the GST portion is removed determines the titer of serum from immunized mice. Reactivity and specificity of serum to full length 254P1D6B variant 1 protein is monitored by Western blotting, immunoprecipitation and flow cytometry using 293T cells transfected with an expression vector encoding the 254P1D6B variant 1 cDNA (see e.g., the Example entitled "Production of Recombinant 254P1D6B in Eukaryotic Systems" and Figure 17). Other recombinant 254P1D6B variant 1-expressing cells or cells endogenously expressing 254P1D6B variant 1 are also used. Mice showing the strongest reactivity are rested and given a final injection of antigen in PBS and then sacrificed four days later. The spleens of the sacrificed mice are harvested and fused to SPO/2 myeloma cells using standard procedures (Harlow and Lane, 1988). Supernatants from HAT selected growth wells are screened by ELISA, Western blot, immunoprecipitation, fluorescent microscopy, and flow cytometry to identify 254P1D6B specific antibody-producing clones.

The binding affinity of 254P1D6B variant specific monoclonal antibodies is determined using standard technologies. Affinity measurements quantify the strength of antibody to epitope binding and are used to help define which 254P1D6B variant monoclonal antibodies preferred for diagnostic or therapeutic use, as appreciated by one of skill in the art. The BIAcore system (Uppsala, Sweden) is a preferred method for determining binding affinity. The BIAcore system uses surface plasmon resonance (SPR, Welford K. 1991, Opt. Quant. Elect. 23:1; Morton and Myszk, 1998, Methods in

Enzymology 295: 268) to monitor biomolecular interactions in real time. BIAcore analysis conveniently generates association rate constants, dissociation rate constants, equilibrium dissociation constants, and affinity constants.

#### **Example 12: HLA Class I and Class II Binding Assays**

HLA class I and class II binding assays using purified HLA molecules are performed in accordance with disclosed protocols (e.g., PCT publications WO 94/20127 and WO 94/03205; Sidney *et al.*, *Current Protocols in Immunology* 18.3.1 (1998); Sidney, *et al.*, *J. Immunol.* 154:247 (1995); Sette, *et al.*, *Mol. Immunol.* 31:813 (1994)). Briefly, purified MHC molecules (5 to 500 nM) are incubated with various unlabeled peptide inhibitors and 1-10 nM <sup>125</sup>I-radiolabeled probe peptides as described. Following incubation, MHC-peptide complexes are separated from free peptide by gel filtration and the fraction of peptide bound is determined. Typically, in preliminary experiments, each MHC preparation is titrated in the presence of fixed amounts of radiolabeled peptides to determine the concentration of HLA molecules necessary to bind 10-20% of the total radioactivity. All subsequent inhibition and direct binding assays are performed using these HLA concentrations.

Since under these conditions  $[label] < [HLA]$  and  $IC_{50} \geq [HLA]$ , the measured  $IC_{50}$  values are reasonable approximations of the true  $K_D$  values. Peptide inhibitors are typically tested at concentrations ranging from 120 µg/ml to 1.2 ng/ml, and are tested in two to four completely independent experiments. To allow comparison of the data obtained in different experiments, a relative binding figure is calculated for each peptide by dividing the  $IC_{50}$  of a positive control for inhibition by the  $IC_{50}$  for each tested peptide (typically unlabeled versions of the radiolabeled probe peptide). For database purposes, and inter-experiment comparisons, relative binding values are compiled. These values can subsequently be converted back into  $IC_{50}$  nM values by dividing the  $IC_{50}$  nM of the positive controls for inhibition by the relative binding of the peptide of interest. This method of data compilation is accurate and consistent for comparing peptides that have been tested on different days, or with different lots of purified MHC.

Binding assays as outlined above may be used to analyze HLA supermotif and/or HLA motif-bearing peptides (see Table IV).

#### **Example 13: Identification of HLA Supermotif- and Motif-Bearing CTL Candidate Epitopes**

HLA vaccine compositions of the invention can include multiple epitopes. The multiple epitopes can comprise multiple HLA supermotifs or motifs to achieve broad population coverage. This example illustrates the identification and confirmation of supermotif- and motif-bearing epitopes for the inclusion in such a vaccine composition. Calculation of population coverage is performed using the strategy described below.

##### **Computer searches and algorithms for identification of supermotif and/or motif-bearing epitopes**

The searches performed to identify the motif-bearing peptide sequences in the Example entitled "Antigenicity Profiles" and Tables VIII-XXI and XXII-XLIX employ the protein sequence data from the gene product of 254P1D6B set forth in Figures 2 and 3, the specific search peptides used to generate the tables are listed in Table VII.

Computer searches for epitopes bearing HLA Class I or Class II supermotifs or motifs are performed as follows. All translated 254P1D6B protein sequences are analyzed using a text string search software program to identify potential peptide sequences containing appropriate HLA binding motifs; such programs are readily produced in accordance with information in the art in view of known motif/supermotif disclosures. Furthermore, such calculations can be made mentally.

Identified A2-, A3-, and DR-supermotif sequences are scored using polynomial algorithms to predict their capacity to bind to specific HLA-Class I or Class II molecules. These polynomial algorithms account for the impact of different amino acids at different positions, and are essentially based on the premise that the overall affinity (or  $\Delta G$ ) of peptide-HLA molecule interactions can be approximated as a linear polynomial function of the type:

$$-\Delta G = a_{1i} \times a_{2i} \times a_{3i} \dots \times a_{ni}$$

where  $a_{ji}$  is a coefficient which represents the effect of the presence of a given amino acid ( $j$ ) at a given position ( $i$ ) along the sequence of a peptide of  $n$  amino acids. The crucial assumption of this method is that the effects at each position are essentially independent of each other (i.e., independent binding of individual side-chains). When residue  $j$  occurs at position  $i$  in the peptide, it is assumed to contribute a constant amount  $j_i$  to the free energy of binding of the peptide irrespective of the sequence of the rest of the peptide.

The method of derivation of specific algorithm coefficients has been described in Gulukota *et al.*, *J. Mol. Biol.* 267:1258-126, 1997; (see also Sidney *et al.*, *Human Immunol.* 45:79-93, 1996; and Southwood *et al.*, *J. Immunol.* 160:3363-3373, 1998). Briefly, for all  $i$  positions, anchor and non-anchor alike, the geometric mean of the average relative binding (ARB) of all peptides carrying  $j$  is calculated relative to the remainder of the group, and used as the estimate of  $j_i$ . For Class II peptides, if multiple alignments are possible, only the highest scoring alignment is utilized, following an iterative procedure. To calculate an algorithm score of a given peptide in a test set, the ARB values corresponding to the sequence of the peptide are multiplied. If this product exceeds a chosen threshold, the peptide is predicted to bind. Appropriate thresholds are chosen as a function of the degree of stringency of prediction desired.

#### Selection of HLA-A2 supertype cross-reactive peptides

Protein sequences from 254P1D6B are scanned utilizing motif identification software, to identify 8-, 9- 10- and 11-mer sequences containing the HLA-A2-supermotif main anchor specificity. Typically, these sequences are then scored using the protocol described above and the peptides corresponding to the positive-scoring sequences are synthesized and tested for their capacity to bind purified HLA-A\*0201 molecules *in vitro* (HLA-A\*0201 is considered a prototype A2 supertype molecule).

These peptides are then tested for the capacity to bind to additional A2-supertype molecules (A\*0202, A\*0203, A\*0206, and A\*6802). Peptides that bind to at least three of the five A2-supertype alleles tested are typically deemed A2-supertype cross-reactive binders. Preferred peptides bind at an affinity equal to or less than 500 nM to three or more HLA-A2 supertype molecules.

#### Selection of HLA-A3 supermotif-bearing epitopes

The 254P1D6B protein sequence(s) scanned above is also examined for the presence of peptides with the HLA-A3-supermotif primary anchors. Peptides corresponding to the HLA A3 supermotif-bearing sequences are then synthesized and tested for binding to HLA-A\*0301 and HLA-A\*1101 molecules, the molecules encoded by the two most prevalent A3-supertype alleles. The peptides that bind at least one of the two alleles with binding affinities of  $\leq 500$  nM, often  $\leq 200$  nM, are then tested for binding cross-reactivity to the other common A3-supertype alleles (e.g., A\*3101, A\*3301, and A\*6801) to identify those that can bind at least three of the five HLA-A3-supertype molecules tested.

#### Selection of HLA-B7 supermotif bearing epitopes

The 254P1D6B protein(s) scanned above is also analyzed for the presence of 8-, 9- 10-, or 11-mer peptides with the HLA-B7-supermotif. Corresponding peptides are synthesized and tested for binding to HLA-B\*0702, the molecule encoded by the most common B7-supertype allele (i.e., the prototype B7 supertype allele). Peptides binding B\*0702 with  $IC_{50}$  of  $\leq 500$  nM are identified using standard methods. These peptides are then tested for binding to other common B7-supertype molecules (e.g., B\*3501, B\*5101, B\*5301, and B\*5401). Peptides capable of binding to three or more of the five B7-supertype alleles tested are thereby identified.

#### Selection of A1 and A24 motif-bearing epitopes

To further increase population coverage, HLA-A1 and -A24 epitopes can also be incorporated into vaccine compositions. An analysis of the 254P1D6B protein can also be performed to identify HLA-A1- and A24-motif-containing sequences.

High affinity and/or cross-reactive binding epitopes that bear other motif and/or supermotifs are identified using analogous methodology.

#### Example 14: Confirmation of Immunogenicity

Cross-reactive candidate CTL A2-supermotif-bearing peptides that are identified as described herein are selected to confirm *in vitro* immunogenicity. Confirmation is performed using the following methodology:

##### Target Cell Lines for Cellular Screening:

The .221A2.1 cell line, produced by transferring the HLA-A2.1 gene into the HLA-A, -B, -C null mutant human B-lymphoblastoid cell line 721.221, is used as the peptide-loaded target to measure activity of HLA-A2.1-restricted CTL. This cell line is grown in RPMI-1640 medium supplemented with antibiotics, sodium pyruvate, nonessential amino acids and 10% (v/v) heat inactivated FCS. Cells that express an antigen of interest, or transfectants comprising the gene encoding the antigen of interest, can be used as target cells to confirm the ability of peptide-specific CTLs to recognize endogenous antigen.

##### Primary CTL Induction Cultures:

*Generation of Dendritic Cells (DC):* PBMCs are thawed in RPMI with 30 µg/ml DNase, washed twice and resuspended in complete medium (RPMI-1640 plus 5% AB human serum, non-essential amino acids, sodium pyruvate, L-glutamine and penicillin/streptomycin). The monocytes are purified by plating  $10 \times 10^6$  PBMC/well in a 6-well plate. After 2 hours at 37°C, the non-adherent cells are removed by gently shaking the plates and aspirating the supernatants. The wells are washed a total of three times with 3 ml RPMI to remove most of the non-adherent and loosely adherent cells. Three ml of complete medium containing 50 ng/ml of GM-CSF and 1,000 U/ml of IL-4 are then added to each well. TNFα is added to the DCs on day 6 at 75 ng/ml and the cells are used for CTL induction cultures on day 7.

*Induction of CTL with DC and Peptide:* CD8+ T-cells are isolated by positive selection with Dynal immunomagnetic beads (Dynabeads® M-450) and the detach-bead® reagent. Typically about  $200\text{--}250 \times 10^6$  PBMC are processed to obtain  $24 \times 10^6$  CD8+ T-cells (enough for a 48-well plate culture). Briefly, the PBMCs are thawed in RPMI with 30 µg/ml DNase, washed once with PBS containing 1% human AB serum and resuspended in PBS/1% AB serum at a concentration of  $20 \times 10^6$  cells/ml. The magnetic beads are washed 3 times with PBS/AB serum, added to the cells (140 µl beads/ $20 \times 10^6$  cells) and incubated for 1 hour at 4°C with continuous mixing. The beads and cells are washed 4x with PBS/AB serum to remove the nonadherent cells and resuspended at  $100 \times 10^6$  cells/ml (based on the original cell number) in PBS/AB serum containing 100 µl/ml detach-bead® reagent and 30 µg/ml DNase. The mixture is incubated for 1 hour at room temperature with continuous mixing. The beads are washed again with PBS/AB/DNase to collect the CD8+ T-cells. The DC are collected and centrifuged at 1300 rpm for 5-7 minutes, washed once with PBS with 1% BSA, counted and pulsed with 40 µg/ml of peptide at a cell concentration of  $1\text{--}2 \times 10^6$ /ml in the presence of 3 µg/ml β<sub>2</sub>-microglobulin for 4 hours at 20°C. The DC are then irradiated (4,200 rads), washed 1 time with medium and counted again.

*Setting up induction cultures:* 0.25 ml cytokine-generated DC (at  $1 \times 10^5$  cells/ml) are co-cultured with 0.25 ml of CD8+ T-cells (at  $2 \times 10^6$  cell/ml) in each well of a 48-well plate in the presence of 10 ng/ml of IL-7. Recombinant human IL-10 is added the next day at a final concentration of 10 ng/ml and rhuman IL-2 is added 48 hours later at 10 IU/ml.

*Restimulation of the induction cultures with peptide-pulsed adherent cells:* Seven and fourteen days after the primary induction, the cells are restimulated with peptide-pulsed adherent cells. The PBMCs are thawed and washed twice

with RPMI and DNase. The cells are resuspended at  $5 \times 10^6$  cells/ml and irradiated at ~4200 rads. The PBMCs are plated at  $2 \times 10^6$  in 0.5 ml complete medium per well and incubated for 2 hours at 37°C. The plates are washed twice with RPMI by tapping the plate gently to remove the nonadherent cells and the adherent cells pulsed with 10 µg/ml of peptide in the presence of 3 µg/ml  $\beta_2$  microglobulin in 0.25ml RPMI/5%AB per well for 2 hours at 37°C. Peptide solution from each well is aspirated and the wells are washed once with RPMI. Most of the media is aspirated from the induction cultures (CD8+ cells) and brought to 0.5 ml with fresh media. The cells are then transferred to the wells containing the peptide-pulsed adherent cells. Twenty four hours later recombinant human IL-10 is added at a final concentration of 10 ng/ml and recombinant human IL-2 is added the next day and again 2-3 days later at 50 IU/ml (Tsai *et al.*, *Critical Reviews in Immunology* 18(1-2):65-75, 1998). Seven days later, the cultures are assayed for CTL activity in a  $^{51}\text{Cr}$  release assay. In some experiments the cultures are assayed for peptide-specific recognition in the *in situ* IFN $\gamma$  ELISA at the time of the second restimulation followed by assay of endogenous recognition 7 days later. After expansion, activity is measured in both assays for a side-by-side comparison.

#### Measurement of CTL lytic activity by $^{51}\text{Cr}$ release.

Seven days after the second restimulation, cytotoxicity is determined in a standard (5 hr)  $^{51}\text{Cr}$  release assay by assaying individual wells at a single E:T. Peptide-pulsed targets are prepared by incubating the cells with 10 µg/ml peptide overnight at 37°C.

Adherent target cells are removed from culture flasks with trypsin-EDTA. Target cells are labeled with 200 µCi of  $^{51}\text{Cr}$  sodium chromate (Dupont, Wilmington, DE) for 1 hour at 37°C. Labeled target cells are resuspended at  $10^6$  per ml and diluted 1:10 with K562 cells at a concentration of  $3.3 \times 10^6$ /ml (an NK-sensitive erythroblastoma cell line used to reduce non-specific lysis). Target cells (100 µl) and effectors (100 µl) are plated in 96 well round-bottom plates and incubated for 5 hours at 37°C. At that time, 100 µl of supernatant are collected from each well and percent lysis is determined according to the formula:

$$\left[ \frac{(\text{cpm of the test sample} - \text{cpm of the spontaneous } ^{51}\text{Cr release sample})}{(\text{cpm of the maximal } ^{51}\text{Cr release sample} - \text{cpm of the spontaneous } ^{51}\text{Cr release sample})} \right] \times 100.$$

Maximum and spontaneous release are determined by incubating the labeled targets with 1% Triton X-100 and media alone, respectively. A positive culture is defined as one in which the specific lysis (sample- background) is 10% or higher in the case of individual wells and is 15% or more at the two highest E:T ratios when expanded cultures are assayed.

#### In situ Measurement of Human IFN $\gamma$ Production as an Indicator of Peptide-specific and Endogenous Recognition

Immulon 2 plates are coated with mouse anti-human IFN $\gamma$  monoclonal antibody (4 µg/ml 0.1M NaHCO $_3$ , pH8.2) overnight at 4°C. The plates are washed with Ca $^{2+}$ , Mg $^{2+}$ -free PBS/0.05% Tween 20 and blocked with PBS/10% FCS for two hours, after which the CTLs (100 µl/well) and targets (100 µl/well) are added to each well, leaving empty wells for the standards and blanks (which received media only). The target cells, either peptide-pulsed or endogenous targets, are used at a concentration of  $1 \times 10^6$  cells/ml. The plates are incubated for 48 hours at 37°C with 5% CO $_2$ .

Recombinant human IFN-gamma is added to the standard wells starting at 400 pg or 1200pg/100 microliter/well and the plate incubated for two hours at 37°C. The plates are washed and 100 µl of biotinylated mouse anti-human IFN-gamma monoclonal antibody (2 microgram/ml in PBS/3%FCS/0.05% Tween 20) are added and incubated for 2 hours at room temperature. After washing again, 100 microliter HRP-streptavidin (1:4000) are added and the plates incubated for one hour at room temperature. The plates are then washed 6x with wash buffer, 100 microliter/well developing solution (TMB 1:1) are added, and the plates allowed to develop for 5-15 minutes. The reaction is stopped with 50 microliter/well 1M H $_3$ PO $_4$  and read at OD450. A culture is considered positive if it measured at least 50 pg of IFN-gamma/well above background and is twice the background level of expression.

#### CTL Expansion.

Those cultures that demonstrate specific lytic activity against peptide-pulsed targets and/or tumor targets are expanded over a two week period with anti-CD3. Briefly,  $5 \times 10^4$  CD8<sup>+</sup> cells are added to a T25 flask containing the following:  $1 \times 10^6$  irradiated (4,200 rad) PBMC (autologous or allogeneic) per ml,  $2 \times 10^5$  irradiated (8,000 rad) EBV-transformed cells per ml, and OKT3 (anti-CD3) at 30ng per ml in RPMI-1640 containing 10% (v/v) human AB serum, non-essential amino acids, sodium pyruvate, 25 $\mu$ M 2-mercaptoethanol, L-glutamine and penicillin/streptomycin. Recombinant human IL2 is added 24 hours later at a final concentration of 200IU/ml and every three days thereafter with fresh media at 50IU/ml. The cells are split if the cell concentration exceeds  $1 \times 10^6$ /ml and the cultures are assayed between days 13 and 15 at E:T ratios of 30, 10, 3 and 1:1 in the <sup>51</sup>Cr release assay or at  $1 \times 10^6$ /ml in the *in situ* IFN $\gamma$  assay using the same targets as before the expansion.

Cultures are expanded in the absence of anti-CD3<sup>+</sup> as follows. Those cultures that demonstrate specific lytic activity against peptide and endogenous targets are selected and  $5 \times 10^4$  CD8<sup>+</sup> cells are added to a T25 flask containing the following:  $1 \times 10^6$  autologous PBMC per ml which have been peptide-pulsed with 10  $\mu$ g/ml peptide for two hours at 37°C and irradiated (4,200 rad);  $2 \times 10^5$  irradiated (8,000 rad) EBV-transformed cells per ml RPMI-1640 containing 10%(v/v) human AB serum, non-essential AA, sodium pyruvate, 25mM 2-ME, L-glutamine and gentamicin.

#### Immunogenicity of A2 supermotif-bearing peptides

A2-supermotif cross-reactive binding peptides are tested in the cellular assay for the ability to induce peptide-specific CTL in normal individuals. In this analysis, a peptide is typically considered to be an epitope if it induces peptide-specific CTLs in at least individuals, and preferably, also recognizes the endogenously expressed peptide.

Immunogenicity can also be confirmed using PBMCs isolated from patients bearing a tumor that expresses 254P1D6B. Briefly, PBMCs are isolated from patients, re-stimulated with peptide-pulsed monocytes and assayed for the ability to recognize peptide-pulsed target cells as well as transfected cells endogenously expressing the antigen.

#### Evaluation of A\*03/A11 immunogenicity

HLA-A3 supermotif-bearing cross-reactive binding peptides are also evaluated for immunogenicity using methodology analogous for that used to evaluate the immunogenicity of the HLA-A2 supermotif peptides.

#### Evaluation of B7 immunogenicity

Immunogenicity screening of the B7-supertype cross-reactive binding peptides identified as set forth herein are confirmed in a manner analogous to the confirmation of A2-and A3-supermotif-bearing peptides.

Peptides bearing other supermotifs/motifs, e.g., HLA-A1, HLA-A24 etc. are also confirmed using similar methodology

### **Example 15: Implementation of the Extended Supermotif to Improve the Binding Capacity of Native Epitopes by Creating Analogs**

HLA motifs and supermotifs (comprising primary and/or secondary residues) are useful in the identification and preparation of highly cross-reactive native peptides, as demonstrated herein. Moreover, the definition of HLA motifs and supermotifs also allows one to engineer highly cross-reactive epitopes by identifying residues within a native peptide sequence which can be analoged to confer upon the peptide certain characteristics, e.g. greater cross-reactivity within the group of HLA molecules that comprise a supertype, and/or greater binding affinity for some or all of those HLA molecules. Examples of analoging peptides to exhibit modulated binding affinity are set forth in this example.

#### Analoging at Primary Anchor Residues

Peptide engineering strategies are implemented to further increase the cross-reactivity of the epitopes. For example, the main anchors of A2-supermotif-bearing peptides are altered, for example, to introduce a preferred L, I, V, or M at position 2, and I or V at the C-terminus.

To analyze the cross-reactivity of the analog peptides, each engineered analog is initially tested for binding to the prototype A2 supertype allele A\*0201, then, if A\*0201 binding capacity is maintained, for A2-supertype cross-reactivity.

Alternatively, a peptide is confirmed as binding one or all supertype members and then analoged to modulate binding affinity to any one (or more) of the supertype members to add population coverage.

The selection of analogs for immunogenicity in a cellular screening analysis is typically further restricted by the capacity of the parent wild type (WT) peptide to bind at least weakly, *i.e.*, bind at an  $IC_{50}$  of 5000nM or less, to three or more A2 supertype alleles. The rationale for this requirement is that the WT peptides must be present endogenously in sufficient quantity to be biologically relevant. Analoged peptides have been shown to have increased immunogenicity and cross-reactivity by T cells specific for the parent epitope (see, *e.g.*, Parkhurst *et al.*, *J. Immunol.* 157:2539, 1996; and Pogue *et al.*, *Proc. Natl. Acad. Sci. USA* 92:8166, 1995).

In the cellular screening of these peptide analogs, it is important to confirm that analog-specific CTLs are also able to recognize the wild-type peptide and, when possible, target cells that endogenously express the epitope.

#### Analoging of HLA-A3 and B7-supermotif-bearing peptides

Analogues of HLA-A3 supermotif-bearing epitopes are generated using strategies similar to those employed in analoging HLA-A2 supermotif-bearing peptides. For example, peptides binding to 3/5 of the A3-supertype molecules are engineered at primary anchor residues to possess a preferred residue (V, S, M, or A) at position 2.

The analog peptides are then tested for the ability to bind A\*03 and A\*11 (prototype A3 supertype alleles). Those peptides that demonstrate  $\leq 500$  nM binding capacity are then confirmed as having A3-supertype cross-reactivity.

Similarly, to the A2- and A3- motif bearing peptides, peptides binding 3 or more B7-supertype alleles can be improved, where possible, to achieve increased cross-reactive binding or greater binding affinity or binding half life. B7 supermotif-bearing peptides are, for example, engineered to possess a preferred residue (V, I, L, or F) at the C-terminal primary anchor position, as demonstrated by Sidney *et al.* (*J. Immunol.* 157:3480-3490, 1996).

Analoging at primary anchor residues of other motif and/or supermotif-bearing epitopes is performed in a like manner.

The analog peptides are then confirmed for immunogenicity, typically in a cellular screening assay. Again, it is generally important to demonstrate that analog-specific CTLs are also able to recognize the wild-type peptide and, when possible, targets that endogenously express the epitope.

#### Analoging at Secondary Anchor Residues

Moreover, HLA supermotifs are of value in engineering highly cross-reactive peptides and/or peptides that bind HLA molecules with increased affinity by identifying particular residues at secondary anchor positions that are associated with such properties. For example, the binding capacity of a B7 supermotif-bearing peptide with an F residue at position 1 is analyzed. The peptide is then analoged to, for example, substitute L for F at position 1. The analoged peptide is evaluated for increased binding affinity, binding half life and/or increased cross-reactivity. Such a procedure identifies analoged peptides with enhanced properties.

Engineered analogs with sufficiently improved binding capacity or cross-reactivity can also be tested for immunogenicity in HLA-B7-transgenic mice, following for example, IFA immunization or lipopeptide immunization. Analoged peptides are additionally tested for the ability to stimulate a recall response using PBMC from patients with 254P1D6B-expressing tumors.

#### Other analoging strategies

Another form of peptide analoging, unrelated to anchor positions, involves the substitution of a cysteine with  $\alpha$ -amino butyric acid. Due to its chemical nature, cysteine has the propensity to form disulfide bridges and sufficiently alter the peptide structurally so as to reduce binding capacity. Substitution of  $\alpha$ -amino butyric acid for cysteine not only alleviates this problem, but has been shown to improve binding and crossbinding capabilities in some instances (see, e.g., the review by Sette *et al.*, In: Persistent Viral Infections, Eds. R. Ahmed and I. Chen, John Wiley & Sons, England, 1999).

Thus, by the use of single amino acid substitutions, the binding properties and/or cross-reactivity of peptide ligands for HLA supertype molecules can be modulated.

#### **Example 16: Identification and confirmation of 254P1D6B-derived sequences with HLA-DR binding motifs**

Peptide epitopes bearing an HLA class II supermotif or motif are identified and confirmed as outlined below using methodology similar to that described for HLA Class I peptides.

##### **Selection of HLA-DR-supermotif-bearing epitopes.**

To identify 254P1D6B-derived, HLA class II HTL epitopes, a 254P1D6B antigen is analyzed for the presence of sequences bearing an HLA-DR-motif or supermotif. Specifically, 15-mer sequences are selected comprising a DR-supermotif, comprising a 9-mer core, and three-residue N- and C-terminal flanking regions (15 amino acids total).

Protocols for predicting peptide binding to DR molecules have been developed (Southwood *et al.*, *J. Immunol.* 160:3363-3373, 1998). These protocols, specific for individual DR molecules, allow the scoring, and ranking, of 9-mer core regions. Each protocol not only scores peptide sequences for the presence of DR-supermotif primary anchors (i.e., at position 1 and position 6) within a 9-mer core, but additionally evaluates sequences for the presence of secondary anchors. Using allele-specific selection tables (see, e.g., Southwood *et al.*, *ibid.*), it has been found that these protocols efficiently select peptide sequences with a high probability of binding a particular DR molecule. Additionally, it has been found that performing these protocols in tandem, specifically those for DR1, DR4w4, and DR7, can efficiently select DR cross-reactive peptides.

The 254P1D6B-derived peptides identified above are tested for their binding capacity for various common HLA-DR molecules. All peptides are initially tested for binding to the DR molecules in the primary panel: DR1, DR4w4, and DR7. Peptides binding at least two of these three DR molecules are then tested for binding to DR2w2  $\beta$ 1, DR2w2  $\beta$ 2, DR6w19, and DR9 molecules in secondary assays. Finally, peptides binding at least two of the four secondary panel DR molecules, and thus cumulatively at least four of seven different DR molecules, are screened for binding to DR4w15, DR5w11, and DR8w2 molecules in tertiary assays. Peptides binding at least seven of the ten DR molecules comprising the primary, secondary, and tertiary screening assays are considered cross-reactive DR binders. 254P1D6B-derived peptides found to bind common HLA-DR alleles are of particular interest.

##### **Selection of DR3 motif peptides**

Because HLA-DR3 is an allele that is prevalent in Caucasian, Black, and Hispanic populations, DR3 binding capacity is a relevant criterion in the selection of HTL epitopes. Thus, peptides shown to be candidates may also be assayed for their DR3 binding capacity. However, in view of the binding specificity of the DR3 motif, peptides binding only to DR3 can also be considered as candidates for inclusion in a vaccine formulation.

To efficiently identify peptides that bind DR3, target 254P1D6B antigens are analyzed for sequences carrying one of the two DR3-specific binding motifs reported by Geluk *et al.* (*J. Immunol.* 152:5742-5748, 1994). The corresponding peptides are then synthesized and confirmed as having the ability to bind DR3 with an affinity of 1  $\mu$ M or better, i.e., less than 1  $\mu$ M. Peptides are found that meet this binding criterion and qualify as HLA class II high affinity binders.

DR3 binding epitopes identified in this manner are included in vaccine compositions with DR supermotif-bearing peptide epitopes.

Similarly to the case of HLA class I motif-bearing peptides, the class II motif-bearing peptides are analogized to improve affinity or cross-reactivity. For example, aspartic acid at position 4 of the 9-mer core sequence is an optimal residue for DR3 binding, and substitution for that residue often improves DR 3 binding.

#### **Example 17: Immunogenicity of 254P1D6B-derived HTL epitopes**

This example determines immunogenic DR supermotif- and DR3 motif-bearing epitopes among those identified using the methodology set forth herein.

Immunogenicity of HTL epitopes are confirmed in a manner analogous to the determination of immunogenicity of CTL epitopes, by assessing the ability to stimulate HTL responses and/or by using appropriate transgenic mouse models. Immunogenicity is determined by screening for: 1.) *in vitro* primary induction using normal PBMC or 2.) recall responses from patients who have 254P1D6B-expressing tumors.

#### **Example 18: Calculation of phenotypic frequencies of HLA-supertypes in various ethnic backgrounds to determine breadth of population coverage**

This example illustrates the assessment of the breadth of population coverage of a vaccine composition comprised of multiple epitopes comprising multiple supermotifs and/or motifs.

In order to analyze population coverage, gene frequencies of HLA alleles are determined. Gene frequencies for each HLA allele are calculated from antigen or allele frequencies utilizing the binomial distribution formulae  $gf=1-(\text{SQRT}(1-af))$  (see, e.g., Sidney *et al.*, *Human Immunol.* 45:79-93, 1996). To obtain overall phenotypic frequencies, cumulative gene frequencies are calculated, and the cumulative antigen frequencies derived by the use of the inverse formula  $[af=1-(1-Cgf)^2]$ .

Where frequency data is not available at the level of DNA typing, correspondence to the serologically defined antigen frequencies is assumed. To obtain total potential supertype population coverage no linkage disequilibrium is assumed, and only alleles confirmed to belong to each of the supertypes are included (minimal estimates). Estimates of total potential coverage achieved by inter-loci combinations are made by adding to the A coverage the proportion of the non-A covered population that could be expected to be covered by the B alleles considered (e.g.,  $\text{total}=A+B*(1-A)$ ). Confirmed members of the A3-like supertype are A3, A11, A31, A\*3301, and A\*6801. Although the A3-like supertype may also include A34, A66, and A\*7401, these alleles were not included in overall frequency calculations. Likewise, confirmed members of the A2-like supertype family are A\*0201, A\*0202, A\*0203, A\*0204, A\*0205, A\*0206, A\*0207, A\*6802, and A\*6901. Finally, the B7-like supertype-confirmed alleles are: B7, B\*3501-03, B51, B\*5301, B\*5401, B\*5501-2, B\*5601, B\*6701, and B\*7801 (potentially also B\*1401, B\*3504-06, B\*4201, and B\*5602).

Population coverage achieved by combining the A2-, A3- and B7-supertypes is approximately 86% in five major ethnic groups. Coverage may be extended by including peptides bearing the A1 and A24 motifs. On average, A1 is present in 12% and A24 in 29% of the population across five different major ethnic groups (Caucasian, North American Black, Chinese, Japanese, and Hispanic). Together, these alleles are represented with an average frequency of 39% in these same ethnic populations. The total coverage across the major ethnicities when A1 and A24 are combined with the coverage of the A2-, A3- and B7-supertype alleles is >95%, see, e.g., Table IV (G). An analogous approach can be used to estimate population coverage achieved with combinations of class II motif-bearing epitopes.

Immunogenicity studies in humans (e.g., Bertoni *et al.*, *J. Clin. Invest.* 100:503, 1997; Doolan *et al.*, *Immunity* 7:97, 1997; and Threlkeld *et al.*, *J. Immunol.* 159:1648, 1997) have shown that highly cross-reactive binding peptides are almost always recognized as epitopes. The use of highly cross-reactive binding peptides is an important selection criterion in identifying candidate epitopes for inclusion in a vaccine that is immunogenic in a diverse population.

With a sufficient number of epitopes (as disclosed herein and from the art), an average population coverage is predicted to be greater than 95% in each of five major ethnic populations. The game theory Monte Carlo simulation analysis,

which is known in the art (see e.g., Osborne, M.J. and Rubinstein, A. "A course in game theory" MIT Press, 1994), can be used to estimate what percentage of the individuals in a population comprised of the Caucasian, North American Black, Japanese, Chinese, and Hispanic ethnic groups would recognize the vaccine epitopes described herein. A preferred percentage is 90%. A more preferred percentage is 95%.

#### **Example 19: CTL Recognition Of Endogenously Processed Antigens After Priming**

This example confirms that CTL induced by native or analoged peptide epitopes identified and selected as described herein recognize endogenously synthesized, *i.e.*, native antigens.

Effector cells isolated from transgenic mice that are immunized with peptide epitopes, for example HLA-A2 supermotif-bearing epitopes, are re-stimulated *in vitro* using peptide-coated stimulator cells. Six days later, effector cells are assayed for cytotoxicity and the cell lines that contain peptide-specific cytotoxic activity are further re-stimulated. An additional six days later, these cell lines are tested for cytotoxic activity on <sup>51</sup>Cr labeled Jurkat-A2.1/K<sup>b</sup> target cells in the absence or presence of peptide, and also tested on <sup>51</sup>Cr labeled target cells bearing the endogenously synthesized antigen, *i.e.* cells that are stably transfected with 254P1D6B expression vectors.

The results demonstrate that CTL lines obtained from animals primed with peptide epitope recognize endogenously synthesized 254P1D6B antigen. The choice of transgenic mouse model to be used for such an analysis depends upon the epitope(s) that are being evaluated. In addition to HLA-A\*0201/K<sup>b</sup> transgenic mice, several other transgenic mouse models including mice with human A11, which may also be used to evaluate A3 epitopes, and B7 alleles have been characterized and others (e.g., transgenic mice for HLA-A1 and A24) are being developed. HLA-DR1 and HLA-DR3 mouse models have also been developed, which may be used to evaluate HTL epitopes.

#### **Example 20: Activity Of CTL-HTL Conjugated Epitopes In Transgenic Mice**

This example illustrates the induction of CTLs and HTLs in transgenic mice, by use of a 254P1D6B-derived CTL and HTL peptide vaccine compositions. The vaccine composition used herein comprise peptides to be administered to a patient with a 254P1D6B-expressing tumor. The peptide composition can comprise multiple CTL and/or HTL epitopes. The epitopes are identified using methodology as described herein. This example also illustrates that enhanced immunogenicity can be achieved by inclusion of one or more HTL epitopes in a CTL vaccine composition; such a peptide composition can comprise an HTL epitope conjugated to a CTL epitope. The CTL epitope can be one that binds to multiple HLA family members at an affinity of 500 nM or less, or analogs of that epitope. The peptides may be lipidated, if desired.

**Immunization procedures:** Immunization of transgenic mice is performed as described (Alexander *et al.*, *J. Immunol.* 159:4753-4761, 1997). For example, A2/K<sup>b</sup> mice, which are transgenic for the human HLA A2.1 allele and are used to confirm the immunogenicity of HLA-A\*0201 motif- or HLA-A2 supermotif-bearing epitopes, and are primed subcutaneously (base of the tail) with a 0.1 ml of peptide in Incomplete Freund's Adjuvant, or if the peptide composition is a lipidated CTL/HTL conjugate, in DMSO/saline, or if the peptide composition is a polypeptide, in PBS or Incomplete Freund's Adjuvant. Seven days after priming, splenocytes obtained from these animals are restimulated with syngenic irradiated LPS-activated lymphoblasts coated with peptide.

**Cell lines:** Target cells for peptide-specific cytotoxicity assays are Jurkat cells transfected with the HLA-A2.1/K<sup>b</sup> chimeric gene (e.g., Vitiello *et al.*, *J. Exp. Med.* 173:1007, 1991)

***In vitro* CTL activation:** One week after priming, spleen cells (30x10<sup>6</sup> cells/flask) are co-cultured at 37°C with syngeneic, irradiated (3000 rads), peptide coated lymphoblasts (10x10<sup>6</sup> cells/flask) in 10 ml of culture medium/T25 flask. After six days, effector cells are harvested and assayed for cytotoxic activity.

*Assay for cytotoxic activity:* Target cells ( $1.0$  to  $1.5 \times 10^6$ ) are incubated at  $37^\circ\text{C}$  in the presence of  $200\ \mu\text{l}$  of  $^{51}\text{Cr}$ . After 60 minutes, cells are washed three times and resuspended in R10 medium. Peptide is added where required at a concentration of  $1\ \mu\text{g/ml}$ . For the assay,  $10^4$   $^{51}\text{Cr}$ -labeled target cells are added to different concentrations of effector cells (final volume of  $200\ \mu\text{l}$ ) in U-bottom 96-well plates. After a six hour incubation period at  $37^\circ\text{C}$ , a  $0.1\text{-ml}$  aliquot of supernatant is removed from each well and radioactivity is determined in a Micromedic automatic gamma counter. The percent specific lysis is determined by the formula: percent specific release =  $100 \times (\text{experimental release} - \text{spontaneous release}) / (\text{maximum release} - \text{spontaneous release})$ . To facilitate comparison between separate CTL assays run under the same conditions, %  $^{51}\text{Cr}$  release data is expressed as lytic units/ $10^6$  cells. One lytic unit is arbitrarily defined as the number of effector cells required to achieve 30% lysis of 10,000 target cells in a six hour  $^{51}\text{Cr}$  release assay. To obtain specific lytic units/ $10^6$ , the lytic units/ $10^6$  obtained in the absence of peptide is subtracted from the lytic units/ $10^6$  obtained in the presence of peptide. For example, if 30%  $^{51}\text{Cr}$  release is obtained at the effector (E): target (T) ratio of 50:1 (i.e.,  $5 \times 10^5$  effector cells for 10,000 targets) in the absence of peptide and 5:1 (i.e.,  $5 \times 10^4$  effector cells for 10,000 targets) in the presence of peptide, the specific lytic units would be:  $[(1/50,000) - (1/500,000)] \times 10^6 = 18\ \text{LU}$ .

The results are analyzed to assess the magnitude of the CTL responses of animals injected with the immunogenic CTL/HTL conjugate vaccine preparation and are compared to the magnitude of the CTL response achieved using, for example, CTL epitopes as outlined above in the Example entitled "Confirmation of Immunogenicity." Analyses similar to this may be performed to confirm the immunogenicity of peptide conjugates containing multiple CTL epitopes and/or multiple HTL epitopes. In accordance with these procedures, it is found that a CTL response is induced, and concomitantly that an HTL response is induced upon administration of such compositions.

#### **Example 21: Selection of CTL and HTL epitopes for inclusion in a 254P1D6B-specific vaccine.**

This example illustrates a procedure for selecting peptide epitopes for vaccine compositions of the invention. The peptides in the composition can be in the form of a nucleic acid sequence, either single or one or more sequences (i.e., minigene) that encodes peptide(s), or can be single and/or polyepitopic peptides.

The following principles are utilized when selecting a plurality of epitopes for inclusion in a vaccine composition. Each of the following principles is balanced in order to make the selection.

Epitopes are selected which, upon administration, mimic immune responses that are correlated with 254P1D6B clearance. The number of epitopes used depends on observations of patients who spontaneously clear 254P1D6B. For example, if it has been observed that patients who spontaneously clear 254P1D6B-expressing cells generate an immune response to at least three (3) epitopes from 254P1D6B antigen, then at least three epitopes should be included for HLA class I. A similar rationale is used to determine HLA class II epitopes.

Epitopes are often selected that have a binding affinity of an  $\text{IC}_{50}$  of 500 nM or less for an HLA class I molecule, or for class II, an  $\text{IC}_{50}$  of 1000 nM or less; or HLA Class I peptides with high binding scores from the BIMAS web site, at URL [bimas.dcrt.nih.gov/](http://bimas.dcrt.nih.gov/).

In order to achieve broad coverage of the vaccine through out a diverse population, sufficient supermotif bearing peptides, or a sufficient array of allele-specific motif bearing peptides, are selected to give broad population coverage. In one embodiment, epitopes are selected to provide at least 80% population coverage. A Monte Carlo analysis, a statistical evaluation known in the art, can be employed to assess breadth, or redundancy, of population coverage.

When creating polyepitopic compositions, or a minigene that encodes same, it is typically desirable to generate the smallest peptide possible that encompasses the epitopes of interest. The principles employed are similar, if not the same, as those employed when selecting a peptide comprising nested epitopes. For example, a protein sequence for the vaccine composition is selected because it has maximal number of epitopes contained within the sequence, i.e., it has a high

concentration of epitopes. Epitopes may be nested or overlapping (*i.e.*, frame shifted relative to one another). For example, with overlapping epitopes, two 9-mer epitopes and one 10-mer epitope can be present in a 10 amino acid peptide. Each epitope can be exposed and bound by an HLA molecule upon administration of such a peptide. A multi-epitopic peptide can be generated synthetically, recombinantly, or via cleavage from the native source. Alternatively, an analog can be made of this native sequence, whereby one or more of the epitopes comprise substitutions that alter the cross-reactivity and/or binding affinity properties of the polypeptidic peptide. Such a vaccine composition is administered for therapeutic or prophylactic purposes. This embodiment provides for the possibility that an as yet undiscovered aspect of immune system processing will apply to the native nested sequence and thereby facilitate the production of therapeutic or prophylactic immune response-inducing vaccine compositions. Additionally such an embodiment provides for the possibility of motif-bearing epitopes for an HLA makeup that is presently unknown. Furthermore, this embodiment (absent the creating of any analogs) directs the immune response to multiple peptide sequences that are actually present in 254P1D6B, thus avoiding the need to evaluate any junctional epitopes. Lastly, the embodiment provides an economy of scale when producing nucleic acid vaccine compositions. Related to this embodiment, computer programs can be derived in accordance with principles in the art, which identify in a target sequence, the greatest number of epitopes per sequence length.

A vaccine composition comprised of selected peptides, when administered, is safe, efficacious, and elicits an immune response similar in magnitude to an immune response that controls or clears cells that bear or overexpress 254P1D6B.

#### **Example 22: Construction of "Minigene" Multi-Epitope DNA Plasmids**

This example discusses the construction of a minigene expression plasmid. Minigene plasmids may, of course, contain various configurations of B cell, CTL and/or HTL epitopes or epitope analogs as described herein.

A minigene expression plasmid typically includes multiple CTL and HTL peptide epitopes. In the present example, HLA-A2, -A3, -B7 supermotif-bearing peptide epitopes and HLA-A1 and -A24 motif-bearing peptide epitopes are used in conjunction with DR supermotif-bearing epitopes and/or DR3 epitopes. HLA class I supermotif or motif-bearing peptide epitopes derived 254P1D6B, are selected such that multiple supermotifs/motifs are represented to ensure broad population coverage. Similarly, HLA class II epitopes are selected from 254P1D6B to provide broad population coverage, *i.e.* both HLA DR-1-4-7 supermotif-bearing epitopes and HLA DR-3 motif-bearing epitopes are selected for inclusion in the minigene construct. The selected CTL and HTL epitopes are then incorporated into a minigene for expression in an expression vector.

Such a construct may additionally include sequences that direct the HTL epitopes to the endoplasmic reticulum. For example, the *Ii* protein may be fused to one or more HTL epitopes as described in the art, wherein the CLIP sequence of the *Ii* protein is removed and replaced with an HLA class II epitope sequence so that HLA class II epitope is directed to the endoplasmic reticulum, where the epitope binds to an HLA class II molecules.

This example illustrates the methods to be used for construction of a minigene-bearing expression plasmid. Other expression vectors that may be used for minigene compositions are available and known to those of skill in the art.

The minigene DNA plasmid of this example contains a consensus Kozak sequence and a consensus murine kappa Ig-light chain signal sequence followed by CTL and/or HTL epitopes selected in accordance with principles disclosed herein. The sequence encodes an open reading frame fused to the Myc and His antibody epitope tag coded for by the pcDNA 3.1 Myc-His vector.

Overlapping oligonucleotides that can, for example, average about 70 nucleotides in length with 15 nucleotide overlaps, are synthesized and HPLC-purified. The oligonucleotides encode the selected peptide epitopes as well as appropriate linker nucleotides, Kozak sequence, and signal sequence. The final multiepitope minigene is assembled by extending the overlapping oligonucleotides in three sets of reactions using PCR. A Perkin/Elmer 9600 PCR machine is used

and a total of 30 cycles are performed using the following conditions: 95°C for 15 sec, annealing temperature (5° below the lowest calculated  $T_m$  of each primer pair) for 30 sec, and 72°C for 1 min.

For example, a minigene is prepared as follows. For a first PCR reaction, 5 µg of each of two oligonucleotides are annealed and extended: In an example using eight oligonucleotides, i.e., four pairs of primers, oligonucleotides 1+2, 3+4, 5+6, and 7+8 are combined in 100 µl reactions containing *Pfu* polymerase buffer (1x= 10 mM KCL, 10 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, 20 mM Tris-chloride, pH 8.75, 2 mM MgSO<sub>4</sub>, 0.1% Triton X-100, 100 µg/ml BSA), 0.25 mM each dNTP, and 2.5 U of *Pfu* polymerase. The full-length dimer products are gel-purified, and two reactions containing the product of 1+2 and 3+4, and the product of 5+6 and 7+8 are mixed, annealed, and extended for 10 cycles. Half of the two reactions are then mixed, and 5 cycles of annealing and extension carried out before flanking primers are added to amplify the full length product. The full-length product is gel-purified and cloned into pCR-blunt (Invitrogen) and individual clones are screened by sequencing.

### **Example 23: The Plasmid Construct and the Degree to Which It Induces Immunogenicity.**

The degree to which a plasmid construct, for example a plasmid constructed in accordance with the previous Example, is able to induce immunogenicity is confirmed *in vitro* by determining epitope presentation by APC following transduction or transfection of the APC with an epitope-expressing nucleic acid construct. Such a study determines "antigenicity" and allows the use of human APC. The assay determines the ability of the epitope to be presented by the APC in a context that is recognized by a T cell by quantifying the density of epitope-HLA class I complexes on the cell surface. Quantitation can be performed by directly measuring the amount of peptide eluted from the APC (see, e.g., Sijts *et al.*, *J. Immunol.* 156:683-692, 1996; Demotz *et al.*, *Nature* 342:682-684, 1989); or the number of peptide-HLA class I complexes can be estimated by measuring the amount of lysis or lymphokine release induced by diseased or transfected target cells, and then determining the concentration of peptide necessary to obtain equivalent levels of lysis or lymphokine release (see, e.g., Kageyama *et al.*, *J. Immunol.* 154:567-576, 1995).

Alternatively, immunogenicity is confirmed through *in vivo* injections into mice and subsequent *in vitro* assessment of CTL and HTL activity, which are analyzed using cytotoxicity and proliferation assays, respectively, as detailed e.g., in Alexander *et al.*, *Immunity* 1:751-761, 1994.

For example, to confirm the capacity of a DNA minigene construct containing at least one HLA-A2 supermotif peptide to induce CTLs *in vivo*, HLA-A2.1/K<sup>b</sup> transgenic mice, for example, are immunized intramuscularly with 100 µg of naked cDNA. As a means of comparing the level of CTLs induced by cDNA immunization, a control group of animals is also immunized with an actual peptide composition that comprises multiple epitopes synthesized as a single polypeptide as they would be encoded by the minigene.

Splenocytes from immunized animals are stimulated twice with each of the respective compositions (peptide epitopes encoded in the minigene or the polyepitopic peptide), then assayed for peptide-specific cytotoxic activity in a <sup>51</sup>Cr release assay. The results indicate the magnitude of the CTL response directed against the A2-restricted epitope, thus indicating the *in vivo* immunogenicity of the minigene vaccine and polyepitopic vaccine.

It is, therefore, found that the minigene elicits immune responses directed toward the HLA-A2 supermotif peptide epitopes as does the polyepitopic peptide vaccine. A similar analysis is also performed using other HLA-A3 and HLA-B7 transgenic mouse models to assess CTL induction by HLA-A3 and HLA-B7 motif or supermotif epitopes, whereby it is also found that the minigene elicits appropriate immune responses directed toward the provided epitopes.

To confirm the capacity of a class II epitope-encoding minigene to induce HTLs *in vivo*, DR transgenic mice, or for those epitopes that cross react with the appropriate mouse MHC molecule, I-A<sup>b</sup>-restricted mice, for example, are immunized intramuscularly with 100 µg of plasmid DNA. As a means of comparing the level of HTLs induced by DNA immunization, a group of control animals is also immunized with an actual peptide composition emulsified in complete Freund's adjuvant.

CD4<sup>+</sup> T cells, i.e. HTLs, are purified from splenocytes of immunized animals and stimulated with each of the respective compositions (peptides encoded in the minigene). The HTL response is measured using a <sup>3</sup>H-thymidine incorporation proliferation assay, (see, e.g., Alexander *et al.* *Immunity* 1:751-761, 1994). The results indicate the magnitude of the HTL response, thus demonstrating the *in vivo* immunogenicity of the minigene.

DNA minigenes, constructed as described in the previous Example, can also be confirmed as a vaccine in combination with a boosting agent using a prime boost protocol. The boosting agent can consist of recombinant protein (e.g., Barnett *et al.*, *Aids Res. and Human Retroviruses* 14, Supplement 3:S299-S309, 1998) or recombinant vaccinia, for example, expressing a minigene or DNA encoding the complete protein of interest (see, e.g., Hanke *et al.*, *Vaccine* 16:439-445, 1998; Sedegah *et al.*, *Proc. Natl. Acad. Sci USA* 95:7648-53, 1998; Hanke and McMichael, *Immunol. Letters* 66:177-181, 1999; and Robinson *et al.*, *Nature Med.* 5:526-34, 1999).

For example, the efficacy of the DNA minigene used in a prime boost protocol is initially evaluated in transgenic mice. In this example, A2.1/K<sup>b</sup> transgenic mice are immunized IM with 100 µg of a DNA minigene encoding the immunogenic peptides including at least one HLA-A2 supermotif-bearing peptide. After an incubation period (ranging from 3-9 weeks), the mice are boosted IP with 10<sup>7</sup> pfu/mouse of a recombinant vaccinia virus expressing the same sequence encoded by the DNA minigene. Control mice are immunized with 100 µg of DNA or recombinant vaccinia without the minigene sequence, or with DNA encoding the minigene, but without the vaccinia boost. After an additional incubation period of two weeks, splenocytes from the mice are immediately assayed for peptide-specific activity in an ELISPOT assay. Additionally, splenocytes are stimulated *in vitro* with the A2-restricted peptide epitopes encoded in the minigene and recombinant vaccinia, then assayed for peptide-specific activity in an alpha, beta and/or gamma IFN ELISA.

It is found that the minigene utilized in a prime-boost protocol elicits greater immune responses toward the HLA-A2 supermotif peptides than with DNA alone. Such an analysis can also be performed using HLA-A11 or HLA-B7 transgenic mouse models to assess CTL induction by HLA-A3 or HLA-B7 motif or supermotif epitopes. The use of prime boost protocols in humans is described below in the Example entitled "Induction of CTL Responses Using a Prime Boost Protocol."

#### **Example 24: Peptide Compositions for Prophylactic Uses**

Vaccine compositions of the present invention can be used to prevent 254P1D6B expression in persons who are at risk for tumors that bear this antigen. For example, a polyepitopic peptide epitope composition (or a nucleic acid comprising the same) containing multiple CTL and HTL epitopes such as those selected in the above Examples, which are also selected to target greater than 80% of the population, is administered to individuals at risk for a 254P1D6B-associated tumor.

For example, a peptide-based composition is provided as a single polypeptide that encompasses multiple epitopes. The vaccine is typically administered in a physiological solution that comprises an adjuvant, such as Incomplete Freund's Adjuvant. The dose of peptide for the initial immunization is from about 1 to about 50,000 µg, generally 100-5,000 µg, for a 70 kg patient. The initial administration of vaccine is followed by booster dosages at 4 weeks followed by evaluation of the magnitude of the immune response in the patient, by techniques that determine the presence of epitope-specific CTL populations in a PBMC sample. Additional booster doses are administered as required. The composition is found to be both safe and efficacious as a prophylaxis against 254P1D6B-associated disease.

Alternatively, a composition typically comprising transfecting agents is used for the administration of a nucleic acid-based vaccine in accordance with methodologies known in the art and disclosed herein.

#### **Example 25: Polyepitopic Vaccine Compositions Derived from Native 254P1D6B Sequences**

A native 254P1D6B polyprotein sequence is analyzed, preferably using computer algorithms defined for each class I and/or class II supermotif or motif, to identify "relatively short" regions of the polyprotein that comprise multiple epitopes.

The "relatively short" regions are preferably less in length than an entire native antigen. This relatively short sequence that contains multiple distinct or overlapping, "nested" epitopes can be used to generate a minigene construct. The construct is engineered to express the peptide, which corresponds to the native protein sequence. The "relatively short" peptide is generally less than 250 amino acids in length, often less than 100 amino acids in length, preferably less than 75 amino acids in length, and more preferably less than 50 amino acids in length. The protein sequence of the vaccine composition is selected because it has maximal number of epitopes contained within the sequence, *i.e.*, it has a high concentration of epitopes. As noted herein, epitope motifs may be nested or overlapping (*i.e.*, frame shifted relative to one another). For example, with overlapping epitopes, two 9-mer epitopes and one 10-mer epitope can be present in a 10 amino acid peptide. Such a vaccine composition is administered for therapeutic or prophylactic purposes.

The vaccine composition will include, for example, multiple CTL epitopes from 254P1D6B antigen and at least one HTL epitope. This polyepitopic native sequence is administered either as a peptide or as a nucleic acid sequence which encodes the peptide. Alternatively, an analog can be made of this native sequence, whereby one or more of the epitopes comprise substitutions that alter the cross-reactivity and/or binding affinity properties of the polyepitopic peptide.

The embodiment of this example provides for the possibility that an as yet undiscovered aspect of immune system processing will apply to the native nested sequence and thereby facilitate the production of therapeutic or prophylactic immune response-inducing vaccine compositions. Additionally, such an embodiment provides for the possibility of motif-bearing epitopes for an HLA makeup(s) that is presently unknown. Furthermore, this embodiment (excluding an analoged embodiment) directs the immune response to multiple peptide sequences that are actually present in native 254P1D6B, thus avoiding the need to evaluate any junctional epitopes. Lastly, the embodiment provides an economy of scale when producing peptide or nucleic acid vaccine compositions.

Related to this embodiment, computer programs are available in the art which can be used to identify in a target sequence, the greatest number of epitopes per sequence length.

#### **Example 26: Polyepitopic Vaccine Compositions from Multiple Antigens**

The 254P1D6B peptide epitopes of the present invention are used in conjunction with epitopes from other target tumor-associated antigens, to create a vaccine composition that is useful for the prevention or treatment of cancer that expresses 254P1D6B and such other antigens. For example, a vaccine composition can be provided as a single polypeptide that incorporates multiple epitopes from 254P1D6B as well as tumor-associated antigens that are often expressed with a target cancer associated with 254P1D6B expression, or can be administered as a composition comprising a cocktail of one or more discrete epitopes. Alternatively, the vaccine can be administered as a minigene construct or as dendritic cells which have been loaded with the peptide epitopes *in vitro*.

#### **Example 27: Use of peptides to evaluate an immune response**

Peptides of the invention may be used to analyze an immune response for the presence of specific antibodies, CTL or HTL directed to 254P1D6B. Such an analysis can be performed in a manner described by Ogg *et al.*, *Science* 279:2103-2106, 1998. In this Example, peptides in accordance with the invention are used as a reagent for diagnostic or prognostic purposes, not as an immunogen.

In this example highly sensitive human leukocyte antigen tetrameric complexes ("tetramers") are used for a cross-sectional analysis of, for example, 254P1D6B HLA-A\*0201-specific CTL frequencies from HLA A\*0201-positive individuals at different stages of disease or following immunization comprising a 254P1D6B peptide containing an A\*0201 motif. Tetrameric complexes are synthesized as described (Musey *et al.*, *N. Engl. J. Med.* 337:1267, 1997). Briefly, purified HLA heavy chain (A\*0201 in this example) and  $\beta$ 2-microglobulin are synthesized by means of a prokaryotic expression system.

The heavy chain is modified by deletion of the transmembrane-cytosolic tail and COOH-terminal addition of a sequence containing a BirA enzymatic biotinylation site. The heavy chain,  $\beta$ 2-microglobulin, and peptide are refolded by dilution. The 45-kD refolded product is isolated by fast protein liquid chromatography and then biotinylated by BirA in the presence of biotin (Sigma, St. Louis, Missouri), adenosine 5' triphosphate and magnesium. Streptavidin-phycoerythrin conjugate is added in a 1:4 molar ratio, and the tetrameric product is concentrated to 1 mg/ml. The resulting product is referred to as tetramer-phycoerythrin.

For the analysis of patient blood samples, approximately one million PBMCs are centrifuged at 300g for 5 minutes and resuspended in 50  $\mu$ l of cold phosphate-buffered saline. Tri-color analysis is performed with the tetramer-phycoerythrin, along with anti-CD8-Tricolor, and anti-CD38. The PBMCs are incubated with tetramer and antibodies on ice for 30 to 60 min and then washed twice before formaldehyde fixation. Gates are applied to contain >99.98% of control samples. Controls for the tetramers include both A\*0201-negative individuals and A\*0201-positive non-diseased donors. The percentage of cells stained with the tetramer is then determined by flow cytometry. The results indicate the number of cells in the PBMC sample that contain epitope-restricted CTLs, thereby readily indicating the extent of immune response to the 254P1D6B epitope, and thus the status of exposure to 254P1D6B, or exposure to a vaccine that elicits a protective or therapeutic response.

#### **Example 28: Use of Peptide Epitopes to Evaluate Recall Responses**

The peptide epitopes of the invention are used as reagents to evaluate T cell responses, such as acute or recall responses, in patients. Such an analysis may be performed on patients who have recovered from 254P1D6B-associated disease or who have been vaccinated with a 254P1D6B vaccine.

For example, the class I restricted CTL response of persons who have been vaccinated may be analyzed. The vaccine may be any 254P1D6B vaccine. PBMC are collected from vaccinated individuals and HLA typed. Appropriate peptide epitopes of the invention that, optimally, bear supermotifs to provide cross-reactivity with multiple HLA supertype family members, are then used for analysis of samples derived from individuals who bear that HLA type.

PBMC from vaccinated individuals are separated on Ficoll-Histopaque density gradients (Sigma Chemical Co., St. Louis, MO), washed three times in HBSS (GIBCO Laboratories), resuspended in RPMI-1640 (GIBCO Laboratories) supplemented with L-glutamine (2mM), penicillin (50U/ml), streptomycin (50  $\mu$ g/ml), and Hepes (10mM) containing 10% heat-inactivated human AB serum (complete RPMI) and plated using microculture formats. A synthetic peptide comprising an epitope of the invention is added at 10  $\mu$ g/ml to each well and HBV core 128-140 epitope is added at 1  $\mu$ g/ml to each well as a source of T cell help during the first week of stimulation.

In the microculture format,  $4 \times 10^5$  PBMC are stimulated with peptide in 8 replicate cultures in 96-well round bottom plate in 100  $\mu$ l/well of complete RPMI. On days 3 and 10, 100  $\mu$ l of complete RPMI and 20 U/ml final concentration of rIL-2 are added to each well. On day 7 the cultures are transferred into a 96-well flat-bottom plate and restimulated with peptide, rIL-2 and  $10^5$  irradiated (3,000 rad) autologous feeder cells. The cultures are tested for cytotoxic activity on day 14. A positive CTL response requires two or more of the eight replicate cultures to display greater than 10% specific  $^{51}\text{Cr}$  release, based on comparison with non-diseased control subjects as previously described (Rehermann, *et al.*, *Nature Med.* 2:1104,1108, 1996; Rehermann *et al.*, *J. Clin. Invest.* 97:1655-1665, 1996; and Rehermann *et al.* *J. Clin. Invest.* 98:1432-1440, 1996).

Target cell lines are autologous and allogeneic EBV-transformed B-LCL that are either purchased from the American Society for Histocompatibility and Immunogenetics (ASHI, Boston, MA) or established from the pool of patients as described (Guilhot, *et al.* *J. Virol.* 66:2670-2678, 1992).

Cytotoxicity assays are performed in the following manner. Target cells consist of either allogeneic HLA-matched or autologous EBV-transformed B lymphoblastoid cell line that are incubated overnight with the synthetic peptide epitope of

the invention at 10  $\mu$ M, and labeled with 100  $\mu$ Ci of  $^{51}\text{Cr}$  (Amersham Corp., Arlington Heights, IL) for 1 hour after which they are washed four times with HBSS.

Cytolytic activity is determined in a standard 4-h, split well  $^{51}\text{Cr}$  release assay using U-bottomed 96 well plates containing 3,000 targets/well. Stimulated PBMC are tested at effector/target (E/T) ratios of 20-50:1 on day 14. Percent cytotoxicity is determined from the formula:  $100 \times [(\text{experimental release} - \text{spontaneous release}) / (\text{maximum release} - \text{spontaneous release})]$ . Maximum release is determined by lysis of targets by detergent (2% Triton X-100; Sigma Chemical Co., St. Louis, MO). Spontaneous release is <25% of maximum release for all experiments.

The results of such an analysis indicate the extent to which HLA-restricted CTL populations have been stimulated by previous exposure to 254P1D6B or a 254P1D6B vaccine.

Similarly, Class II restricted HTL responses may also be analyzed. Purified PBMC are cultured in a 96-well flat bottom plate at a density of  $1.5 \times 10^5$  cells/well and are stimulated with 10  $\mu\text{g/ml}$  synthetic peptide of the invention, whole 254P1D6B antigen, or PHA. Cells are routinely plated in replicates of 4-6 wells for each condition. After seven days of culture, the medium is removed and replaced with fresh medium containing 10U/ml IL-2. Two days later, 1  $\mu\text{Ci}$   $^3\text{H}$ -thymidine is added to each well and incubation is continued for an additional 18 hours. Cellular DNA is then harvested on glass fiber mats and analyzed for  $^3\text{H}$ -thymidine incorporation. Antigen-specific T cell proliferation is calculated as the ratio of  $^3\text{H}$ -thymidine incorporation in the presence of antigen divided by the  $^3\text{H}$ -thymidine incorporation in the absence of antigen.

#### **Example 29: Induction Of Specific CTL Response In Humans**

A human clinical trial for an immunogenic composition comprising CTL and HTL epitopes of the invention is set up as an IND Phase I, dose escalation study and carried out as a randomized, double-blind, placebo-controlled trial. Such a trial is designed, for example, as follows:

A total of about 27 individuals are enrolled and divided into 3 groups:

Group I: 3 subjects are injected with placebo and 6 subjects are injected with 5  $\mu\text{g}$  of peptide composition;

Group II: 3 subjects are injected with placebo and 6 subjects are injected with 50  $\mu\text{g}$  peptide composition;

Group III: 3 subjects are injected with placebo and 6 subjects are injected with 500  $\mu\text{g}$  of peptide composition.

After 4 weeks following the first injection, all subjects receive a booster inoculation at the same dosage.

The endpoints measured in this study relate to the safety and tolerability of the peptide composition as well as its immunogenicity. Cellular immune responses to the peptide composition are an index of the intrinsic activity of this the peptide composition, and can therefore be viewed as a measure of biological efficacy. The following summarize the clinical and laboratory data that relate to safety and efficacy endpoints.

**Safety:** The incidence of adverse events is monitored in the placebo and drug treatment group and assessed in terms of degree and reversibility.

**Evaluation of Vaccine Efficacy:** For evaluation of vaccine efficacy, subjects are bled before and after injection. Peripheral blood mononuclear cells are isolated from fresh heparinized blood by Ficoll-Hypaque density gradient centrifugation, aliquoted in freezing media and stored frozen. Samples are assayed for CTL and HTL activity.

The vaccine is found to be both safe and efficacious.

#### **Example 30: Phase II Trials In Patients Expressing 254P1D6B**

Phase II trials are performed to study the effect of administering the CTL-HTL peptide compositions to patients having cancer that expresses 254P1D6B. The main objectives of the trial are to determine an effective dose and regimen for inducing CTLs in cancer patients that express 254P1D6B, to establish the safety of inducing a CTL and HTL response in

these patients, and to see to what extent activation of CTLs improves the clinical picture of these patients, as manifested, e.g., by the reduction and/or shrinking of lesions. Such a study is designed, for example, as follows:

The studies are performed in multiple centers. The trial design is an open-label, uncontrolled, dose escalation protocol wherein the peptide composition is administered as a single dose followed six weeks later by a single booster shot of the same dose. The dosages are 50, 500 and 5,000 micrograms per injection. Drug-associated adverse effects (severity and reversibility) are recorded.

There are three patient groupings. The first group is injected with 50 micrograms of the peptide composition and the second and third groups with 500 and 5,000 micrograms of peptide composition, respectively. The patients within each group range in age from 21-65 and represent diverse ethnic backgrounds. All of them have a tumor that expresses 254P1D6B.

Clinical manifestations or antigen-specific T-cell responses are monitored to assess the effects of administering the peptide compositions. The vaccine composition is found to be both safe and efficacious in the treatment of 254P1D6B-associated disease.

#### **Example 31: Induction of CTL Responses Using a Prime Boost Protocol**

A prime boost protocol similar in its underlying principle to that used to confirm the efficacy of a DNA vaccine in transgenic mice, such as described above in the Example entitled "The Plasmid Construct and the Degree to Which It Induces Immunogenicity," can also be used for the administration of the vaccine to humans. Such a vaccine regimen can include an initial administration of, for example, naked DNA followed by a boost using recombinant virus encoding the vaccine, or recombinant protein/polypeptide or a peptide mixture administered in an adjuvant.

For example, the initial immunization may be performed using an expression vector, such as that constructed in the Example entitled "Construction of "Minigene" Multi-Epitope DNA Plasmids" in the form of naked nucleic acid administered IM (or SC or ID) in the amounts of 0.5-5 mg at multiple sites. The nucleic acid (0.1 to 1000 µg) can also be administered using a gene gun. Following an incubation period of 3-4 weeks, a booster dose is then administered. The booster can be recombinant fowlpox virus administered at a dose of  $5 \cdot 10^7$  to  $5 \cdot 10^9$  pfu. An alternative recombinant virus, such as an MVA, canarypox, adenovirus, or adeno-associated virus, can also be used for the booster, or the polypeptidic protein or a mixture of the peptides can be administered. For evaluation of vaccine efficacy, patient blood samples are obtained before immunization as well as at intervals following administration of the initial vaccine and booster doses of the vaccine. Peripheral blood mononuclear cells are isolated from fresh heparinized blood by Ficoll-Hypaque density gradient centrifugation, aliquoted in freezing media and stored frozen. Samples are assayed for CTL and HTL activity.

Analysis of the results indicates that a magnitude of response sufficient to achieve a therapeutic or protective immunity against 254P1D6B is generated.

#### **Example 32: Administration of Vaccine Compositions Using Dendritic Cells (DC)**

Vaccines comprising peptide epitopes of the invention can be administered using APCs, or "professional" APCs such as DC. In this example, peptide-pulsed DC are administered to a patient to stimulate a CTL response *in vivo*. In this method, dendritic cells are isolated, expanded, and pulsed with a vaccine comprising peptide CTL and HTL epitopes of the invention. The dendritic cells are infused back into the patient to elicit CTL and HTL responses *in vivo*. The induced CTL and HTL then destroy or facilitate destruction, respectively, of the target cells that bear the 254P1D6B protein from which the epitopes in the vaccine are derived.

For example, a cocktail of epitope-comprising peptides is administered *ex vivo* to PBMC, or isolated DC therefrom. A pharmaceutical to facilitate harvesting of DC can be used, such as Progenipoietin™ (Monsanto, St. Louis, MO) or GM-

CSF/IL-4. After pulsing the DC with peptides, and prior to reinfusion into patients, the DC are washed to remove unbound peptides.

As appreciated clinically, and readily determined by one of skill based on clinical outcomes, the number of DC reinfused into the patient can vary (see, e.g., *Nature Med.* 4:328, 1998; *Nature Med.* 2:52, 1996 and *Prostate* 32:272, 1997). Although  $2\text{--}50 \times 10^6$  DC per patient are typically administered, larger number of DC, such as  $10^7$  or  $10^8$  can also be provided. Such cell populations typically contain between 50-90% DC.

In some embodiments, peptide-loaded PBMC are injected into patients without purification of the DC. For example, PBMC generated after treatment with an agent such as Progenipoiectin™ are injected into patients without purification of the DC. The total number of PBMC that are administered often ranges from  $10^8$  to  $10^{10}$ . Generally, the cell doses injected into patients is based on the percentage of DC in the blood of each patient, as determined, for example, by immunofluorescence analysis with specific anti-DC antibodies. Thus, for example, if Progenipoiectin™ mobilizes 2% DC in the peripheral blood of a given patient, and that patient is to receive  $5 \times 10^6$  DC, then the patient will be injected with a total of  $2.5 \times 10^8$  peptide-loaded PBMC. The percent DC mobilized by an agent such as Progenipoiectin™ is typically estimated to be between 2-10%, but can vary as appreciated by one of skill in the art.

#### Ex vivo activation of CTL/HTL responses

Alternatively, ex vivo CTL or HTL responses to 254P1D6B antigens can be induced by incubating, in tissue culture, the patient's, or genetically compatible, CTL or HTL precursor cells together with a source of APC, such as DC, and immunogenic peptides. After an appropriate incubation time (typically about 7-28 days), in which the precursor cells are activated and expanded into effector cells, the cells are infused into the patient, where they will destroy (CTL) or facilitate destruction (HTL) of their specific target cells, i.e., tumor cells.

#### Example 33: An Alternative Method of Identifying and Confirming Motif-Bearing Peptides

Another method of identifying and confirming motif-bearing peptides is to elute them from cells bearing defined MHC molecules. For example, EBV transformed B cell lines used for tissue typing have been extensively characterized to determine which HLA molecules they express. In certain cases these cells express only a single type of HLA molecule. These cells can be transfected with nucleic acids that express the antigen of interest, e.g. 254P1D6B. Peptides produced by endogenous antigen processing of peptides produced as a result of transfection will then bind to HLA molecules within the cell and be transported and displayed on the cell's surface. Peptides are then eluted from the HLA molecules by exposure to mild acid conditions and their amino acid sequence determined, e.g., by mass spectral analysis (e.g., Kubo *et al.*, *J. Immunol.* 152:3913, 1994). Because the majority of peptides that bind a particular HLA molecule are motif-bearing, this is an alternative modality for obtaining the motif-bearing peptides correlated with the particular HLA molecule expressed on the cell.

Alternatively, cell lines that do not express endogenous HLA molecules can be transfected with an expression construct encoding a single HLA allele. These cells can then be used as described, i.e., they can then be transfected with nucleic acids that encode 254P1D6B to isolate peptides corresponding to 254P1D6B that have been presented on the cell surface. Peptides obtained from such an analysis will bear motif(s) that correspond to binding to the single HLA allele that is expressed in the cell.

As appreciated by one in the art, one can perform a similar analysis on a cell bearing more than one HLA allele and subsequently determine peptides specific for each HLA allele expressed. Moreover, one of skill would also recognize that means other than transfection, such as loading with a protein antigen, can be used to provide a source of antigen to the cell.

**Example 34: Complementary Polynucleotides**

Sequences complementary to the 254P1D6B-encoding sequences, or any parts thereof, are used to detect, decrease, or inhibit expression of naturally occurring 254P1D6B. Although use of oligonucleotides comprising from about 15 to 30 base pairs is described, essentially the same procedure is used with smaller or with larger sequence fragments. Appropriate oligonucleotides are designed using, e.g., OLIGO 4.06 software (National Biosciences) and the coding sequence of 254P1D6B. To inhibit transcription, a complementary oligonucleotide is designed from the most unique 5' sequence and used to prevent promoter binding to the coding sequence. To inhibit translation, a complementary oligonucleotide is designed to prevent ribosomal binding to a 254P1D6B-encoding transcript.

**Example 35: Purification of Naturally-occurring or Recombinant 254P1D6B Using 254P1D6B-Specific Antibodies**

Naturally occurring or recombinant 254P1D6B is substantially purified by immunoaffinity chromatography using antibodies specific for 254P1D6B. An immunoaffinity column is constructed by covalently coupling anti-254P1D6B antibody to an activated chromatographic resin, such as CNBr-activated SEPHAROSE (Amersham Pharmacia Biotech). After the coupling, the resin is blocked and washed according to the manufacturer's instructions.

Media containing 254P1D6B are passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of 254P1D6B (e.g., high ionic strength buffers in the presence of detergent). The column is eluted under conditions that disrupt antibody/254P1D6B binding (e.g., a buffer of pH 2 to pH 3, or a high concentration of a chaotrope, such as urea or thiocyanate ion), and GCR.P is collected.

**Example 36: Identification of Molecules Which Interact with 254P1D6B**

254P1D6B, or biologically active fragments thereof, are labeled with 121 I Bolton-Hunter reagent. (See, e.g., Bolton *et al.* (1973) *Biochem. J.* 133:529.) Candidate molecules previously arrayed in the wells of a multi-well plate are incubated with the labeled 254P1D6B, washed, and any wells with labeled 254P1D6B complex are assayed. Data obtained using different concentrations of 254P1D6B are used to calculate values for the number, affinity, and association of 254P1D6B with the candidate molecules.

**Example 37: *In Vivo* Assay for 254P1D6B Tumor Growth Promotion**

The effect of a 254P1D6B protein on tumor cell growth can be confirmed *in vivo* by gene overexpression in a variety of cancer cells such as those in Table I. For example, as appropriate, SCID mice can be injected SQ on each flank with  $1 \times 10^6$  prostate, kidney, colon or bladder cancer cells (such as PC3, LNCaP, SCaBER, UM-UC-3, HT1376, SK-CO, Caco, RT4, T24, Caki, A-498 and SW839 cells) containing tkNeo empty vector or 254P1D6B.

At least two strategies can be used:

(1) Constitutive 254P1D6B expression under regulation of a promoter such as a constitutive promoter obtained from the genomes of viruses such as polyoma virus, fowlpox virus (UK 2,211,504 published 5 July 1989), adenovirus (such as Adenovirus 2), bovine papilloma virus, avian sarcoma virus, cytomegalovirus, a retrovirus, hepatitis-B virus and Simian Virus 40 (SV40), or from heterologous mammalian promoters, e.g., the actin promoter or an immunoglobulin promoter, provided such promoters are compatible with the host cell systems.

(2) Regulated expression under control of an inducible vector system, such as ecdysone, tet, etc., can be used provided such promoters are compatible with the host cell systems. Tumor volume is then monitored at the appearance of palpable tumors or by following serum markers such as PSA. Tumor development is followed over time to validate that 254P1D6B-expressing cells grow at a faster rate and/or that tumors produced by 254P1D6B-expressing cells demonstrate characteristics of altered aggressiveness (e.g., enhanced metastasis, vascularization, reduced responsiveness to

chemotherapeutic drugs). Tumor volume is evaluated by caliper measurements. Additionally, mice can be implanted with the same cells orthotopically in the prostate, bladder, colon or kidney to determine if 254P1D6B has an effect on local growth, e.g., in the prostate, bladder, colon or kidney or on the ability of the cells to metastasize, specifically to lungs or lymph nodes (Saffran *et al.*, Proc Natl Acad Sci U S A. 2001, 98: 2658; Fu, X., *et al.*, Int. J. Cancer, 1991, 49: 938-939; Chang, S., *et al.*, Anticancer Res., 1997, 17: 3239-3242; Peralta, E. A., *et al.*, J. Urol., 1999, 162: 1806-1811). For instance, the orthotopic growth of PC3 and PC3-254P1D6B can be compared in the prostate of SCID mice. Such experiments reveal the effect of 254P1D6B on orthotopic tumor growth, metastasis and/or angiogenic potential.

Furthermore, this assay is useful to confirm the inhibitory effect of candidate therapeutic compositions, such as 254P1D6B antibodies or intrabodies, and 254P1D6B antisense molecules or ribozymes, or 254P1D6B directed small molecules, on cells that express a 254P1D6B protein.

### **Example 38: 254P1D6B Monoclonal Antibody-mediated Inhibition of Tumors *In Vivo***

The significant expression of 254P1D6B, in cancer tissues, together with its restricted expression in normal tissues makes 254P1D6B an excellent target for antibody therapy. Similarly, 254P1D6B is a target for T cell-based immunotherapy. Thus, the therapeutic efficacy of anti-254P1D6B mAbs is evaluated, e.g., in human prostate cancer xenograft mouse models using androgen-independent LAPC-4 and LAPC-9 xenografts (Craft, N., *et al.* Cancer Res, 1999, 59(19): p. 5030-5036), kidney cancer xenografts (AGS-K3, AGS-K6), kidney cancer metastases to lymph node (AGS-K6 met) xenografts, and kidney cancer cell lines transfected with 254P1D6B, such as 769P-254P1D6B, A498-254P1D6B.

Antibody efficacy on tumor growth and metastasis formation is studied, e.g., in mouse orthotopic prostate cancer xenograft models and mouse kidney xenograft models. The antibodies can be unconjugated, as discussed in this example, or can be conjugated to a therapeutic modality, as appreciated in the art. Anti-254P1D6B mAbs inhibit formation of both the androgen-dependent LAPC-9 and androgen-independent PC3-254P1D6B tumor xenografts. Anti-254P1D6B mAbs also retard the growth of established orthotopic tumors and prolonged survival of tumor-bearing mice. These results indicate the utility of anti-254P1D6B mAbs in the treatment of local and advanced stages of, e.g., prostate cancer. (See, e.g., Saffran, D., *et al.*, PNAS 10:1073-1078 or located on the World Wide Web at ([pnas.org/cgi/doi/10.1073/pnas.051624698](http://pnas.org/cgi/doi/10.1073/pnas.051624698)). Similarly, anti-254P1D6B mAbs inhibit formation of AGS-K3 and AGS-K6 tumors in SCID mice, and prevent or retard the growth A498-254P1D6B tumor xenografts. These results indicate the use of anti-254P1D6B mAbs in the treatment of prostate and/or kidney cancer.

Administration of the anti-254P1D6B mAbs leads to retardation of established orthotopic tumor growth and inhibition of metastasis to distant sites, resulting in a significant prolongation in the survival of tumor-bearing mice. These studies indicate that 254P1D6B is an attractive target for immunotherapy and demonstrate the therapeutic use of anti-254P1D6B mAbs for the treatment of local and metastatic cancer. This example demonstrates that unconjugated 254P1D6B monoclonal antibodies are effective to inhibit the growth of human prostate tumor xenografts and human kidney xenografts grown in SCID mice.

#### **Tumor inhibition using multiple unconjugated 254P1D6B mAbs**

##### **Materials and Methods**

##### **254P1D6B Monoclonal Antibodies:**

Monoclonal antibodies are obtained against 254P1D6B, as described in Example 11 entitled: Generation of 254P1D6B Monoclonal Antibodies (mAbs), or may be obtained commercially. The antibodies are characterized by ELISA, Western blot, FACS, and immunoprecipitation for their capacity to bind 254P1D6B. Epitope mapping data for the anti-254P1D6B mAbs, as determined by ELISA and Western analysis, recognize epitopes on a 254P1D6B protein. Immunohistochemical analysis of cancer tissues and cells is performed with these antibodies.

The monoclonal antibodies are purified from ascites or hybridoma tissue culture supernatants by Protein-G Sepharose chromatography, dialyzed against PBS, filter sterilized, and stored at -20°C. Protein determinations are performed by a Bradford assay (Bio-Rad, Hercules, CA). A therapeutic monoclonal antibody or a cocktail comprising a mixture of individual monoclonal antibodies is prepared and used for the treatment of mice receiving subcutaneous or orthotopic injections of, e.g., LAPC-9 prostate tumor xenografts.

#### Cancer Xenografts and Cell Lines

The LAPC-9 xenograft, which expresses a wild-type androgen receptor and produces prostate-specific antigen (PSA), is passaged in 6- to 8-week-old male ICR-severe combined immunodeficient (SCID) mice (Taconic Farms) by subcutaneous (s.c.) trocar implant (Craft, N., *et al.*, 1999, *Cancer Res.* 59:5030-5036). The AGS-K3 and AGS-K6 kidney xenografts are also passaged by subcutaneous implants in 6- to 8-week old SCID mice. Single-cell suspensions of tumor cells are prepared as described in Craft, *et al.* The prostate carcinoma cell line PC3 (American Type Culture Collection) is maintained in RPMI supplemented with L-glutamine and 10% FBS, and the kidney carcinoma line A498 (American Type Culture Collection) is maintained in DMEM supplemented with L-glutamine and 10% FBS.

PC3-254P1D6B and A498-254P1D6B cell populations are generated by retroviral gene transfer as described in Hubert, R.S., *et al.*, STEAP: A Prostate-specific Cell-surface Antigen Highly Expressed in Human Prostate Tumors, *Proc Natl. Acad. Sci. U S A*, 1999, 96(25): p. 14523-14528. Anti-254P1D6B staining is detected by using, e.g., an FITC-conjugated goat anti-mouse antibody (Southern Biotechnology Associates) followed by analysis on a Coulter Epics-XL flow cytometer.

#### Xenograft Mouse Models

Subcutaneous (s.c.) tumors are generated by injection of  $1 \times 10^6$  LAPC-9, AGS-K3, AGS-K6, PC3, PC3-254P1D6B, A498 or A498-254P1D6B cells mixed at a 1:1 dilution with Matrigel (Collaborative Research) in the right flank of male SCID mice. To test antibody efficacy on tumor formation, i.p. antibody injections are started on the same day as tumor-cell injections. As a control, mice are injected with either purified mouse IgG (ICN) or PBS; or a purified monoclonal antibody that recognizes an irrelevant antigen not expressed in human cells. In preliminary studies, no difference is found between mouse IgG or PBS on tumor growth. Tumor sizes are determined by vernier caliper measurements, and the tumor volume is calculated as length x width x height. Mice with s.c. tumors greater than 1.5 cm in diameter are sacrificed. PSA levels are determined by using a PSA ELISA kit (Anogen, Mississauga, Ontario). Circulating levels of anti-254P1D6B mAbs are determined by a capture ELISA kit (Bethyl Laboratories, Montgomery, TX). (See, e.g., (Saffran, D., *et al.*, *PNAS* 10:1073-1078 or on the world wide web as [pnas.org/cgi/doi/10.1073/pnas.051624698](http://pnas.org/cgi/doi/10.1073/pnas.051624698))

Orthotopic prostate injections are performed under anesthesia by using ketamine/xylazine. For prostate orthotopic studies, an incision is made through the abdominal muscles to expose the bladder and seminal vesicles, which then are delivered through the incision to expose the dorsal prostate. LAPC-9 cells ( $5 \times 10^5$ ) mixed with Matrigel are injected into each dorsal lobe in a 10  $\mu$ l volume. To monitor tumor growth, mice are bled on a weekly basis for determination of PSA levels. For kidney orthotopic models, an incision is made through the abdominal muscles to expose the kidney. AGS-K3 or AGS-K6 cells mixed with Matrigel are injected under the kidney capsule. The mice are segregated into groups for appropriate treatments, with anti-254P1D6B or control mAbs being injected i.p.

#### Anti-254P1D6B mAbs Inhibit Growth of 254P1D6B-Expressing Xenograft-Cancer Tumors

The effect of anti-254P1D6B mAbs on tumor formation is tested by using, e.g., LAPC-9 and/or AGS-K3 orthotopic models. As compared with the s.c. tumor model, the orthotopic model, which requires injection of tumor cells directly in the mouse prostate or kidney, respectively, results in a local tumor growth, development of metastasis in distal sites, deterioration of mouse health, and subsequent death (Saffran, D., *et al.*, *PNAS* supra; Fu, X., *et al.*, *Int J Cancer*, 1992, 52(6): p. 987-90; Kubota, T., *J Cell Biochem*, 1994, 56(1): p. 4-8). The features make the orthotopic model more

representative of human disease progression and allow for tracking of the therapeutic effect of mAbs on clinically relevant end points.

Accordingly, tumor cells are injected into the mouse prostate or kidney, and the mice are segregated into two groups and treated with either: a) 200-500 µg, of anti-254P1D6B Ab, or b) PBS for two to five weeks.

As noted, a major advantage of the orthotopic prostate-cancer model is the ability to study the development of metastases. Formation of metastasis in mice bearing established orthotopic tumors is studied by IHC analysis on lung sections using an antibody against a prostate-specific cell-surface protein STEAP expressed at high levels in LAPC-9 xenografts (Hubert, R.S., *et al.*, Proc Natl. Acad. Sci. U S A, 1999, 96(25): p. 14523-14528) or anti-G250 antibody for kidney cancer models. G250 is a clinically relevant marker for renal clear cell carcinoma, which is selectively expressed on tumor but not normal kidney cells (Grabmaier K *et al.*, Int J Cancer. 2000, 85: 865).

Mice bearing established orthotopic LAPC-9 tumors are administered 500-1000 µg injections of either anti-254P1D6B mAb or PBS over a 4-week period. Mice in both groups are allowed to establish a high tumor burden (PSA levels greater than 300 ng/ml), to ensure a high frequency of metastasis formation in mouse lungs. Mice then are killed and their prostate/kidney and lungs are analyzed for the presence of tumor cells by IHC analysis.

These studies demonstrate a broad anti-tumor efficacy of anti-254P1D6B antibodies on initiation and/or progression of prostate and kidney cancer in xenograft mouse models. Anti-254P1D6B antibodies inhibit tumor formation of both androgen-dependent and androgen-independent prostate tumors as well as retarding the growth of already established tumors and prolong the survival of treated mice. Moreover, anti-254P1D6B mAbs demonstrate a dramatic inhibitory effect on the spread of local prostate tumor to distal sites, even in the presence of a large tumor burden. Similar therapeutic effects are seen in the kidney cancer model. Thus, anti-254P1D6B mAbs are efficacious on major clinically relevant end points (tumor growth), prolongation of survival, and health.

#### **Example 39: Therapeutic and Diagnostic use of Anti-254P1D6B Antibodies in Humans.**

Anti-254P1D6B monoclonal antibodies are safely and effectively used for diagnostic, prophylactic, prognostic and/or therapeutic purposes in humans. Western blot and immunohistochemical analysis of cancer tissues and cancer xenografts with anti-254P1D6B mAb show strong extensive staining in carcinoma but significantly lower or undetectable levels in normal tissues. Detection of 254P1D6B in carcinoma and in metastatic disease demonstrates the usefulness of the mAb as a diagnostic and/or prognostic indicator. Anti-254P1D6B antibodies are therefore used in diagnostic applications such as immunohistochemistry of kidney biopsy specimens to detect cancer from suspect patients.

As determined by flow cytometry, anti-254P1D6B mAb specifically binds to carcinoma cells. Thus, anti-254P1D6B antibodies are used in diagnostic whole body imaging applications, such as radioimmunoscintigraphy and radioimmunotherapy, (see, e.g., Potamianos S., *et. al.* Anticancer Res 20(2A):925-948 (2000)) for the detection of localized and metastatic cancers that exhibit expression of 254P1D6B. Shedding or release of an extracellular domain of 254P1D6B into the extracellular milieu, such as that seen for alkaline phosphodiesterase B10 (Meerson, N. R., Hepatology 27:563-568 (1998)), allows diagnostic detection of 254P1D6B by anti-254P1D6B antibodies in serum and/or urine samples from suspect patients.

Anti-254P1D6B antibodies that specifically bind 254P1D6B are used in therapeutic applications for the treatment of cancers that express 254P1D6B. Anti-254P1D6B antibodies are used as an unconjugated modality and as conjugated form in which the antibodies are attached to one of various therapeutic or imaging modalities well known in the art, such as a prodrugs, enzymes or radioisotopes. In preclinical studies, unconjugated and conjugated anti-254P1D6B antibodies are tested for efficacy of tumor prevention and growth inhibition in the SCID mouse cancer xenograft models, e.g., kidney cancer models AGS-K3 and AGS-K6, (see, e.g., the Example entitled "254P1D6B Monoclonal Antibody-mediated Inhibition of

Bladder and Lung Tumors *In Vivo*). Either conjugated and unconjugated anti-254P1D6B antibodies are used as a therapeutic modality in human clinical trials either alone or in combination with other treatments as described in following Examples.

**Example 40: Human Clinical Trials for the Treatment and Diagnosis of Human Carcinomas through use of Human Anti-254P1D6B Antibodies *In vivo***

Antibodies are used in accordance with the present invention which recognize an epitope on 254P1D6B, and are used in the treatment of certain tumors such as those listed in Table I. Based upon a number of factors, including 254P1D6B expression levels, tumors such as those listed in Table I are presently preferred indications. In connection with each of these indications, three clinical approaches are successfully pursued.

I.) **Adjunctive therapy:** In adjunctive therapy, patients are treated with anti-254P1D6B antibodies in combination with a chemotherapeutic or antineoplastic agent and/or radiation therapy. Primary cancer targets, such as those listed in Table I, are treated under standard protocols by the addition anti-254P1D6B antibodies to standard first and second line therapy. Protocol designs address effectiveness as assessed by reduction in tumor mass as well as the ability to reduce usual doses of standard chemotherapy. These dosage reductions allow additional and/or prolonged therapy by reducing dose-related toxicity of the chemotherapeutic agent. Anti-254P1D6B antibodies are utilized in several adjunctive clinical trials in combination with the chemotherapeutic or antineoplastic agents adriamycin (advanced prostate carcinoma), cisplatin (advanced head and neck and lung carcinomas), taxol (breast cancer), and doxorubicin (preclinical).

II.) **Monotherapy:** In connection with the use of the anti-254P1D6B antibodies in monotherapy of tumors, the antibodies are administered to patients without a chemotherapeutic or antineoplastic agent. In one embodiment, monotherapy is conducted clinically in end stage cancer patients with extensive metastatic disease. Patients show some disease stabilization. Trials demonstrate an effect in refractory patients with cancerous tumors.

III.) **Imaging Agent:** Through binding a radionuclide (e.g., iodine or yttrium ( $^{131}\text{I}$ ,  $^{90}\text{Y}$ ) to anti-254P1D6B antibodies, the radiolabeled antibodies are utilized as a diagnostic and/or imaging agent. In such a role, the labeled antibodies localize to both solid tumors, as well as, metastatic lesions of cells expressing 254P1D6B. In connection with the use of the anti-254P1D6B antibodies as imaging agents, the antibodies are used as an adjunct to surgical treatment of solid tumors, as both a pre-surgical screen as well as a post-operative follow-up to determine what tumor remains and/or returns. In one embodiment, a ( $^{111}\text{In}$ )-254P1D6B antibody is used as an imaging agent in a Phase I human clinical trial in patients having a carcinoma that expresses 254P1D6B (by analogy see, e.g., Divgi *et al. J. Natl. Cancer Inst.* 83:97-104 (1991)). Patients are followed with standard anterior and posterior gamma camera. The results indicate that primary lesions and metastatic lesions are identified.

**Dose and Route of Administration**

As appreciated by those of ordinary skill in the art, dosing considerations can be determined through comparison with the analogous products that are in the clinic. Thus, anti-254P1D6B antibodies can be administered with doses in the range of 5 to 400 mg/m<sup>2</sup>, with the lower doses used, e.g., in connection with safety studies. The affinity of anti-254P1D6B antibodies relative to the affinity of a known antibody for its target is one parameter used by those of skill in the art for determining analogous dose regimens. Further, anti-254P1D6B antibodies that are fully human antibodies, as compared to the chimeric antibody, have slower clearance; accordingly, dosing in patients with such fully human anti-254P1D6B antibodies can be lower, perhaps in the range of 50 to 300 mg/m<sup>2</sup>, and still remain efficacious. Dosing in mg/m<sup>2</sup>, as opposed to the conventional measurement of dose in mg/kg, is a measurement based on surface area and is a convenient dosing measurement that is designed to include patients of all sizes from infants to adults.

Three distinct delivery approaches are useful for delivery of anti-254P1D6B antibodies. Conventional intravenous delivery is one standard delivery technique for many tumors. However, in connection with tumors in the peritoneal cavity, such as tumors of the ovaries, biliary duct, other ducts, and the like, intraperitoneal administration may prove favorable for obtaining high dose of antibody at the tumor and to also minimize antibody clearance. In a similar manner, certain solid tumors possess vasculature that is appropriate for regional perfusion. Regional perfusion allows for a high dose of antibody at the site of a tumor and minimizes short term clearance of the antibody.

#### Clinical Development Plan (CDP)

Overview: The CDP follows and develops treatments of anti-254P1D6B antibodies in connection with adjunctive therapy, monotherapy, and as an imaging agent. Trials initially demonstrate safety and thereafter confirm efficacy in repeat doses. Trials are open label comparing standard chemotherapy with standard therapy plus anti-254P1D6B antibodies. As will be appreciated, one criteria that can be utilized in connection with enrollment of patients is 254P1D6B expression levels in their tumors as determined by biopsy.

As with any protein or antibody infusion-based therapeutic, safety concerns are related primarily to (i) cytokine release syndrome, i.e., hypotension, fever, shaking, chills; (ii) the development of an immunogenic response to the material (i.e., development of human antibodies by the patient to the antibody therapeutic, or HAHA response); and, (iii) toxicity to normal cells that express 254P1D6B. Standard tests and follow-up are utilized to monitor each of these safety concerns. Anti-254P1D6B antibodies are found to be safe upon human administration.

#### Example 41: Human Clinical Trial Adjunctive Therapy with Human Anti-254P1D6B Antibody and Chemotherapeutic Agent

A phase I human clinical trial is initiated to assess the safety of six intravenous doses of a human anti-254P1D6B antibody in connection with the treatment of a solid tumor, e.g., a cancer of a tissue listed in Table I. In the study, the safety of single doses of anti-254P1D6B antibodies when utilized as an adjunctive therapy to an antineoplastic or chemotherapeutic agent as defined herein, such as, without limitation: cisplatin, topotecan, doxorubicin, adriamycin, taxol, or the like, is assessed. The trial design includes delivery of six single doses of an anti-254P1D6B antibody with dosage of antibody escalating from approximately about 25 mg/m<sup>2</sup> to about 275 mg/m<sup>2</sup> over the course of the treatment in accordance with the following schedule:

	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35
mAb Dose	25	75	125	175	225	275
	mg/m <sup>2</sup>	mg/m <sup>2</sup>	mg/m <sup>2</sup>	mg/m <sup>2</sup>	mg/m <sup>2</sup>	mg/m <sup>2</sup>
Chemotherapy	+	+	+	+	+	+
(standard dose)						

Patients are closely followed for one-week following each administration of antibody and chemotherapy. In particular, patients are assessed for the safety concerns mentioned above: (i) cytokine release syndrome, i.e., hypotension, fever, shaking, chills; (ii) the development of an immunogenic response to the material (i.e., development of human antibodies by the patient to the human antibody therapeutic, or HAHA response); and, (iii) toxicity to normal cells that express 254P1D6B. Standard tests and follow-up are utilized to monitor each of these safety concerns. Patients are also assessed for clinical outcome, and particularly reduction in tumor mass as evidenced by MRI or other imaging.

The anti-254P1D6B antibodies are demonstrated to be safe and efficacious, Phase II trials confirm the efficacy and refine optimum dosing.

**Example 42: Human Clinical Trial: Monotherapy with Human Anti-254P1D6B Antibody**

Anti-254P1D6B antibodies are safe in connection with the above-discussed adjunctive trial, a Phase II human clinical trial confirms the efficacy and optimum dosing for monotherapy. Such trial is accomplished, and entails the same safety and outcome analyses, to the above-described adjunctive trial with the exception being that patients do not receive chemotherapy concurrently with the receipt of doses of anti-254P1D6B antibodies.

**Example 43: Human Clinical Trial: Diagnostic Imaging with Anti-254P1D6B Antibody**

Once again, as the adjunctive therapy discussed above is safe within the safety criteria discussed above, a human clinical trial is conducted concerning the use of anti-254P1D6B antibodies as a diagnostic imaging agent. The protocol is designed in a substantially similar manner to those described in the art, such as in Divgi *et al. J. Natl. Cancer Inst.* 83:97-104 (1991). The antibodies are found to be both safe and efficacious when used as a diagnostic modality.

**Example 44: Involvement in Tumor Progression**

The 254P1D6B gene contributes to the growth of cancer cells. The role of 254P1D6B in tumor growth is confirmed in a variety of primary and transfected cell lines including prostate, colon, bladder and kidney cell lines, as well as NIH 3T3 cells engineered to stably express 254P1D6B. Parental cells lacking 254P1D6B and cells expressing 254P1D6B are evaluated for cell growth using a well-documented proliferation assay (Fraser SP, et al., *Prostate* 2000;44:61, Johnson DE, Ochieng J, Evans SL. *Anticancer Drugs*. 1996, 7:288). The effect of 254P1D6B can also be observed on cell cycle progression. Control and 254P1D6B-expressing cells are grown in low serum overnight, and treated with 10% FBS for 48 and 72 hrs. Cells are analyzed for BrdU and propidium iodide incorporation by FACS analysis.

To confirm the role of 254P1D6B in the transformation process, its effect in colony forming assays is investigated. Parental NIH-3T3 cells lacking 254P1D6B are compared to NIH-3T3 cells expressing 254P1D6B, using a soft agar assay under stringent and more permissive conditions (Song Z. et al. *Cancer Res.* 2000;60:6730).

To confirm the role of 254P1D6B in invasion and metastasis of cancer cells, a well-established assay is used. A non-limiting example is the use of an assay which provides a basement membrane or an analog thereof used to detect whether cells are invasive (e.g., a Transwell Insert System assay (Becton Dickinson) (*Cancer Res.* 1999; 59:6010)). Control cells, including prostate, and bladder cell lines lacking 254P1D6B are compared to cells expressing 254P1D6B. Cells are loaded with the fluorescent dye, calcein, and plated in the top well of a support structure coated with a basement membrane analog (e.g. the Transwell insert) and used in the assay. Invasion is determined by fluorescence of cells in the lower chamber relative to the fluorescence of the entire cell population.

254P1D6B also plays a role in cell cycle and apoptosis. Parental cells and cells expressing 254P1D6B are compared for differences in cell cycle regulation using a well-established BrdU assay (Abdel-Malek ZA. *J Cell Physiol.* 1988, 136:247). In short, cells are grown under both optimal (full serum) and limiting (low serum) conditions are labeled with BrdU and stained with anti-BrdU Ab and propidium iodide. Cells are analyzed for entry into the G1, S, and G2M phases of the cell cycle. Alternatively, the effect of stress on apoptosis is evaluated in control parental cells and cells expressing 254P1D6B, including normal and tumor prostate, and kidney cells. Engineered and parental cells are treated with various chemotherapeutic agents, such as etoposide, flutamide, etc, and protein synthesis inhibitors, such as cycloheximide. Cells are stained with annexin V-FITC and cell death is measured by FACS analysis. The modulation of cell death by 254P1D6B can play a critical role in regulating tumor progression and tumor load.

When 254P1D6B plays a role in cell growth, transformation, invasion or apoptosis, it is used as a target for diagnostic, prognostic, preventative and/or therapeutic purposes.

#### **Example 45: Involvement in Angiogenesis**

Angiogenesis or new capillary blood vessel formation is necessary for tumor growth (Hanahan D, Folkman J. *Cell*. 1996, 86:353; Folkman J. *Endocrinology*. 1998 139:441). 254P1D6B plays a role in angiogenesis. Several assays have been developed to measure angiogenesis *in vitro* and *in vivo*, such as the tissue culture assays endothelial cell tube formation and endothelial cell proliferation. Using these assays as well as *in vitro* neo-vascularization, the role of 254P1D6B in angiogenesis, enhancement or inhibition, is confirmed. For example, endothelial cells engineered to express 254P1D6B are evaluated using tube formation and proliferation assays. The effect of 254P1D6B is also confirmed in animal models *in vivo*. For example, cells either expressing or lacking 254P1D6B are implanted subcutaneously in immunocompromised mice. Endothelial cell migration and angiogenesis are evaluated 5-15 days later using immunohistochemistry techniques. 254P1D6B affects angiogenesis, and it is used as a target for diagnostic, prognostic, preventative and/or therapeutic purposes.

#### **Example 46: Involvement in Cell Adhesion**

Cell adhesion plays a critical role in tissue colonization and metastasis. 254P1D6B participates in cellular organization, and as a consequence cell adhesion and motility. To confirm that 254P1D6B regulates cell adhesion, control cells lacking 254P1D6B are compared to cells expressing 254P1D6B, using techniques previously described (see, e.g., Haier et al, *Br. J. Cancer*. 1999, 80:1867; Lehr and Pienta, *J. Natl. Cancer Inst.* 1998, 90:118). Briefly, in one embodiment, cells labeled with a fluorescent indicator, such as calcein, are incubated on tissue culture wells coated with media alone or with matrix proteins. Adherent cells are detected by fluorimetric analysis and percent adhesion is calculated. In another embodiment, cells lacking or expressing 254P1D6B are analyzed for their ability to mediate cell-cell adhesion using similar experimental techniques as described above. Both of these experimental systems are used to identify proteins, antibodies and/or small molecules that modulate cell adhesion to extracellular matrix and cell-cell interaction. Cell adhesion plays a critical role in tumor growth, progression, and, colonization, and 254P1D6B is involved in these processes. Thus, it serves as a diagnostic, prognostic, preventative and/or therapeutic modality.

#### **Example 47: *In vitro* biologic target validation: Target activation / inactivation; RNA interference (RNAi)**

Systematic alteration of 254P1D6B gene activity in relevant cell assays or in animal models is an approach for understanding gene function. There are two complementary platforms to alter gene function: Target activation and target inactivation. 254P1D6B target gene activation induces a disease phenotype (i.e. tumorigenesis) by mimicking the differential gene activity that occurs in several tumors. Conversely, 254P1D6B target inactivation reverses a phenotype found in a particular disease and mimics the inhibition of the target with a putative lead compound/agent.

RNA interference (RNAi) technology is implemented to a variety of cell assays relevant to oncology. RNAi is a post-transcriptional gene silencing mechanism activated by double stranded RNA (dsRNA). RNAi induces specific mRNA degradation leading to changes in protein expression and subsequently in gene function. In mammalian cells, dsRNAs (>30 bp) can activate the interferon pathway which induces non-specific mRNA degradation and protein translation inhibition. When transfecting small synthetic dsRNA (21-23 nucleotides in length), the activation of the interferon pathway is no longer observed, however these dsRNAs have the correct composition to activate the RNAi pathway targeting for degradation, specifically some mRNAs. See, Elbashir S.M., *et. al.*, Duplexes of 21-nucleotide RNAs Mediate RNA interference in

Cultured Mammalian Cells, Nature 411(6836):494-8 (2001). Thus, RNAi technology is used successfully in mammalian cells to silence targeted genes.

Loss of cell proliferation control is a hallmark of cancerous cells; thus, assessing the role of 254P1D6B specific target genes in cell survival/proliferation assays is relevant. RNAi technology is implemented to the cell survival (cellular metabolic activity as measured by MTS) and proliferation (DNA synthesis as measured by  $^3\text{H}$ -thymidine uptake) assays as a first filter to assess 254P1D6B target validation (TV). Tetrazolium-based colorimetric assays (i.e. MTT and MTS) detect viable cells exclusively. Living cells are metabolically active and can reduce tetrazolium salts to colored formazan compounds. Dead cells do not reduce the salts.

An alternative method to analyze 254P1D6B cell proliferation is the measurement of DNA synthesis as a marker for proliferation. Labeled DNA precursors (i.e.  $^3\text{H}$ -Thymidine) are used and their incorporation to DNA is quantified. Incorporation of the labeled precursor into DNA is directly proportional to the amount of cell division occurring in the culture.

Correlating 254P1D6B cellular phenotype with gene knockdown is critical following RNAi treatments to draw valid conclusions and rule out toxicity or other non-specific effects of these reagents. Assays to measure the levels of expression of both protein and mRNA for the 254P1D6B target after RNAi treatments are important. Specific antibodies against the 254P1D6B target permit this question to be addressed by performing Western blotting with whole cell lysates.

An alternative method is the use of a tagged full length 254P1D6B target cDNA inserted in a mammalian expression vector (i.e. pcDNA3 series) providing a tag for which commercial Abs are available (Myc, His, V5 etc) is transiently co-transfected with individual siRNAs for 254P1D6B gene target, for instance in COS cells. Transgene expression permits the evaluation of which siRNA is efficiently silencing target gene expression, thus providing the necessary information to correlate gene function with protein knockdown. Both endogenous and transgene expression approaches show similar results.

A further alternative method for 254P1D6B target gene expression is measurement of mRNA levels by RT-PCR or by Taqman/Cybergreen. These methods are applied in a high throughput manner and are used in cases where neither Abs nor full length cDNAs are available. Using this method, poly-A mRNA purification and a careful design of primers/probes (should be 5' to the siRNA targeted sequence) is needed for the Taqman approach. Some considerations apply to the primer design if pursuing RT-PCR from total RNA (primers should flank the siRNA targeted sequence). However, in some instances, the correlation between mRNA/protein is not complete (i.e., protein with long half life) and the results could be misleading.

Several siRNAs per 254P1D6B target gene are selected and tested in parallel in numerous cell lines (usually with different tissue origin) in the survival and proliferation assays. Any phenotypic effect of the siRNAs in these assays is correlated with the protein and/or mRNA knockdown levels in the same cell lines. To further correlate cell phenotype and specific gene knockdown by RNAi, serial siRNA titrations are performed and are tested in parallel cell phenotype and gene knockdown. When 254P1D6B is responsible for the phenotype, a similar  $\text{IC}_{50}$  value in both assays is obtained.

Another method used to measure cell proliferation is performing clonogenic assays. In these assays, a defined number of cells are plated onto the appropriate matrix and the number of colonies formed after a period of growth following siRNA treatment is counted.

In 254P1D6B cancer target validation, complementing the cell survival/proliferation analysis with apoptosis and cell cycle profiling studies are considered. The biochemical hallmark of the apoptotic process is genomic DNA fragmentation, an irreversible event that commits the cell to die. A method to observe fragmented DNA in cells is the immunological detection of histone-complexed DNA fragments by an immunoassay (i.e. cell death detection ELISA) which measures the enrichment of histone-complexed DNA fragments (mono- and oligo-nucleosomes) in the cytoplasm of apoptotic cells. This assay does

not require pre-labeling of the cells and can detect DNA degradation in cells that do not proliferate in vitro (i.e. freshly isolated tumor cells).

The most important effector molecules for triggering apoptotic cell death are caspases. Caspases are proteases that when activated cleave numerous substrates at the carboxy-terminal site of an aspartate residue mediating very early stages of apoptosis upon activation. All caspases are synthesized as pro-enzymes and activation involves cleavage at aspartate residues. In particular, caspase 3 seems to play a central role in the initiation of cellular events of apoptosis. Assays for determination of caspase 3 activation detect early events of apoptosis. Following RNAi treatments, Western blot detection of active caspase 3 presence or proteolytic cleavage of products (i.e. PARP) found in apoptotic cells further support an active induction of apoptosis. Because the cellular mechanisms that result in apoptosis are complex, each has its advantages and limitations. Consideration of other criteria/endpoints such as cellular morphology, chromatin condensation, membrane bebbing, apoptotic bodies help to further support cell death as apoptotic.

Not all the gene targets that regulate cell growth are anti-apoptotic, the DNA content of permeabilized cells is measured to obtain the profile of DNA content or cell cycle profile. Nuclei of apoptotic cells contain less DNA due to the leaking out to the cytoplasm (sub-G1 population). In addition, the use of DNA stains (i.e. propidium iodide) also differentiate between the different phases of the cell cycle in the cell population due to the presence of different quantities of DNA in G0/G1, S and G2/M. In these studies the subpopulations can be quantified.

For the 254P1D6B gene, RNAi studies facilitate the contribution of the gene product in cancer pathways. Such active RNAi molecules have use in identifying assays to screen for mAbs that are active anti-tumor therapeutics. When 254P1D6B plays a role in cell survival, cell proliferation, tumorigenesis, or apoptosis, it is used as a target for diagnostic, prognostic, preventative and/or therapeutic purposes.

#### **Example 48: RNA interference (RNAi)**

Various protocols for achieving RNA interference are available.

##### **exemplary protocol 1**

RNA interference (RNAi) makes use of sequence specific double stranded RNA to prevent gene expression. Small interfering RNA (siRNA) is transfected into mammalian cells and thereby induce sequence specific mRNA degradation (Elbashir, *et al*, *Nature*, 2001; vol. 411: 494-498).

The sense strand of 254P1D6B is labeled at 3' with fluorescein, 6-FAM (ABS 494nm, EMM 525 nm, green). The siRNA is dissolved in RNA-free sterile buffer (100mM KOAc, 30 mM HEPES KOH, 2mM MOAc, at pH 7.4) to make 20  $\mu$ M stock (200-fold concentration). The siRNA is transfected into cells seeded on 6-well plates with oligofectamine reagent (GIBCO/Invitrogen, Carlsbad, CA). The final concentration of siRNA is determined.

254P1D6B protein expression is detected 24 hours after transfection by immunostaining followed by flow cytometry. In addition, confirmation of altered gene expression is performed by Western blotting. Expression reduction is confirmed by Western blot analysis where 254P1D6B protein is substantially reduced in 254P1D6B RNAi treated cells relative to control and untreated cells.

##### **exemplary protocol 2**

In one embodiment, the day before siRNA transfection, cells are plated in media (e.g., RPMI 1640 (GIBCO/Invitrogen, Carlsbad, CA) with 10% FBS without antibiotics) at  $2 \times 10^3$  cells/well in 80  $\mu$ l (96 well plate format) for the survival, proliferation and apoptosis assays. In another embodiment, the day before siRNA transfection, cells are plated in media (e.g., RPMI 1640 with 10% FBS without antibiotics) at  $5 \times 10^4$  cells/well in 800  $\mu$ l (12 well plate format) for the cell cycle analysis by flow cytometry, gene silencing by Western blot and/or PCR analysis. In parallel with the 254P1D6B siRNA sequences, the following sequences are included in every experiment as controls. Mock transfected cells with Lipofectamine 2000 (GIBCO/Invitrogen, Carlsbad, CA) and annealing buffer (no siRNA), non-specific siRNA (targeted sequence not

represented in the human genome 5' AATTCTCCGAACGTGTACGTTT 3'; commercial control from Xeragon/Qiagen, Valencia, CA) (SEQ ID NO: 275); Luciferase specific siRNA (targeted sequence: 5' AAGGGACGAAGACGAACACUUCTT 3') (SEQ ID NO: 276) and Eg5 specific siRNA (targeted sequence: 5' AACTGAAGACCTGAAGACAATAA 3') (SEQ ID NO: 277). The siRNAs are used at various concentrations (ranging from 200 pM to 100 nM) and 1 µg/ml Lipofectamine 2000.

The procedure is as follows: First siRNAs are diluted in OPTIMEM (serum-free transfection media, Invitrogen) at suitable µM (10-fold concentrated) and incubated 5-10 min at room temperature (RT). Lipofectamine 2000 was diluted at 10 µg/ml (10-fold concentrated) for the total number transfections and incubated 5-10 min RT. Appropriate amounts of diluted 10-fold concentrated Lipofectamine 2000 are mixed 1:1 with diluted 10-fold concentrated siRNA and incubated at RT for 20-30 minutes (5-fold concentrated transfection solution). 20 or 200 µl of the 5-fold concentrated transfection solutions were added to the respective samples and incubated at 37°C for 48 to 96 hours (depending upon the assay employed, such as proliferation, apoptosis, survival, cell cycle analysis, migration or Western blot).

Reduced gene expression of 254P1D6B using siRNA transfection results in significantly diminished proliferation of transformed cancer cells that endogenously express the antigen. Cells treated with specific siRNAs show reduced survival as measured, e.g., by a metabolic readout of cell viability, corresponding to the reduced proliferative capacity. Further, such cells undergo apoptosis in response to RNAi as measured, e.g., by a nucleosome-release assay (Roche Applied Science, Indianapolis, IN) or detection of sub-G1 populations during cell cycle analysis by propidium iodide staining and flow cytometry. These results demonstrate that siRNA treatment provides an effective therapeutic for the elimination of cancer cells that specifically express the 254P1D6B antigen.

Throughout this application, various website data content, publications, patent applications and patents are referenced. (Websites are referenced by their Uniform Resource Locator, or URL, addresses on the World Wide Web.) The disclosures of each of these references are hereby incorporated by reference herein in their entireties.

The present invention is not to be limited in scope by the embodiments disclosed herein, which are intended as single illustrations of individual aspects of the invention, and any that are functionally equivalent are within the scope of the invention. Various modifications to the models and methods of the invention, in addition to those described herein, will become apparent to those skilled in the art from the foregoing description and teachings, and are similarly intended to fall within the scope of the invention. Such modifications or other embodiments can be practiced without departing from the true scope and spirit of the invention.

**TABLES:****TABLE I: Tissues that Express 254P1D6B when malignant:**

Lung  
Ovary  
Prostate  
Pancreas  
Breast

**TABLE II: Amino Acid Abbreviations**

SINGLE LETTER	THREE LETTER	FULL NAME
F	Phe	phenylalanine
L	Leu	leucine
S	Ser	serine
Y	Tyr	tyrosine
C	Cys	cysteine
W	Trp	tryptophan
P	Pro	proline
H	His	histidine
Q	Gln	glutamine
R	Arg	arginine
I	Ile	isoleucine
M	Met	methionine
T	Thr	threonine
N	Asn	asparagine
K	Lys	lysine
V	Val	valine
A	Ala	alanine
D	Asp	aspartic acid
E	Glu	glutamic acid
G	Gly	glycine

TABLE III: Amino Acid Substitution Matrix

Adapted from the GCG Software 9.0 BLOSUM62 amino acid substitution matrix (block substitution matrix). The higher the value, the more likely a substitution is found in related, natural proteins. (See world wide web URL [ikp.unibe.ch/manual/blosum62.html](http://ikp.unibe.ch/manual/blosum62.html) )

A	C	D	E	F	G	H	I	K	L	M	N	P	Q	R	S	T	V	W	Y	.
4	0	-2	-1	-2	0	-2	-1	-1	-1	-1	-2	-1	-1	-1	1	0	0	-3	-2	A
	9	-3	-4	-2	-3	-3	-1	-3	-1	-1	-3	-3	-3	-3	-1	-1	-1	-2	-2	C
		6	2	-3	-1	-1	-3	-1	-4	-3	1	-1	0	-2	0	-1	-3	-4	-3	D
			5	-3	-2	0	-3	1	-3	-2	0	-1	2	0	0	-1	-2	-3	-2	E
				6	-3	-1	0	-3	0	0	-3	-4	-3	-3	-2	-2	-1	1	3	F
					6	-2	-4	-2	-4	-3	0	-2	-2	-2	0	-2	-3	-2	-3	G
						8	-3	-1	-3	-2	1	-2	0	0	-1	-2	-3	-2	2	H
							4	-3	2	1	-3	-3	-3	-3	-2	-1	3	-3	-1	I
								5	-2	-1	0	-1	1	2	0	-1	-2	-3	-2	K
									4	2	-3	-3	-2	-2	-2	-1	1	-2	-1	L
										5	-2	-2	0	-1	-1	-1	1	-1	-1	M
											6	-2	0	0	1	0	-3	-4	-2	N
												7	-1	-2	-1	-1	-2	-4	-3	P
													5	1	0	-1	-2	-2	-1	Q
														5	-1	-1	-3	-3	-2	R
															4	1	-2	-3	-2	S
																5	0	-2	-2	T
																	4	-3	-1	V
																		11	2	W
																			7	Y

TABLE IV:  
HLA Class I/II Motifs/Supermotifs

TABLE IV (A): HLA Class I Supermotifs/Motifs

SUPERMOTIF	POSITION	POSITION	POSITION
	2 (Primary Anchor)	3 (Primary Anchor)	C Terminus (Primary Anchor)
A1	<b>T</b> ILVMS		FWY
A2	LIV <b>M</b> ATQ		IV <b>M</b> ATL
A3	V <b>S</b> MA <b>T</b> LI		RK
A24	YFWIVL <b>M</b> T		FIYWLM
B7	P		VILFMWYA
B27	RHK		FYLWMIVA
B44	ED		FWYLIMVA
B58	ATS		FWYLIVMA
B62	QLIVMP		FWYMI <b>V</b> LA
MOTIFS			
A1	<b>T</b> SM		Y
A1		DEAS	Y
A2.1	LMVQ <b>I</b> AT		VLIMAT
A3	LMVISAT <b>F</b> CGD		KYRHFA
A11	VTMLISAG <b>N</b> CDF		KRYH
A24	YFW <b>M</b>		FLIW
A*3101	MV <b>T</b> ALIS		RK
A*3301	MV <b>A</b> L <b>F</b> IST		RK
A*6801	AV <b>T</b> MSLI		RK
B*0702	P		LMFWYAIV
B*3501	P		LMFWYIVA
B51	P		LIVFWYAM
B*5301	P		IMFWYALV
B*5401	P		ATIVLMFWY

Bolded residues are preferred, italicized residues are less preferred: A peptide is considered motif-bearing if it has primary anchors at each primary anchor position for a motif or supermotif as specified in the above table.

TABLE IV (B): HLA Class II Supermotif

1	6	9
W, F, Y, V, .I, L	A, V, I, L, P, C, S, T	A, V, I, L, C, S, T, M, Y

TABLE IV (C): HLA Class II Motifs

MOTIFS		1° anchor 1	2	3	4	5	1° anchor 6	7	8	9
DR4	preferred deleterious	FMYL/VW	M	T	W	I	VSTCPALIM	MH R		MH WDE
DR1	preferred deleterious	MFL/VWY		C	CH	FD	VMATSPLIC	M GDE	D	AVM
DR7	preferred deleterious	MFL/VWY	M	W	A		IVMSACTPL	M GRD	N	IV G
DR3	<u>MOTIFS</u>	1° anchor 1	2	3	1° anchor 4	5	1° anchor 6			
Motif a preferred		LIVMFY			D					
Motif b preferred		LIVMFAY			DNQEST		KRH			
DR Supermotif		MFL/VWY					VMSTACPLI			

*Italicized residues indicate less preferred or "tolerated" residues*

TABLE IV (D): HLA Class I Supermotifs

	POSITION:	1	2	3	4	5	6	7	8	C-terminus
<u>SUPER-MOTIFS</u>										
A1			1° Anchor TILVMS							1° Anchor FWY
A2			1° Anchor LIVMATQ							1° Anchor LIVMAT
A3	Preferred  deleterious	  DE (3/5); P (5/5)	1° Anchor VSMATLI	YFW (4/5) DE (4/5)			YFW (3/5)	YFW (4/5)	P (4/5)	1° Anchor RK
A24			1° Anchor YFWIVLMT							1° Anchor FIYWLM
B7	Preferred  deleterious	FWY (5/5) LIVM (3/5) DE (3/5); P(5/5); G(4/5); A(3/5); QN(3/5)	1° Anchor P	FWY (4/5)		DE (3/5)	G (4/5)	QN (4/5)	FWY (3/5) DE (4/5)	1° Anchor VILFMWYA
B27			1° Anchor RHK							1° Anchor FYLWMIVA
B44			1° Anchor ED							1° Anchor FWYLIMVA
B58			1° Anchor ATS							1° Anchor FWYLIVMA
B62			1° Anchor QLIVMP							1° Anchor FWYMIIVLA

*Italicized residues indicate less preferred or "tolerated" residues*

TABLE IV (E): HLA Class I Motifs

	POSITION 1	2	3	4	5	6	7	8	9	C-terminus
									or C-terminus	
A1 9-mer	preferred GFYW	<u>1°Anchor</u> STM	DEA	YFW		P	DEQN	YFW	<u>1°Anchor</u> Y	
	deleterious DE		RHKLIVMP	A	G	A				
A1 9-mer	preferred GRHK	ASTCLIVM	<u>1°Anchor</u> DEAS	GSTC		ASTC	LIVM	DE	<u>1°Anchor</u> Y	
	deleterious A	RHKDEPYFW		DE	PQN	RHK	PG	GP		
A1 10-mer	preferred YFW	<u>1°Anchor</u> STM	DEAQN	A	YFWQN		PASTC	GDE	P	<u>1°Anchor</u> Y
	deleterious GP		RHKGLIVM	DE	RHK	QNA	RHKYFW	RHK	A	
A1 10-mer	preferred YFW	STCLIVM	<u>1°Anchor</u> DEAS	A	YFW		PG	G	YFW	<u>1°Anchor</u> Y
	deleterious RHK	RHKDEPYFW			P	G		PRHK	QN	
A2.1 9-mer	preferred YFW	<u>1°Anchor</u> LM/VQAT	YFW	STC	YFW		A	P	<u>1°Anchor</u> VLIMAT	
	deleterious DEP		DERKH			RKH	DERKH			
	POSITION: 1	2	3	4	5	6	7	8	9	C-Terminus
A2.1 10-mer	preferred AYFW	<u>1°Anchor</u> LM/VQAT	LVIM	G		G		FYWL VIM		<u>1°Anchor</u> VLIMAT
	deleterious DEP		DE	RKHA	P		RKH	DERKH	RKH	
A3	preferred RHK	<u>1°Anchor</u> LMVISATFCGD	YFW	PRHKYF W	A	YFW		P	<u>1°Anchor</u> KYRHFA	
	deleterious DEP		DE							
A11	preferred A	<u>1°Anchor</u> VTLMISAGNCD F	YFW	YFW	A	YFW	YFW	P	<u>1°Anchor</u> KRYH	
	deleterious DEP						A	G		
A24 9-mer	preferred YFWRHK	<u>1°Anchor</u> YFWM		STC			YFW	YFW	<u>1°Anchor</u> FLIW	
	deleterious DEG		DE	G	QNP	DERHKG		AQN		
A24 10-mer	Preferred	<u>1°Anchor</u> YFWM		P	YFWP		P			<u>1°Anchor</u> FLIW
	Deleterious		GDE	QN	RHK	DE	A	QN	DEA	
A3101 Preferred	RHK	<u>1°Anchor</u> MVTALIS	YFW	P		YFW	YFW	AP	<u>1°Anchor</u> RK	
	Deleterious DEP		DE		ADE	DE	DE	DE		
A3301 Preferred		<u>1°Anchor</u> MVALF/ST	YFW				AYFW		<u>1°Anchor</u> RK	
	Deleterious GP		DE							
A6801 Preferred	YFWSTC	<u>1°Anchor</u> AVTMSLI			YFWLIV M		YFW	P	<u>1°Anchor</u> RK	
	deleterious GP		DEG		RHK			A		
B0702 Preferred	RHKFWY	<u>1°Anchor</u> P	RHK		RHK	RHK	RHK	PA	<u>1°Anchor</u> LMFWYA/ V	
	deleterious DEQNP		DEP	DE	DE	GDE	QN	DE		
B3501 Preferred	FWYLIVM	<u>1°Anchor</u> P	FWY				FWY		<u>1°Anchor</u> LMFWYIV A	

	POSITION 1	2	3	4	5	6	7	8	9	C-terminus
									or C-terminus	
A1 9-mer	preferred	GFYW	<u>1°Anchor</u> STM	DEA	YFW		P	DEQN	YFW	<u>1°Anchor</u> Y
	deleterious	DE		RHKLIVMP	A	G	A			
A1 9-mer	preferred	GRHK	ASTCLIVM	<u>1°Anchor</u> DEAS	GSTC		ASTC	LIVM	DE	<u>1°Anchor</u> Y
	deleterious	A	RHKDEPYFW		DE	PQN	RHK	PG	GP	
	deleterious	AGP			G	G				
B51	Preferred	LIVMFWY	<u>1°Anchor</u> P	FWY	STC	FWY		G	FWY	<u>1°Anchor</u> LIVFWYA M
	deleterious	AGPDER HKSTC				DE	G	DEQN	GDE	
B5301	preferred	LIVMFWY	<u>1°Anchor</u> P	FWY	STC	FWY		LIVMFWYFWY		<u>1°Anchor</u> IMFWYAL V
	deleterious	AGPQN					G	RHKQN	DE	
B5401	preferred	FWY	<u>1°Anchor</u> P	FWYLIVM		LIVM		ALIVM	FWYA P	<u>1°Anchor</u> ATIVLMF WY
	deleterious	GPQNDE		GDESTC		RHKDE	DE	QNDGE	DE	

TABLE IV (F):

Summary of HLA-supertypes								
Overall phenotypic frequencies of HLA-supertypes in different ethnic populations								
Specificity			Phenotypic frequency					
Supertype	Position 2	C-Terminus	Caucasian	N.A. Black	Japanese	Chinese	Hispanic	Average
B7	P	AILMVFWY	43.2	55.1	57.1	43.0	49.3	49.5
A3	AILMVST	RK	37.5	42.1	45.8	52.7	43.1	44.2
A2	AILMVT	AILMVT	45.8	39.0	42.4	45.9	43.0	42.2
A24	YF (WIVLMT)	FI (YWLM)	23.9	38.9	58.6	40.1	38.3	40.0
B44	E (D)	FWYLIMVA	43.0	21.2	42.9	39.1	39.0	37.0
A1	TI (LVMS)	FWY	47.1	16.1	21.8	14.7	26.3	25.2
B27	RHK	FYL (WMI)	28.4	26.1	13.3	13.9	35.3	23.4
B62	QL (IVMP)	FWY (MIV)	12.6	4.8	36.5	25.4	11.1	18.1
B58	ATS	FWY (LIV)	10.0	25.1	1.6	9.0	5.9	10.3

TABLE IV (G):

Calculated population coverage afforded by different HLA-supertype combinations

HLA-supertypes	Phenotypic frequency					
	Caucasian	N.A Blacks	Japanese	Chinese	Hispanic	Average
A2, A3 and B7	83.0	86.1	87.5	88.4	86.3	86.2
A2, A3, B7, A24, B44 and A1	99.5	98.1	100.0	99.5	99.4	99.3
A2, A3, B7, A24, B44, A1, B27, B62, and B 58	99.9	99.6	100.0	99.8	99.9	99.8

Motifs indicate the residues defining supertype specificities. The motifs incorporate residues determined on the basis of published data to be recognized by multiple alleles within the supertype. Residues within brackets are additional residues also predicted to be tolerated by multiple alleles within the supertype.

Table V: Frequently Occurring Motifs

Name	avrg. % identity	Description	Potential Function
zf-C2H2	34%	Zinc finger, C2H2 type	Nucleic acid-binding protein functions as transcription factor, nuclear location probable
cytochrome_b_N	68%	Cytochrome b(N-terminal)/b6/petB	membrane bound oxidase, generate superoxide
Ig	19%	Immunoglobulin domain	domains are one hundred amino acids long and include a conserved intradomain disulfide bond.
WD40	18%	WD domain, G-beta repeat	tandem repeats of about 40 residues, each containing a Trp-Asp motif. Function in signal transduction and protein interaction
PDZ	23%	PDZ domain	may function in targeting signaling molecules to sub-membranous sites
LRR	28%	Leucine Rich Repeat	short sequence motifs involved in protein-protein interactions
Pkinase	23%	Protein kinase domain	conserved catalytic core common to both serine/threonine and tyrosine protein kinases containing an ATP binding site and a catalytic site

PH	16%	PH domain	pleckstrin homology involved in intracellular signaling or as constituents of the cytoskeleton
EGF	34%	EGF-like domain	30-40 amino-acid long found in the extracellular domain of membrane-bound proteins or in secreted proteins
Rvt	49%	Reverse transcriptase (RNA-dependent DNA polymerase)	
Ank	25%	Ank repeat	Cytoplasmic protein, associates integral membrane proteins to the cytoskeleton
Oxidored_q1	32%	NADH-Ubiquinone/plastoquinone (complex I), various chains	membrane associated. Involved in proton translocation across the membrane
Efhand	24%	EF hand	calcium-binding domain, consists of a 12 residue loop flanked on both sides by a 12 residue alpha-helical domain
Rvp	79%	Retroviral aspartyl protease	Aspartyl or acid proteases, centered on a catalytic aspartyl residue
Collagen	42%	Collagen triple helix repeat (20 copies)	extracellular structural proteins involved in formation of connective tissue. The sequence consists of the G-X-Y and the polypeptide chains forms a triple helix.
Fn3	20%	Fibronectin type III domain	Located in the extracellular ligand-binding region of receptors and is about 200 amino acid residues long with two pairs of cysteines involved in disulfide bonds
7tm_1	19%	7 transmembrane receptor (rhodopsin family)	seven hydrophobic transmembrane regions, with the N-terminus located extracellularly while the C-terminus is cytoplasmic. Signal through G proteins

Table VI: Post-translational modifications of 254P1D6B

N-Glycosylation site (start position indicated)

196 NSSV (SEQ ID NO: 28)  
 219 NESA (SEQ ID NO: 29)  
 262 NSSG (SEQ ID NO: 30)  
 394 NLSQ (SEQ ID NO: 31)  
 421 NVTV (SEQ ID NO: 32)  
 498 NYSF (SEQ ID NO: 33)  
 513 NSTT (SEQ ID NO: 34)  
 536 NHTI (SEQ ID NO: 35)  
 551 NQSS (SEQ ID NO: 36)  
 715 NNSP (SEQ ID NO: 37)  
 733 NNSI (SEQ ID NO: 38)  
 1023 NSSL (SEQ ID NO: 39)  
 1056 NGSI (SEQ ID NO: 40)

Tyrosine sulfation site (Start Position indicated)

156 EEMSEYSDDYRE (SEQ ID NO: 41)  
 160 EYSDDYRELEK (SEQ ID NO: 42)  
 527 NNAVDYPPVANAGPNH (SEQ ID NO: 43)

Serine predictions (Start Position indicated)

9 TGVLSLLLL (SEQ ID NO: 44)

10 GVLSSLLLL (SEQ ID NO: 45)  
 26 RKQCSEGR (SEQ ID NO: 46)  
 32 GRTYNAVI (SEQ ID NO: 47)  
 37 NAVISPNLE (SEQ ID NO: 48)  
 49 IMRVSHTFP (SEQ ID NO: 49)  
 65 CCDLSSCDL (SEQ ID NO: 50)  
 66 CDLSSCDLA (SEQ ID NO: 51)  
 81 CYLVSCPHK (SEQ ID NO: 52)  
 98 GPIRSYLT (SEQ ID NO: 53)  
 125 LNRGSPSGI (SEQ ID NO: 54)  
 127 RGSPSGIWG (SEQ ID NO: 55)  
 133 IWGDSPEDI (SEQ ID NO: 56)  
 154 LEEMSEYSD (SEQ ID NO: 57)  
 157 MSEYSDDYR (SEQ ID NO: 58)  
 171 LLQPSGKQE (SEQ ID NO: 59)  
 179 EPRGSAEYT (SEQ ID NO: 60)  
 191 LLPGSEGAF (SEQ ID NO: 61)  
 197 GAFNSSVGD (SEQ ID NO: 62)  
 198 AFNSSVGDS (SEQ ID NO: 63)  
 202 SVGDSPAVP (SEQ ID NO: 64)  
 221 YLNESASTP (SEQ ID NO: 65)  
 223 NESASTPAP (SEQ ID NO: 66)  
 233 LPERSVLLP (SEQ ID NO: 67)  
 243 PTPSSGEV (SEQ ID NO: 68)  
 244 TTPSSGEVL (SEQ ID NO: 69)  
 254 KEKASQLQE (SEQ ID NO: 70)  
 264 SSNSSGKEV (SEQ ID NO: 71)  
 272 VLMPSHSLP (SEQ ID NO: 72)  
 274 MP SHSLPPA (SEQ ID NO: 73)  
 279 LPPASLELS (SEQ ID NO: 74)  
 283 SLELSSVT (SEQ ID NO: 75)  
 284 LELSSVTVE (SEQ ID NO: 76)  
 290 TVEKSPVLT (SEQ ID NO: 77)  
 299 VTPGSTEH (SEQ ID NO: 78)  
 303 STEHSIPT (SEQ ID NO: 79)  
 310 TPPTSAAPS (SEQ ID NO: 80)  
 314 SAAPSESTP (SEQ ID NO: 81)  
 316 APSESTPSE (SEQ ID NO: 82)  
 319 ESTPSELPI (SEQ ID NO: 83)  
 324 ELPISPTTA (SEQ ID NO: 84)  
 338 ELTVSAGDN (SEQ ID NO: 85)  
 376 WNLISHPTD (SEQ ID NO: 86)  
 396 TLNLSQLSV (SEQ ID NO: 87)  
 399 LSQLSVGLY (SEQ ID NO: 88)  
 410 KVTVSSENA (SEQ ID NO: 89)  
 411 VTVSSENAF (SEQ ID NO: 90)  
 439 VAVVSPQLQ (SEQ ID NO: 91)  
 451 LPLTSALID (SEQ ID NO: 92)  
 457 LIDGSQSTD (SEQ ID NO: 93)  
 459 DGSQSTDDT (SEQ ID NO: 94)  
 467 TEIVSYHWE (SEQ ID NO: 95)  
 483 EEKTSVDSP (SEQ ID NO: 96)  
 486 TSVDSPVLR (SEQ ID NO: 97)  
 492 VLRLSNLDP (SEQ ID NO: 98)  
 500 PGNYSFRLT (SEQ ID NO: 99)  
 508 TVTDSGDAT (SEQ ID NO: 100)  
 514 GATNSTTAA (SEQ ID NO: 101)  
 545 LPQNSITLN (SEQ ID NO: 102)  
 553 NGNQSSDDH (SEQ ID NO: 103)  
 554 GNQSSDDHQ (SEQ ID NO: 104)  
 565 LYEWSLGPG (SEQ ID NO: 105)  
 570 LGPGSEGKH (SEQ ID NO: 106)  
 588 YLHLSAMQE (SEQ ID NO: 107)

604 KVTDSSRQQ (SEQ ID NO: 108)  
 605 VTDSSRQQS (SEQ ID NO: 109)  
 609 SRQQSTAVV (SEQ ID NO: 110)  
 641 FPVESATLD (SEQ ID NO: 111)  
 647 TLDGSSSSD (SEQ ID NO: 112)  
 648 LDGSSSSDD (SEQ ID NO: 113)  
 649 DGSSSSDDH (SEQ ID NO: 114)  
 650 GSSSSDDHG (SEQ ID NO: 115)  
 667 VRGPSAVEM (SEQ ID NO: 116)  
 702 QQGLSSTST (SEQ ID NO: 117)  
 703 QGLSSTSTL (SEQ ID NO: 118)  
 705 LSSTSTLTV (SEQ ID NO: 119)  
 717 KENNPPRA (SEQ ID NO: 120)  
 735 LPNNSITLD (SEQ ID NO: 121)  
 741 TLDGSRSTD (SEQ ID NO: 122)  
 743 DGSRSTDDQ (SEQ ID NO: 123)  
 751 QRIVSYLWI (SEQ ID NO: 124)  
 760 RDGQSPAAG (SEQ ID NO: 125)  
 770 VIDGSDHSV (SEQ ID NO: 126)  
 773 GSDHSVALQ (SEQ ID NO: 127)  
 795 RVTDSQGAS (SEQ ID NO: 128)  
 799 SQGASDSTD (SEQ ID NO: 129)  
 815 DPRKSGLVE (SEQ ID NO: 130)  
 850 NVLDSDIKV (SEQ ID NO: 131)  
 861 IRAHSDLST (SEQ ID NO: 132)  
 864 HSDLSTVIV (SEQ ID NO: 133)  
 873 FYVQSRPPF (SEQ ID NO: 134)  
 894 HMRLSKEKA (SEQ ID NO: 135)  
 918 LLKCSGHGH (SEQ ID NO: 136)  
 933 RCICSHLWM (SEQ ID NO: 137)  
 950 WDGESNCEW (SEQ ID NO: 138)  
 955 NCEWSIFYV (SEQ ID NO: 139)  
 1019 IKHRSTEHN (SEQ ID NO: 140)  
 1024 TEHNSSLMV (SEQ ID NO: 141)  
 1025 EHNSSLMVS (SEQ ID NO: 142)  
 1029 SLMVSESEF (SEQ ID NO: 143)  
 1031 MVSESEFDS (SEQ ID NO: 144)  
 1035 SEFSDSQDT (SEQ ID NO: 145)  
 1042 DTIFSREKM (SEQ ID NO: 146)  
 1054 NPKVSMNGS (SEQ ID NO: 147)  
 1058 SMNGSIRNG (SEQ ID NO: 148)  
 1064 RNGASFSYC (SEQ ID NO: 149)  
 1066 GASFSYCSK (SEQ ID NO: 150)  
 1069 FSYCSKDR (SEQ ID NO: 151)

Threonine predictions (Start Position indicated)

5 MAPPTGVLS (SEQ ID NO: 152)  
 16 LLLVTIAGC (SEQ ID NO: 153)  
 30 SEGRTYSNA (SEQ ID NO: 154)  
 42 PNLETTRIM (SEQ ID NO: 155)  
 43 NLETTRIMR (SEQ ID NO: 156)  
 51 RVSHTFPVV (SEQ ID NO: 157)  
 58 VVDCTAACC (SEQ ID NO: 158)  
 101 RSYLTFVLR (SEQ ID NO: 159)  
 183 SAEYTDWGL (SEQ ID NO: 160)  
 209 VPAETQQDP (SEQ ID NO: 161)  
 224 ESASTPAPK (SEQ ID NO: 162)  
 240 LPLPTTPSS (SEQ ID NO: 163)  
 241 PLPTTPSSG (SEQ ID NO: 164)  
 286 LSSVTVEKS (SEQ ID NO: 165)  
 294 SPVLTVTPG (SEQ ID NO: 166)  
 296 VLTVTPGST (SEQ ID NO: 167)

300 TPGSTEHSI (SEQ ID NO: 168)  
306 HSIPTPPTS (SEQ ID NO: 169)  
309 PTPPTSAAP (SEQ ID NO: 170)  
317 PSESTPSEL (SEQ ID NO: 171)  
326 PISPTTAPR (SEQ ID NO: 172)  
327 ISPTTAPRT (SEQ ID NO: 173)  
331 TAPRTVKEL (SEQ ID NO: 174)  
336 VKELTVSAG (SEQ ID NO: 175)  
346 NLIITLPDN (SEQ ID NO: 176)  
366 PPVETTYNY (SEQ ID NO: 177)  
367 PVETTYNYE (SEQ ID NO: 178)  
379 ISHPTDYQG (SEQ ID NO: 179)  
392 GHKQTLNLS (SEQ ID NO: 180)  
408 VFKVTVSSE (SEQ ID NO: 181)  
423 FVNVTVKPA (SEQ ID NO: 182)  
446 LQELTLPLT (SEQ ID NO: 183)  
450 TLPLTSALI (SEQ ID NO: 184)  
460 GSQSTDDTE (SEQ ID NO: 185)  
463 STDDTEIVS (SEQ ID NO: 186)  
482 IEEKTSVDS (SEQ ID NO: 187)  
506 RLTVTDS DG (SEQ ID NO: 188)  
512 SDGATNSTT (SEQ ID NO: 189)  
515 ATNSTTAAL (SEQ ID NO: 190)  
516 TNSTTAALI (SEQ ID NO: 191)  
538 GPNHTITLP (SEQ ID NO: 192)  
540 NHTITLPQN (SEQ ID NO: 193)  
547 QNSITLNGN (SEQ ID NO: 194)  
582 QGVQTPYLH (SEQ ID NO: 195)  
596 EGDYTFQLK (SEQ ID NO: 196)  
602 QLKVTDSSR (SEQ ID NO: 197)  
610 RQQSTAVVT (SEQ ID NO: 198)  
614 TAVVTVIVQ (SEQ ID NO: 199)  
643 VESATLDGS (SEQ ID NO: 200)  
680 KAIATVTGL (SEQ ID NO: 201)  
682 IATVTGLQV (SEQ ID NO: 202)  
688 LQVGTYHFR (SEQ ID NO: 203)  
694 HFRLTVKDQ (SEQ ID NO: 204)  
704 GLSSTSTLT (SEQ ID NO: 205)  
706 SSTSTLTVA (SEQ ID NO: 206)  
708 TSTLTVAVK (SEQ ID NO: 207)  
737 NNSITLDGS (SEQ ID NO: 208)  
744 GSRSTDDQR (SEQ ID NO: 209)  
779 ALQLTNLVE (SEQ ID NO: 210)  
787 EGVYTFHLR (SEQ ID NO: 211)  
793 HLRVTD SQG (SEQ ID NO: 212)  
801 GASD TDAT (SEQ ID NO: 213)  
803 S DTDATVE (SEQ ID NO: 214)  
805 T DTDATVEVQ (SEQ ID NO: 215)  
821 LVELTLQVG (SEQ ID NO: 216)  
830 VGQLTEQRK (SEQ ID NO: 217)  
836 QRKDTLVRQ (SEQ ID NO: 218)  
865 SDLSTVIVF (SEQ ID NO: 219)  
910 LRVDTAGCL (SEQ ID NO: 220)  
927 CDPLTKRCI (SEQ ID NO: 221)  
960 IFYVTVLAF (SEQ ID NO: 222)  
965 VLAFTLIVL (SEQ ID NO: 223)  
970 LIVLTGGFT (SEQ ID NO: 224)  
974 TGGFTWLCI (SEQ ID NO: 225)  
987 RQKRTKIRK (SEQ ID NO: 226)  
993 IRKKT KYTI (SEQ ID NO: 227)  
996 KTKYTILDN (SEQ ID NO: 228)  
1020 KHRSTEHNS (SEQ ID NO: 229)  
1039 SDQDTIFSR (SEQ ID NO: 230)

Tyrosine predictions (Start Position indicated)

31 EGRTYNAV (SEQ ID NO: 231)  
 78 EGRCYLVSC (SEQ ID NO: 232)  
 99 PIRSYLTFV (SEQ ID NO: 233)  
 116 QLLDYGDM (SEQ ID NO: 234)  
 156 EMSEYSDDY (SEQ ID NO: 235)  
 160 YSDDYRELE (SEQ ID NO: 236)  
 182 GSAEYTDWG (SEQ ID NO: 237)  
 217 PELHYLNE (SEQ ID NO: 238)  
 368 VETTYNYEW (SEQ ID NO: 239)  
 370 TTYNYEWNL (SEQ ID NO: 240)  
 381 HPTDYQGEI (SEQ ID NO: 241)  
 403 SVGLYVFKV (SEQ ID NO: 242)  
 468 EIVSYHWEE (SEQ ID NO: 243)  
 499 DPGNYSFRL (SEQ ID NO: 244)  
 527 NAVDYPPVA (SEQ ID NO: 245)  
 562 QIVLYEWSL (SEQ ID NO: 246)  
 584 VQTPYLHLS (SEQ ID NO: 247)  
 595 QEGDYTFQL (SEQ ID NO: 248)  
 658 GIVFYHWEH (SEQ ID NO: 249)  
 689 QVGTYHFRL (SEQ ID NO: 250)  
 752 RIVSYLWIR (SEQ ID NO: 251)  
 786 VEGVYTFHL (SEQ ID NO: 252)  
 870 VIVFYVQSR (SEQ ID NO: 253)  
 944 LIQRYIWDG (SEQ ID NO: 254)  
 958 WSIFYVTVL (SEQ ID NO: 255)  
 995 KKTKYTILD (SEQ ID NO: 256)  
 1013 LRPKYGIKH (SEQ ID NO: 257)  
 1067 ASFSYCSKD (SEQ ID NO: 258)

Table VII:Search Peptides254P1D6Bv.1 (SEQ ID NO: 259)

1	MAPPTGVLSS	LLLLVTIAGC	ARKQCSEGR	YNAVISP	ETTRIMRVSH	TFPVVDCTAA
61	CCDLSSCDLA	WWFEGRCYLV	SCPHKENCEP	KKMGPIRSYL	TFVLRPVQRP	AQLLDYGDM
121	LNRGSPSGIW	GDSPEIRK	LPFLGKDWGL	EEMSEYSDDY	RELEKDLLQP	SGKQEPGSA
181	EYTDWGLLP	SEGAFNSSVG	DSPAVPAETQ	QDPELHYLNE	SASTPAPKLP	ERSVLLPLPT
241	TPSSGEVLEK	EKASQLQEQS	SNSSGKEVLM	PSHSLPPASL	ELSSVTVEKS	PVLTVPST
301	EHSIPTPTS	AAPSESTPSE	LPISPTTAPR	TVKELTVSAG	DNLIITLPDN	EVELKAFVAP
361	APPVETTYNY	EWNLISHPTD	YQGEIKQGHK	QTLNLSQLSV	GLYVFKVTVS	SENAFGEFV
421	NVTVKPARRV	NLPPVAVVSP	QLQELTLP	SALIDGSQST	DDTEIVSYHW	EEINGPFIEE
481	KTSVDSPVLR	LSNLDPGNYS	FRLTVDSDG	ATNSTTAALI	VNNAVDPVP	ANAGPNHTIT
541	LPQNSITLNG	NQSSDDHQIV	LYEWSLGP	EGKHVVMQGV	QTPYLHLSAM	QEGDYTFQLK
601	VTDSRQST	AVTVIVQPE	NNRPPVAVAG	PDKELIFPVE	SATLDGSSSS	DDHGIVFYHW
661	EHVRGPSAVE	MENIDKAIAT	VTGLQVGYH	FRLTVKDQ	LSSTSTLTVA	VKKENNSPPR
721	ARAGGRHVLV	LPNNSITLDG	SRSTDDQRI	SYLWIRDG	PAAGDVIDGS	DHSVALQLTN
781	LVEGVYTFHL	RVTDSQGASD	TDTATVEVQ	DPRKSGLVEL	TLQVGVGQLT	EQRKDTLVRQ
841	LAVLLNVLDS	DIKVQKIRAH	SDLSTVIVFY	VQSRPPFKVL	KAAEVARNLH	MRLSKEKADF
901	LLFKVLRVDT	AGCLLKCSGH	GHCDPLTKRC	ICSHLWMENL	IQRYIWDGES	NCEWSIFYVT
961	VLAFTLIVLT	GGFTWLCICC	CKRQKRTKIR	KKTKYTILDN	MDEQERMELR	PKYGIKIRST
1021	EHNSSLMVSE	SEFDSQDTI	FSREKMERGN	PKVSMNGSIR	NGASFSYCSK	DR

254P1D6Bv.2

9-mers, aa 149-175  
 GLEEMSEYADDYRELEK (SEQ ID NO: 260)  
 10-mers, aa 148-176  
 WGLEEMSEYADDYRELEKD (SEQ ID NO: 261)  
 15-mers, aa 143-181  
 FLGKDWGLEEMSEYADDYRELEKDLLQPS (SEQ ID NO: 262)

254P1D6BV.3

9-mers, aa 1-18  
MTRLGWPSPPCCARKQCSE (SEQ ID NO: 263)  
10-mers, aa 1-19  
MTRLGWPSPPCCARKQCSEG (SEQ ID NO: 264)  
15-mers, aa 1-24  
MTRLGWPSPPCCARKQCSEGRYSN (SEQ ID NO: 265)

254P1D6Bv.5

9-mers, aa 134-150  
PEDIRKDLTFLGKDWGL (SEQ ID NO: 266)  
10-mers, aa 133-151  
SPEDIRKDLTFLGKDWGLE (SEQ ID NO: 267)  
15-mers, aa 128-156  
GIWGDSPEDIRKDLTFLGKDWGLEEMSEY (SEQ ID NO: 268)

Tables VIII – XXI:

Table VIII – 254P1D6B v.1 HLA A1 9-mers		
Each peptide is a portion of SEQ ID NO: 1; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		
Pos	Subsequence	Score
493	NLDPGNYSF	100.0
668	AVEMENIDK	90.000
39	NLETRIMR	45.000
649	SSDDHGIVF	37.500
936	WMENLIQRY	22.500
153	MSEYSDDYR	13.500
805	TVEVQPDPR	9.000
743	STDDQRIVS	6.250
182	YTDWGLLPG	6.250
459	STDDTEIVS	6.250
922	HCDPLTKRC	5.000
351	EVELKAFVA	4.500
87	NCEPKKMGP	4.500
244	SGEVLEKEK	4.500
382	QGEIKQGHK	4.500
462	DTEIVSYHW	4.500
951	NCEWSIFYV	4.500
553	SSDDHQIVL	3.750
103 4	DSDQDTIFS	3.750
569	GSEGKHVVM	2.700
25	CSEGRYSN	2.700
554	SDDHQIVLY	2.500
650	SDDHGIVFY	2.500
460	TDDTEIVSY	2.500
138	RKDLPLFGK	2.500
157	SDDYRELEK	2.500
897	KADFLLFKV	2.500
378	PTDYQGEIK	2.500
800	DTDATVEV	2.500
483	SVDSPVLR	2.500
113	LLDYGDMML	2.500
347	LPDNEVELK	2.500
505	VTSDSGATN	2.500
744	TDDQRIVSY	2.500

Table VIII – 254P1D6B v.1 HLA A1 9-mers		
Each peptide is a portion of SEQ ID NO: 1; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		
Pos	Subsequence	Score
592	EGDYTFQLK	2.500
349	DNEVELKAF	2.250
829	LTEQRKDTL	2.250
101 9	STEHNSSLML	2.250
565	SLGPGSEGK	2.000
84	HKENCEPKK	1.800
279	SLELSSVTV	1.800
860	HSDLSTVIV	1.500
769	GSDHSVALQ	1.500
798	ASDTDATV	1.500
410	SSENAFGEG	1.350
190	GSEGAFNSS	1.350
778	LTNLVEGVY	1.250
130	WGDSPEDIR	1.250
809	QPDPRKSG	1.250
681	VTGLQVGTY	1.250
601	VTDSSRQQS	1.250
519	LIVNNAVDY	1.000
705	STLTVAVKK	1.000
862	DLSTVIVFY	1.000
54	VVDCTAAC	1.000
15	VTIAGCARK	1.000
524	AVDYPPVAN	1.000
179	SAEYTDWGL	0.900
712	KKENNSPPR	0.900
149	GLEEMSEYS	0.900
781	LVEGVYTFH	0.900
882	AAEVARNLH	0.900
817	LVELTLQVG	0.900
210	QQDPELHYL	0.750
395	LSQLSVGLY	0.750
491	LSNLDPGNY	0.750
315	ESTPSELPI	0.750
849	DSDIKVQKI	0.750

Table VIII – 254P1D6B v.1 HLA A1 9-mers		
Each peptide is a portion of SEQ ID NO: 1; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		
Pos	Subsequence	Score
507	DSDGATNST	0.750
587	LSAMQEGDY	0.750
950	SNCEWSIFY	0.625
339	AGDNLITL	0.625
398	LSVGLYVFK	0.600
220	ESASTPAPK	0.600
704	TSTLTVAVK	0.600
224	TPAPKLPER	0.500
131	GDSPEDIRK	0.500
766	VIDGSDHSV	0.500
473	INGPFIEEK	0.500
373	NLISHPTDY	0.500
274	SLPPASLEL	0.500
847	VLDSDIKVQ	0.500
360	PAPPVETTY	0.500
61	CCDLSSCDL	0.500
907	RVDTAGCLL	0.500
670	EMENIDKAI	0.450
618	QPENNRPPV	0.450
299	STHSIPTP	0.450
100 6	RMELRPKYG	0.450
638	PVESATLDG	0.450
469	HWEEINGPF	0.450
281	ELSSVTVEK	0.400
870	YVQSRPPFK	0.400
209	TQQDPELHY	0.375
482	TSVDSPVLR	0.300
302	HSIPTPPTS	0.300
97	RSYLTFLVR	0.300
375	ISHPTDYQG	0.300
442	LQELTLPLT	0.270
576	VMQGVQTPY	0.250

Table VIII-V2-HLA-A1-9mers-254P1D68		
Each peptide is a portion of SEQ ID NO: 5; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		
Start	Subsequence	Score
5	MSEYADDYR	13.500
9	ADDYRELEK	2.500
1	GLEEMSEYA	0.900
4	EMSEYADDY	0.250
8	YADDYRELE	0.050
2	LEEMSEYAD	0.009
7	EYADDYREL	0.001
6	SEYADDYRE	0.000
3	EEMSEYADD	0.000

Table VIII-V3-HLA-A1-9mers-254P1D68		
Each peptide is a portion of SEQ ID NO: 7; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		
Start	Subsequence	Score
6	WPSPCCARK	1.000
3	RLGWSPCC	0.020
5	GWSPCCAR	0.005
8	SPCCARKQC	0.003
4	LGWSPCCA	0.003
7	PSPCCARKQ	0.002
9	PCCARKQCS	0.001
1	MTRLGWSP	0.001
2	TRLGWSPC	0.001
10	CCARKQCSE	0.000

Table VIII-V5-HLA-A1-9mers-254P1D68		
Each peptide is a portion of SEQ ID NO: 11; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		
Start	Subsequence	Score

5	RKDLTFLGK	2.500
8	LTFLGKDWG	0.025
7	DLTFLGKDW	0.010
1	PEDIRKDLT	0.003
2	EDIRKDLTF	0.003
9	TFLGKDWGL	0.001
4	IRKDLTFLG	0.000
3	DIRKDLTFL	0.000
6	KDLTFLGKD	0.000

TABLE IX- HLA-A1-10-mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Start	Subsequence	Score
173	KQEPRGSAE Y	135.000
743	STDDQRIVS Y	125.000
459	STDDTEIVSY	125.000
649	SSDDHGIVF Y	75.000
156	YSDDYRELE K	75.000
553	SSDDHQIVL Y	75.000
907	RVDTAGCLL K	50.000
493	NLDPGNYSF R	50.000
860	HSDLSTVIVF	37.500
1034	DSDQDTIFS R	37.500
805	TVEVQPDPR K	36.000
847	VLDSDIKVQ K	20.000
410	SSENAFGEG F	13.500
130	WGDSPEDIR K	12.500
1019	STEHNSSLM V	11.250

TABLE IX- HLA-A1-10-mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Start	Subsequence	Score
87	NCEPKKMG PI	9.000
849	DSDIKVQKIR	7.500
208	ETQQDPELH Y	6.250
922	HCDPLTKRC I	5.000
628	VAGPDKELIF	5.000
997	ILDNMDEQE R	5.000
781	LVEGVYTFH L	4.500
39	NLETRIMR V	4.500
882	AAEVARNLH M	4.500
949	ESNCEWSIF Y	3.750
769	GSDHSVALQ L	3.750
569	GSEGKHVV MQ	2.700
66	SCDLAWWF EG	2.500
182	YTDWGLLP S	2.500
113	LLDYGDMML N	2.500
829	LTEQRKDTL V	2.250
951	NCEWSIFYV T	1.800
477	FIEEKTSVDS	1.800
817	LVELTLQVG V	1.800
210	QQDPHELHYL N	1.500
1036	DQDTIFSRE K	1.500

TABLE IX- HLA-A1-10-mers-254P1D6B

Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.

Start	Subsequence	Score
1028	VSESEFSDSD Q	1.35 0
25	CSEGRITYSN A	1.35 0
1030	ESEFSDSDQD T	1.35 0
190	GSEGAFNSS V	1.35 0
601	VTDSRQQS T	1.25 0
792	VTDSQGASD T	1.25 0
505	VTDSDGATN S	1.25 0
539	ITLPQNSITL	1.25 0
1000	NMDEQERM EL	1.25 0
359	APAPPVETT Y	1.25 0
800	DTDATVEV Q	1.25 0
809	QPDPRKSG L	1.25 0
35	VISPNETTR	1.00 0
524	AVDYPPVAN A	1.00 0
518	ALIVNNAV DY	1.00 0
186	GLLPGSEGA F	1.00 0
667	SAVEMENID K	1.00 0
703	STSTLTAV K	1.00 0
670	EMENIDKAIA	0.90 0
1006	RMELRPKYG I	0.90 0
179	SAEYTDWGL L	0.90 0

TABLE IX- HLA-A1-10-mers-254P1D6B

Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.

Start	Subsequence	Score
668	AVEMENIDK A	0.90 0
648	SSDDHGIV F	0.75 0
507	DSDGATNST T	0.75 0
273	HSLPPASLE L	0.75 0
590	MQEGDYTF QL	0.67 5
442	LQELTLPLTS	0.67 5
592	EGDYTFQLK V	0.62 5
378	PTYQGEIK Q	0.62 5
347	LPDNEVELK A	0.62 5
872	QSRPPFKVL K	0.60 0
704	TSTLTAVK K	0.60 0
777	QLTNLVEGV Y	0.50 0
687	GTYHFRLTV K	0.50 0
897	KADFLFKVL	0.50 0
766	VIDGSDHSV A	0.50 0
729	LVLNNITL	0.50 0
394	NLSQLSVGL Y	0.50 0
586	HLSAMQEG DY	0.50 0
445	LTLPLTSALI	0.50 0
61	CCDLSSCDL A	0.50 0
680	TVTGLQVGT Y	0.50 0

TABLE IX- HLA-A1-10-mers-254P1D6B

Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.

Start	Subsequence	Score
223	STPAPKLPE R	0.50 0
100	LTFVLRPVQ R	0.50 0
483	SVDSPVLR L	0.50 0
1	MAPPTGVLS S	0.50 0
575	VVMQGVQT PY	0.50 0
955	SIFYVTVLA F	0.50 0
345	ITLPDNEVEL	0.50 0
164	EKDLLQPSG K	0.50 0
1039	TIFSREKME R	0.50 0
481	KTSVDSPVL R	0.50 0
490	RLSNLDPGN Y	0.50 0
532	NAGPNHTITL	0.50 0
415	FGEGFVNVT V	0.45 0
936	WMENLIQRY I	0.45 0
349	DNEVELKAF V	0.45 0
618	QPENNRPPV A	0.45 0
286	TVEKSPVLT V	0.45 0
1001	MDEQERME LR	0.45 0
76	RCYLVSCPH K	0.40 0
397	QLSVGLYVF K	0.40 0
14	LVTIAGCARK	0.40 0

TABLE IX- HLA-A1-10-mers-254P1D6B

Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.

Start	Subsequence	Score
107	VQRPAQLLDY	0.375

Table IX-V2-HLA-A1-10mers-254P1D68

Each peptide is a portion of SEQ ID NO: 5; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.

Start	Subsequence	Score
9	YADDYRELEK	50.000
6	MSEYADDYRE	0.270
2	GLEEMSEYAD	0.180
5	EMSEYADDYR	0.050
4	EEMSEYADDY	0.025
3	LEEMSEYADD	0.009
10	ADDYRELEKD	0.003
1	WGLEEMSEYA	0.003
7	SEYADDYREL	0.001
8	EYADDYRELE	0.000

Table IX-V3-HLA-A1-10mers-254P1D68

Each peptide is a portion of SEQ ID NO: 7; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.

Start	Subsequence	Score
4	LGWSPCCAR	0.025
6	WPSPCCARKQ	0.025
5	GWSPCCARK	0.020
3	RLGWSPCCA	0.010
8	SPCCARKQCS	0.003
1	MTRLGWSPC	0.003
7	PSPCCARKQC	0.002
10	CCARKQCSEG	0.001
2	TRLGWSPCC	0.001
9	PCCARKQCSE	0.000

Table IX-V5-HLA-A1-10mers-254P1D68

Each peptide is a portion of SEQ ID NO: 11; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.

Start	Subsequence	Score
1	SPEDIRKDLT	0.225
2	PEDIRKDLTF	0.125
9	LTFLGKDWGL	0.025
8	DLTFLGKDWG	0.010
5	IRKDLTFLGK	0.005
6	RKDLTFLGKD	0.003
4	DIRKDLTFLG	0.001
7	KDLTFLGKDW	0.001
10	TFLGKDWGLE	0.000
3	EDIRKDLTFL	0.000

Table X-V1-HLA-A0201-HLA-9mers-254P1D68

Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.

Start	Subsequence	Score
900	FLLFKVLRV	2722.683
401	GLYVFKVTV	845.752
968	VLTTGGFTWL	379.503
228	KLPERSVLL	306.550
92	KMGPIRSYL	296.997
816	GLVELTLQV	285.163
7	VLSSLLLLV	271.948
99	YLTFVLRPV	147.172
396	SQLSVGLYV	143.504
944	YIWDGESNC	106.931
846	NVLDSDIKV	92.322
441	QLQELTLPL	87.586
346	TLPDNEVEL	87.586
399	SVGLYVFKV	81.185
777	QLTNLVEGV	78.385
784	GVYTFHLRV	74.003
12	LLLVTIAGC	71.872
392	TLNLSQLSV	69.552
871	VQSRPPFKV	69.531
839	RQLAVLLNV	60.011
863	LSTVIVFYV	56.629
958	YVTVLAFTL	49.871
112	QLLDYGDMM	36.92

Table X-V1-HLA-A0201-  
HLA-9mers-254P1D68

Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.

Start	Subsequence	Score
		9
730	VLPNNSITL	36.31 6
960	TVLAFTLIV	35.08 2
961	VLAFTLIVL	34.24 6
655	IVFYHWEHV	31.88 7
828	QLTEQRKDT	30.55 3
452	ALIDGSQST	30.55 3
350	NEVELKAFV	30.49 7
558	QIVLYEWSL	22.03 0
394	NLSQLSVGL	21.36 2
540	TLPQNSITL	21.36 2
274	SLPPASLEL	21.36 2
577	MQGVQTPYL	20.25 1
840	QLAVLLNVL	20.14 5
836	TLVRQLAVL	20.14 5
897	KADFLFKV	18.04 1
844	LLNVLDSDI	17.73 6
728	VLVLPNNSI	17.73 6
390	KQTLNLSQL	17.43 6
10	SLLLLVTIA	17.33 4
344	IITLPDNEV	16.25 8
607	QQSTAVVTV	16.21 9

Table X-V1-HLA-A0201-  
HLA-9mers-254P1D68

Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.

Start	Subsequence	Score
6	GVLSSLLLL	15.90 7
113	LLDYGDMML	14.52 6
687	GTYHFRLTV	11.74 7
1045	KMERGNPKV	11.25 2
210	QQDPHELHYL	10.96 0
685	QVGTYHFRL	10.84 1
446	TLPLTSALI	10.43 3
591	QEGDYTFQL	9.878
186	GLLPGSEGA	9.007
673	NIDKAIATV	8.798
818	VELTLQVGV	8.507
700	GLSSTSTLT	7.452
437	VVSPQLQEL	7.309
366	TTYNYEWNL	7.121
766	VIDGSDHSV	6.503
635	LIFPVESAT	6.445
821	TLQVGVGQL	6.387
429	RVNLPVAV	6.086
284	SVTVEKSPV	6.086
774	VALQLTNLV	6.076
973	FTWLCICCC	6.059
233	SVLLPLPTT	5.549
497	GNYSFRLTV	5.521
40	LETTRIMRV	5.288
191	SEGAFNSSV	5.139
47	RVSHTFPVV	4.741
419	FVNVTVKPA	4.599
279	SLELSSVTV	4.451
773	SVALQLTNL	4.299
782	VEGVYTFHL	4.096
517	AALIVNNAV	3.574
969	LTGGFTWLC	3.343

Table X-V1-HLA-A0201-  
HLA-9mers-254P1D68

Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.

Start	Subsequence	Score
669	VEMENIDKA	2.808
579	GVQTPYLHL	2.804
430	VNLPPVAVV	2.693
955	SIFYVTVLA	2.527
676	KAIATVTGL	2.388
858	RAHSDLSTV	2.222
1031	SEFDSDQDT	2.198
951	NCEWSIFYV	2.132
35	VISPNETT	1.963
627	AVAGPDKEL	1.869
445	LTLPLTSAL	1.866
483	SVDSPVLRL	1.720
729	LVLNNSIT	1.682
292	VLTVTGSGT	1.647
678	IATVTGLQV	1.642
948	GESNCEWSI	1.521
988	KIRKKT KYT	1.499
962	LAFTLIVLT	1.497
538	TITLPQNSI	1.435
830	TEQRKDTLV	1.352
416	GEGFVNVTV	1.352
1020	TEHNSSLMV	1.352
465	IVSYHWEEI	1.293
822	LQVGVGQLT	1.284

Table X-V2-HLA-A0201-  
9mers-254P1D68

Each peptide is a portion of SEQ ID NO: 5; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.

Start	Subsequence	Score
1	GLEEMSEYA	3.513
4	EMSEYADDY	0.008
6	SEYADDYRE	0.001
8	YADDYRELE	0.001

Table X-V2-HLA-A0201-  
9mers-254P1D68

Each peptide is a portion of SEQ ID NO: 5; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.

Start	Subsequence	Score
7	EYADDYREL	0.000
3	EEMSEYADD	0.000
2	LEEMSEYAD	0.000
5	MSEYADDYR	0.000
9	ADDYRELEK	0.000

Table X-V3-HLA-A0201-  
9mers-254P1D68

Each peptide is a portion of SEQ ID NO: 7; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.

Start	Subsequence	Score
3	RLGWSPSCC	4.968
4	LGWSPSCCA	0.458
8	SPCCARKQC	0.032
2	TRLGWSPSC	0.003
6	WPSPCCARK	0.000
10	CCARKQCSE	0.000
1	MTRLGWSPSP	0.000
9	PCCARKQCS	0.000
5	GWSPCCAR	0.000
7	PSPCCARKQ	0.000

Table X-V5-HLA-A0201-  
9mers-254P1D68

Each peptide is a portion of SEQ ID NO: 11; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.

Start	Subsequence	Score
9	TFLGKDWGL	0.412
3	DIRKDLTFL	0.212
8	LTFLGKDWG	0.018
7	DLTFLGKDW	0.006

1	PEDIRKDLT	0.001
6	KDLTFLGKD	0.000
5	RKDLTFLGK	0.000
4	IRKDLTFLG	0.000
2	EDIRKDLTF	0.000

Table XI-V1-HLA-A0201-  
10mers-254P1D68

Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.

Start	Subsequence	Score
862	DLSTVIVFYV	382.7 27
112	QLLDYGDMM L	324.0 68
968	VLTTGGFTWL C	240.7 00
870	YVQSRPPFK V	162.3 69
576	VMQGVQTPY L	144.2 56
950	SNCEWSIFYV	136.5 77
967	IVLTGGFTWL	122.8 64
209	TQQDPELHY L	112.3 35
217	YLNESASTPA	93.69 6
11	LLLLVTIAGC	71.87 2
441	QLQELTLPLT	70.27 2
700	GLSSTSTLTV	69.55 2
843	VLLNVLDSDI	65.62 2
952	CEWSIFYVTV	63.98 2
892	RLSKEKADFL	57.57 2
6	GVLSLLLLLV	51.79 0
776	LQLTNLVEGV	49.98 9
617	VQPENNRPP V	49.15 1

Table XI-V1-HLA-A0201-  
10mers-254P1D68

Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.

Start	Subsequence	Score
901	LLFKVLRVDT	46.87 3
828	QLTEQRKDT L	42.91 7
45	IMRVSHTFPV	37.64 2
961	VLAFTLIVLT	29.13 7
1000	NMDEQERME L	25.30 3
692	RLTVKDQQG L	21.36 2
836	TLVRQLAVLL	21.36 2
684	LQVGTYHFR L	21.35 6
92	KMGPIRSYLT	18.83 7
635	LIFPVESATL	18.47 6
120	MLNRGSPSG I	17.73 6
343	LIITLPDNEV	16.25 8
606	RQQSTAVVT V	16.21 9
808	VQDPDRKSG L	15.09 6
269	LMPSHSLPP A	14.02 9
355	KAFVAPAPPV	12.51 0
7	VLSSLLLLVT	11.94 6
729	LVLPNNSITL	11.75 7
400	VGLYVFKVTV	10.85 2
398	LSVGLYVFKV	10.29 6
39	NLETTTRIMRV	10.23 8
677	AIATVTGLQV	9.563

Table XI-V1-HLA-A0201-- 10mers-254P1D68		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Start	Subsequence	Score
958	YVTVLAFTLI	7.978
654	GIVFYHWEH V	7.966
386	KQGHKQTLN L	7.581
839	RQLAVLLNVL	7.557
821	TLQVGVGQL T	7.452
278	ASLELSSVTV	6.887
413	NAFGEGFVN V	6.791
141	LPFLGKDWG L	6.579
960	TVLAFTLIVL	6.522
660	WEHVRGPSA V	6.221
773	SVALQLTNLV	6.086
128	GIWGDSPEDI	5.834
94	GPIRSYLTFV	5.743
429	RVNLPPVAV V	5.739
904	KVLRVDTAG C	5.629
370	YEWNLISHPT	5.532
965	TLIVLTGGFT	5.328
352	VELKAFVAPA	5.311
669	VEMENIDKAI	5.232
728	VLVLPNNSIT	5.194
436	AVVSPQLQE L	4.299
178	GSAEYTDWG L	4.288
395	LSQLSVGLYV	4.245
12	LLLVTIAGCA	4.062
797	GASDTDTAT V	3.961
1054	SMNGSIRNG A	3.588
391	QTLNLSQLSV	3.574
357	FVAPAPPVET	2.999

Table XI-V1-HLA-A0201-- 10mers-254P1D68		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Start	Subsequence	Score
686	VGTYHFRLTV	2.933
551	NQSSDDHQI V	2.891
871	VQSRPPFKV L	2.868
338	SAGDNLITL	2.798
827	GQLTEQRKD T	2.796
959	VTVLAFTLIV	2.559
780	NLVEGVYTF H	2.521
936	WMENLIQRYI	2.440
502	RLTVTDS DG A	2.434
630	GPDKELIFPV	2.423
247	VLEKEKASQL	2.324
698	QQGLSSTST L	2.166
91	KKMGPIRSYL	2.113
765	DVIDGSDHSV	1.871
539	ITLPQNSITL	1.866
345	ITLPDNEVEL	1.866
198	SVGDSPAVP A	1.782
815	SGLVELTLQV	1.680
475	GPFIEEKTSV	1.680
444	ELTLPLTSAL	1.602
1031	SEFSDSQDTI	1.508
102	FVLRPVQRP A	1.480
266	KEVLMPSHS L	1.454
457	SQSTDDEIV	1.417
633	KELIFPVESA	1.410
590	MQEGDYTFQ L	1.367
26	SEGRTYSNA V	1.352
482	TSVDSPVLRL	1.315
939	NLIQRYIWDG	1.285

Table XI-V1-HLA-A0201-- 10mers-254P1D68		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Start	Subsequence	Score
421	NVTVKPARR V	1.217
781	LVEGVYTFHL	1.180
521	VNNAVDYPP V	1.158

Table XI-V2-HLA-A0201-- 10mers-254P1D68		
Each peptide is a portion of SEQ ID NO: 5; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Start	Subsequence	Score
1	WGLEEMSEYA	6.099
7	SEYADDYREL	0.399
5	EMSEYADDYR	0.009
2	GLEEMSEYAD	0.004
9	YADDYRELEK	0.002
4	EEMSEYADDY	0.000
3	LEEMSEYADD	0.000
6	MSEYADDYRE	0.000
10	ADDYRELEKD	0.000
8	EYADDYRELE	0.000

Table XI-V3-HLA-A0201-- 10mers-254P1D68		
Each peptide is a portion of SEQ ID NO: 7; each start position is specified, the length of peptide is 10 amino		

acids, and the end position for each peptide is the start position plus nine.		
Start	Subsequence	Score
3	RLGWSPCCA	4.968
1	MTRLGWSPC	0.009
2	TRLGWSPCC	0.003
4	LGWSPCCAR	0.001
7	PSPCCARKQC	0.001
10	CCARKQCSEG	0.000
8	SPCCARKQCS	0.000
6	WPSPCCARKQ	0.000
9	PCCARKQCSE	0.000
5	GWSPCCARK	0.000

Table XI-V5-HLA-A0201-10mers-254P1D68		
Each peptide is a portion of SEQ ID NO: 11; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Start	Subsequence	Score
9	LTFLGKDWGL	13.997
3	EDIRKDLTFL	0.028
8	DLTFLGKDWG	0.015
1	SPEDIRKDLT	0.006
7	KDLTFLGKDW	0.001
4	DIRKDLTFLG	0.000
2	PEDIRKDLTF	0.000
6	RKDLTFLGKD	0.000

Table XI-V5-HLA-A0201-10mers-254P1D68		
Each peptide is a portion of SEQ ID NO: 11; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Start	Subsequence	Score
10	TFLGKDWGLE	0.000
5	IRKDLTFLGK	0.000

Table XII-V1-HLA-A3-9mers-254P1D68		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		
Start	Subsequence	Score
780	NLVEGVYTF	40.500
565	SLGPGSEGK	30.000
683	GLQVGTYHF	18.000
68	DLAWWFEGR	10.800
576	VMQGVQTPY	9.000
397	QLSVGLYVF	9.000
589	AMQEGDYTF	9.000
281	ELSSVTVEK	9.000
401	GLYVFKVTV	9.000
493	NLDPGNYSF	9.000
748	RIVSYLWIR	8.100
39	NLETRIMR	8.000
936	WMENLIQRY	6.000
373	NLISHPTDY	6.000
866	VIVFYVQSR	5.400
152	EMSEYSDDY	5.400
92	KMGPIRSYL	4.050
879	VLKAAEVAR	4.000
668	AVEMENIDK	4.000
598	QLKVTDSSR	4.000
975	WLCICCKR	4.000

Table XII-V1-HLA-A3-9mers-254P1D68		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		
Start	Subsequence	Score
1025	SLMVSESEF	3.000
968	VLGGFTWL	2.700
816	GLVELTLQV	2.700
228	KLPERSVLL	2.700
1008	ELRPKYGIK	2.700
862	DLSTVIVFY	2.700
705	STLTVAVKK	2.250
892	RLSKEKADF	2.000
870	YVQSRPPFK	2.000
900	FLLFKVLRV	1.800
441	QLQELTLPL	1.800
961	VLAFTLIVL	1.800
784	GVYTFHLRV	1.800
274	SLPPASLEL	1.800
15	VTIAGCARK	1.500
366	TTYNYEWNL	1.350
728	VLVLPNNSI	1.350
186	GLLPGSEGA	1.350
836	TLVRQLAVL	1.350
113	LLDYGDMMML	1.200
825	GVGQLTEQR	1.200
730	VLNNSITL	1.200
540	TLPQNSITL	1.200
1052	KVSMNGSIR	1.200
983	RQKRTRKIRK	1.200
112	QLLDYGDMM	0.900
840	QLAVLLNVL	0.900
615	VIVQPENNR	0.900
965	TLIVLTGGF	0.900
10	SLLLLVTIA	0.900
560	VLYEWSLGP	0.900
187	LLPGSEGAF	0.900
687	GTYHFRLTV	0.900
558	QIVLYEWSL	0.810
654	GIVFYHWEH	0.810
6	GVLSLLLLL	0.810
7	VLSSLLLLLV	0.600

Table XII-V1-HLA-A3-9mers-254P1D68		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		
Start	Subsequence	Score
519	LIVNNAVDY	0.600
346	TLPDNEVEL	0.600
446	TLPLTSALI	0.600
394	NLSQLSVGL	0.600
347	LPDNEVELK	0.600
1062	GASFSYCSK	0.600
1045	KMERGNPKV	0.600
844	LLNVLDSI	0.600
777	QLTNLVEGV	0.600
579	GVQTPYLHL	0.540
353	ELKAFVAPA	0.540
685	QVGTYHFRL	0.540
483	SVDSPVLRL	0.540
821	TLQVGVGQL	0.540
399	SVGLYVFKV	0.540
986	RTKIRKGTK	0.500
44	RIMRVSHTF	0.450
12	LLLVTIAGC	0.450
634	ELIFPVESA	0.405
14	LVTIAGCAR	0.400
392	TLNLSQLSV	0.400
421	NVTVKPARR	0.400
805	TVEVQPDPR	0.400
209	TQQDPELHY	0.360
97	RSYLTFLVR	0.300
700	GLSSTSTLT	0.300
704	TSTLTVAVK	0.300
473	INGPFIEEK	0.270
684	LQVGTYHFR	0.270
398	LSVGLYVFK	0.225
934	HLWMENLIQ	0.200
890	HMRLSKEKA	0.200
977	CICCCQRQK	0.200
905	VLRVDTAGC	0.200
625	PVAVAGPDK	0.200
914	LLKCSGHGH	0.200
279	SLELSSVTV	0.200

Table XII-V1-HLA-A3-9mers-254P1D68		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		
Start	Subsequence	Score
138	RKDLPFLGK	0.180
131	GDSPEDIRK	0.180
681	VTGLQVGTY	0.180
960	TVLAFTLIV	0.180
884	EVARNLHMR	0.180

Table XII-V2-HLA-A3-9mers-254P1D68		
Each peptide is a portion of SEQ ID NO: 5; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		
Start	Subsequence	Score
4	EMSEYADDY	5.400
1	GLEEMSEYA	0.900
9	ADDYRELEK	0.040
5	MSEYADDYR	0.020
6	SEYADDYRE	0.001
8	YADDYRELE	0.001
2	LEEMSEYAD	0.000
3	EEMSEYADD	0.000
7	EYADDYREL	0.000

Table XII-V3-HLA-A3-9mers-254P1D68		
Each peptide is a portion of SEQ ID NO: 7; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		
Start	Subsequence	Score
3	RLGWSPCC	0.300
6	WPSPCCARK	0.300
5	GWSPCCAR	0.018
4	LGWSPCCA	0.002
2	TRLGWSPC	0.001

Table XII-V3-HLA-A3-9mers-254P1D68		
Each peptide is a portion of SEQ ID NO: 7; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		
Start	Subsequence	Score
8	SPCCARKQC	0.001
1	MTRLGWPS	0.001
10	CCARKQCSE	0.000
9	PCCARKQCS	0.000
7	PSPCCARKQ	0.000

Table XII-V5-HLA-A3-9mers-254P1D68		
Each peptide is a portion of SEQ ID NO: 11; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		
Start	Subsequence	Score
5	RKDLTFLGK	0.120
7	DLTFLGKDW	0.030
3	DIRKDLTFL	0.027
8	LTLGKDWG	0.005
9	TFLGKDWGL	0.004
2	EDIRKDLTF	0.002
6	KDLTFLGKD	0.000
4	IRKDLTFLG	0.000
1	PEDIRKDLT	0.000

Table XIII-V1-HLA-A3-10mers-254P1D68		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Start	Subsequence	Score
934	HLWMENLIQR	60.000
346	TLPDNEVELK	60.000
847	VLDSIKVQK	30.0

Table XIII-V1-HLA-A3-10mers-254P1D68		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Start	Subsequence	Score
		00
687	GTYHFRITVK	22.500
844	LLNVLDSDIK	20.000
397	QLSVGLYVFK	20.000
683	GLQVGTYHFR	12.000
888	NLHMRLSKEK	10.000
973	FTWLCICCK	7.500
655	IVFYHWEHVR	6.000
955	SIFYVTVLAF	6.000
13	LLVTIAGCAR	6.000
825	GVGQLTEQRK	6.000
518	ALIVNNAVVDY	6.000
493	NLDPGNYSFR	6.000
865	TVIVFYVQSR	5.400
186	GLLPGSEGA	4.050
472	EINGPFIEEK	4.050
1039	TIFSREKMER	4.000
907	RVDTAGCLLK	4.000
997	ILDNMDEQER	4.000
394	NLSQLSVGLY	3.600
805	TVEVQPDPRK	3.000
703	STSTLTVAVK	3.000

Table XIII-V1-HLA-A3-10mers-254P1D68		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Start	Subsequence	Score
		0
968	VLTTGGFTWLC	2.700
1006	RMELRPKYGI	2.700
14	LVTIAGCARK	2.000
878	KVLKAAEVAR	1.800
152	EMSEYSDDYR	1.800
112	QLLDYGDMMML	1.800
777	QLTNLVEGVY	1.800
1000	NMDEQERMEL	1.800
401	GLYVFKVTVS	1.800
895	KEKADFLLFK	1.620
128	GIWGDSPEDI	1.350
92	KMGPIRSYLT	1.350
586	HLSAMQEGDY	1.200
1058	SIRNGASFYSY	1.200
241	TPSSGEVLEK	1.200
490	RLSNLDPGNY	1.200
700	GLSSTSTLTV	1.200
100	LTFVLRPVQR	1.000
76	RCYLVSCHPK	1.000
836	TLVRQLAVLL	0.900
828	QLTEQRKDTL	0.900

Table XIII-V1-HLA-A3-10mers-254P1D68		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Start	Subsequence	Score
		0
667	SAVEMENIDK	0.900
575	VVMQGVQTPY	0.900
843	VLLNVLDSDI	0.900
576	VMQGVQTPYL	0.900
614	TVIVQPENNR	0.900
862	DLSTVIVFYV	0.810
781	LVEGVYTFHL	0.810
780	NLVEGVYTFH	0.675
892	RLSKEKADFL	0.600
39	NLETTIRMRV	0.600
35	VISPNETTR	0.600
406	KVTVSSENAF	0.600
692	RLTVKDQQGL	0.600
247	VLEKEKASQL	0.600
120	MLNRGSPSGI	0.600
45	IMRVSHTFPV	0.600
481	KTSVDSPVLR	0.600
419	FVNVTVKPAR	0.600
416	GEGFVNVTVK	0.540
1008	ELRPKYGIKH	0.540
988	KIRKKTKYTI	0.540

Table XIII-V1-HLA-A3-10mers-254P1D68		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Start	Subsequence	Score
		0
228	KLPERSVLLP	0.540
173	KQEPRGSAEY	0.540
107	VQRPAQLLDY	0.540
680	TVTGLQVGTY	0.540
901	LLFKVLRVDT	0.500
635	LIFPVESATL	0.450
804	ATVEVQPDPR	0.450
872	QSRPPFKVLK	0.450
1054	SMNGSIRNGA	0.450
11	LLLLVTIAGC	0.450
396	SQLSVGLYVF	0.405
939	NLIQRYIWDG	0.405
977	CICCCCKRQKR	0.400
684	LQVGTYHFRL	0.364
7	VLSSLLLLVT	0.300
459	STDDTEIVSY	0.300
324	SPTTAPRTVK	0.300
269	LMPSHSLPPA	0.300
217	YLNESASTPA	0.300
743	STDDQRIVSY	0.300
913	CLKKCSGHGH	0.300

Table XIII-V1-HLA-A3-10mers-254P1D68		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Start	Subsequence	Score
		0
223	STPAPKLPER	0.300
381	YQGEIKQGHK	0.270
729	LVLPNNSITL	0.270
960	TVLAFTLIVL	0.270
6	GVLSLLLLLV	0.270
967	IVLTGGFTWL	0.270
149	GLEEMSEYSD	0.270
557	HQIVLYEWSL	0.243
590	MQEGDYTFQL	0.243
564	WSLGPGESEK	0.225
441	QLQELTLPLT	0.225
816	GLVELTLQVG	0.203
986	RTKIRKTKTY	0.200

Table XIII-V2-HLA-A3-10mers-254P1D68		
Each peptide is a portion of SEQ ID NO: 5; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Start	Subsequence	Score
5	EMSEYADDYR	1.800
9	YADDYRELEK	0.400

Table XIII-V2-HLA-A3-10mers-254P1D68		
Each peptide is a portion of SEQ ID NO: 5; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Start	Subsequence	Score
2	GLEEMSEYAD	0.270
4	EEMSEYADDY	0.016
7	SEYADDYREL	0.001
1	WGLEEMSEYA	0.000
6	MSEYADDYRE	0.000
3	LEEMSEYADD	0.000
10	ADDYRELEKD	0.000
8	EYADDYRELE	0.000

Table XIII-V3-HLA-A3-10mers-254P1D68		
Each peptide is a portion of SEQ ID NO: 7; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Start	Subsequence	Score
3	RLGWSPCCA	0.200
5	GWSPCCARK	0.060
4	LGWSPCCAR	0.045
1	MTRLGWSPC	0.030
2	TRLGWSPCC	0.001
8	SPCCARKQCS	0.000
10	CCARKQCSEG	0.000
7	PSPCCARKQC	0.000

Table XIII-V3-HLA-A3-10mers-254P1D68		
Each peptide is a portion of SEQ ID NO: 7; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Start	Subsequence	Score
		0
6	WPSPCCARKQ	0.000
9	PCCARKQCSE	0.000

Table XIII-V5-HLA-A3-10mers-254P1D68		
Each peptide is a portion of SEQ ID NO: 11; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Start	Subsequence	Score
9	LTFLGKDWGL	0.450
5	IRKDLTFLGK	0.120
8	DLTFLGKDWG	0.006
4	DIRKDLTFLG	0.002
2	PEDIRKDLTF	0.001
1	SPEDIRKDLT	0.001
7	KDLTFLGKDW	0.000
3	EDIRKDLTFL	0.000
6	RKDLTFLGKD	0.000
10	TFLGKDWGLE	0.000

Table XIV-V1-HLA-A1101-9mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		
Start	Subsequence	Score
668	AVEMENIDK	4.000
983	RQKRTKIRK	3.600
870	YVQSRPPFK	2.000
15	VTIAGCARK	1.500

Table XIV-V1-HLA-A1101-9mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		
Start	Subsequence	Score
705	STLTVAVKK	1.500
986	RTKIRKTK	1.500
825	GVGQLTEQR	1.200
1052	KVSMNGSIR	1.200
748	RIVSYLWIR	0.720
1062	GASFSYCSK	0.600
77	CYLVSCPHK	0.600
421	NVTVKPARR	0.400
565	SLGPGSEGK	0.400
688	TYHFRLTVK	0.400
14	LVTIAGCAR	0.400
805	TVEVQDPDR	0.400
887	RNLHMRSLK	0.360
784	GVYTFHLRV	0.240
347	LPDNEVELK	0.200
625	PVAVAGPDK	0.200
6	GVLSSLLL	0.180
684	LQVGTYHFR	0.180
258	EQSSNSSGK	0.180
39	NLETRIMR	0.160
131	GDSPEDIRK	0.120
138	RKDLPLGK	0.120
884	EVARNLHMR	0.120
687	GTYHFRLTV	0.120
615	VIVQPENNR	0.120
281	ELSSVTEK	0.120
1008	ELRPKYGIK	0.120
866	VIVFYVQSR	0.120
579	GVQTPYLHL	0.120
325	PTTAPRTVK	0.100
378	PTDYQGEIK	0.100
165	KDLLQPSGK	0.090
967	IVLTGGFTW	0.090
878	KVLKAAEVA	0.090
806	VEVQDPDRK	0.090
598	QLKVTDSSR	0.080
879	VLKAAEVAR	0.080

Table XIV-V1-HLA-A1101-9mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		
Start	Subsequence	Score
656	VFYHWEHVR	0.080
975	WLCICCKKR	0.080
1040	IFSREKMER	0.080
831	EQRKDTLVR	0.072
845	LNVLDSDIK	0.060
685	QVGTYHFRL	0.060
958	YVTVLAFTL	0.060
429	RVNLPPVAV	0.060
1010	RPKYGIKHR	0.060
907	RVDTAGCLL	0.060
960	TVLAFTLIV	0.060
47	RVSHTFPVV	0.060
101	TFVLRPVQR	0.060
399	SVGLYVFKV	0.060
846	NVLDSDIKV	0.060
406	KVTVSSENA	0.060
839	RQLAVLLNV	0.054
115	DYGDMMMLNR	0.048
169	QPSGKQEPR	0.040
908	VDTAGCLLK	0.040
483	SVDSPVLRL	0.040
224	TPAPKLPER	0.040
366	TTYNYEWNL	0.040
920	HGHCDPLTK	0.040
157	SDDYRELEK	0.040
655	IVFYHWEHV	0.040
977	CICCKRQK	0.040
978	ICCKRQKR	0.040
473	INGPFIEEK	0.040
816	GLVELTLQV	0.036
654	GIVFYHWEH	0.036
974	TWLCICCK	0.030
398	LSVGLYVFK	0.030
481	KTSVDSPL	0.030
97	RSYLTFLVR	0.024
68	DLAWWFEGR	0.024
401	GLYVFKVTV	0.024

Table XIV-V1-HLA-A1101-9mers-254P1D6B

Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.

Start	Subsequence	Score
683	GLQVGTYHF	0.024
44	RIMRVSTF	0.024
826	VGQLTEQRK	0.020
889	LHMRLSKEK	0.020
382	QGEIKQGHK	0.020
980	CCKRQKRTK	0.020
1064	SFSYCSKDR	0.020
848	LDSDIKVQK	0.020
773	SVALQLTNL	0.020
84	HKENCEPKK	0.020
294	TVTPGSTEH	0.020
465	IVSYHWEEI	0.020
704	TSTLTVAVK	0.020
336	TVSAGDNLI	0.020
781	LVEGVYTFH	0.020
837	LVRQLAVLL	0.020
873	SRPPFKVLK	0.020
581	QTPYLHLSA	0.020
284	SVTVEKSPV	0.020
437	VVSPQLQEL	0.020
331	TVKELTVSA	0.020
351	EVELKAFVA	0.018

Table XIV-V2-HLA-A1101-9mers-254P1D68

Each peptide is a portion of SEQ ID NO: 5; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.

Start	Subsequence	Score
9	ADDYRELEK	0.040
1	GLEEMSEYA	0.012
5	MSEYADDYR	0.004
4	EMSEYADDY	0.001
6	SEYADDYRE	0.000
8	YADDYRELE	0.000

Table XIV-V2-HLA-A1101-9mers-254P1D68

Each peptide is a portion of SEQ ID NO: 5; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.

Start	Subsequence	Score
7	EYADDYREL	0.000
2	LEEMSEYAD	0.000
3	EEMSEYADD	0.000

Table XIV-V3-HLA-A1101-9mers-254P1D68

Each peptide is a portion of SEQ ID NO: 7; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.

Start	Subsequence	Score
6	WPSPCCARK	0.200
5	GWSPCCAR	0.012
3	RLGWSPCC	0.001
1	MTRLGWSP	0.001
4	LGWSPCCA	0.000
10	CCARKQCSE	0.000
8	SPCCARKQC	0.000
2	TRLGWSPC	0.000
9	PCCARKQCS	0.000
7	PSPCCARKQ	0.000

Table XIV-V5-HLA-A1101-9mers-254P1D68

Each peptide is a portion of SEQ ID NO: 11; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.

Start	Subsequence	Score
5	RKDLTFLGK	0.120
9	TFLGKDWGL	0.006
8	LTFLGKDWG	0.002
3	DIRKDLTFL	0.001
7	DLTFLGKDW	0.001
2	EDIRKDLTF	0.000

Table XIV-V5-HLA-A1101-9mers-254P1D68

Each peptide is a portion of SEQ ID NO: 11; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.

Start	Subsequence	Score
6	KDLTFLGKD	0.000
4	IRKDLTFLG	0.000
1	PEDIRKDLT	0.000

Table XV-V1-HLA-A1101-10mers-254P1D68

Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.

Start	Subsequence	Score
907	RVDTAGCLLK	12.000
825	GVGQLTEQRK	6.000
687	GTYHFRLTVK	6.000
14	LVTIAGCARK	2.000
805	TVEVQPDPRK	2.000
973	FTWLCICCK	2.000
878	KVLKAAEVAR	1.800
76	RCYLVSCPHK	1.200
703	STSTLTVAVK	1.000
655	IVFYHWEHVR	0.800
667	SAVEMENIDK	0.600
865	TVIVFYVQSR	0.600
614	TVIVQPENNR	0.600
869	FYVQSRPPFK	0.600

Table XV-V1-HLA-A1101-10mers-254P1D68		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Start	Subsequence	Score
481	KTSVDSPVLR	0.600
381	YQGEIKQGHK	0.600
100	LTFVLRPVQR	0.400
346	TLPDNEVELK	0.400
847	VLDSDIKVQK	0.400
419	FVNVTVKPAR	0.400
844	LLNVLDSDIK	0.400
241	TPSSGEVLEK	0.400
397	QLSVGLYVFK	0.400
895	KEKADFLLFK	0.360
934	HLWMENLIQR	0.320
1039	TIFSREKMER	0.320
804	ATVEVQPDPR	0.300
683	GLQVGTYHFR	0.240
888	NLHMRLSKEK	0.200
223	STPAPKLPER	0.200
82	CPHKENCEPK	0.200
324	SPTTAPRTVK	0.200
377	HPTDYQGEIK	0.200
6	GVLSSLLLLV	0.180
597	FQLKVTSSSR	0.180

Table XV-V1-HLA-A1101-10mers-254P1D68		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Start	Subsequence	Score
983	RQKRTKIRKK	0.180
416	GEGFVNVTVK	0.180
1043	REKMERGNPK	0.180
919	GHHGCDPLTK	0.120
982	KRQKRTKIRK	0.120
472	EINGPFIEEK	0.120
13	LLVTIAGCAR	0.120
168	LQPSGKQEPR	0.120
280	LELSSVTVEK	0.090
1007	MELRPKYGIK	0.090
977	CICCCRKQKR	0.080
35	VISPNETTR	0.080
493	NLDPGNYSFR	0.080
997	ILDNMDEQER	0.080
321	LPISPTTAPR	0.060
870	YVQSRPPFKV	0.060
257	QEQSSNSSGK	0.060
406	KVTVSSENAF	0.060
781	LVEGVYTFHL	0.060
960	TVLAFTLIVL	0.060
429	RVNLPPVAVV	0.060

Table XV-V1-HLA-A1101-10mers-254P1D68		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Start	Subsequence	Score
591	QEGDYTFQLK	0.060
219	NESASTPAPK	0.060
729	LVLPNNSITL	0.060
330	RTVKELTVSA	0.045
575	VVMQGVQTPY	0.040
130	WGDSPEDIRK	0.040
20	CARKQCSEGR	0.040
137	IRKDLPLGK	0.040
886	ARNLHMRLSK	0.040
286	TVEKSPVLTV	0.040
717	SPPRARAGGR	0.040
156	YSDDYRELEK	0.040
336	TVSAGDNLI	0.040
386	KQGHKQTLNL	0.036
624	PPVAVAGPDK	0.030
976	LCICCCRKQK	0.030
564	WSLPGGSEGK	0.030
985	KRTKIRKTK	0.030
992	KTKYTILDNM	0.030
959	VTVLAFTLIV	0.030
967	IVLTGGFTWL	0.030

Table XV-V1-HLA-A1101-10mers-254P1D68		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Start	Subsequence	Score
986	RTKIRKKTKY	0.030
391	QTLNLSQLSV	0.030
436	AVVSPQLQEL	0.030
539	ITLPQNSITL	0.030
727	HVLVLPNNSI	0.030
684	LQVGTYHFRL	0.027
839	RQLAVLLNLV	0.027
1006	RMELRPKYGI	0.024
830	TEQRKDTLVR	0.024
152	EMSEYSDDYR	0.024
988	KIRKTKYTI	0.024
700	GLSSTSTLTV	0.024
128	GIWGDSPEDI	0.024
979	CCCKRQKRTK	0.020
423	TVKPARRVNL	0.020
958	YVTVLAFITLI	0.020
680	TVTGLQVGTY	0.020
366	TTYNYEWNLI	0.020
1061	NGASFYSYCSK	0.020
1019	STEHNSSLMV	0.020
284	SVTVEKSPVL	0.020

Table XV-V1-HLA-A1101-10mers-254P1D68		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Start	Subsequence	Score
872	QSRPPFKVLK	0.020
524	AVDYPPVANA	0.020

Table XV-V2-HLA-A1101-10mers-254P1D68		
Each peptide is a portion of SEQ ID NO: 5; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Start	Subsequence	Score
9	YADDYRELEK	0.400
5	EMSEYADDYR	0.024
2	GLEEMSEYAD	0.002
4	EEMSEYADDY	0.000
1	WGLEEMSEYA	0.000
8	EYADDYRELE	0.000
7	SEYADDYREL	0.000
3	LEEMSEYADD	0.000
6	MSEYADDYRE	0.000
10	ADDYRELEKD	0.000

Table XV-V3-HLA-A1101-10mers-254P1D68

Each peptide is a portion of SEQ ID NO: 7; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Start	Subsequence	Score
5	GWSPCCAR K	0.060
3	RLGWSPCCCA	0.012
4	LGWSPCCAR	0.008
1	MTRLGWSP C	0.001
10	CCARKQCSEG	0.000
8	SPCCARKQCS	0.000
2	TRLGWSPCC	0.000
6	WSPCCARK Q	0.000
9	PCCARKQCSE	0.000
7	PSPCCARKQC	0.000

Table XV-V5-HLA-A1101-10mers-254P1D68		
Each peptide is a portion of SEQ ID NO: 11; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Start	Subsequence	Score
9	LTFLGKDW GL	0.040
5	IRKDLTFLG K	0.040
7	KDLTFLGKD W	0.000
4	DIRKDLTFL G	0.000
10	TFLGKDWG LE	0.000
1	SPEDIRKDL T	0.000
8	DLTFLGKD WG	0.000
2	PEDIRKDLT F	0.000
3	EDIRKDLTF L	0.000
6	RKDLTFLGK D	0.000

Table XVI-V1-HLA-A24-9mers-254P1D68		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		
Start	Subsequence	Score
159	DYRELEKDL	288.000
155	EYSDDYREL	264.000
869	FYVQSRPPF	150.000
367	TNYEWNLI	90.000
636	IFPVESATL	30.000
943	RYIWDGESN	15.000
228	KLPERSVLL	14.400
92	KMGPIRSYL	13.440
881	KAAEVARNL	13.440
676	KAIATVTGL	12.000
105	RPVQRPAQL	12.000
814	KSGLVELTL	11.200
957	FYVTVLAFT	10.500
133	SPEDIRKDL	10.080
956	IFYVTVLAF	10.000
1012	KYGIKHRST	10.000
1018	RSTEHNSSL	9.600
441	QLQELTLPL	8.640
445	LTLPITSAL	8.640
44	RIMRVSHTF	8.400
481	KTSVDSPVL	8.000
390	KQTLNLSQL	8.000
907	RVDTAGCLL	8.000
274	SLPPASLEL	7.920
346	TLPDNEVEL	7.920

Table XVI-V1-HLA-A24-9mers-254P1D68		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		
Start	Subsequence	Score
216	HYLNESAST	7.500
402	LYVFKVTVS	7.500
693	LTVKDQQGL	7.200
285	VTVEKSPVL	7.200
327	TAPRTVKEL	6.600
437	VVSPQLQEL	6.336
836	TLVRQLAVL	6.000
439	SPQLQELTL	6.000
6	GVLSSLLLL	6.000
829	LTEQRKDTL	6.000
540	TLPQNSITL	6.000
821	TLQVGVGQL	6.000
730	VLPNNSITL	6.000
579	GVQTPYLHL	6.000
486	SPVLRLSNL	6.000
954	WSIFYVTVL	6.000
240	TTPSSGEVL	6.000
511	ATNSTTAAL	6.000
533	AGPNHTITL	6.000
179	SAEYTDWGL	6.000
558	QIVLYEWSL	6.000
267	EVLMPSHSL	6.000
335	LTVSAGDNL	6.000
699	QGLSSTSTL	6.000
5	TGVLSSLLL	6.000
840	QLAVLLNVL	5.760
872	QSRPPFKVL	5.760
32	SNAVISPNI	5.600
469	HWEEINGPF	5.040
1032	EFDSDQDTI	5.000
594	DYTFQLKVT	5.000
498	NYSFRLTVT	5.000
785	VYTFHLRVT	5.000
885	VARNLHMRL	4.800
71	WWFEGRCYL	4.800
893	LSKEKADFL	4.800
968	VLGGFTWL	4.800

Table XVI-V1-HLA-A24-9mers-254P1D68		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		
Start	Subsequence	Score
553	SSDDHQIVL	4.800
809	QPDPRKSGI	4.800
837	LVRQLAVLL	4.800
210	QQDPQLHYL	4.800
339	AGDNLITL	4.800
394	NLSQLSVGL	4.800
768	DGSDHSVAL	4.800
958	YVTVLAFTL	4.800
627	AVAGPDKEL	4.400
221	SASTPAPKL	4.400
113	LLDYGDMML	4.000
685	QVGTYHFRL	4.000
261	SNSSGKEVL	4.000
773	SVALQLTNL	4.000
387	QGHKQTLNL	4.000
56	DCTAACCDL	4.000
918	SGHGHCDPL	4.000
577	MQGVQTPYL	4.000
483	SVDSPVLRL	4.000
366	TTYNYEWNL	4.000
932	CSHLWMENL	4.000
961	VLAFTLIVL	4.000
61	CCDLSSCDL	4.000
495	DPGNYSFRL	4.000
136	DIRKDLPLL	4.000
892	RLSKEKADF	4.000
723	AGGRHVLVL	4.000
589	AMQEGDYTF	3.600
629	AGPDKELIF	3.600
780	NLVEGVYTF	3.600
407	VTVSSENAF	3.600
965	TLIVLTGGF	3.600
1025	SLMVSESEF	3.300
142	PFLGKDWGL	3.000
1057	GSIRNGASF	3.000
683	GLQVGTYHF	3.000
187	LLPGSEGAF	3.000

Table XVI-V1-HLA-A24-9mers-254P1D68		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		
Start	Subsequence	Score
349	DNEVELKAF	3.000

Table XVI-V2-HLA-A24-9mers-254P1D68		
Each peptide is a portion of SEQ ID NO: 5; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		
Start	Subsequence	Score
7	EYADDYREL	264.000
1	GLEEMSEYA	0.180
4	EMSEYADDY	0.120
5	MSEYADDYR	0.015
8	YADDYRELE	0.012
3	EEMSEYADD	0.002
2	LEEMSEYAD	0.002
9	ADDYRELEK	0.001
6	SEYADDYRE	0.001

Table XVI-V3-HLA-A24-9mers-254P1D68		
Each peptide is a portion of SEQ ID NO: 7; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		
Start	Subsequence	Score
3	RLGWSPCC	0.200
4	LGWSPCCA	0.120
8	SPCCARKQC	0.100
5	GWSPCCAR	0.015
2	TRLGWSPC	0.015
6	WSPCCARK	0.012
9	PCCARKQCS	0.012
10	CCARKQCSE	0.010

1	MTRLGWSP	0.010
7	PSPCCARKQ	0.002

Table XVI-V5-HLA-A24-9mers-254P1D68		
Each peptide is a portion of SEQ ID NO: 11; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		
Start	Subsequence	Score
9	TFLGKDWGL	30.000
3	DIRKDLTFL	4.000
2	EDIRKDLTF	0.300
7	DLTFLGKDW	0.120
8	LTLFLGKDWG	0.010
6	KDLTFLGKD	0.003
5	RKDLTFLGK	0.002
4	IRKDLTFLG	0.001
1	PEDIRKDLT	0.001

Table XVII-V1-HLA-A24-10mers-254P1D68		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Start	Subsequence	Score
957	FYVTVLAFTL	360.000
159	DYRELEKDLL	240.000
839	RQLAVLLNVL	17.280
943	RYIWDGESN C	15.000
105	RPVQRPAQL L	14.400
897	KADFLLFKVL	11.520
402	LYVFKVTVSS	10.500
98	SYLTFVLRPV	10.500
132	DSPEDIRKDL	10.080
868	VFYVQSRPP	10.000

Table XVII-V1-HLA-A24-10mers-254P1D68		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Start	Subsequence	Score
	F	0
1032	EFDSQDQDTIF	10.000
692	RLTVKDQQG L	9.600
561	LYEWSLGP S	9.000
229	LPERSVLLPL	8.400
31	YSNAVISPNL	8.400
2	APPTGVLSSL	8.400
892	RLSKEADFL	8.000
720	RARAGGRHV L	8.000
386	KQGHKQTLN L	8.000
722	RAGGRHVLV L	8.000
436	AVVSPQLQE L	7.920
273	HSLPPASLEL	7.920
345	ITLPDNEVEL	7.920
367	TNYEWNLLIS	7.500
751	SYLWIRDGQ S	7.500
482	TSVDSPLVRL	7.200
539	ITLPQNSITL	7.200
209	TQQDPELHY L	7.200
967	IVLTGGFTWL	7.200
836	TLVRQLAVLL	7.200
393	LNLSQLSVGL	7.200
729	LVLNNNSITL	7.200
808	VQPDPRKSG L	7.200
112	QLLDYGDMM L	7.200
30	TYSNAVISPN	7.000
626	VAVAGPDKE L	6.600
557	HQIVLYEWSL	6.000

Table XVII-V1-HLA-A24-10mers-254P1D68		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Start	Subsequence	Score
684	LQVGTYHFR L	6.000
835	DTLVRQLAVL	6.000
590	MQEGDYTFQ L	6.000
438	VSPQLQELTL	6.000
247	VLEKEKASQL	6.000
820	LTLQVGVGQ L	6.000
260	SSNSSGKEV L	6.000
576	VMQGVQTPY L	6.000
179	SAEYTDWGL L	6.000
485	DSPVLRLSNL	6.000
5	TGVLSSLLLL	6.000
960	TVLAFTLIVL	6.000
781	LVEGVYTFHL	6.000
578	QGVQTPYLH L	6.000
772	HSVALQLTNL	6.000
338	SAGDNLITL	5.760
769	GSDHSVALQ L	5.600
926	LTKRCICSHL	5.600
326	TTAPRTVKEL	5.280
1000	NMDEQERME L	5.280
312	APSESTPSEL	5.280
893	LSKEADFL	4.800
60	ACCDLSSCD L	4.800
635	LIFPVESATL	4.800
406	KVTVSENAF	4.800
423	TVKPARRVN L	4.800
444	ELTLPLTSAL	4.800
828	QLTEQRKDT L	4.800

Table XVII-V1-HLA-A24-10mers-254P1D68		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Start	Subsequence	Score
884	EVARNLHMR L	4.800
384	EIKQGHKQTL	4.800
532	NAGPNHTITL	4.800
552	QSSDDHQIVL	4.800
871	VQSRPPFKV L	4.800
178	GSAEYTDWG L	4.800
220	ESASTPAPKL	4.400
811	DPRKSGLVE L	4.400
905	VLRVDTAGC L	4.000
141	LPFLGKDWG L	4.000
284	SVTVEKSPVL	4.000
510	GATNSTTAAL	4.000
698	QQGLSSTST L	4.000
334	ELTVSAGDNL	4.000
854	VQKIRAHSDL	4.000
917	CSGHGHCDP L	4.000
931	ICSHLWMEN L	4.000
365	ETTYNYEWN L	4.000
953	EWSIFYVTVL	4.000
226	APKLPERSVL	4.000
70	AWWFEGRC YL	4.000
186	GLLPGSEGA F	3.600
964	FTLIVLTGGF	3.600
492	SNLDPGNYS F	3.600
1024	SSLMVSESE F	3.300
1006	RMELRPKYGI	3.000
779	TNLVEGVYTF	3.000

Table XVII-V1-HLA-A24-10mers-254P1D68		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Start	Subsequence	Score
682	TGLQVGTYH F	3.000
588	SAMQEGDYT F	3.000
93	MGPIRSYLT	3.000
410	SSENAFGEG F	3.000
396	SQLSVGLYVF	3.000
648	SSSDDHGIVF	2.400
64	LSSCDLAWW F	2.400
858	RAHSDLSTVI	2.400

Table XVII-V2-HLA-A24-10mers-254P1D68		
Each peptide is a portion of SEQ ID NO: 5; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Start	Subsequence	Score
8	EYADDYRELE	0.600
7	SEYADDYREL	0.440
1	WGLEEMSEYA	0.180
2	GLEEMSEYAD	0.018
6	MSEYADDYRE	0.015
4	EEMSEYADDY	0.015
9	YADDYRELEK	0.013
5	EMSEYADDYR	0.012
3	LEEMSEYADD	0.002
10	ADDYRELEKD	0.000

Table XVII-V2-HLA-A24-10mers-254P1D68		
Each peptide is a portion of SEQ ID NO: 5; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Start	Subsequence	Score
		1

Table XVII-V3-HLA-A24-10mers-254P1D68		
Each peptide is a portion of SEQ ID NO: 7; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Start	Subsequence	Score
3	RLGWSPCCA	0.200
8	SPCCARKQCS	0.120
1	MTRLGWSPSPC	0.100
7	PSPCCARKQC	0.015
5	GWSPCCARK	0.015
2	TRLGWSPCC	0.015
6	WPSPCCARKQ	0.013
4	LGWSPCCAR	0.012
10	CCARKQCSEG	0.011
9	PCCARKQCSE	0.001

Table XVII-V5-HLA-A24-10mers-254P1D68		
Each peptide is a portion of SEQ ID NO: 11; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		

Start	Subsequence	Score
9	LTFLGKDWGL	4.000
3	EDIRKDLTFL	0.600
1	SPEDIRKDLT	0.180
10	TFLGKDWGLE	0.075
7	KDLTFLGKDW	0.036
2	PEDIRKDLTF	0.020
4	DIRKDLTFLG	0.012
8	DLTFLGKDWG	0.010
6	RKDLTFLGKD	0.002
5	IRKDLTFLGK	0.001

Table XVIII-V1-HLA-B7-9mers-254P1D68		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		
Start	Subsequence	Score
837	LVRQLAVLL	200.000
885	VARNLHMRL	120.000
627	AVAGPDKEL	90.000
105	RPVQRPAQL	80.000
486	SPVLRLSNL	80.000
495	DPGNYSFRL	80.000
439	SPQLQELTL	80.000
872	QSRPPFKVL	60.000
328	APRTVKELT	60.000
136	DIRKDLPL	40.000

Table XVIII-V1-HLA-B7-9mers-254P1D68		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		
Start	Subsequence	Score
133	SPEDIRKDL	36.000
267	EVLMPSHSL	30.000
579	GVQTPYLHL	30.000
809	QPDPRKSG	24.000
437	VVSPQLQEL	20.000
685	QVGTYHFRL	20.000
773	SVALQLTNL	20.000
175	EPRGSAEYT	20.000
6	GVLSSLLLL	20.000
958	YVTVLAFTL	20.000
582	TPYLHLSAM	20.000
226	APKLPERSV	18.000
221	SASTPAPKL	18.000
533	AGPNHTITL	12.000
327	TAPRTVKEL	12.000
676	KAIATVTGL	12.000
881	KAAEVARNL	12.000
723	AGGRHVLVL	12.000
511	ATNSTTAAL	12.000
359	APAPPVETT	9.000
483	SVDSPVLRL	9.000
3	PPTGVLSSL	8.000
296	TPGSTHSI	8.000

Table XVIII-V1-HLA-B7-9mers-254P1D68

Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.

Start	Subsequence	Score
37	SPNLETTRI	8.000
377	HPTDYQGEI	8.000
92	KMGPIRSYL	6.000
720	RARAGGRHV	6.000
907	RVDTAGCLL	6.000
1018	RSTEHNSSL	4.000
346	TLPDNEVEL	4.000
32	SNAVISPNI	4.000
954	WSIFYVTVL	4.000
324	SPTTAPRTV	4.000
821	TLQVGVGQL	4.000
540	TLPQNSITL	4.000
918	SGHGHCDPL	4.000
927	TKRCICSHL	4.000
121	LNRGSPSGI	4.000
814	KSGLVELTL	4.000
240	TTPSSGEVL	4.000
699	QGLSSTSTL	4.000
968	VLGGFTWL	4.000
56	DCTAACCDL	4.000
445	LTLPLTSAL	4.000
932	CSHLWMENL	4.000
558	QIVLYEWSL	4.000
274	SLPPASLEL	4.000
961	VLAFTLIVL	4.000
390	KQTLNLSQL	4.000
768	DGSDHSVAL	4.000
893	LSKEKADFL	4.000
577	MQGVQTPYL	4.000
730	VLPNNSITL	4.000
228	KLPERSVLL	4.000
285	VTVEKSPVL	4.000
366	TTYNYEWNL	4.000
335	LTVSAGDNL	4.000
693	LTVKDQQGL	4.000
840	QLAVLLNVL	4.000
159	DYRELEKDL	4.000

Table XVIII-V1-HLA-B7-9mers-254P1D68

Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.

Start	Subsequence	Score
567	GPGSEGKHV	4.000
836	TLVRQLAVL	4.000
5	TGVLSSLL	4.000
387	QGHKQTLNL	4.000
261	SNSSGKEVL	4.000
481	KTSVDSPVL	4.000
441	QLQELTLPL	4.000
394	NLSQLSVGL	4.000
179	SAEYTDWGL	3.600
339	AGDNLITL	3.600
999	DNMDEQER M	3.000
106	PVQRPAQLL	3.000
304	IPTPPTSAA	3.000
924	DPLTKRCIC	3.000
111	AQLLDYGDM	3.000
34	AVISPNIET	2.250
434	PVAVVSPQL	2.000
270	MPSHSLPPA	2.000
811	DPRKSGLVE	2.000
336	TVSAGDNLI	2.000
465	IVSYHWEEI	2.000
874	RPPFKVLKA	2.000
604	SSRQQSTAV	2.000
27	EGRTYNAV	2.000
52	FPVVDCTAA	2.000
721	ARAGGRHVL	1.800
531	ANAGPNHTI	1.800
618	QPENNRPPV	1.800
517	AALIVNNAV	1.800
621	NNRPPVAVA	1.500

Table XVIII-V2-HLA-B7-9mers-254P1D68

Each peptide is a portion of SEQ ID NO: 5; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.

Start	Subsequence	Score
7	EYADDYREL	0.400
1	GLEEMSEYA	0.030
4	EMSEYADDY	0.020
8	YADDYRELE	0.013
3	EEMSEYADD	0.003
5	MSEYADDYR	0.003
6	SEYADDYRE	0.001
9	ADDYRELEK	0.001
2	LEEMSEYAD	0.000

Table XVIII-V3-HLA-B7-9mers-254P1D68

Each peptide is a portion of SEQ ID NO: 7; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.

Start	Subsequence	Score
8	SPCCARKQC	3.000
6	WPSPCCARK	0.200
3	RLGWSPCC	0.150
1	MTRLGWSP	0.100
4	LGWSPCCA	0.100
10	CCARKQCSE	0.010
2	TRLGWSPC	0.010
9	PCCARKQCS	0.002
5	GWSPCCAR	0.002
7	PSPCCARKQ	0.001

Table XVIII-V5-HLA-B7-9mers-254P1D68

Each peptide is a portion of SEQ ID NO: 11; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.

Start	Subsequence	Score
3	DIRKDLTFL	40.00
9	TFLGKDWGL	0.400

Table XVIII-V5-HLA-B7-9mers-254P1D68		
Each peptide is a portion of SEQ ID NO: 11; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		
Start	Subsequence	Score
7	DLTFLGKDW	0.020
8	LTFLGKDWG	0.010
2	EDIRKDLTF	0.002
4	IRKDLTFLG	0.001
6	KDLTFLGKD	0.001
1	PEDIRKDLT	0.000
5	RKDLTFLGK	0.000

Table XIX-V1-HLA-B7-10mers-254P1D68		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Start	Subsequence	Score
811	DPRKSGLEVEL	800.000
226	APKLPERSVL	360.000
312	APSESTPSEL	240.000
2	APPTGVLSSL	240.000
720	RARAGGRHVL	180.000
105	RPVQRPAQLL	120.000
328	APRTVKELTV	120.000
141	LPFLGKDWGL	80.000
436	AVVSPQLQEL	60.000
662	HVRGPSAVEM	50.000
905	VLRVDTAGCL	40.000
423	TVKPARRVNL	30.000

Table XIX-V1-HLA-B7-10mers-254P1D68		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Start	Subsequence	Score
229	LPERSVLLPL	24.000
37	SPNLETTRIM	20.000
284	SVTVEKSPVL	20.000
967	IVLTGGFTWL	20.000
960	TVLAFTLIVL	20.000
729	LVLPNNSITL	20.000
884	EVARNLHMRL	20.000
626	VAVAGPDKEL	18.000
338	SAGDNLIITL	12.000
722	RAGGRHVLVL	12.000
60	ACCDLSSCDL	12.000
510	GATNSTTAAL	12.000
532	NAGPNHTITL	12.000
665	GPSAVEMENI	8.000
1050	NPKVSMNGSI	8.000
3	PPTGVLSSLL	8.000
433	PPVAVVSPQL	8.000
781	LVEGVYTFHL	6.000
871	VQSRPPFKVL	6.000
578	QGVQTPYLHL	6.000
627	AVAGPDKELI	6.000
220	ESASTPAPKL	6.000

Table XIX-V1-HLA-B7-10mers-254P1D68		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Start	Subsequence	Score
		0
482	TSVDSPLRL	6.000
132	DSPEDIRKDL	6.000
892	RLSKEKADFL	4.000
260	SSNSSGKEVL	4.000
828	QLTEQRKDTL	4.000
384	EIKQGHKQTL	4.000
159	DYRELEKDLL	4.000
917	CSGHGHCDPL	4.000
438	VSPQLQELTL	4.000
485	DSPVLRLSNL	4.000
893	LSKEKADFLL	4.000
27	EGRTYSNAVI	4.000
326	TTAPRTVKEL	4.000
698	QQGLSSTSTL	4.000
393	LNLSQLSVGL	4.000
365	ETTYNYEWNL	4.000
238	LPTTPSSGEV	4.000
386	KQGHKQTLNL	4.000
95	PIRSYLTFVL	4.000
835	DTLVRQLAVL	4.000
820	LTLQVGVGQL	4.000

Table XIX-V1-HLA-B7-10mers-254P1D68		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Start	Subsequence	Score
31	YRNAVISPNL	4.000
926	LTKRCICSHL	4.000
539	ITLPQNSITL	4.000
692	RLTVKDQQGL	4.000
5	TGVLSSLLLL	4.000
635	LIFPVESATL	4.000
557	HQIVLYEWSL	4.000
854	VQKIRAHSDL	4.000
836	TLVRQLAVLL	4.000
552	QSSDDHQIVL	4.000
740	GSIRSTDDQRI	4.000
475	GPFIEEKTSV	4.000
112	QLLDYGDMMML	4.000
345	ITLPDNEVEL	4.000
334	ELTVSAGDNL	4.000
273	HSLPPASLEL	4.000
988	KIRKTKTYTI	4.000
746	DQRIVSYLWI	4.000
444	ELTLPLTSAL	4.000
576	VMQGVQTPYL	4.000
684	LQVGTYHFRL	4.000
772	HSVALQLTNL	4.000

Table XIX-V1-HLA-B7-10mers-254P1D68		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Start	Subsequence	Score
		0
839	RQLAVLLNVL	4.000
567	GPGSEGKHVV	4.000
931	ICSHLWMENL	4.000
209	TQQDPELHYL	4.000
178	GSAEYTDWGL	4.000
808	VQPDPRKSGL	4.000
94	GPIRSYLTfV	4.000
897	KADFLLFKVL	3.600
179	SAEYTDWGLL	3.600
111	AQLLDYGDMM	3.000
317	TPSELPISPT	3.000
727	HVLVLPNNSI	3.000
882	AAEVARNLHM	2.700
175	EPRGSAEYTD	2.000
52	FPVVDCTAAC	2.000
336	TVSAGDNLII	2.000
45	IMRVSHTFPV	2.000
495	DPGNYSFRLT	2.0
874	RPPFKVLKAA	2.000
958	YVTVLAFTLI	2.000
604	SSRQQSTAVV	2.000

Table XIX-V1-HLA-B7-10mers-254P1D68		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Start	Subsequence	Score
70	AWWFEGRCYL	1.800
91	KKMGPIRSYL	1.800

Table XIX-V2-HLA-B7-10mers-254P1D68		
Each peptide is a portion of SEQ ID NO: 5; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Start	Subsequence	Score
7	SEYADDYREL	0.400
1	WGLEEMSEYA	0.100
5	EMSEYADDYR	0.010
9	YADDYRELEK	0.009
4	EEMSEYADDY	0.006
2	GLEEMSEYAD	0.003
6	MSEYADDYRE	0.003
8	EYADDYRELE	0.002
10	ADDYRELEKD	0.001
3	LEEMSEYADD	0.000

Table XIX-V3-HLA-B7-10mers-254P1D68		
-------------------------------------	--	--

Each peptide is a portion of SEQ ID NO: 7; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.

Start	Subsequence	Score
1	MTRLGWSPSPC	1.000
8	SPCCARKQCS	0.400
6	WPSPCCARKQ	0.200
3	RLGWSPCCA	0.100
7	PSPCCARKQC	0.015
2	TRLGWSPCC	0.015
4	LGWSPCCAR	0.015
10	CCARKQCSEG	0.010
9	PCCARKQCSE	0.001
5	GWSPCCARK	0.001

Table XIX-V5-HLA-B7-10mers-254P1D68

Each peptide is a portion of SEQ ID NO: 11; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.

Start	Subsequence	Score
9	LTFLGKDWGL	4.000
1	SPEDIRKDLT	0.600
3	EDIRKDLTFL	0.400
4	DIRKDLTFLG	0.100
8	DLTFLGKDWG	0.010
7	KDLTFLGKDW	0.002
10	TFLGKDWGLE	0.001

Table XIX-V5-HLA-B7-10mers-254P1D68

Each peptide is a portion of SEQ ID NO: 11; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.

Start	Subsequence	Score
5	IRKDLTFLGK	0.001
6	RKDLTFLGKD	0.000
2	PEDIRKDLTF	0.000

Table XX-V1-HLA-B3501-9mers-254P1D68

Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.

Start	Subsequence	Score
105	RPVQRPAQL	40.000
582	TPYLHLSAM	40.000
893	LSKEKADFL	30.000
1018	RSTEHNSSL	20.000
94	GPIRSYLT	20.000
495	DPGNYSFRL	20.000
439	SPQLQELTL	20.000
486	SPVLRLSNL	20.000
377	HPTDYQGEI	16.000
491	LSNLDPGNY	15.000
872	QSRPPFKVL	15.000
133	SPEDIRKDL	12.000
226	APKLPERSV	12.000

Table XX-V1-HLA-B3501-9mers-254P1D68

Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.

Start	Subsequence	Score
881	KAAEVARNL	12.000
37	SPNLETTRI	12.000
587	LSAMQEGDY	10.000
814	KSGLEVELTL	10.000
262	NSSGKEVLM	10.000
65	SSCDLAWWF	10.000
395	LSQLSVGLY	10.000
885	VARNLHMRL	9.000
296	TPGSTEHSI	8.000
362	PPVETTYNY	8.000
949	ESNCEWSIF	7.500
742	RSTDDQRIV	6.000
999	DNMDEQERM	6.000
148	WGLEEMSEY	6.000
676	KAIATVTGL	6.000
23	KQCSEGRTY	6.000
567	GPGSEGKHV	6.000
175	EPRGSAEYT	6.000
809	QDPDRKSG	6.000
1050	NPKVSMNGS	6.000
328	APRTVKELT	6.000
932	CSHLWMENL	5.000
1057	GSIRNGASF	5.000
954	WSIFYVTVL	5.000
136	DIRKDLPL	4.500
228	KLPERSVLL	4.000
929	RCICSHLWM	4.000
874	RPPFKVLKA	4.000
112	QLLDYGDM	4.000
950	SNCEWSIFY	4.000
209	TQQDPELHY	4.000
152	EMSEYSDDY	4.000

Table XX-V1-HLA-B3501-9mers-254P1D68		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		
Start	Subsequence	Score
324	SPTTAPRTV	4.000
64	LSSCDLAWW	3.750
720	RARAGGRHV	3.600
327	TAPRTVKEL	3.000
649	SSDDHGIVF	3.000
552	QSSDDHQIV	3.000
221	SASTPAPKL	3.000
52	FPVVDCTAA	3.000
337	VSAGDNLII	3.000
604	SSRQQSTAV	3.000
647	SSSSDDHGI	3.000
475	GPFIEEKT	3.000
569	GSEGKHVVM	3.000
361	APPVETTYN	3.000
188	LPGSEGAFN	3.000
553	SSDDHQIVL	3.000
648	SSSDDHGIV	3.000
892	RLSKEKADF	3.000
111	AQLLDYGDM	3.000
481	KTSVDSPVL	3.000
837	LVRQLAVLL	3.000
458	QSTDDTEIV	3.000
759	QSPAAGDVI	2.000
780	NLVEGVYTF	2.000
346	TLPDNEVEL	2.000
681	VTGLQVGTY	2.000
304	ITPPTSAA	2.000
541	LPQNSITLN	2.000
125	SPSGIWGDS	2.000
275	LPPASLELS	2.000
862	DLSTVIVFY	2.000
236	LPLPTTPSS	2.000
373	NLISHPTDY	2.000
665	GPSAVEMEN	2.000
9	SSLLLLVTI	2.000
270	MPSHSLPPA	2.000
441	QLQELTLPL	2.000

Table XX-V1-HLA-B3501-9mers-254P1D68		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		
Start	Subsequence	Score
589	AMQEGDYTF	2.000
576	VMQGVQTPY	2.000
519	LIVNNAVDY	2.000
924	DPLTKRCIC	2.000
629	AGPDKELIF	2.000
359	APAPPVETT	2.000
778	LTNLVEGVY	2.000
3	PPTGVLSSL	2.000
608	QSTAVVTVI	2.000
306	TPPTSAAPS	2.000
285	VTVEKSPVL	2.000
315	ESTPSELPI	2.000
44	RIMRVSHTF	2.000
2	APPTGVLSS	2.000
390	KQTLNLSQL	2.000
1038	DTIFSREKM	2.000
92	KMGPIRSYL	2.000
768	DGSDHSVAL	2.000

Table XX-V2-HLA-B3501-9mers-254P1D68		
Each peptide is a portion of SEQ ID NO: 5; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		
Start	Subsequence	Score
4	EMSEYADDY	4.000
7	EYADDYREL	0.300
1	GLEEMSEYA	0.060
8	YADDYRELE	0.018
5	MSEYADDYR	0.015
6	SEYADDYRE	0.002
3	EEMSEYADD	0.002
2	LEEMSEYAD	0.000
9	ADDYRELEK	0.000

Table XX-V3-HLA-B3501-9mers-254P1D68		
Each peptide is a portion of SEQ ID NO: 7; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		
Start	Subsequence	Score
8	SPCCARKQC	2.000
3	RLGWSPCC	0.200
6	WPSPCCARK	0.200
4	LGWSPCCA	0.100
1	MTRLGWSP	0.030
10	CCARKQCSE	0.010
9	PCCARKQCS	0.010
2	TRLGWSPC	0.010
7	PSPCCARKQ	0.005
5	GWSPCCAR	0.001

Table XX-V5-HLA-B3501-9mers-254P1D68		
Each peptide is a portion of SEQ ID NO: 11; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		
Start	Subsequence	Score
3	DIRKDLTFL	4.500
7	DLTFLGKDW	0.500
9	TFLGKDWGL	0.100
2	EDIRKDLTF	0.100
8	LTFLGKDWG	0.010
4	IRKDLTFLG	0.006
6	KDLTFLGKD	0.002
5	RKDLTFLGK	0.001
1	PEDIRKDLT	0.000

Table XXI-V1-HLA-B3501-10mers-254P1D68		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Start	Subsequence	Score

Table XXI-V1-HLA-B3501-10mers-254P1D68		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Start	Subsequence	Score
226	APKLPERSVL	90.00 0
811	DPRKSGLVE L	60.00 0
361	APPVETTYNY	40.00 0
312	APSESTPSEL	40.00 0
1018	RSTEHNSSL M	40.00 0
359	APAPPVETTY	40.00 0
37	SPNLETRIM	40.00 0
105	RPVQRPAQL L	40.00 0
893	LSKEKADFL	30.00 0
1050	NPKVSMNGS I	24.00 0
141	LPFLGKDWG L	20.00 0
2	APPTGVLSSL	20.00 0
720	RARAGGRHV L	18.00
986	RTKIRKTKY	12.00 0
1010	RPKYGIKHS	12.00 0
992	KTKYTILDNM	12.00 0
144	LGKDWGLEE M	12.00 0
665	GPSAVEMENI	12.00 0
328	APRTVKELTV	12.00 0
552	QSSDDHQIVL	10.00 0
648	SSSDDHGIVF	10.00 0
132	DSPEDIRKDL	10.00

Table XXI-V1-HLA-B3501-10mers-254P1D68		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Start	Subsequence	Score
		0
178	GSAEYTDWG L	10.00 0
482	TSVDSPVLR	10.00 0
949	ESNCEWSIFY	10.00 0
69	LAWWFEGRC Y	9.000
740	GSRTDDQR I	9.000
553	SSDDHQIVLY	6.000
649	SSDDHGIVFY	6.000
475	GPFIIEKTSV	6.000
89	EPKKMGPIRS	6.000
490	RLSNLDPGN Y	6.000
722	RAGGRHVLV L	6.000
1058	SIRNGASFSY	6.000
107	VQRPAQLLD Y	6.000
338	SAGDNLIITL	6.000
229	LPERSVLLPL	6.000
662	HVRGPSAVE M	6.000
485	DSPVLRSLNL	5.000
260	SSNSSGKEV L	5.000
31	YSNAVISPNI	5.000
1024	SSLMVSESE F	5.000
64	LSSCDLAWW F	5.000
917	CSGHGHCDP L	5.000
220	ESASTPAPKL	5.000
772	HSVALQLTNL	5.000
273	HSLPPASLEL	5.000
438	VSPQLQELTL	5.000

Table XXI-V1-HLA-B3501-10mers-254P1D68		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Start	Subsequence	Score
567	GPGSEGKHV V	4.000
94	GPIRSYLTFV	4.000
238	LPTTPSSGEV	4.000
317	TPSELPISPT	4.000
874	RPPFKVLKAA	4.000
646	GSSSDDHG I	3.000
628	VAGPDKELIF	3.000
510	GATNSTTAAL	3.000
209	TQQDPELHY L	3.000
905	VLRVDTAGC L	3.000
456	GSQSTDDTEI	3.000
692	RLTVKDQQG L	3.000
854	VQKIRAHSDL	3.000
36	ISPNLETRI	3.000
588	SAMQEGDYT F	3.000
926	LTKRCICSHL	3.000
423	TVKPARRVN L	3.000
1041	FSREKMERG N	3.000
604	SSRQQSTAV V	3.000
532	NAGPNHTITL	3.000
384	EIKQGHKQTL	3.000
626	VAVAGPDKE L	3.000
858	RAHSDLSTVI	2.400
988	KIRKTKYTI	2.400
892	RLSKEKADFL	2.000
208	ETQQDPELH Y	2.000
495	DPGNYSFRL T	2.000
188	LPGSEGAFN	2.000

Table XXI-V1-HLA-B3501-10mers-254P1D68

Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.

Start	Subsequence	Score
	S	
278	ASLELSSVTV	2.000
270	MPSHSLPPA S	2.000
372	WNLISHPTDY	2.000
777	QLTNLVEGV Y	2.000
581	QTPYLHLSA M	2.000
828	QLTEQRKDT L	2.000
808	VQPDPRKSG L	2.000
275	LPPASLELSS	2.000
3	PPTGVLSLL	2.000
924	DPLTKRCICS	2.000
680	TVTGLQVGT Y	2.000
575	VVMQGVQTP Y	2.000
492	SNLDPGNYS F	2.000
386	KQGHKQTLN L	2.000
52	FPVVDCTAA C	2.000
112	QLLDYGDMM L	2.000
111	AQLLDYGDM M	2.000
433	PPVAVVSPQ L	2.000
290	SPVLTVT PGS	2.000
527	YPPVANAGP N	2.000
586	HLSAMQEGD Y	2.000
742	RSTDDQRIVS	2.000
224	TPAPKLPERS	2.000
8	LSSLLLLVTI	2.000

Table XXI-V1-HLA-B3501-10mers-254P1D68

Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.

Start	Subsequence	Score
Table XXI-V2-HLA-B3501-10mers-254P1D68		
Each peptide is a portion of SEQ ID NO: 5; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Start	Subsequence	Score
1	WGLEEMSEY A	0.200
4	EEMSEYADDY	0.200
7	SEYADDYREL	0.150
6	MSEYADDYRE	0.023
5	EMSEYADDYR	0.020
9	YADDYRELEK	0.018
2	GLEEMSEYAD	0.006
8	EYADDYRELE	0.002
10	ADDYRELEKD	0.000
3	LEEMSEYADD	0.000

Table XXI-V3-HLA-B3501-10mers-254P1D68

Each peptide is a portion of SEQ ID NO: 7; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.

Start	Subsequence	Score
8	SPCCARKQC S	2.000
1	MTRLGWPS C	0.300
6	WPSPCCARK Q	0.200
3	RLGWPSGCC A	0.200
7	PSPCCARKQ	0.050

Table XXI-V3-HLA-B3501-10mers-254P1D68

Each peptide is a portion of SEQ ID NO: 7; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.

Start	Subsequence	Score
	C	
10	CCARKQCSE G	0.010
4	LGWSPCCA R	0.010
2	TRLGWSPC C	0.010
9	PCCARKQCS E	0.001
5	GWSPCCAR K	0.001

Table XXI-V5-HLA-B3501-10mers-254P1D68

Each peptide is a portion of SEQ ID NO: 11; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.

Start	Subsequence	Score
1	SPEDIRKDLT	1.200
9	LTLGKDWG L	1.000
3	EDIRKDLTFL	0.150
7	KDLTFLGKD W	0.100
4	DIRKDLTFLG	0.030
8	DLTFLGKDW G	0.010
5	IRKDLTFLGK	0.006
2	PEDIRKDLTF	0.003
10	TFLGKDWGL E	0.002
6	RKDLTFLGKD	0.001

Tables XXII – XLIX:

TableXXII-V1-HLA-A1-9mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		
Pos	123456789	score
554	SDDHQIVLY	31
650	SDDHGIVFY	29
182	YTDWGLLP	26
743	STDDQRIVS	26
460	TDDTEIVSY	25
681	VTGLQVGTY	25
744	TDDQRIVSY	25
936	WMENLIQRY	25
778	LTNLVEGVY	24
108	QRPAQLLDY	23
459	STDDTEIVS	23
209	TQQDPELHY	22
395	LSQLSVGLY	22
649	SSDDHGIVF	22
360	PAPPVETTY	21
553	SSDDHQIVL	21
587	LSAMQEGDY	21
950	SNCEWSIFY	21
138	RKDLPFLGK	20
156	YSDDYRELE	20
483	SVDSPVLRL	20
695	VKDQQLSS	20
792	VTDSQGASD	20
1019	STEHNSSLM	20
229	LPERSVLLP	19
378	PTDYQGEIK	19
410	SSENAFGEG	19
491	LSNLDPGNY	19
576	VMQGVQTPY	19
157	SDDYRELEK	18
190	GSEGAFNSS	18
299	STEHSIPTP	18
462	DTEIVSYHW	18
493	NLDPGNYSF	18
505	VTDSQGATN	18
601	VTDSRQQS	18
862	DLSTVIVFY	18

TableXXII-V1-HLA-A1-9mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		
1005	ERMELRPKY	18
1028	VSESEFSDS	18
1034	DSDQDTIFS	18
39	NLETTRIMR	17
70	AWWFEGRCY	17
91	KKMGPIRSY	17
162	ELEKDLLQP	17
174	QEPRGSAEY	17
769	GSDHSVALQ	17
849	DSDIKVQKI	17
987	TKIRKTKY	17
23	KQCSEGRY	16
152	EMSEYSDDY	16
212	DPELHYLNE	16
373	NLISHPTDY	16
569	GSEGKHVVM	16
638	PVESATLDG	16
668	AVEMENIDK	16
800	DTDTATVEV	16
829	LTEQRKDTL	16
1003	EQERMELRP	16
1059	IRNGASFSY	16
25	CSEGRYTSN	15
148	WGLEEMSEY	15
173	KQEPRGSAE	15
223	STPAPKLE	15
318	PSELPISPT	15
339	AGDNLIITL	15
362	PPVETTYNY	15
507	DSDGATNST	15
519	LIVNNAVDY	15
592	EGDYTFQLK	15
798	ASDTDTATV	15
909	DTAGCLLKC	15
1045	KMERGNPKV	15

TableXXII-V2-HLA-A1-9mers-254P1D6B

Each peptide is a portion of SEQ ID NO: 5; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		
Pos	123456789	score
9	ADDYRELEK	17
4	EMSEYADDY	16
8	YADDYRELE	16
5	MSEYADDYR	14
1	GLEEMSEYA	11
2	LEEMSEYAD	10

TableXXII-V3-HLA-A1-9mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 7; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		
Pos	123456789	score
1	MTRLGWSPSP	8
7	PSPCCARKQ	6
4	LGWSPCCA	4
6	WPSPCCARK	4
8	SPCCARKQC	3

TableXXII-V5-HLA-A1-9mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 11; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		
Pos	1 2 3 4 5 6 7 8 9	score
5	RKDLTFLGK	19
1	PEDIRKDLT	12

TableXXIII-V1-HLA-A0201-9mers-254P1D6B

Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.

Pos	123456789	score
840	QLAVLLNVL	28
900	FLLFKVLRV	28
7	VLSSLLLLV	27
274	SLPPASLEL	27
401	GLYVFQVTV	27
816	GLVELTLQV	27
441	QLQELTLPL	26
673	NIDKAIATV	26
821	TLQVGVGQL	26
836	TLVRQLAVL	26
961	VLAFTLIVL	26
228	KLPERSVLL	25
279	SLELSSVTV	25
346	TLPDNEVEL	25
777	QLTNLVEGV	25
99	YLTFVLRPV	24
392	TLNLSQLSV	24
394	NLSQLSVGL	24
445	LTPLPLTSAL	24
766	VIDGSDHSV	24
968	VLTTGGFTWL	24
10	SLLLLVTIA	23
113	LLDYGDMMML	23
344	IITLPDNEV	23
399	SVGLYVFKV	23
437	VVSPQLQEL	23
452	ALIDGSQST	23
728	VLVLPNNSI	23
730	VLPNNSITL	23
1045	KMERGNPKV	23
6	GVLSSLLLL	22
136	DIRKDLPL	22
186	GLLPGSEGA	22
430	VNLPPVAVV	22
483	SVDSPVLR	22
511	ATNSTIAAL	22
540	TLPQNSITL	22
609	STAVVTIV	22
627	AVAGPDKEL	22
676	KAIATVTGL	22

TableXXIII-V1-HLA-A0201-9mers-254P1D6B

Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.

Pos	123456789	score
703	STSTLIVAV	22
773	SVALQLTNL	22
844	LLNVLDSDI	22
9	SSLLLLVTI	21
12	LLLVTIAGC	21
35	VISPNIETT	21
92	KMGPIRSYL	21
558	QIVLYEWSL	21
774	VALQLTNLV	21
780	NLVEGVYTF	21
897	KADFLLFKV	21
95	PIRSYLTfV	20
221	SASTPAPKL	20
233	SVLLPLPTT	20
446	TLPLTSALI	20
517	AALIVNNAV	20
687	GTYHFRITV	20
858	RAHSDLSTV	20
960	TVLAFTLIV	20
285	VTVEKSPVL	19
327	TAPRTVKEL	19
339	AGDNLITL	19
429	RVNLPPVAV	19
538	TITLPQNSI	19
634	ELIFPVESA	19
721	ARAGGRHVL	19
800	DTDTATVEV	19
837	LVRQLAVLL	19
843	VLLNVLDSD	19
846	NVLDSDIKV	19
881	KAAEVARNL	19
112	QLLDYGDMM	18
234	VLLPLPTTP	18
287	VEKSPVLTV	18
414	AFGEGFVNV	18
531	ANAGPNHTI	18
607	QQSTAVVTV	18
635	LIFPVESAT	18

TableXXIII-V1-HLA-A0201-9mers-254P1D6B

Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.

Pos	123456789	score
722	RAGGRHVLV	18
784	GVYTFHLRV	18
798	ASDQDTATV	18
955	SIFYVTVLA	18
958	YVTVLAFTL	18
962	LAFTLIVLT	18
11	LLLLVTIAG	17
103	VLRPVQRPA	17
210	QQDPELHYL	17
217	YLNESASTP	17
267	EVLMPSHSL	17
272	SHSLPPASL	17
277	PASLELSSV	17
303	SIPTPPTSA	17
342	NLIITLPDN	17
353	ELKAFVAPA	17
359	APAPPVETT	17
397	QLSVGLYVF	17
427	ARRVNLPV	17
444	ELTLPLTSA	17
493	NLDPGNYSF	17
565	SLGPGSEGK	17
579	GVQTPYLHL	17
589	AMQEGDYTF	17
693	LTVKDQQGL	17
701	LSSTSTLTV	17
723	AGGRHVLVL	17
736	ITLDGSRST	17
818	VELTLQVGV	17
829	LTEQRKDTL	17
835	DTLVRQLAV	17
839	RQLAVLLNV	17
901	LLFKVLRVD	17
1054	SMNGSIRNG	17
13	LLVTIAGCA	16
34	AVISPNLET	16
120	MLNRGSPSG	16
197	SSVGDSPAV	16

TableXXIII-V1-HLA-A0201-9mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		
Pos	123456789	score
292	VLTVTPGST	16
331	TVKELTVSA	16
335	LTVSAGDNL	16
366	TTYNYEWNL	16
385	IKQGHKQTL	16
422	VTVKPARRV	16
481	KTSVDSPL	16
486	SPVLRLSNL	16
497	GNYSFRLTV	16
518	ALIVNNAVD	16
533	AGPNHTITL	16
560	VLYEWSLGP	16
593	GDYTFQLKV	16
605	SRQQSTIAVV	16
636	IFPVESATL	16
655	IVFYHWEHV	16
678	IATVTGLQV	16
683	GLQVGTYHF	16
699	QGLSSTSTL	16
720	RARAGGRHV	16
812	PRKSGLVEL	16
877	FKVLKAAEV	16
885	VARNLHMRL	16
888	NLHMRLSKE	16
905	VLRVDIAGC	16
954	WSIFYVTVL	16
965	TLIVLTGGF	16
32	SNAVISPNL	15
40	LETTRIMRV	15
47	RVSHTFPVV	15
50	HTFPVVDCT	15
71	WWFEGRCYL	15
78	YLVSCPHKE	15
128	GIWGDSPED	15
179	SAEYTDWGL	15
187	LLPGSEGAF	15
191	SEGAFNSSV	15
235	LLPLPTTPS	15

TableXXIII-V1-HLA-A0201-9mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		
Pos	123456789	score
284	SVTVEKSPV	15
336	TVSAGDNL	15
338	SAGDNLIT	15
350	NEVELKAFV	15
396	SQLSVGLYV	15
439	SPQLQELTL	15
465	IVSYHWEEI	15
516	TAALIVNNA	15
525	VDYPPVANA	15
547	TLNGNQSSD	15
628	VAGPDKELI	15
685	QVGTYHFRL	15
700	GLSSTSTLT	15
754	WIRDGQSPA	15
833	RKDTLVRQL	15
862	DLSTVIVFY	15
863	LSTVIVFYV	15
866	VIVFYVQSR	15
940	LIQRYIWDG	15
988	KIRKKTKYT	15
1025	SLMVSESEF	15
3	PPTGVLSSL	14
16	TIAGCARKQ	14
96	IRSYLTFVL	14
166	DLLQPSGKQ	14
207	AETQQDPQL	14
226	APKLPERSV	14
239	PTTPSSGEV	14
240	TTPSSGEVL	14
247	VLEKEKASQ	14
248	LEKEKASQL	14
260	SSNSSGKEV	14
261	SNSSGKEVL	14
268	VLMPSHSLP	14
326	TTAPRTVKE	14
337	VSAGDNLII	14
356	AFVAPAPPV	14
358	VAPAPPVET	14

TableXXIII-V1-HLA-A0201-9mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		
Pos	123456789	score
390	KQTLNLSQL	14
416	GEGFVNVTV	14
431	NLPPVAVVS	14
434	PVAVVSPQL	14
453	LIDGSQSTD	14
539	ITLPQNSIT	14
575	VVMQGVQTP	14
591	QEGDYTFQL	14
643	TLDGSSSSD	14
669	VEMENIDKA	14
677	AIATVTGLQ	14
706	TLTVAVKKE	14
729	LVLPNNSIT	14
737	TLDGSRSTD	14
782	VEGVYTFHL	14
814	KSGLVELTL	14
828	QLTEQRKDT	14
847	VLDSDIKVQ	14
849	DSDIKVQKI	14
860	HSDLSTVIV	14
871	VQSRPPFKV	14
890	HMRLSKEKA	14
893	LSKEADFL	14
907	RVDTAGCLL	14
909	DTAGCLLKC	14
918	SGHGHCDPL	14
944	YIWDGESNC	14
966	LIVLTGGFT	14
37	SPNLETTRI	13
121	LNRGSPSGI	13
142	PFLGKDWGL	13
145	GKDWGLEEM	13
167	LLQPSGKQE	13
180	AEYTDWGLL	13
182	YTDWGLLPG	13
214	ELHYLNESA	13
281	ELSSVTVEK	13
319	SELPISPTT	13

TableXXIII-V1-HLA-A0201-9mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		
Pos	123456789	score
320	ELPISPTTA	13
324	SPTTAPRTV	13
343	LIITLPDNE	13
374	LISHPTDYQ	13
387	QGHKQTLNL	13
403	YVFKVTYSS	13
419	FVNVTVKPA	13
424	VKPARRVNL	13
476	PFIEEKTSV	13
477	FIEEKTSDV	13
490	RLSNLDPGN	13
515	TTAALIVNN	13
522	NNAVDPYPV	13
530	VANAGPNHT	13
553	SSDDHQIVL	13
577	MQGVQTPYL	13
604	SSRQQSTAV	13
621	NNRPPVAVA	13
631	PDKELIFPV	13
642	ATLDGSSSS	13
648	SSSDDHGIV	13
680	TVTGLQVGT	13
696	KDQQGLSST	13
745	DDQRIVSYL	13
748	RIVSYLWIR	13
752	YLWIRDGQS	13
758	GQSPAAGDV	13
768	DGSDHSVAL	13
770	SDHSVALQL	13
775	ALQLTNLVE	13
809	QPDPRKSGI	13
842	AVLLNVLDS	13
879	VLKAAEVAR	13
898	ADFLLFKVL	13
906	LRVDTAGCL	13
914	LLKCSGHGH	13
933	SHLWMENLI	13
951	NCEWSIFYV	13

TableXXIII-V1-HLA-A0201-9mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		
Pos	123456789	score
959	VTVLAFTLI	13
996	TILDNMDEQ	13
1007	MELRPKYGI	13
1018	RSTEHNSSL	13

TableXXIII-V2-HLA-A0201-9mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 5; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		
Pos	123456789	score
1	GLEEMSEYA	16
7	EYADDYREL	12
4	EMSEYADDY	8
8	YADDYRELE	8

TableXXIII-V3-HLA-A0201-9mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 7; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		
Pos	123456789	score
3	RLGWSPCC	12
1	MTRLGWSP	9
4	LGWSPCCA	9
10	CCARKQCSE	5

Table XXIII 254P1D6B v5-HLA-0201-p-mers		
---	--	--

Each peptide is a portion of SEQ ID NO: 11; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		
Pos	1 2 3 4 5 6 7 8 9	score
3	DIRKDLTFL	21
9	TFLGKDWGL	16
6	KDLTFLGKD	10

TableXXIV-V1-HLA-A0203-9mers-254P1D6B		
NoResultsFound.		

TableXXIV-V2-HLA-A0203-9mers-254P1D6B		
NoResultsFound.		

TableXXIV-V3-HLA-A0203-9mers-254P1D6B		
NoResultsFound.		

TableXXIV-V5-HLA-A0203-9mers-254P1D6B		
NoResultsFound.		

TableXXV-V1-HLA-A0203-9mers-254P1D6B		
NoResultsFound.		

TableXXV-V2-HLA-A0203-9mers-254P1D6B		
--------------------------------------	--	--

NoResultsFound.

TableXXV-V3-HLA-A3-9mers-254P1D6B

Each peptide is a portion of SEQ ID NO: 7; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.

Pos	123456789	score
6	WPSPCCARK	16
3	RLGWSPCC	14
1	MTRLGWSP	8
2	TRLGWSPC	8
10	CCARKQCSE	7

TableXXV-V5-HLA-A3-9mers-254P1D6B

Each peptide is a portion of SEQ ID NO: 11; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.

Pos	1 2 3 4 5 6 7 8 9	score
2	EDIRKDLTF	18
5	RKDLTFLGK	18
7	DLTFLGKDW	13
3	DIRKDLTFL	12

TableXXVI-V1-HLA-A26-9mers-254P1D6B

Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.

Pos	123456789	score
267	EVLMPSHSL	29
884	EVARNLHMR	26
483	SVDSPVLRL	25
6	GVLSSLLLL	24
135	EDIRKDLPF	24
136	DIRKDLPFL	24
246	EVLEKEKAS	24
681	VTGLQVGTY	24

TableXXVI-V1-HLA-A26-9mers-254P1D6B

Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.

Pos	123456789	score
1005	ERMELRPKY	24
285	VTVEKSPVL	23
437	VVSPQLQEL	23
745	DDQRIVSYL	23
765	DVIDGSDHS	23
773	SVALQLTNL	23
152	EMSEYSDDY	22
335	LTVSAGDNL	22
407	VTVSSENAF	22
807	EVQPDPRKS	22
862	DLSTVIVFY	22
909	DTAGCLLKC	22
41	ETTRIMRVS	21
349	DNEVELKAF	21
351	EVELKAFVA	21
958	YVTVLAFTL	21
1038	DTIFSREKM	21
365	ETTYNYEWN	20
445	LTLPLTSAL	20
693	LTVKDQQGL	20
155	EYSDDYREL	19
159	DYRELEKDL	19
240	TTPSSGEVL	19
417	EGFVNVTVK	19
434	PVAVVSPQL	19
464	EIVSYHWEE	19
519	LIVNNAVDY	19
579	GVQTPYLHL	19
611	AVVTIVVQP	19
634	ELIFPVESA	19
778	LTNLVEGVY	19
780	NLVEGVYTF	19
837	LVRQLAVLL	19
907	RVDTAGCLL	19
949	ESNCEWSIF	19
4	PTGVLSSLL	18
106	PVQRPAQLL	18
208	ETQQDPELH	18

TableXXVI-V1-HLA-A26-9mers-254P1D6B

Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.

Pos	123456789	score
461	DDTEIVSYH	18
486	SPVLRLSNL	18
511	ATNSTTAAL	18
627	AVAGPDKEL	18
672	ENIDKAIAT	18
685	QVGTYHFRL	18
768	DGSDHSVAL	18
835	DTLVRQLAV	18
50	HTFPVVDCT	17
56	DCTAACCDL	17
366	TTYNYEWNL	17
436	AVVSPQLQE	17
558	QIVLYEWSL	17
612	VVTIVVQPE	17
802	DTATVEVQP	17
829	LTEQRKDTL	17
836	TLVRQLAVL	17
987	TKIRKTKKY	17
34	AVISPNLET	16
53	PVVDCTAAC	16
162	ELEKDLLQP	16
233	SVLLPLPTT	16
330	RTVKELTVS	16
362	PPVETTYNY	16
390	KQTLNLSQL	16
399	SVGLYVFKV	16
444	ELTLPLTSA	16
460	TDDTEIVSY	16
462	DTEIVSYHW	16
481	KTSVDSPVL	16
495	DPGNYSFRL	16
574	HVVMQGVQT	16
661	EHVRGPSAV	16
676	KAIATVTGL	16
679	ATVTGLQVG	16
744	TDDQRIVSY	16
800	DTDTATVEV	16
819	ELTLQVGVG	16

TableXXVI-V1-HLA-A26-9mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		
Pos	123456789	score
842	AVLLNVLD	16
865	TVIVFYVQS	16
896	EKADFLLFK	16
954	WSIFYVTVL	16
3	PPTGVLSSL	15
74	EGRCYLWSC	15
91	KKMGPIRSY	15
108	QRPAQLLDY	15
132	DSPEDIRKD	15
231	ERSVLLPLP	15
251	EKASQLQEQ	15
288	EKSPVLTVT	15
293	LTVTPGSTE	15
331	TVKELTVSA	15
339	AGDNLITL	15
373	NLISHPTDY	15
384	EIKQGHKQT	15
395	LSQLSVGLY	15
403	YVFKVTVSS	15
472	EINGPFIEE	15
479	EKTSVDS	15
504	TVTDSGAT	15
514	STTAALIVN	15
554	SDDHQIVLY	15
555	DDHQIVLYE	15
571	EGKHVVMQG	15
575	VVMQGVQTP	15
614	TVIVQPENN	15
650	SDDHGIVFY	15
821	TLQVGVGQL	15
861	SDLSTVIVF	15
867	IVFYVQSRP	15
936	WMENLIQRY	15
965	TLIVLTGGF	15
1021	EHNSSLMVS	15
1057	GSIRNGASF	15
5	TGVLSSLLL	14
71	WWFEGRCYL	14

TableXXVI-V1-HLA-A26-9mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		
Pos	123456789	score
94	GPIRSYLT	14
102	FVLRPVQRP	14
181	EYTDWGLLP	14
230	PERSVLLPL	14
299	STHSIPTP	14
316	STPSELPIS	14
353	ELKAFVAPA	14
419	FVNVTVKPA	14
471	EEINGPFIE	14
515	TTAALIVNN	14
520	IVNNAVDYP	14
595	YTFQLKVT	14
651	DDHGIVFYH	14
655	IVFYHWEHV	14
783	EGVYTFHLR	14
786	YTFHLRVTD	14
791	RVTDSQGAS	14
804	ATVEVQDP	14
817	LVELTLQVG	14
833	RKDTLVRQL	14
849	DSDIKVQKI	14
906	LRVDTAGCL	14
950	SNCEWSIFY	14
956	IFYVTVLAF	14

TableXXVI-V2A26-9mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 5; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		
Pos	123456789	score
4	EMSEYADDY	22
7	EYADDYREL	19
3	EEMSEYADD	11

TableXXVI-V3-A26-9mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 7; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		
Pos	123456789	score
1	MTRLGWSP	9

TableXXVI-V5-A26-9mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 11; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		
Pos	1 2 3 4 5 6 7 8 9	score
2	EDIRKDLTF	25
3	DIRKDLTFL	24
8	LTFLGKDWG	12

TableXXVII-V1-HLA-B0702-9mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		
Pos	123456789	score
359	APAPPVETT	24
304	IPTPPTSAA	23
3	PPTGVLSSL	22
105	RPVQRPAQL	22
439	SPQLQELTL	22
809	QPDPRKSG	22
133	SPEDIRKDL	21
175	EPRGSAEYT	21
226	APKLPERSV	21
495	DPGNYSFRL	21
270	MPSHSLPPA	20
328	APRTVKELT	20
486	SPVLRLSNL	20
874	RPPFKVLKA	20
618	QPENNRPPV	19

TableXXVII-V1-HLA-B0702-9mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		
Pos	123456789	score
37	SPNLETTRI	18
52	FPVVDCTAA	18
94	GPIRSYLTF	18
567	GPGSEGKHV	18
627	AVAGPDKEL	18
872	QSRPPFKVL	18
875	PPFKVLKAA	18
296	TPGSTHSI	17
483	SVDSPVLR	17
582	TPYLHLSAM	17
721	ARAGGRHVL	17
723	AGGRHVLVL	17
811	DPRKSGLVE	17
221	SASTPAPKL	16
272	SHSLPPASL	16
312	APSESTPSE	16
321	LPISPTTAP	16
324	SPTTAPRTV	16
377	HPTDYQGEI	16
2	APPTGVLSS	15
96	IRSYLTFVL	15
136	DIRKDLPL	15
169	QPSGKQEPR	15
230	PERSVLLPL	15
301	EHSIPTPT	15
481	KTSVDSPVL	15
511	ATNSTTAAL	15
579	GVQTPYLHL	15
621	NNRPPVAVA	15
768	DGSDHSVAL	15
89	EPKMGPIR	14
92	KMGPIRSYL	14
125	SPSGIWGDS	14
188	LPGSEGAFN	14
202	SPAVPAETQ	14
241	TPSSGEVLE	14
267	EVLMPSHSL	14
356	AFVAPAPPV	14

TableXXVII-V1-HLA-B0702-9mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		
Pos	123456789	score
361	APPVETTYN	14
387	QGHKQTLNL	14
394	NLSQLSVGL	14
424	VKPARRVNL	14
441	QLQELTLPL	14
531	ANAGPNHTI	14
676	KAIATVTGL	14
715	NNSPPRARA	14
760	SPAAGDVID	14
814	KSGLVELTL	14
837	LVRQLAVLL	14
898	ADFLLFKVL	14
968	VTGGFTWL	14
34	AVISPNLET	13
106	PVQRPAQLL	13
155	EYSDDYREL	13
199	VGDSPAVPA	13
207	AETQQDPEL	13
224	TPAPKLPER	13
227	PKLPERSVL	13
228	KLPERSVLL	13
229	LPERSVLLP	13
236	LPLPTTPSS	13
238	LPTTPSSGE	13
261	SNSSGKEVL	13
274	SLPPASLEL	13
276	PPASLELSS	13
290	SPVLTVTPG	13
339	AGDNLITL	13
385	IKQGHKQTL	13
425	KPARRVNLP	13
429	RVNLPPVAV	13
430	VNLPPVAVV	13
432	LPPVAVVSP	13
433	PPVAVVSPQ	13
437	VVSPQLQEL	13
445	LTLPLTSAL	13
533	AGPNHTITL	13

TableXXVII-V1-HLA-B0702-9mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		
Pos	123456789	score
577	MQGVQTPYL	13
620	ENNRPPVAV	13
623	RPPVAVAGP	13
630	GPDKELIFP	13
665	GPSAVEMEN	13
718	PPRARAGGR	13
833	RKDTLVRQL	13
907	RVDTAGCLL	13
918	SGHGHCDPL	13
954	WSIFYVTVL	13
1047	ERGNPKVSM	13
5	TGVLSSLLL	12
6	GVLSSLLL	12
32	SNAVISPNI	12
47	RVSHTFPVV	12
109	RPAQLLDYG	12
142	PFLGKDWGL	12
159	DYRELEKDL	12
180	AEYTDWGLL	12
210	QQDPELHYL	12
212	DPELHYLNE	12
240	TTPSSGEVL	12
262	NSSGKEVLM	12
285	VTVEKSPVL	12
287	VEKSPVLTV	12
288	EKSPVLTVT	12
306	TPPTSAAPS	12
317	TPSELPISP	12
346	TLPDNEVEL	12
347	LPDNEVELK	12
358	VAPAPPVET	12
414	AFGEGFVNV	12
427	ARRVNLPPV	12
434	PVAVVSPQL	12
447	LPLTSALID	12
525	VDYPPVANA	12
528	PPVANAGPN	12
553	SSDDHQIVL	12

TableXXVII-V1-HLA-B0702-9mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		
Pos	123456789	score
591	QEGDYTFQL	12
624	PPVAVAGPD	12
636	IFPVESATL	12
703	STSTLTVAV	12
717	SPPRARAGG	12
722	RAGGRHVLV	12
755	IRDGQSPAA	12
770	SDHSVALQL	12
773	SVALQLTNL	12
782	VEGVYTFHL	12
812	PRKSGLVEL	12
813	RKSGLVELT	12
836	TLVRQLAVL	12
840	QLAVLLNVL	12
859	AHSDLSTVI	12
881	KAAEVARNL	12
885	VARNLHMRL	12
927	TKRCICSHL	12
961	VLAFTLIVL	12
990	RKKT KYTIL	12
4	PTGVLSSLL	11
8	LSSLLLLVT	11
56	DCTAACCDL	11
61	CCDLSSCDL	11
71	WWFEGRCYL	11
82	CPHKENCEP	11
113	LLDYGDMMML	11
205	VPAETQQDP	11
275	LPPASLELS	11
307	PPTSAAPSE	11
309	TSAAPSEST	11
315	ESTPSELPI	11
327	TAPRTVKEL	11
335	LTVSAGDNL	11
337	VSAGDNLII	11
353	ELKAFVAPA	11
362	PPVETTYNY	11
390	KQTLNLSQL	11

TableXXVII-V1-HLA-B0702-9mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		
Pos	123456789	score
444	ELTLPLTSA	11
527	YPPVANAGP	11
534	GNPHITLPL	11
541	LPQNSITLN	11
569	GSEGKHVVM	11
607	QQSTAVVTV	11
634	ELIFPVESA	11
637	FPVESATLD	11
685	QVGTYHFRL	11
693	LTVKDQQGL	11
699	QGLSSTSTL	11
701	LSSTSTLTV	11
720	RARAGGRHV	11
731	LPNNSITLD	11
745	DDQRIVSYL	11
798	ASD TDTATV	11
821	TLQVGVGQL	11
871	VQSRPPFKV	11
883	AEVARNLHM	11
892	RLSKEKADF	11
893	LSKEKADFL	11
894	SKEKADFL	11
895	KEKADFLF	11
924	DPLTKRCIC	11
953	EWSIFYVTV	11
956	IFYVTVLAF	11
988	KIRKKT KYT	11
1001	MDEQERMEL	11
1010	RPKYGIKHR	11
1018	RSTEHNSSL	11

TableXXVII-V2-HLA-B0702-9mers-254P1D6B

Each peptide is a portion of SEQ ID NO: 5; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		
Pos	123456789	score
7	EYADDYREL	12
1	GLEEMSEYA	6
9	ADDYRELEK	5

TableXXVII-V3-HLA-B0702-9mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 7; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		
Pos	123456789	score
6	WPSPCCARK	14
8	SPCCARKQC	11
4	LGWSPCCA	7
3	RLGWSPCC	6

TableXXVII-V5-HLA-B0702-9mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 11; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		
Pos	1 2 3 4 5 6 7 8 9	score
3	DIRKDLTFL	15
9	TFLGKDWGL	12
2	EDIRKDLTF	9
1	PEDIRKDLT	7

TableXXVIII-V1-HLA-B08-9mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		

Pos	123456789	score
248	LEKEKASQL	32
893	LSKEKADFL	32
990	RKKT KYTIL	30
228	KLPERSVLL	27
486	SPVLRLSNL	27
105	RPVQRPAQL	24
809	QDPKRKSGL	24
1008	ELRPKYGIK	24
1014	GIKHRSTEH	24
285	VTVEKSPVL	23
812	PRKSGLVEL	22
981	CKRQKRTKI	22
885	VARNLHMRL	21
988	KIRKKT KYT	21
136	DIRKDL PFL	20
142	PFLGKDWGL	20
424	VKPARRVNL	20
718	PPRARAGGR	20
133	SPEDIRKDL	19
159	DYRELEKDL	19
274	SLPPASLEL	19
353	ELKAFVAPA	19
439	SPQLQELTL	19
854	VQKIRAHSD	19
879	VLKAAEVAR	19
986	RTKIRK KTK	19
1010	RPKYGIKHR	19
1041	FSREKMERG	19
89	EPKKMGPIR	18
135	EDIRKDL PF	18
346	TLPDNEVEL	18
441	QLQELTLPL	18
821	TLQVGVGQL	18
829	LTEQRKDTL	18
900	FLLFKVL RV	18
113	LLDYGDMML	17
179	SAEYTDWGL	17
224	TPAPKLPER	17
226	APKLPERSV	17
327	TAPRTVKEL	17
384	EIKQGHKQT	17
394	NLSQLSVGL	17
477	FIEEKTSDV	17
598	QLKVT DSSR	17
692	RLTVKDQQG	17

TableXXVIII-V1-HLA-B08-9mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		
Pos	123456789	score
730	VLPNNSITL	17
837	LVRQLAVLL	17
840	QLAVLLNVL	17
849	DSDIKVQKI	17
872	QSRPPFKVL	17
874	RPPFKVLKA	17
961	VLAFTLIVL	17
968	VL TGGFTWL	17
984	QKRTKIRKK	17
989	IRKKT KYTI	17
1050	NPKVSMNGS	17
3	PPTGVLSSL	16
88	CEPKKMGPI	16
169	QPSGKQEPR	16
221	SASTPAPKL	16
230	PERSVLLPL	16
246	EVLEKEKAS	16
495	DPGNYSFRL	16
540	TLPQNSITL	16
629	AGPDKELIF	16
836	TLVRQLAVL	16
881	KAAEVARNL	16
895	KEKADFLF	16
914	LLKCSGHGH	16
924	DPLTKRCIC	16
927	TKRCICSHL	16
1025	SLMVSESEF	16
37	SPNLETTRI	15
425	KPARRVNLP	15
488	VLRLSNLDP	15
558	QIVLYEWSL	15
676	KAIATVTGL	15
709	VAVKKENNS	15
728	VLVLPNNSI	15
780	NLVEGVYTF	15
851	DIKVQKIRA	15

TableXXVIII-V2-HLA-B08-9mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 5; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		
Pos	123456789	score
7	EYADDYREL	13
9	ADDYRELEK	10
1	GLEEMSEYA	9

TableXXVIII-V3-HLA-B08-9mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 7; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		
Pos	123456789	score
10	CCARKQCSE	10
8	SPCCARKQC	9
9	PCCARKQCS	8
1	MTRLGWPS P	7
3	RLGWSPCC	6
6	WPSPCCARK	6

TableXXVIII-V5-HLA-B08-9mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 11; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		
Pos	1 2 3 4 5 6 7 8 9	score
3	DIRKDLTFL	20
9	TFLGKDWGL	20
2	EDIRKDLTF	18
4	IRKDLTFLG	11

TableXXIX-V1-HLA-B1510-9mers-254P1D6B		
---------------------------------------	--	--

Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.

Pos	123456789	score
272	SHSLPPASL	23
155	EYSDDYREL	16
346	TLPDNEVEL	16
721	ARAGGRHVL	16
96	IRSYLTFVL	15
227	PKLPERSVL	15
261	SNSSGKEVL	15
385	IKQGHKQTL	15
481	KTSVDSPL	15
658	YHWEHVRGP	15
768	DGSDHSVAL	15
872	QSRPPFKVL	15
49	SHTFPVDC	14
285	VTVEKSPVL	14
301	EHSIPTPT	14
394	NLSQLSVGL	14
437	VVSPQLQEL	14
483	SVDSPVLR	14
540	TLPQNSITL	14
627	AVAGPDKEL	14
636	IFPVESATL	14
661	EHVRGPSAV	14
812	PRKSGLVEL	14
821	TLQVGVGQL	14
829	LTEQRKDTL	14
840	QLAVLLNVL	14
859	AHSDLSTVI	14
881	KAAEVARNL	14
1001	MDEQERMEL	14
32	SNAVISPNL	13
71	WWFEGRCYL	13
92	KMGPIRSYL	13
133	SPEDIRKDL	13
160	YRELEKDLL	13
207	AETQQDPEL	13
221	SASTPAPKL	13
228	KLPERSVLL	13
240	TTPSSGEVL	13
274	SLPPASLEL	13
313	PSESTPSEL	13

TableXXIX-V1-HLA-B1510-9mers-254P1D6B

Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.

Pos	123456789	score
327	TAPRTVKEL	13
424	VKPARRVNL	13
434	PVAVVSPQL	13
445	LTLPLTSAL	13
468	YHWEEINGP	13
553	SSDDHQIVL	13
569	GSEGGKVVVM	13
573	KHVVMQGVQ	13
689	YHFRLTVKD	13
723	AGGRHVLVL	13
809	QDPKRKSG	13
833	RKDTLVRQL	13
836	TLVRQLAVL	13
837	LVRQLAVLL	13
921	GHCPLTKR	13
954	WSIFYVTVL	13
958	YVTVLAFTL	13
961	VLAFTLIVL	13
1021	EHNSLMVS	13
83	PHKENCEPK	12
105	RPVQRPAQL	12
136	DIRKDLPL	12
210	QQDPELHYL	12
215	LHYLNESAS	12
267	EVLMPSHSL	12
339	AGDNLITL	12
388	GHKQTLNLS	12
495	DPGNYSFRL	12
577	MQGVQTPYL	12
579	GVQTPYLHL	12
585	LHLSAMQEG	12
685	QVGTYHFRL	12
730	VLPNNSITL	12
771	DHSVALQLT	12
885	VARNLHMRL	12
894	SKEKADFL	12
898	ADFLLFKVL	12
919	GHGHCPLT	12

TableXXIX-V1-HLA-B1510-9mers-254P1D6B

Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.

Pos	123456789	score
968	VTGGFTWL	12
3	PPTGVLSSL	11
4	PTGVLSSLL	11
5	TGVLSSLLL	11
6	GVLSSLLLL	11
106	PVQRPAQLL	11
113	LLDYGDMML	11
142	PFLGKDWGL	11
159	DYRELEKDL	11
179	SAEYTDWGL	11
248	LEKEKASQL	11
366	TTYNYEWNL	11
387	QGHKQTLNL	11
390	KQTLNLSQL	11
397	QLSVGLYVF	11
439	SPQLQELTL	11
441	QLQELTLPL	11
511	ATNSTTAAL	11
533	AGPNHTITL	11
536	NHTITLPQN	11
556	DHQIMLYEW	11
591	QEGDYTFQL	11
663	VRGPSAVEM	11
676	KAIATVTGL	11
693	LTVKDQQGL	11
699	QGLSSTSTL	11
726	RHVLVLPNN	11
745	DDQRIVSYL	11
773	SVALQLTNL	11
782	VEGVYTFHL	11
814	KSGLVELTL	11
889	LHMRLSKEK	11
893	LSKEKADFL	11
906	LRVDTAGCL	11
918	SGHGHCDPL	11
927	TKRCICSHL	11
932	CSHLWMENL	11
956	IFYVTVLAF	11

TableXXIX-V1-HLA-B1510-9mers-254P1D6B

Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.

Pos	123456789	score
1018	RSTEHNSSL	11
1047	ERGNPKVSM	11

TableXXIX-V2-HLA-B1510-9mers-254P1D6B

Each peptide is a portion of SEQ ID NO: 5; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.

Pos	123456789	score
7	EYADDYREL	16

TableXXIX-V3-HLA-B1510-9mers-254P1D6B

Each peptide is a portion of SEQ ID NO: 7; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.

Pos	123456789	score
6	WPSPCCARK	5
2	TRLGWSPSPC	3
4	LGWSPCCA	3
5	GWSPCCAR	3
1	MTRLGWSPSP	2
3	RLGWSPSPCC	2
7	PSPCCARKQ	2

TableXXIX-V5-HLA-B1510-9mers-254P1D6B

Each peptide is a portion of SEQ ID NO: 11; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.

Pos	1 2 3 4 5 6 7 8 9	score
9	TFLGKDWGL	12
3	DIRKDLTFL	11
2	EDIRKDLTF	8

TableXXX-V1-HLA-B2705-9mers-254P1D6B

NoResultsFound.

TableXXX-V2-B2705-9mers-254P1D6B

Each peptide is a portion of SEQ ID NO: 5; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.

Pos	123456789	score
9	ADDYRELEK	13
5	MSEYADDYR	11
7	EYADDYREL	11
4	EMSEYADDY	10
6	SEYADDYRE	6

TableXXX-V3-B2705-9mers-254P1D6B

Each peptide is a portion of SEQ ID NO: 7; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.

Pos	123456789	score
2	TRLGWSPSPC	15
5	GWSPCCAR	14
6	WPSPCCARK	14
3	RLGWSPSPCC	7

TableXXX-V5-B2705-9mers-254P1D6B

Each peptide is a portion of SEQ ID NO: 11; each start position is specified, the length of peptide is 9 amino acids, and the end position

for each peptide is the start position plus eight.

Pos	1 2 3 4 5 6 7 8 9	score
9	TFLGKDWGL	17
2	EDIRKDLTF	16
5	RKDLTFLGK	16
3	DIRKDLTFL	15
4	IRKDLTFLG	12

TableXXXI-V1-HLA-B2709-9mers-254P1D6B

NoResultsFound.

TableXXXI-V2-HLA-B2709-9mers-254P1D6B

NoResultsFound.

TableXXXI-V3-HLA-B2709-9mers-254P1D6B

NoResultsFound.

TableXXXI-V5-HLA-B2709-9mers-254P1D6B

NoResultsFound.

TableXXXII-V1-HLA-B2709-9mers-254P1D6B

Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.

Pos	123456789	score
28	GRTYSNAVI	22
812	PRKSGLEVEL	22
906	LRVDTAGCL	22
96	IRSYLTFVL	21

TableXXXII-V1-HLA-B2709-9mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		
Pos	123456789	score
663	VRGPSAVEM	21
721	ARAGGRHVL	21
46	MRVSHTFPV	20
160	YRELEKDLL	20
329	PRTVKELTV	20
427	ARRVNLPPV	20
741	SRSTDDQRI	20
747	QRIVSYLWI	20
989	IRKTKYTI	20
1047	ERGNPKVSM	19
605	SRQQSTAVV	18
6	GVLSLLLL	17
105	RPVQRPAQL	16
428	RRVNLPPVA	16
833	RKDTLVRQL	16
839	RQLAVLLNV	16
497	GNYSFRLTV	15
725	GRHVLVLPN	15
784	GVYTFHLRV	15
1018	RSTEHNSSL	15
75	GRCYLVSCL	14
92	KMGPIRSYL	14
180	AEYTDWGLL	14
390	KQTLNLSQL	14
401	GLYVFQVTV	14
481	KTSVDSPLV	14
483	SVDSPVLR	14
579	GVQTPYLHL	14
593	GDYTFQLKV	14
676	KAIATVTGL	14
687	GTYHFRLTV	14
742	RSTDDQRI	14
770	SDHSVALQL	14
816	GLVELTLQV	14
858	RAHSDLSTV	14
881	KAAEVARNL	14
907	RVDTAGCLL	14
929	RCICSHLWM	14

TableXXXII-V1-HLA-B2709-9mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		
Pos	123456789	score
985	KRTKIRKKT	14
990	RKKTKYTI	14
32	SNAVISPNL	13
47	RVSHTFPVV	13
94	GPIRSYLT	13
207	AETQQDPEL	13
227	PKLPERSVL	13
228	KLPERSVLL	13
335	LTVSAGDNL	13
366	TTYNYEWNL	13
429	RVNLPPVAV	13
445	LTLPLTSAL	13
489	LRLSNLDPG	13
622	NRPPVAVAG	13
691	FRLTVKDQ	13
699	QGLSSTSTL	13
722	RAGGRHVLV	13
723	AGGRHVLVL	13
758	GQSPAAGDV	13
814	KSGLVELTL	13
891	MRLSKEKAD	13
898	ADFLFKVL	13
900	FLLFKVLRV	13
956	IFYVTVLAF	13
5	TGVLSSLLL	12
43	TRIMRVSH	12
44	RIMRVSH	12
71	WWFEGRCYL	12
111	AQLLDYGDM	12
136	DIRKDLPL	12
142	PFLGKDWGL	12
176	PRGSAEYTD	12
221	SASTPAPKL	12
230	PERSVLLPL	12
248	LEKEKASQL	12
267	EVLMPHSL	12
274	SLPPASLEL	12
285	VTVEKSPVL	12

TableXXXII-V1-HLA-B2709-9mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		
Pos	123456789	score
356	AFVAPAPPV	12
387	QGHKQTLNL	12
396	SQLSVGLYV	12
416	GEGFVNVT	12
424	VKPARRVNL	12
430	VNLPPVAVV	12
434	PVAVVSPQL	12
486	SPVLRLSNL	12
501	FRLTVTDS	12
511	ATNSTTAAL	12
567	GPGSEGKHV	12
569	GSEGKHVVM	12
678	IATVTGLQV	12
683	GLQVGTYHF	12
693	LTVKDQQGL	12
720	RARAGGRHV	12
745	DDQRIVSYL	12
755	IRDGQSPAA	12
790	LRVTDSQGA	12
821	TLQVGVGQL	12
832	QRKDTLVRQ	12
837	LVRQLAVLL	12
838	VRQLAVLLN	12
857	IRAHSCLST	12
861	SDLSTVIVF	12
873	SRPPFKVLK	12
892	RLSKEKADF	12
895	KEKADFLF	12
928	KRCICSHLW	12
942	QRYIWDGES	12
954	WSIFYVTVL	12
958	YVTVLAFTL	12
982	KRQKRTKIR	12
993	TKYTILDNM	12
1057	GSIRNGASF	12
3	PPTGVLSLL	11
9	SSLLLLVTI	11
21	ARKQCSEGR	11

TableXXXII-V1-HLA-B2709-9mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		
Pos	123456789	score
56	DCTAACCDL	11
104	LRPVQRPAQ	11
106	PVQRPAQLL	11
108	QRPAQLLDY	11
122	NRGSPSGIW	11
133	SPEDIRKDL	11
137	IRKDLPFLG	11
145	GKDWGLEEM	11
155	EYSDDYREL	11
197	SSVGDSPAV	11
210	QQDPQLHYL	11
231	ERSVLLPLP	11
240	TTPSSGEVL	11
261	SNSSGKEVL	11
287	VEKSPVLTV	11
313	PSESTPSEL	11
315	ESTPSELPI	11
327	TAPRTVKEL	11
339	AGDNLITL	11
346	TLPDNEVEL	11
385	IKQGHKQTL	11
394	NLSQLSVGL	11
414	AFGEGFVNV	11
422	VTVKPARRV	11
437	VVSPQLQEL	11
439	SPQLQELTL	11
441	QLQELTLPL	11
495	DPGNYSFRL	11
513	NSTTAALIV	11
517	AALIVNNAV	11
533	AGPNHTITL	11
551	NQSSDDHQI	11
558	QIVLYEWSL	11
572	GKHVVMQGV	11
577	MQGVQTPYL	11
591	QEGDYTFQL	11
627	AVAGDPKEL	11
636	IFPVESATL	11

TableXXXII-V1-HLA-B2709-9mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		
Pos	123456789	score
655	IVFYHWEHV	11
685	QVGTYHFRL	11
719	PRARAGGRH	11
768	DGSDHSVAL	11
773	SVALQLTNL	11
780	NLVEGVYTF	11
809	QDPDRKSGL	11
818	VELTLQVGV	11
835	DTLVRQLAV	11
836	TLVRQLAVL	11
855	QKIRAHSDL	11
863	LSTVIVFYV	11
872	QSRPPFKVL	11
883	AEVARNLHM	11
885	VARNLHMRL	11
886	ARNLHMRLS	11
893	LSKEKADFL	11
927	TKRCICSHL	11
932	CSHLWMENL	11
948	GESNCEWSI	11
960	TVLAFTLIV	11
968	VLTTGGFTWL	11
1005	ERMELRPKY	11
1007	MELRPKYGI	11
1045	KMERGNPKV	11
1059	IRNGASFSY	11
4	PTGVLSSLL	10
7	VLSSLLLLV	10
38	PNLETRIM	10
40	LETTRIMRV	10
61	CCDLSSCDL	10
85	KENCEPKKM	10
112	QLLDYGDMM	10
113	LLDYGDMMML	10
135	EDIRKDLPF	10
159	DYRELEKDL	10
179	SAEYTDWGL	10
239	PTTPSSGEV	10

TableXXXII-V1-HLA-B2709-9mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		
Pos	123456789	score
272	SHSLPPASL	10
337	VSAGDNLII	10
344	IITLPDNEV	10
407	VTVSSENAF	10
458	QSTDDTEIV	10
480	EKTSVDSPV	10
493	NLDPGNYSF	10
522	NNAVDYPPV	10
540	TLPQNSITL	10
553	SSDDHQIVL	10
582	TPYLHLSAM	10
589	AMQEGDYTF	10
607	QQSTAVVTV	10
608	QSTAVVTVI	10
628	VAGDPKELI	10
629	AGDPKELIF	10
647	SSSSDDHGI	10
730	VLNNNSITL	10
774	VALQLTNLV	10
777	QLTNLVEGV	10
782	VEGVYTFHL	10
798	ASDTDATV	10
829	LTEQRKDTL	10
840	QLAVLLNVL	10
846	NVLDSDIKV	10
869	FYVQSRPPF	10
877	FKVLKAAEV	10
894	SKEKADFL	10
897	KADFLLFKV	10
918	SGHGHCDPL	10
933	SHLWMENLI	10
961	VLAFTLIVL	10
1001	MDEQERMEL	10
1009	LRPKYGIKH	10
1017	HRSTEHNSS	10
1032	EFDSDQDTI	10
1042	SREKMERGN	10
1051	PKVSMNGSI	10

TableXXXI-V2-HLA-B2709-9mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 5; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		
Pos	123456789	score
7	EYADDYREL	11
6	SEYADDYRE	5

TableXXXI-V3-HLA-B2709-9mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 7; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		
Pos	123456789	score
2	TRLGWSPSPC	12
3	RLGWSPSPCC	5

TableXXXI-V5-HLA-B2709-9mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 11; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		
Pos	1 2 3 4 5 6 7 8 9	score
9	TFLGKDWGL	12
3	DIRKDLTFL	11
4	IRKDLTFLG	11
2	EDIRKDLTF	10
5	RKDLTFLGK	5

TableXXXII-V1-HLA-B4402-9mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		

Pos	123456789	score
180	AEYTDWGLL	25
895	KEKADFLLF	24
207	AETQQDPEL	23
591	QEGDYTFQL	23
174	QEPGRSAEY	22
230	PERSVLLPL	22
248	LEKEKASQL	22
364	VETTYNYEW	21
411	SENAFGEGF	21
782	VEGVYTFHL	21
937	MENLIQRYI	21
339	AGDNLITL	20
898	ADFLLFKVL	20
948	GESNCEWSI	20
1007	MELRPKYGI	20
88	CEPKKMGPI	19
470	WEEINGPFI	19
533	AGPNHTITL	18
91	KKMGPIRSY	17
135	EDIRKDLPF	17
319	SELPISPTT	17
445	LTLPLTSAL	17
471	EEINGPFIE	17
554	SDDHQIVLY	17
721	ARAGGRHVL	17
723	AGGRHVLVL	17
872	QSRPPFKVL	17
92	KMGPIRSYL	16
94	GPIRSYLTF	16
133	SPEDIRKDL	16
210	QQDPELHYL	16
227	PKLPERSVL	16
274	SLPPASLEL	16
460	TDDTEIVSY	16
511	ATNSTTAAL	16
627	AVAGPDKEL	16
629	AGPDKELIF	16
650	SDDHGIVFY	16
669	VEMENIDKA	16
670	EMENIDKAI	16
744	TDDQRIVSY	16
862	DLSTVIVFY	16
1046	MERGNPKVS	16
40	LETTRIMRV	15
85	KENCEPKKM	15

TableXXXII-V1-HLA-B4402-9mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		
Pos	123456789	score
155	EYSDDYREL	15
219	NESASTPAP	15
221	SASTPAPKL	15
228	KLPERSVLL	15
327	TAPRTVKEL	15
349	DNEVELKAF	15
352	VELKAFVAP	15
360	PAPPVETTY	15
373	NLISHPTDY	15
383	GEIKQGHKQ	15
390	KQTLNLSQL	15
437	VVSPQLQEL	15
443	QELTLPLTS	15
493	NLDPGNYSF	15
553	SSDDHQIVL	15
649	SSDDHGIVF	15
676	KAIATVTGL	15
730	VLPNNSITL	15
768	DGSDHSVAL	15
809	QPDPRKSGL	15
833	RKDTLVRQL	15
861	SDLSTVIVF	15
883	AEVARNLHM	15
954	WSIFYVTVL	15
987	TKIRKTKKY	15
1005	ERMELRPKY	15
1057	GSIRNGASF	15
6	GVLSLLLLL	14
9	SSLLLLVTI	14
44	RIMRVSHTF	14
63	DLSSCDLAW	14
70	AWWFEGRCY	14
187	LLPGSEGAF	14
267	EVLMPSHSL	14
272	SHSLPPASL	14
314	SESTPSELP	14
315	ESTPSELP	14
346	TLPDNEVEL	14

TableXXXII-V1-HLA-B4402-9mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		
Pos	123456789	score
370	YEWNLISHP	14
424	VKPARRVNL	14
439	SPQLQELTL	14
463	TEIVSYHWE	14
479	EECTSVDSP	14
483	SVDSPVLR	14
486	SPVLRSLNL	14
519	LIVNNAVDY	14
531	ANAGPNHTI	14
540	TLPQNSITL	14
589	AMQEGDYTF	14
619	PENNRPPVA	14
633	KELIFPVES	14
770	SDHSVALQL	14
814	KSGLVELTL	14
855	QKIRAHSDL	14
859	AHSDLSTVI	14
936	WMENLIQRY	14
938	ENLIQRYIW	14
956	IFYVTVLAF	14
965	TLIVLTGGF	14
1031	SEFSDQDQT	14
5	TGVLSLLL	13
23	KQCSEGRTY	13
65	SSCDLAWWF	13
71	WWFEGRCYL	13
73	FEGRCYLVS	13
96	IRSYLTFVL	13
105	RPVQRPAQL	13
106	PVQRPAQLL	13
108	QRPAQLLDY	13
134	PEDIRKDLP	13
140	DLPFLGKDW	13
151	EEMSEYSDD	13
152	EMSEYSDDY	13
161	RELEKDLLQ	13
213	PELHYLNE	13
250	KEKASQLQE	13

TableXXXII-V1-HLA-B4402-9mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		
Pos	123456789	score
261	SNSSGKEVL	13
266	KEVLMPSHS	13
280	LELSSVTVE	13
287	VEKSPVLTV	13
333	KELTVSAGD	13
394	NLSQLSVGL	13
395	LSQLSVGLY	13
397	QLSVGLYVF	13
407	VTVSSENAF	13
481	KTSVDSPVL	13
570	SEGHVVMQ	13
681	VTGLQVGTY	13
699	QGLSSTSTL	13
713	KENNSPPRA	13
745	DDQRIVSYL	13
773	SVALQLTNL	13
780	NLVEGVYTF	13
818	VELTLQGVV	13
836	TLVRQLAVL	13
837	LVRQLAVLL	13
840	QLAVLLNVL	13
881	KAAEVARNL	13
907	RVDTAGCLL	13
928	KRCICSHLW	13
952	CEWSIFYVT	13
961	VLAFTLIVL	13
967	IVLTGGFTW	13
3	PPTGVLSSL	12
26	SEGRTYSNA	12
32	SNAVISPNI	12
61	CCDLSSCDL	12
64	LSSCDLAWW	12
142	PFLGKDWGL	12
159	DYRELEKDL	12
160	YRELEKDLL	12
163	LEKDLLQPS	12
209	TQQDPELHY	12
240	TTPSSGEVL	12

TableXXXII-V1-HLA-B4402-9mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		
Pos	123456789	score
245	GEVLEKEKA	12
300	TEHSIPTPP	12
385	IKQGHKQTL	12
387	QGHKQTLNL	12
416	GEGFVNVTV	12
441	QLQELTLPL	12
491	LSNLDPGNY	12
512	TNSTTAALI	12
551	NQSSDDHQI	12
579	GVQTPYLHL	12
628	VAGPDKELI	12
636	IFPVESATL	12
639	VESATLDGS	12
747	QRIVSYLWI	12
778	LTNLVEGVY	12
812	PRKSGLVEL	12
821	TLQVGVGQL	12
829	LTEQRKDTL	12
830	TEQRKDTLV	12
894	SKEKADFLI	12
906	LRVDTAGCL	12
918	SGHGHCDPL	12
933	SHLWMENLI	12
949	ESNCEWSIF	12
950	SNCEWSIFY	12
958	YVTVLAFTL	12
968	VLTGGFTWL	12
1002	DEQERMELR	12
1004	QERMELRPK	12
1020	TEHNSSLMV	12
1025	SLMVSESEF	12
1029	SESEFSDSQ	12
1032	EFDSDQDTI	12
1033	FDSQDQDTIF	12

TableXXXII-V2-HLA-B4402-9mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 5; each		

start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.

Pos	123456789	score
4	EMSEYADDY	14
7	EYADDYREL	14
3	EEMSEYADD	13
2	LEEMSEYAD	12
6	SEYADDYRE	11
9	ADDYRELEK	6

TableXXXII-V3-HLA-B4402-9mers-254P1D6B

Each peptide is a portion of SEQ ID NO: 7; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.

Pos	123456789	score
8	SPCCARKQC	5
4	LGWSPCCA	4
6	WPSPCCARK	4
7	PSPCCARKQ	4
2	TRLGWSPC	3
5	GWSPCCAR	3

TableXXXII-V5-HLA-B4402-9mers-254P1D6B

Each peptide is a portion of SEQ ID NO: 11; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.

Pos	1 2 3 4 5 6 7 8 9	score
2	EDIRKDLTF	18
1	PEDIRKDLT	13
7	DLTFLGKDW	12
9	TFLGKDWGL	12
3	DIRKDLTFL	11

TableXXXIII-V1-HLA-B5101-9mers-254P1D6B

Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.

Pos	123456789	score
517	AALIVNNAV	24
324	SPTTAPRTV	23
37	SPNLETRI	22
296	TPGSTEHSI	22
327	TAPRTVKEL	22
377	HPTDYQGEI	22
495	DPGNYSFRL	22
678	IATVTGLQV	22
774	VALQLTNLV	22
881	KAAEVARNL	22
628	VAGPDKELI	21
676	KAIATVTGL	21
720	RARAGGRHV	21
858	RAHSDLSTV	21
897	KADFLLFKV	21
3	PPTGVLSL	20
221	SASTPAKL	20
567	GPGSEGKHV	20
722	RAGGRHVLV	20
811	DPRKSGLVE	20
226	APKLPERSV	19
277	PASLELSSV	19
439	SPQLQELTL	19
568	PGSEGKHVV	19
608	QSTAVVTVI	19
849	DSDIKVQKI	19
970	TGGFTWLCI	19
133	SPEDIRKDL	18
447	LPLTSALID	18
610	TAVVTVIVQ	18
618	QPENNRPPV	18
723	AGGRHVLVL	18
768	DGSDHSVAL	18
885	VARNLHMRL	18
924	DPLTKRCIC	18
27	EGRTYSNAV	17
105	RPVQRPAQL	17
179	SAEYTDWGL	17
486	SPVLRSLNL	17
523	NAVDPYPPVA	17

TableXXXIII-V1-HLA-B5101-9mers-254P1D6B

Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.

Pos	123456789	score
699	QGLSSTSTL	17
874	RPPFKVLKA	17
9	SSLLLLVTI	16
229	LPERSVLLP	16
275	LPPASLELS	16
339	AGDNLITL	16
360	PAPPVETTY	16
400	VGLYVFKVT	16
413	NAFGEGFVN	16
430	VNLPPVAVV	16
432	LPPVAVVSP	16
533	AGPNHTITL	16
582	TPYLHLSAM	16
593	GDYTFQLKV	16
637	FPVESATLD	16
809	QPDPRKSGL	16
846	NVLDSDIKV	16
875	PPFKVLKAA	16
900	FLLFKVLRV	16
962	LAFTLIVLT	16
989	IRKTKYTI	16
2	APPTGVLSL	15
5	TGVLSSLIL	15
28	GRTYSNAVI	15
121	LNRGSPSGI	15
129	IWGDSPEDI	15
212	DPELHYLNE	15
236	LPLPTTPSS	15
306	TPPTSAAPS	15
317	TPSELPISP	15
358	VAPAPPVET	15
401	GLYVFKVTV	15
433	PPVAVVSPQ	15
497	GNYSFRLTV	15
530	VANAGPNHT	15
541	LPQNSITLN	15
626	VAVAGPDKE	15
687	GTYHFRLTV	15

TableXXXIII-V1-HLA-B5101-9mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		
Pos	123456789	score
701	LSSTSTLTV	15
731	LPNNSITLD	15
759	QSPAAGDVI	15
784	GVYTFHLRV	15
835	DTLVRQLAV	15
839	RQLAVLLNV	15
859	AHSDLSTVI	15
1	MAPPTGVLS	14
33	NAVISP NLE	14
69	LAWWFEGRC	14
94	GPIRSYLTF	14
99	YLTFVLRPV	14
205	VPAETQQDP	14
225	PAPKLPERS	14
287	VEKSPVLTV	14
290	SPVLTVTPG	14
337	VSAGDNLII	14
347	LPDNEVELK	14
359	APAPPVETT	14
387	QGHKQTLNL	14
415	FGEGFVNVT	14
416	GEGFVNVTV	14
426	PARRVNLPP	14
475	GPFIEEKTS	14
509	DGATNSTTA	14
512	TNSTTAALI	14
516	TAALIVNNA	14
527	YPPVANAGP	14
531	ANAGPNHTI	14
607	QQSTAVVTV	14
624	PPVAVAGPD	14
667	SAVEMENID	14
709	VAVKKENNS	14
761	PAAGDVIDG	14
762	AAGDVIDGS	14
800	DTDATATVEV	14
841	LAVLLNVLD	14
933	SHLWMENLI	14

TableXXXIII-V1-HLA-B5101-9mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		
Pos	123456789	score
981	CKRQKRTKI	14
17	IAGCARKQC	13
40	LETTRIMRV	13
47	RVSHTFPVV	13
88	CEPKKM GPI	13
141	LPFLGKDWG	13
159	DYRELEKDL	13
175	EPRGSAEYT	13
193	GAFNSSVGD	13
202	SPAVPAETQ	13
224	TPAPKLPER	13
238	LPTTPSSGE	13
270	MPSHSLPPA	13
285	VTVEKSPVL	13
310	SAAPSESTP	13
312	APSESTPSE	13
321	LPISPTTAP	13
328	APRTVKELT	13
336	TVSAGDNLI	13
338	SAGDNLII	13
362	PPVETTYNY	13
396	SQLSVGLYV	13
399	SVGLYVFKV	13
417	EGFVNVTVK	13
422	VTVKPARRV	13
425	KPARRVNLP	13
435	VAVVSPQLQ	13
446	TLPLTSALI	13
534	GNHTITLP	13
566	LPGGSEGKH	13
623	RPPVAVAGP	13
630	GPDKELIFP	13
665	GSAVEMEN	13
673	NIDKAIATV	13
728	VLVLPNNSI	13
797	GASD TDTAT	13
803	TATVEVQPD	13
818	VELTLQGVV	13

TableXXXIII-V1-HLA-B5101-9mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		
Pos	123456789	score
910	TAGCLKCS	13
918	SGHGHCDPL	13
923	CDPLTKRCI	13
954	WSIFYVTVL	13
959	VTVLAFTLI	13
960	TVLAFTLIV	13
961	VLAFTLIVL	13
1007	MELRPKYGI	13
1010	RPKYGIKHR	13
1050	NPKVSMNGS	13
52	FPVVDCTAA	12
58	TAACCDLSS	12
82	CPHKENCEP	12
89	EPKMGPIR	12
116	YGDMM LN RG	12
136	DIRKDL PFL	12
169	QPSGKQEPR	12
188	LPGSEGAFN	12
240	TTPSSGEVL	12
241	TPSSGEVLE	12
248	LEKEKASQL	12
279	SLELSSVTV	12
304	IPTPPTSAA	12
311	AAPSESTPS	12
315	ESTPSELPI	12
329	PRTVKELTV	12
355	KAFVAPAPP	12
361	APPVETTYN	12
366	TTYNYEWNL	12
367	TYNYEWNLI	12
414	AFGEGFVNV	12
451	SALIDGSQS	12
457	SQSTDDTEI	12
465	IVSYHWEEI	12
510	GATNSTTAA	12
513	NSTTAALIV	12
528	PPVANAGPN	12
532	NAGPNHTIT	12

TableXXXIII-V1-HLA-B5101-9mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		
Pos	123456789	score
538	TITLPQNSI	12
605	SRQQSTAVV	12
655	IVFYHWEHV	12
682	TGLQVGTYH	12
718	PPRARAGGR	12
741	SRSTDDQRI	12
745	DDQRIVSYL	12
747	QRIVSYLWI	12
760	SPAAGDVID	12
844	LLNVLDSDI	12
863	LSTVIVFYV	12
871	VQSRPPFKV	12
893	LSKEKADFL	12
898	ADFLLFKVL	12
937	MENLIQRYI	12
1032	EFDSDQDTI	12
1051	PKVSMNGSI	12
6	GVLSSLLLL	11
7	VLSSLLLLV	11
20	CARKQCSEG	11
56	DCTAACCDL	11
59	AACCDLSSC	11
95	PIRSYLTFV	11
96	IRSYLTFVL	11
109	RPAQLLDYG	11
125	SPSGIWGDS	11
132	DSPEDIRKD	11
158	DDYRELEKD	11
180	AEYTDWGLL	11
203	PAVPAETQQ	11
206	PAETQQDPE	11
227	PKLPERSVL	11
264	SGKEVLMPS	11
276	PPASLELSS	11
280	LELSSVTVE	11
307	PPTSAAPSE	11
344	IITLPDNEV	11
350	NEVELKAFV	11

TableXXXIII-V1-HLA-B5101-9mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		
Pos	123456789	score
385	IKQGHKQTL	11
392	TLNLSQLSV	11
455	DGSQSTDDT	11
476	PFIEEKTSV	11
540	TLPQNSITL	11
551	NQSSDDHQI	11
553	SSDDHQIVL	11
609	STAVVTIV	11
631	PKELIFPV	11
636	IFPVESATL	11
645	DGSSSSDDH	11
670	EMENIDKAI	11
717	SPPRARAGG	11
730	VLNNISITL	11
739	DGSRSTDDQ	11
757	DGQSPAAGD	11
766	VIDGSDHSV	11
798	ASDITDATT	11
814	KSGLVELTL	11
816	GLVELTLQV	11
830	TEQRKDTLV	11
836	TLVRQLAVL	11
840	QLAVLLNVL	11
872	QSRPPFKVL	11
877	FKVLKAAEV	11
882	AAEVARNLH	11
901	LLFKVLRVD	11
906	LRVDTAGCL	11
951	NCEWSIFYV	11
953	EWSIFYVTV	11
958	YVTVLAFTL	11
1013	YGIKHRSTE	11
1020	TEHNSSLMV	11
1045	KMERGNPKV	11
1062	GASFSYCSK	11

TableXXXIII-V2-HLA-B5101-9mers-254P1D6B

Each peptide is a portion of SEQ ID NO: 5; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		
Pos	123456789	score
8	YADDYRELE	14
7	EYADDYREL	8
6	SEYADDYRE	6

TableXXXIII-V3-HLA-B5101-9mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 7; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		
Pos	123456789	score
4	LGWSPCCA	11
6	WPSPCCARK	11
8	SPCCARKQC	11
11	CARKQCSEG	11
2	TRLGWSPSC	5
7	PSPCCARKQ	5

TableXXXIII-V5-HLA-B5101-9mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 11; each start position is specified, the length of peptide is 9 amino acids, and the end position for each peptide is the start position plus eight.		
Pos	1 2 3 4 5 6 7 8 9	score
3	DIRKDLTFL	13
9	TFLGKDWGL	11
6	KDLTFLGKD	6

TableXXXIV-V1-HLA-A1-10mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		

Pos	1234567890	score
459	STDDTEIVSY	33
553	SSDDHQIVLY	33
743	STDDQRIVSY	33
649	SSDDHGIVFY	31
173	KQEPRGSAEY	29
208	ETQQDP <del>E</del> LHY	27
107	VQRPAQLLDY	26
1019	STEHNSSL <del>M</del> V	25
894	SKEKADFL <del>L</del> F	23
949	ESNCEWSIF <del>Y</del>	23
986	RTKIRK <del>K</del> TKY	23
156	YSDDYRELEK	22
378	PTDYQGEIKQ	22
160	YRELEKDLLQ	20
359	APAPPVETTY	20
769	GSDHSVALQL	20
860	HSDLSTVIVF	20
394	NLSQLSVGLY	19
554	SDDHQIVLYE	19
72	WFEGRCYLVS	18
182	YTDWGLLP <del>G</del> S	18
299	STEHSIPTPP	18
347	LPDNEVELKA	18
592	EGDYTFQLKV	18
800	DTDTATVEVQ	18
829	LTEQRKDTLV	18
882	AAEVARNLHM	18
907	RVDTAGCLLK	18
1004	QERMELRPKY	18
286	TVEKSPVLTV	17
410	SSENAFGEGF	17
505	VTSDGATNS	17
518	ALIVNNAV <del>D</del> Y	17
569	GSEGKHVVMQ	17
601	VTDSRQ <del>Q</del> ST	17
680	TVTGLQVGTY	17
777	QLTNLVEGVY	17
792	VTDSQGASDT	17
861	SDLSTVIVFY	17
1058	SIRNGASFSY	17
22	RKQCSEGR <del>T</del> Y	16
69	LAWWFEGRCY	16
134	PEDIRKDL <del>P</del> F	16
190	GSEGAFN <del>S</del> SV	16
210	QQDP <del>E</del> LHYLN	16

TableXXXIV-V1-HLA-A1-10mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Pos	1234567890	score
229	LPERSVLLPL	16
249	EKEKASQLQE	16
313	PSESTPSELP	16
361	APPVETTYNY	16
442	LQELTLPLTS	16
462	DTEIVSYHWE	16
490	RLSNLDPGNY	16
507	DSDGATNSTT	16
575	VVMQGVQTPY	16
586	HL <del>S</del> AMQEGDY	16
798	ASDTDTATVE	16
809	QDP <del>P</del> RKSGLV	16

TableXXXIV-V2-HLA-A1-10mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 5; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Pos	1234567890	score
9	YADDYRELEK	18
4	EEMSEYADDY	15
6	MSEYADDYRE	14
10	ADDYRELEKD	13
2	GLEEMSEYAD	11
3	LEEMSEYADD	10

TableXXXIV-V3-HLA-A1-10mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 7; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Pos	1234567890	score
1	MTRLGWSPC	6
6	WPSPCCARKQ	6

7	PSPCCARKQC	5
4	LGWPSPCCAR	4
8	SPCCARKQCS	2

TableXXXIV-V5-HLA-A1-10mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 11; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Pos	1 2 3 4 5 6 7 8 9 0	score
2	PEDIRKDLTF	16
1	SPEDIRKDLT	14
6	RKDLTFLGKD	12
5	IRKDLTFLGK	9

TableXXXV-V1-A0201-10mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Pos	1234567890	score
635	LIFPVESATL	27
343	LIITLPDNEV	25
345	ITLPDNEVEL	24
700	GLSSTSTLTV	24
39	NLETRIMRV	23
112	QLLDYGD <del>M</del> ML	23
326	TTAPRTVKEL	23
338	SAGDNLITL	23
677	AIATVTGLQV	23
828	QLTEQRKDTL	23
862	DLSTVIVFYV	23
6	GVLSSLLLLV	22
436	AVVSPQLQEL	22
539	ITLPQNSITL	22
576	VMQGVQTPYL	22
729	LVL <del>P</del> NNSITL	22
820	LTLQVGVGQL	22
836	TLVRQLAVLL	22
961	VLAFTLIVLT	22
1000	NMDEQERMEL	22
11	LLLLVTIAGC	21

TableXXXV-V1-A0201-10mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Pos	1234567890	score
429	RVNLP <u>P</u> VAVV	21
441	QLQEL <u>T</u> LPLT	21
722	RAGGR <u>H</u> VLVL	21
835	DTLVR <u>Q</u> LAVL	21
843	VLLN <u>V</u> LDSI	21
905	VLRVD <u>T</u> AGCL	21
7	VLSS <u>L</u> LLVT	20
45	IMRV <u>S</u> HTFPV	20
120	MLNR <u>G</u> SPSGI	20
128	GIWGD <u>S</u> PEDI	20
247	VLEKE <u>K</u> ASQL	20
278	ASLE <u>L</u> SSVT	20
286	TVEK <u>S</u> PVLT	20
398	LSVGL <u>Y</u> VFKV	20
431	NLPP <u>V</u> AVVSP	20
445	LTLP <u>L</u> TSALI	20
692	RLTVK <u>D</u> QQGL	20
775	ALQLT <u>N</u> LVEG	20
797	GASDT <u>D</u> TATV	20
857	IRAH <u>S</u> DLSTV	20
892	RLSKE <u>K</u> ADFL	20
960	TVLAF <u>T</u> LIVL	20
988	KIRK <u>K</u> TKYTI	20
217	YLNES <u>A</u> STPA	19
269	LMP <u>S</u> HSLPPA	19
391	QTLN <u>L</u> SQLSV	19
413	NAFG <u>E</u> GFVNV	19
765	DVIDG <u>S</u> DHSV	19
773	SVALQ <u>L</u> TNLV	19
776	LQLTN <u>L</u> VEGV	19
901	LLFKV <u>L</u> RVDT	19
1054	SMNGS <u>I</u> RNGA	19
2	APPTG <u>V</u> LSSL	18
8	LSS <u>L</u> LLVTI	18
12	LLLVT <u>I</u> AGCA	18
34	AVISP <u>N</u> LETT	18
98	SYLTF <u>V</u> LRPV	18
228	KLPERS <u>V</u> LLP	18

TableXXXV-V1-A0201-10mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Pos	1234567890	score
274	SLPPA <u>S</u> LELS	18
295	VTPG <u>S</u> TEHSI	18
516	TAALIV <u>N</u> NAV	18
532	NAGPN <u>H</u> ITIL	18
560	VL <u>Y</u> EW <u>S</u> LGPG	18
606	RQQT <u>A</u> VVTV	18
627	AVAGP <u>D</u> KELI	18
654	GIVFY <u>H</u> WEHV	18
672	ENIDK <u>A</u> IATV	18
721	ARAGGR <u>H</u> VLV	18
817	LVELT <u>L</u> QVGV	18
870	YVQSR <u>P</u> PFKV	18
950	SNCEW <u>S</u> IFYV	18
967	IVLTG <u>G</u> FTWL	18
94	GPIRS <u>Y</u> LTFV	17
273	HSLPPA <u>S</u> LEL	17
355	KAFVAP <u>P</u> PPV	17
357	FVAPAP <u>P</u> VET	17
393	LNLSQ <u>L</u> SVGL	17
423	TVKPARR <u>V</u> NL	17
444	ELTLP <u>L</u> TSAL	17
452	ALIDG <u>S</u> QSTD	17
510	GATNST <u>T</u> AAL	17
511	ATNST <u>T</u> AALI	17
530	VANAGP <u>N</u> HTI	17
537	HTITL <u>P</u> QNSI	17
727	HVLVLP <u>N</u> NSI	17
781	LVEGV <u>Y</u> TFHL	17
811	DPRK <u>S</u> GLVEL	17
816	GLVELT <u>L</u> QVG	17
839	RQLAV <u>L</u> LNVL	17
848	LDSDIK <u>V</u> QKI	17
969	LTGGF <u>T</u> WLCI	17
1006	RMELRP <u>K</u> YGI	17
92	KMGPIRS <u>Y</u> L	16
167	LLQPSG <u>K</u> QEP	16
178	GSAEY <u>T</u> DWGL	16
186	GLLPG <u>S</u> EGAF	16

TableXXXV-V1-A0201-10mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Pos	1234567890	score
187	LLPG <u>S</u> EGAFN	16
209	TQQD <u>P</u> ELHYL	16
229	LPERS <u>V</u> LLPL	16
284	SVTVE <u>K</u> SPVL	16
312	APSE <u>S</u> TSEL	16
334	ELTVS <u>A</u> GDNL	16
384	EIKQG <u>H</u> KQTL	16
400	VGLYV <u>F</u> KVTV	16
401	GLYV <u>F</u> KVTVS	16
415	FGEGF <u>V</u> NVTV	16
426	PARRV <u>N</u> LPPV	16
482	TSVDS <u>P</u> VLRL	16
518	ALIVN <u>N</u> AVDY	16
565	SLGPG <u>S</u> EGKH	16
626	VAVAGP <u>D</u> KEL	16
675	DKAIAT <u>V</u> TGL	16
799	SDTDT <u>A</u> TVEV	16
838	VRQLAV <u>L</u> LN	16
856	KIRAH <u>S</u> DLST	16
879	VLKAA <u>E</u> VARN	16
896	EKADF <u>L</u> LKVV	16
899	DFLLF <u>K</u> VLRV	16
900	FLLFKV <u>L</u> RVD	16
939	NLIQR <u>Y</u> IWDG	16
955	SIFYV <u>T</u> VLAF	16
959	VTVLAF <u>T</u> LIV	16
965	TLIVLT <u>G</u> GFT	16
1019	STEHN <u>S</u> SLMV	16
5	TGVLSS <u>L</u> LL	15
10	SLLLV <u>T</u> IAG	15
63	DLSSC <u>D</u> LAWW	15
95	PIRSY <u>L</u> TFVL	15
103	VLRPV <u>Q</u> RPAQ	15
149	GLEEM <u>S</u> EYSD	15
154	SEYSD <u>D</u> YREL	15
234	VLLPL <u>P</u> TTPS	15
235	LLPLP <u>T</u> TPSS	15
255	QLQE <u>Q</u> SSNSS	15

TableXXXV-V1-A0201-10mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Pos	1234567890	score
268	VLMPSHSLPP	15
276	PPASLELSSV	15
279	SLELSSVTVE	15
303	SIPTPPTSAA	15
328	APRTVKELTV	15
335	LTVSAGDNLI	15
346	TLPDNEVELK	15
358	VAPAPPVETT	15
392	TLNLSQLSVG	15
459	STDDTEIVSY	15
464	EIVSYHWEEI	15
488	VLRLSNLDPG	15
515	TTAALIVNNA	15
524	AVDYPPVANA	15
630	GPDKEILFPV	15
668	AVEMENIDKA	15
720	RARAGGRHVL	15
728	VLVLPNNSIT	15
730	VLPNNSITLD	15
735	SITLDGSRST	15
743	STDDQRIVSY	15
752	YLWIRDGQSP	15
754	WIRDGQSPAA	15
766	VIDGSDHSVA	15
767	IDGSDHSVAL	15
789	HLRVTD SQGA	15
813	RKSGLVLT	15
815	SGLVELTLQV	15
829	LTEQRKDTLV	15
859	AHSDLSTVIV	15
873	SRPPFKVLKA	15
926	LTKRCICSHL	15
934	HLWMENLIQR	15
936	WMENLIQRYI	15
952	CEWSIFYVTV	15
26	SEGRITYSNAV	14
31	YSNAVISPNI	14
71	WWFEGRCYLV	14

TableXXXV-V1-A0201-10mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Pos	1234567890	score
91	KKMGPIRSYL	14
104	LRPVQRPAQL	14
135	EDIRKDL PFL	14
141	LPFLGKDWGL	14
143	FLGKDWGLEE	14
179	SAEYTDWGLL	14
190	GSEGA FNSSV	14
266	KEVLMP SHSL	14
323	ISPTTAPRTV	14
366	TTYNYEWNLI	14
389	HKQTLNLSQL	14
394	NLSQLSVGLY	14
438	VSPQLQELTL	14
451	SALIDGSQST	14
472	EINGPFIEEK	14
475	GPFIEEKT SV	14
494	LDPGNYSFRL	14
502	RLTVTDSDGA	14
519	LIVNNAVDYP	14
540	TLPQNSITLN	14
557	HQIVLYEWSL	14
584	YLHLSAMQEG	14
604	SSRQQSTAVV	14
617	VQPENNRPPV	14
662	HVRGPSAVEM	14
684	LQVGTYHFRL	14
702	SSTSTLTVAV	14
744	TDDQRIVSYL	14
772	HSVALQLTNL	14
784	GYTFHLRVT	14
821	TLQVGVGQLT	14
832	QRKDTLVRQL	14
840	QLAVLLNVLD	14
842	AVLLNVLDSD	14
845	LNVLDS DIKV	14
880	LKAAEVARNL	14
913	CLLKCSGHGH	14
962	LAFTLIVLTG	14

TableXXXV-V1-A0201-10mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Pos	1234567890	score
997	ILDNMDEQER	14
1031	SEFDSQDQTI	14
1	MAPPTGVLSS	13
13	LLVTIAGCAR	13
35	VISPNLETTR	13
50	HTFPVVDCTA	13
60	ACCDLSSCDL	13
78	YLVSCPHKEN	13
119	MMLNRGSPSG	13
198	SVGDSPAVPA	13
206	PAETQQDPEL	13
223	STPAPKLPER	13
225	PAPKLPERSV	13
227	PKLPERSVLL	13
238	LPTTPSSGEV	13
260	SSNSSGKEVL	13
281	ELSSVTVEKS	13
285	VTVEKSPVLT	13
336	TVSAGDNLII	13
337	VSAGDNLIIIT	13
352	VELKAFVAPA	13
395	LSQLSVGLYV	13
403	YVFKVTVSSE	13
411	SENAFGGEFV	13
414	AFGEGFVNVT	13
421	NVTVKPARRV	13
428	RRVNLPPVAV	13
485	DSPVLRLSNL	13
521	VNNAVDYPPV	13
547	TLNGNQSSDD	13
566	LPGSGEGKHV	13
633	KELIFPVESA	13
634	ELIFPVESAT	13
679	ATVTGLQVGT	13
705	STLTVAVKKE	13
778	LTNLVEGVYT	13
808	VQPDPRKSGL	13
844	LLNVLDSDIK	13

TableXXXV-V1-A0201-10mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Pos	1234567890	score
847	VLDSDIKVQK	13
884	EVARNLHMRL	13
893	LSKEKADFL	13
897	KADFLFKVL	13
906	LRVDTAGCLL	13
944	YIWDGESNCE	13
956	IFYVTVLAFT	13
957	FYVTVLAFTL	13
958	YVTVLAFTLI	13
1025	SLMVSESEFD	13
1044	EKMERGNPKV	13

TableXXXV-V2-HLA-A0201-10mers-254P16B		
Each peptide is a portion of SEQ ID NO: 5; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Pos	1234567890	score
7	SEYADDYREL	15
2	GLEEMSEYAD	14
9	YADDYRELEK	10
1	WGLEEMSEYA	8
5	EMSEYADDYR	7
10	ADDYRELEKD	7

TableXXXV-V3-HLA-A0201-10mers-254P16B		
Each peptide is a portion of SEQ ID NO: 7; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Pos	1234567890	score
3	RLGWSPCCA	14
4	LGWSPCCAR	6

TableXXXV-V5-HLA-A0201-10mers-254P16B		
Each peptide is a portion of SEQ ID NO: 11; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Pos	1 2 3 4 5 6 7 8 9 0	score
9	LTFLGKDWGL	10
3	EDIRKDLTFL	13

TableXXXVI-V1-HLA-A0203-10mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Pos	1234567890	score
51	TFPVVDCTAA	19
303	SIPTPTTSA	19
509	DGATNSTTAA	19
754	WIRDGQSPAA	19
874	RPPFKVLKAA	19
352	VELKAFVAPA	18
524	AVDYPPVANA	18
620	ENNRPPVAVA	18
670	EMENIDKAI	18
714	ENNSPPRARA	10
52	FPVVDCTAAC	17
304	IPTPTTSAAP	17
510	GATNSTTAA	17
755	IRDGQSPAAG	17
875	PFFKVLKAAE	17
9	SSLLLVTIA	10
12	LLLVTIAGCA	10
25	CSEGRYTSSNA	10
50	HTFPVVDCTA	10
61	CCDLSSCDLA	10
102	FVLRPVQRPA	10
171	SGKQEPGRSA	10
185	WGLLPGSEGA	10
195	FNSSVGDSAPA	10
198	SVGDSPAVPA	10
213	PELHYLNESA	10
217	YLNESASTPA	10

TableXXXVI-V1-HLA-A0203-10mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Pos	1234567890	score
244	SGEVLEKEKA	10
269	LMPSHSLPPA	10
302	HSIPTPTTSA	10
319	SELPISPTTA	10
330	RTVKELTVSA	10
347	LPDNEVELKA	10
350	NEVELKAFVA	10
405	FKVTVSSENA	10
418	GFVNVTVKPA	10
427	ARRVNLPPVA	10
443	QELTLPLTSA	10
502	RLTVTDSGGA	10
508	SDGATNSTTA	10
515	TTAALIVNNA	10
522	NNAVDYPPVA	10
580	VQTPYLHLSA	10
602	TDSSRQQSTA	10
618	QPENNRPPVA	10
633	KELIFPVESA	10
659	HWEHVRGPASA	10
668	AVEMENIDKA	10
701	LSSTSTLTVA	10
712	KKENNSPPRA	10
753	LWIRDGQSPA	10
766	VIDGSDHSVA	10
789	HLRVTD SQGA	10
795	SQGASDTDTA	10
833	RKDTLVRQLA	10
850	SDIKVQKIRA	10
873	SRPPFKVLKA	10
877	FKVLKAAEVA	10
889	LHMRLSKEKA	10
902	LFKVLRVDTA	10
954	WSIFYVTVLA	10
1054	SMNGSIRNGA	10
10	SLLLVTIAG	9
13	LLVTIAGCAR	9
26	SEGRYTSSNAV	9

TableXXXVI-V1-HLA-A0203-10mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Pos	1234567890	score
62	CDLSSCDLAW	9
103	VLRPVQRPAQ	9
172	GKQEPRGSAE	9
186	GLLPGSEGA	9
196	NSSVGDSPAV	9
199	VGDSPAVPAE	9
214	ELHYLNE <del>S</del> AS	9
218	LNESASTPAP	9
245	GEVLEKEKAS	9
270	MPSHSLPPAS	9
320	ELPISPTTAP	9
331	TVKELTVSAG	9
348	PDNEVELKAF	9
351	EVELKAFVAP	9
353	ELKAFVAPAP	9
406	KVTVSSSENAF	9
419	FVNVTVKPAR	9
428	RRVNLPPVAV	9
444	ELTLPLTSAL	9
503	LTVTDS <del>S</del> GAT	9
516	TAALIVNNAV	9
523	NAV <del>D</del> YPPVAN	9
525	VDYPPVANAG	9
581	QTPYLHLSAM	9
603	DSSRQQSTAV	9
619	PENNRPPVAV	9
621	NNRPPVAVAG	9
634	ELIFPVESAT	9
660	WEHVRGPSAV	9
669	VEMENIDKAI	9
671	MENIDKAIAT	9
702	SSTSTLTVAV	9
713	KENNSPPRAR	9
715	NNSPPRARAG	9
767	IDGSDHSVAL	9
790	LRVTD <del>S</del> QGAS	9
796	QGASDTDTAT	9
834	KDTLVRQLAV	9

TableXXXVI-V1-HLA-A0203-10mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Pos	1234567890	score
851	DIKVQKIRAH	9
878	KVLKAAEVAR	9
890	HMRLSKEKAD	9
903	FKVLRVD <del>T</del> AG	9
955	SIFYVTVLAF	9
1055	MNGSIRNGAS	9

TableXXXVI-V2-HLA-A0203-10mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 5; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Pos	1234567890	score
1	WGLEEMSEYA	10
2	GLEEMSEYAD	9
3	LEEMSEYADD	8

TableXXXVI-V3-HLA-A0203-10mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 7; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Pos	1234567890	score
3	RLGWSPCCA	10
4	LGWSPCCAR	9
5	GWSPCCARK	8

TableXXXVI-V5-HLA-A0203-10mers-254P1D6B		
No Results Found.		
Pos	1234567890	score

TableXXXVII-V1-HLA-A3-10mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Pos	1234567890	score
518	ALIVNNAV <del>D</del> Y	29
847	VLDSDIKVQK	27
907	RVD <del>T</del> AGCLLK	27
397	QLSVGLYVFK	26
14	LVTIAGCARK	24
452	ALIDGSQSTD	24
777	QLTNLVEGVY	24
878	KVLKAAEVAR	24
47	RVSHTFPVVD	23
490	RLSNLD <del>P</del> GNVY	23
680	TVTGLQVGTY	23
791	RVTDSQ <del>G</del> ASD	23
1008	ELRPKYGIKH	23
429	RVNLPPVAVV	22
662	HVRGPSA <del>V</del> EM	22
872	QSRPPFKVLK	22
186	GLLPGSEGA	21
346	TLPDNEVELK	21
504	TVTDS <del>S</del> GATN	21
677	AIATVTGLQV	21
856	KIRAHSD <del>L</del> ST	21
904	KVLRVD <del>T</del> AGC	21
1058	SIRNGASFSY	21
34	AVISP <del>N</del> LETT	20
35	VISP <del>N</del> LETT	20
233	SVLLPLPTTP	20
292	VLTVTPGSTE	20
472	EINGPFIEEK	20
493	NLD <del>P</del> GNYSFR	20
655	IVFYHWEHVR	20
694	TVKDQQGLSS	20
805	TVEVQDP <del>R</del> K	20
825	GVGQLTEQRK	20
836	TLVRQLAVLL	20
844	LLNVLDSDIK	20
886	ARNLHMRLSK	20
888	NLHMRLSKEK	20
76	RCYLVS <del>CPHK</del>	19

TableXXXVII-V1-HLA-A3-10mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Pos	1234567890	score
198	SVGDSPA VPA	19
247	VLEKEKASQL	19
357	FVAPAPPVET	19
401	GLYVFKVTVS	19
423	TVKPARRVNL	19
431	NLPPVAVVSP	19
565	SLGPGSEGKH	19
586	HLSAMQEGDY	19
687	GTYHFRLTVK	19
729	LVL PNN SITL	19
865	TVIVFYVQSR	19
895	KEKADFL LFK	19
913	CLLKCSGHGH	19
13	LLVTIAGCAR	18
103	VLRPVQRPAQ	18
166	DLLQPSGKQE	18
187	LLPGSEGAFN	18
246	EVLEKEKASQ	18
359	APAPPVETTY	18
392	TLNLSQLSVG	18
406	KVTVSSENAF	18
487	PVLR LSNLDP	18
600	KVTDSSRQQS	18
635	LIFPVESATL	18
703	STSTLTVAVK	18
704	TSTLTVA VKK	18
775	ALQLTNLVEG	18
784	GVYTFHLRVT	18
819	ELTLQVGVGQ	18
842	AVLLNVLDSD	18
853	KVQKIRAHSD	18
919	GHGHC DPLTK	18
960	TVLAFTLIVL	18
983	RQKRTKIRKK	18
988	KIRKKT KYTI	18
1043	REKMERGNPK	18
7	VLSSLLLLVT	17
22	RKQCSEGR TY	17

TableXXXVII-V1-HLA-A3-10mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Pos	1234567890	score
53	PVV DCTAACC	17
112	QLLDYGD MML	17
120	MLNRGSPSGI	17
137	IRKDL PFLGK	17
228	KL PERSVLLP	17
279	SL ELSSVTVE	17
286	TVEKSPV LTV	17
324	SPTTAPRTVK	17
353	ELKAFVAPAP	17
394	NLSQLSVGLY	17
446	TLPLTSALID	17
559	IVLYEWSLGP	17
575	VVMQGVQTPY	17
614	TVIVQ PENNR	17
634	ELIFPVESAT	17
700	GLSSTSTLTV	17
710	AVKKENNSPP	17
766	VIDGSDHSVA	17
828	QLTEQRKDTL	17
840	QLAVLLNVLD	17
846	NVLDSDIKVQ	17
892	RLSKEKADFL	17
905	VLRVDTAGCL	17
934	HLWMENLIQR	17
955	SIFYVTVLAF	17
965	TLIVLTGGFT	17
985	KRTKIRK KTK	17
997	ILDNMDEQER	17
11	LLLLVTIAGC	16
12	LLLLVTIAGCA	16
44	RIMRVSH TFP	16
106	PVQRPAQLLD	16
143	FLGKDWGLEE	16
219	NESASTPAPK	16
234	VLLPLPTPS	16
268	VLMPSHSLPP	16
280	LELSSVTVEK	16
291	PVLTVT PGST	16

TableXXXVII-V1-HLA-A3-10mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Pos	1234567890	score
331	TVKELTVSAG	16
351	EVELKAFVAP	16
399	SVGLYVFKVT	16
430	VNLPPVAVVS	16
524	AVDYPPVANA	16
560	VLYEWSL GPG	16
598	QLKVT DSSRQ	16
627	AVAGPDKELI	16
673	NIDKAIATVT	16
752	YLWIR DGQSP	16
765	DVIDGSDHSV	16
780	NLVEGVYTFH	16
807	EVQPDPRKSG	16
837	LVRQLAVLLN	16
843	VLLNVLDSDI	16
879	VLKAAEVARN	16
900	FLLFKVLRVD	16
925	PLTKRCICSH	16
966	LIVLTGGFTW	16
967	IVLTGGFTWL	16
976	LCICCC K RQK	16
1007	MELRPKYGIK	16
6	GVLSLLLLLV	15
10	SLLLLVTIAG	15
16	TIAGCARKQC	15
95	PIRSYLT FVL	15
99	YLT FVLRPVQ	15
102	FVLRPVQRPA	15
107	VQRPAQLLDY	15
164	EKDLLQPSGK	15
173	KQEPRGSAEY	15
204	AVPAETQQDP	15
255	QLQEQQSSNS	15
257	QEQQSSNSGK	15
267	EVLMPSHSLP	15
284	SVTVEKSPVL	15
336	TVSAGDNLII	15
342	NLIITLPDNE	15

TableXXXVII-V1-HLA-A3-10mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Pos	1234567890	score
344	IITLPDNEVE	15
403	YVFKVTVSSE	15
416	GEGFVNVTVK	15
419	FVNVTVKPAR	15
444	ELTLPLTSAL	15
547	TLNGNQSSDD	15
616	IVQPENNRPP	15
624	PPVAVAGPDK	15
643	TLDGSSSSDD	15
816	GLVELTLQVG	15
817	LVELTLQGV	15
884	EVARNLHMRL	15
901	LLFKVLRVDT	15
961	VLAFTLIVLT	15
41	ETTRIMRVSH	14
63	DLSSCDLAWW	14
156	YSDDYRELEK	14
214	ELHYL NESAS	14
274	SLPPASLELS	14
278	ASLELSSVTV	14
322	PISPTIAPRT	14
377	HPTDYQGEIK	14
459	STDDTEIVSY	14
488	VLRLSNLDPG	14
502	RLTVTDSGGA	14
558	QIVLYEWSLG	14
564	WSLGPQSEGK	14
574	HVVMQGVQTP	14
621	NNRPPVAVAG	14
683	GLQVGTYHFR	14
692	RLTVKDQQGL	14
720	RARAGGRHVL	14
727	HVLVLPNNSI	14
728	VLVLPNNSIT	14
743	STDDQRIVSY	14
830	TEQRKDTLVR	14
851	DIKVQKIRAH	14
979	CCCKRQKRTK	14

TableXXXVII-V1-HLA-A3-10mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Pos	1234567890	score
996	TILDNMDEQE	14

TableXXXVII-V2-HLA-A3-10mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 5; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Pos	1234567890	score
9	YADDYRELEK	14
2	GLEEMSEYAD	12
4	EEMSEYADDY	9
7	SEYADDYREL	7

TableXXXVII-V3-HLA-A3-10mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 7; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Pos	1234567890	score
3	RLGWSPSCCA	15
5	GWSPSCCARK	13
1	MTRLGWSPSPC	8
4	LGWSPSCCAR	8
10	CCARKQCSEG	7

TableXXXVII-V5-HLA-A3-10mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 11; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Pos	1 2 3 4 5 6 7 8 9 0	score
5	IRKDLTFLGK	17

TableXXXVII-V5-HLA-A3-10mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 11; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Pos	1 2 3 4 5 6 7 8 9 0	score
2	PEDIRKDLTF	12
4	DIRKDLTFLG	11
8	DLTFLGKDWG	11
7	KDLTFLGKDW	8

TableXXXVIII-V1-HLA-A26-10mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Pos	1234567890	score
208	ETQQDPELHY	29
680	TVTGLQVGTY	28
835	DTLVRQLAVL	28
884	EVARNLHMRL	28
365	ETTYNYEWNL	27
436	AVVSPQLQEL	27
135	EDIRKDLPFL	26
459	STDDTEIVSY	25
743	STDDQRIVSY	25
765	DVIDGSDHSV	24
960	TVLAFTLIVL	24
246	EVLEKEKASQ	23
384	EIKQGHKQTL	23
955	SIFYVTVLAF	23
326	TTAPRTVKEL	22
807	EVQPDPRKSG	22
820	LTLQGVGQQL	22
953	EWSIFYVTVL	22
151	EEMSEYSDDY	21
267	EVLMPSHSLP	21
351	EVELKAFVAP	21
444	ELTLPLTSAL	21
485	DSPVLRLSNL	21
729	LVLNNSITL	21
949	ESNCEWSIFY	21

TableXXXVIII-V1-HLA-A26-10mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Pos	1234567890	score
1038	DTIFSREKME	21
34	AVISPNETT	20
41	ETTRIMRVSH	20
220	ESASTPAPKL	20
284	SVTVEKSPVL	20
334	ELTVSAGDNL	20
403	YVFKVTVSSE	20
406	KVTVSSENAF	20
423	TVKPARRVNL	20
480	EKTSVDSPL	20
575	VVMQGVQTPY	20
672	ENIDKAIATV	20
675	DKAIATVTGL	20
800	DTDTATVEVQ	20
802	DTATVEVQPD	20
811	DPRKSGLVEL	20
865	TVIVFYVQSR	20
909	DTAGCLLKCS	20
147	DWGLEEMSEY	19
239	PTTPSSGEVL	19
331	TVKELTVSAG	19
464	EIVSYHWEEI	19
482	TSVDSPLRL	19
539	ITLPQNSITL	19
574	HVVMQGVQTP	19
986	RTKIRKTKKY	19
1032	EFDSDQDTIF	19
5	TGVLSSLLLL	18
132	DSPEDIRKDL	18
159	DYRELEKDLL	18
472	EINGPFIEEK	18
611	AVVTVIVQPE	18
635	LIFPVESATL	18
781	LVEGVYTFHL	18
967	IVLTGGFTWL	18
4	PTGVLSSLLL	17
181	EYTDWGLLPG	17
286	TVEKSPVLTV	17

TableXXXVIII-V1-HLA-A26-10mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Pos	1234567890	score
345	ITLPDNEVEL	17
851	DIKVQKIRAH	17
926	LTKRCICSHL	17
964	FTLIVLTGGF	17
6	GVLSLLLLLV	16
107	VQRPAQLLDY	16
158	DDYRELEKDL	16
281	ELSSVTEKS	16
315	ESTPSELPIS	16
338	SAGDNLITL	16
462	DTEIVSYHWE	16
483	SVDSPVLRSL	16
553	SSDDHQIVLY	16
595	YTFQLKVTDS	16
634	ELIFPVESAT	16
649	SSDDHGIVFY	16
772	HSVALQLTNL	16
786	YTFHLRVTD	16
861	SDLSTVIVFY	16
896	EKADFLLFKV	16
935	LWMENLIQRY	16
1047	ERGNPKVSMN	16
1058	SIRNGASFYS	16
29	RTYSNAVISP	15
53	PVVDCTAAC	15
74	EGRCYLVSCL	15
90	PKKMGPIRSY	15
348	PDNEVELKAF	15
394	NLSQLSVGLY	15
417	EGFVNVTVKP	15
471	EEINGPFIEE	15
504	TVTDSGDGATN	15
614	TVIVQPENNR	15
638	PVESATLDGS	15
668	AVEMENIDKA	15
694	TVKDQQLGSS	15
783	EGVYTFHLRV	15
837	LVRQLAVLLN	15

TableXXXVIII-V1-HLA-A26-10mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Pos	1234567890	score
842	AVLLNVLDSD	15
846	NVLDSDIKVQ	15
2	APPTGVLSSL	14
42	TTRIMRVSH	14
43	TRIMRVSH	14
50	HTFPVVDCTA	14
162	ELEKDLLQPS	14
209	TQQDPELHYL	14
285	VTVEKSPVL	14
389	HKQTLNLSQL	14
396	SQLSVGLYVF	14
429	RVNLPPVAVV	14
503	LTVTDSGDAT	14
514	STJAALIVNN	14
518	ALIVNNAVDY	14
524	AVDYPPVANA	14
579	GVQTPYLHLS	14
581	QTPYLHLSAM	14
609	STAVVTIVQ	14
620	ENNRPPVAVA	14
655	IVFYHWEHVR	14
661	EHVRGPSAVE	14
705	STLTVAVKKE	14
744	TDDQRIVSYL	14
749	IVSYLWIRDG	14
779	TNLVEGVYTF	14
784	GVYTFHLRVT	14
791	RVTDSQGASD	14
804	ATVEVQPDPR	14
823	QVGVGQLTEQ	14
831	EQRKDTLVRQ	14
832	QRKDTLVRQL	14
864	STVIVFYVQS	14
867	IVFYVQSRPP	14
906	LRVDTAGCLL	14
1003	EQERMELRPK	14
1008	ELRPKYGIKH	14

TableXXXVIII-V2-HLA-A26-10mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 5; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Pos	1234567890	score
4	EEMSEYADDY	21
5	EMSEYADDYR	12
8	EYADDYRELE	11

TableXXXVIII-V3-HLA-A26-10mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 7; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Pos	1234567890	score
1	MTRLGWSPSC	9

TableXXXVIII-V5-HLA-A26-10mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 11; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Pos	1 2 3 4 5 6 7 8 9 0	score
3	EDIRKDLTFL	26
9	LTFLGKDWGL	20
4	DIRKDLTFLG	12

TableXXXIX-V1-HLA-B0702-10mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Pos	1234567890	score
811	DPRKSGLVEL	25
226	APKLPERSVL	24
312	APSESTPSEL	24
229	LPERSVLLPL	23

TableXXXIX-V1-HLA-B0702-10mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Pos	1234567890	score
2	APPTGVLSSL	22
3	PPTGVLSSL	22
328	APRTVKELTV	22
433	PPVAVVSQQL	22
105	RPVQRPAQLL	21
141	LPFLGKDWGL	20
317	TPSELPISPT	19
347	LPDNEVELKA	19
630	GPDKELIFPV	19
665	GPSAVEMENI	19
94	GPIRSYLTfV	18
495	DPGNYSFRLT	18
567	GPGSEGKHVV	18
618	QPENNRPPVA	18
722	RAGGRHVLVL	18
809	QPDPRKSGLV	18
874	RPPFKVLKAA	18
37	SPNLETTRIM	17
276	PPASLELSSV	17
475	GPFIEEKTSV	17
813	RKSGLVELTL	17
238	LPTTPSSGEV	16
720	RARAGGRHVL	16
953	EWSIFYVTVL	16
1050	NPKVSMNGSI	16
91	KKMGPIRSYL	15
169	QPSGKQEPRG	15
175	EPRGSAEYTD	15
241	TPSSGEVLEK	15
359	APAPPVETTY	15
386	KQGHKQTLNL	15
425	KPARRVNLPP	15
767	IDGSDHSVAL	15
892	RLSKEKADFL	15
95	PIRSYLTfVL	14
125	SPSGIWGDSP	14
270	MPSHSLPPAS	14
304	IPTPPTSAAP	14

TableXXXIX-V1-HLA-B0702-10mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Pos	1234567890	score
345	ITLPDNEVEL	14
423	TVKPARRVNL	14
440	PQLQELTLPL	14
534	GNHTITLPQ	14
576	VMQGVQTPYL	14
871	VQSRPPFKVL	14
897	KADFLFKVL	14
4	PTGVLSSLLL	13
52	FPVVDCTAAC	13
70	AWWFEGRCYL	13
135	EDIRKDLPFL	13
220	ESASTPAPKL	13
227	PKLPERSVLL	13
273	HSLPPASLEL	13
275	LPPASLELSS	13
321	LPISPTTAPR	13
324	SPTTAPRTVK	13
326	TTAPRTVKEL	13
361	APPVETTYNY	13
444	ELTLPLTSAL	13
480	EKTSVDSPVL	13
482	TSVDSPVLRL	13
510	GATNSTTAAL	13
532	NAGPNHTITL	13
541	LPQNSITLNG	13
552	QSSDDHQIVL	13
590	MQEGDYTFQL	13
637	FPVESATLDG	13
675	DKAIAVTGL	13
718	PPRARAGGRH	13
721	ARAGGRHVLV	13
731	LPNNSITLDG	13
760	SPAAGDVIDG	13
769	GSDHSVALQL	13
781	LVEGVYTFHL	13
839	RQLAVLLNLV	13
859	AHSDLSTVIV	13
875	PPFKVLKAAE	13

TableXXXIX-V1-HLA-B0702-10mers-254P1D6B

Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.

Pos	1234567890	score
931	ICSHLWMENL	13
967	IVLTGGFTWL	13
989	IRKKT KYTIL	13
5	TGVLSSLLLL	12
31	YNAVISPNL	12
60	ACCDLSSCDL	12
82	CPHKENCEPK	12
89	EPKKMGPIRS	12
109	RPAQLLDYGD	12
159	DYRELEKDLL	12
202	SPAVPAETQQ	12
205	VPAETQQDPE	12
224	TPAPKLPERS	12
231	ERSVLLPLPT	12
239	PTTPSSGEVL	12
284	SVTVEKSPVL	12
290	SPVLT VTPGS	12
393	LNLSQLSVGL	12
427	ARRVNLPPVA	12
432	LPPVAVVSPQ	12
436	AVVSPQLQEL	12
438	VSPQLQELTL	12
494	LDPGNYSFRL	12
528	PRVANAGPNH	12
531	ANAGPNHTIT	12
539	ITLPQNSITL	12
578	QGVQTPYLHL	12
623	RPPVAVAGPD	12
624	PPVAVAGPDK	12
635	LIFPVESATL	12
662	HVRGPSAVEM	12
684	LQVGTYHFRL	12
698	QQGLSSTSTL	12
744	TDDQRIVSYL	12
772	HSVALQLTNL	12
835	DTLVRQLAVL	12
836	TLVRQLAVLL	12
856	KIRAHSDLST	12

TableXXXIX-V1-HLA-B0702-10mers-254P1D6B

Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.

Pos	1234567890	score
880	LKAAEVARNL	12
884	EVARNLHMRL	12
905	VLRVDTAGCL	12
917	CSGHGHCDPL	12
960	TVLAFTLIVL	12
1000	NMDEQERMEL	12
1017	HRSTEHNSSL	12
1046	MERGNPKVSM	12

TableXXXIX-V2-HLA-B0702-10mers-254P1D6B

Each peptide is a portion of SEQ ID NO: 5; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.

Pos	1234567890	score
7	SEYADDYREL	11
1	WGLEEMSEYA	6

TableXXXIX-V3-HLA-B0702-10mers-254P1D6B

Each peptide is a portion of SEQ ID NO: 7; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.

Pos	1234567890	score
6	WPSPCCARKQ	13
8	SPCCARKQCS	10
3	RLGWSPCCA	8

TableXXXIX-V5-HLA-B0702-10mers-254P1D6B

Each peptide is a portion of SEQ ID NO: 11; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.

Pos	1 2 3 4 5 6 7 8 9 0	score
1	SPEDIRKDLT	16
3	EDIRKDLTFL	13
9	LTFLGKDWGL	10
2	PEDIRKDLTF	9

TableXL-V1-HLA-B08-10mers-254P1D6B

Pos	1234567890	score
NoResultsFound.		

TableXL-V2-HLA-B08-10mers-254P1D6B

Pos	1234567890	score
NoResultsFound.		

TableXL-V3-HLA-B08-10mers-254P1D6B

Pos	1234567890	score
NoResultsFound.		

TableXL-V5-HLA-B08-10mers-254P1D6B

Pos	1234567890	score
NoResultsFound.		

TableXLI-V1-HLA-B1510-10mers-254P1D6B

Pos	1234567890	score
NoResultsFound.		

TableXLI-V2-HLA-B1510-10mers-254P1D6B

Pos	1234567890	score
NoResultsFound.		

TableXLI-V3-HLA-B1510-10mers-254P1D6B		
Pos	1234567890	score
NoResultsFound.		

TableXLI-V5-HLA-B1510-10mers-254P1D6B		
Pos	1234567890	score
NoResultsFound.		

TableXLII-V1-HLA-B2705-10mers-254P1D6B		
Pos	1234567890	score
NoResultsFound.		

TableXLII-V2-HLA-B2705-10mers-254P1D6B		
Pos	1234567890	score
NoResultsFound.		

TableXLII-V3-HLA-B2705-10mers-254P1D6B		
Pos	1234567890	score
NoResultsFound.		

TableXLII-V5-HLA-B2705-10mers-254P1D6B		
Pos	1234567890	score
NoResultsFound.		

TableXLIII-V1-HLA-B2709-10mers-254P1D6B		
Pos	1234567890	score
NoResultsFound.		

TableXLIII-V2-HLA-B2709-10mers-		
---------------------------------	--	--

254P1D6B		
Pos	1234567890	score
NoResultsFound.		

TableXLIII-V3-HLA-B2709-10mers-254P1D6B		
Pos	1234567890	score
NoResultsFound.		

TableXLIII-V5-HLA-B2709-10mers-254P1D6B		
Pos	1234567890	score
NoResultsFound.		

TableXLIV-V2-HLA-B4402-10mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 5; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Pos	1234567890	score
4	EEMSEYADDY	24
7	SEYADDYREL	22

TableXLIV-V3-HLA-B4402-10mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 7; each start position is specified, the length of peptide is 10 amino acids, and the end position for each peptide is the start position plus nine.		
Pos	1234567890	score
6	WPSPCCARKQ	7
4	LGWPSPCCAR	5
7	PSPCCARKQC	5

TableXLIV-V5-HLA-B4402-10mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 11; each start position is specified, the length of peptide is 10 amino acids, and the end position for		

each peptide is the start position plus nine.		
Pos	1 2 3 4 5 6 7 8 9 0	score
2	PEDIRKDLTF	23
3	EDIRKDLTFL	17
7	KDLTFLGKDW	15
9	LTFLGKDWGL	13

TableXLV-V1-HLA-B5101-10mers-254P1D6B		
Pos	1234567890	score
NoResultsFound.		

TableXLV-V2-HLA-B5101-10mers-254P1D6B		
Pos	1234567890	score
NoResultsFound.		

TableXLV-V3-HLA-B5101-10mers-254P1D6B		
Pos	1234567890	score
NoResultsFound.		

TableXLV-V5-HLA-B5101-10mers-254P1D6B		
Pos	1234567890	score
NoResultsFound.		

TableXLVI-v1-HLA-B5101-15mers-254P1D6B		
Pos	123456789012345	score
NoResultsFound.		

TableXLVI-V2-HLA-DRB1-0101-15mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 5; each start position is specified, the length of peptide is 15 amino acids, and the end position for each peptide is the start position plus fourteen.		
Pos	123456789012345	score

15	ADDYRELEKDLLQPS	29
4	KDWGLEEMSEYADDY	14
5	DWGLEEMSEYADDYR	14

TableXLVI-V3-HLA-DRB1-0101-15mers-254P1D6B

Each peptide is a portion of SEQ ID NO: 7; each start position is specified, the length of peptide is 15 amino acids, and the end position for each peptide is the start position plus fourteen.

Pos	123456789012345	score
1	MTRLGWSPCCARKQ	22
9	PCCARKQCSEGRYTS	18
3	RLGWSPCCARKQCS	10
4	LGWSPCCARKQCSE	10

TableXLVI-V5-HLA-DRB1-0101-15mers-254P1D6B

Each peptide is a portion of SEQ ID NO: 11; each start position is specified, the length of peptide is 15 amino acids, and the end position for each peptide is the start position plus fourteen.

Pos	1 2 3 4 5 6 7 8 9 0 1 2 3 4 5	score
11	RKDLTFLGKDWGLEE	19
7	PEDIRKDLTFLGKDW	18
14	LTFLGKDWGLEEMSE	18
5	DSPEDIRKDLTFLGK	11
8	EDIRKDLTFLGKDWG	11
12	KDLTFLGKDWGLEEM	11
13	DLTFLGKDWGLEEMS	10
15	TFLGKDWGLEEMSEY	10
3	WGDSPEDIRKDLTFL	9
6	SPEDIRKDLTFLGKD	9
10	IRKDLTFLGKDWGLE	9

TableXLVII-V1-HLA-DRB1-0301-15MERS-254P1D6B

Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 15 amino acids, and the end position for each peptide is the start position plus fourteen.

Pos	123456789012345	score
184	DWGLLPGSEGAFFNS	29
903	FKVLRVDTAGCLLK	29
343	LIITLPDNEVELKAF	28
404	VFKVTSSSENAFGEG	28

TableXLVII-V1-HLA-DRB1-0301-15MERS-254P1D6B

Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 15 amino acids, and the end position for each peptide is the start position plus fourteen.

Pos	123456789012345	score
421	NVTVKPARRVNLPPV	28
805	TVEVQDPKRKSGLE	28
845	LNVLDSDIKVQKIRA	28
626	VAVAGPKELIFPVE	27
1030	ESEFSDQDTIFSRE	27
206	PAETQQDPHELHYLNE	26
382	QGEIKQGHKQTLNLS	26
690	HFRLTVKDDQGLSST	26
826	VGQLTEQRKDTLVRQ	26
998	LDNMDEQERMELRPK	26
130	WGDSPEDIRKDLPL	25
775	ALQLTNLVEGVYTFH	25
550	GNQSSDDHQIVLYEW	24
573	KHVVMMQGVQTPYLHL	24
584	YLHLSAMQEGDYTFQ	24
134	PEDIRKDLPLFGKDW	23
733	NNSITLDGSRSTDDQ	23
866	VIVFYVQSRPPFKVL	23
160	YRELEKDLLQPSGKQ	22
442	LQELTLPLTSALIDG	22
834	KDTLVRQLAVLLNVL	22
93	MGPIRSYLTFLRPV	21
110	PAQLLDYGDMMNLNRG	21
126	PSGIWGDSPEDIRKD	21
141	LPFLGKDWGLEEMSE	21
244	SGEVLEKEKASQLQE	21
434	PVAVVSPQLQELTLP	21
633	KELIFPVESATLDGS	21
727	HVLVLPNNSITLDGS	21
765	DVIDGSDHSVALQLT	21
965	TLIVLTGGFTWLCIC	21
282	LSSVTVEKSPVLTVT	20
332	VKELTVSAGDNLIT	20
392	TLNLSQLSVGLYVFK	20
485	DSPVLRLSNLDPGNY	20
516	TAALIVNNAVDYPPV	20
543	QNSITLNGNQSSDDH	20
612	VVTIVQPENNRPPV	20
725	GRHVLVLPNNSITLD	20

TableXLVII-V1-HLA-DRB1-0301-15MERS-254P1D6B

Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 15 amino acids, and the end position for each peptide is the start position plus fourteen.

Pos	123456789012345	score
876	PFKVLKAAEVARNLH	20
888	NLHMRLSKEKADFL	20
953	EWSIFYVTVLAFITL	20
958	YVTVLAFITLIVLTGG	20
62	CDLSSCDLAWWFEGR	19
101	TFVLRPVQRPAQLD	19
152	EMSEYSDDYRELEKD	19
165	KDLLQPSGKQEPGRS	19
245	GEVLEKEKASQLQEQ	19
435	VAVVSPQLQELTLP	19
488	VLRLSNLDPGNYSFR	19
563	EWSLPGSGEGKHVVM	19
598	QLKVTDSRQQSTAV	19
613	VTVIVQPENNRPPVA	19
678	IATVTGLQVGYHFR	19
706	TLTAVVKKENNSPPR	19
788	FHLRVTDSSQASD	19
815	SGLVELTLQVGVGQL	19
838	VRQLAVLLNVLDSDI	19
882	AAEVARNLHMRLSKE	19
889	LHMRLSKEKADFLF	19
890	HMRLSKEKADFLFK	19
941	IQRYIWDGESNCEWS	19
975	WLCICCKRQKRTKI	19
1024	SSLMVSESEFSDQD	19
1056	NGSIRNGASFYSYCSK	19
33	NAVISPNETTRIMR	18
97	RSYLTFLVRPVQRPA	18
100	LTFLVRPVQRPAQLL	18
104	LRPVQRPAQLLDYGD	18
147	DWGLEEMSEYSDDYR	18
157	SDDYRELEKDLLQPS	18
342	NLIITLPDNEVELKA	18
450	TSALIDGSQSTDDTE	18
536	NHTITLPQNSITLNG	18
574	HVVMQGVQTPYLHLS	18
588	SAMQEGDYTFQLKVT	18
632	DKELIFPVESATLDG	18
646	GSSSSDDHGIVFYHW	18

TableXLVII-V1-HLA-DRB1-0301-15MERS-254P1D6B		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 15 amino acids, and the end position for each peptide is the start position plus fourteen.		
Pos	123456789012345	score
691	FRLTVKDQQLSSTS	18
726	RHVLVLPNNSITLDG	18
751	SYLWIRDGQSPAAGD	18
779	TNLVEGVYTFHLRVT	18
899	DFLLFKVLRVDTAGC	18
996	TILDNMDEQERMELR	18
1002	DEQERMELRPKYGIK	18
1004	QERMELRPKYGIKHR	18
1022	HNSSLMVSESEFSD	18
1037	QDTIFSREKMERGNP	18
77	CYLVSCPHKENCEPK	17
138	RKDLPLGKDWGLEE	17
153	MSEYSDDYRELEKDL	17
202	SPAIPAETQQDPELH	17
212	DPELHYLNESASTPA	17
224	TPAPKLPERSVLLPL	17
334	ELTVSAGDNLITLP	17
417	EGFVNVTVKPARRVN	17
456	GSQSTDDTEIVSYHW	17
490	RLSNLDPGNYSFRLT	17
610	TAVVTVIVQPENNR	17
614	TVIVQPENNRPPVAV	17
625	PVAVAGPDKELIFPV	17
668	AVEMENIDKAIATVT	17
704	TSTLTAVVKKENNSP	17
708	TVAVKKENNSPPRAR	17
740	GSRSTDDQRIVSYLW	17
823	QVGVGQLTEQRKDTL	17
864	STVIVFYVQSRPPFK	17
984	QKRTKIRKTKYTIL	17
986	RTKIRKTKYTILDN	17
995	YTILDNMDEQERMEL	17
1052	KVSMNGSIRNGASF	17
4	PTGVLSLLLLVTIA	16
14	LVTIAGCARKQCSEG	16
66	SCDLAWWFEGRCYLV	16
258	EQSSNSSGKEVLMP	16
361	APPVETTYNYEWNLI	16
363	PVETTYNYEWNLISH	16

TableXLVII-V1-HLA-DRB1-0301-15MERS-254P1D6B		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 15 amino acids, and the end position for each peptide is the start position plus fourteen.		
Pos	123456789012345	score
374	LISHPTDYQGEIKQG	16
463	TEIVSYHWEEINGPF	16
653	HGIVFYHWEHVRGPS	16
688	TYHFRLTVKDQQLS	16
718	PPRARAGGRHVLVLP	16
739	DGSRSTDDQRIVSYL	16
934	HLWMENLIQRYIWDG	16
68	DLAWWFEGRCYLVSC	15
156	YSDDYRELEKDLLQP	15
265	GKEVLMPSHSLPPAS	15
357	FVAPAPPVETTYNYE	15
436	AVVSPQLQELTLPLT	15
466	VSYHWEEINGPFIEE	15
555	DDHQIVLYEWSLPGG	15
811	DPRKSGLVLTQVG	15
8	LSSLLLLVTIAGCAR	14
9	SSLLLLVTIAGCARK	14
89	EPKMGPIRSYLTFFV	14
226	APKLPERSVLLPLPT	14
231	ERSVLLPLPTTPSSG	14
232	RSVLLPLPTTPSSGE	14
449	LTSALIDGSQSTDDT	14
556	DHQIVLYEWSLPGGS	14
572	GKHVVMQGVQTPYLH	14
771	DHSVALQLTNLVEGV	14
806	VEVQPDPRKSGLVEL	14
843	VLLNVLDSIKVQKI	14
1015	IKHRSTEHNSSLMVS	14

TableXLVII-V2HLA-DRB1-0301-15mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 5; each start position is specified, the length of peptide is 15 amino acids, and the end position for each peptide is the start position plus fourteen.		
Pos	123456789012345	score
5	DWGLEEMSEYADDYR	19
10	EMSEYADDYRELEKD	18

TableXLVII-V2HLA-DRB1-0301-15mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 5; each start position is specified, the length of peptide is 15 amino acids, and the end position for each peptide is the start position plus fourteen.		
Pos	123456789012345	score
15	ADDYRELEKDLLQPS	18
11	MSEYADDYRELEKDL	17
14	YADDYRELEKDLLQP	15
8	LEEMSEYADDYRELE	11
3	GKDWGLEEMSEYADD	10
7	GLEEMSEYADDYREL	9

TableXLVII-V3HLA-DRB1-0301-15mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 7; each start position is specified, the length of peptide is 15 amino acids, and the end position for each peptide is the start position plus fourteen.		
Pos	123456789012345	score
1	MTRLGWSPCCARKQ	11
10	CCARKQCSEGRYSN	8
6	WPSPCCARKQCSEGR	7
7	PSPCCARKQCSEGR	7
5	GWSPCCARKQCSEG	6

TableXLVII-V5HLA-DRB1-0301-15mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 11; each start position is specified, the length of peptide is 15 amino acids, and the end position for each peptide is the start position plus fourteen.		
Pos	1 2 3 4 5 6 7 8 9 0 1 2 3 4 5	score
3	WGDSPEDIRKDLTFL	25
7	PEDIRKDLTFLGKDW	23
14	LTFLGKDWGLEEMSE	21
11	RKDLTFLGKDWGLEE	18
13	DLTFLGKDWGLEEMS	11

TableXLVIII-V1-HLA-DR1-0401-15mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 15 amino acids, and the end position for each peptide is the start position plus fourteen.		
Pos	123456789012345	score
5	DWGLEEMSEYADDYR	19
10	EMSEYADDYRELEKD	18

Pos	123456789012345	score
68	DLAWWFEGRCYLVSC	28
365	ETTYNYEWNLISHPT	28
751	SYLWIRDGQSPAAGD	28
90	PKKMGPIRSYLTFLV	26
97	RSYLTFLVRPVQRPA	26
101	TFVLRPVQRPAQLLD	26
232	RSVLLPLPTTPSSGE	26
282	LSSVTVEKSPVLTVT	26
421	NVTVKPARRVNLPPV	26
574	HVVMQGVQTPYLHLS	26
610	TAVVTVIVQPENNR	26
633	KELIFPVESATLDGS	26
725	GRHVLVLPNNSITLD	26
733	NNSITLDGSRSTDDQ	26
779	TNLVEGVYTFHLRVT	26
842	AVLLNVLDSDIKVQK	26
899	DFLLFKVLRVDTAGC	26
934	HLWMENLIQRYIWDG	26
28	GRTYSNAVISPNLET	22
49	SHTFPVVDCTAACCD	22
96	IRSYLTFLVRPVQRP	22
153	MSEYSDDYRELEKDL	22
157	SDDYRELEKDLLQPS	22
369	NYEWNLISHPTDYQG	22
402	LYVFKVTSSSENAFG	22
416	GEGFVNVTVPARRV	22
467	SYHWEEINGPFIEEK	22
474	NGPFIEEKTSVDSPV	22
524	AVDYPPVANAGPNHT	22
657	FYHWEHVRGSAVEM	22
749	IVSYLWIRDGQSPA	22
874	RPPFKVLKAAEVARN	22
897	KADFLFKVLRVDTA	22
900	FLLFKVLRVDTAGCL	22
943	RYIWDGESNCEWSIF	22
951	NCEWSIFYVTVLAFT	22
955	SIFYVTVLAFTLIVL	22
992	KTKYTILDNMDEQER	22
5	TGVLSSLLLLVTIAG	20
8	LSSLLLLVTIAGCAR	20
12	LLLVTIAGCARKQCS	20
42	TTRIMRVSHTFPVVD	20
43	TRIMRVSHTFPVDC	20
76	RCYLVSCHKENCEP	20
93	MGPIRSYLTFLVRPV	20

TableXLVIII-V1-HLA-DR1-0401-15mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 15 amino acids, and the end position for each peptide is the start position plus fourteen.		
Pos	123456789012345	score
100	LTFVLRPVQRPAQLL	20
126	PSGIWGDSPEDIRKD	20
160	YRELEKDLLQPSGKQ	20
202	SPAVPAETQQDPELH	20
212	DPELHYLNESASTPA	20
215	LHYLNESASTPAPKL	20
233	SVLLPLPTTPSSGEV	20
245	GEVLEKEKASQLQEQ	20
253	ASQLQEQSSNSSGKE	20
272	SHSLPPASLELSSVT	20
279	SLELSSVTVEKSPVL	20
289	KSPVLTVTPGSTSHS	20
292	VLTVTPGSTSHSIPT	20
301	EHSIPTPPTSAAPSE	20
334	ELTVSAGDNLITLP	20
341	DNLIITLPDNEVELK	20
355	KAFVAPAPPVETTYN	20
371	EWNLISHPTDYQGEI	20
399	SVGLYVFKVTSSSEN	20
432	LPPVAVVSPQLQELT	20
435	VAVVSPQLQELTLPL	20
439	SPQLQELTLPLTSAL	20
442	LQELTLPLTSALIDG	20
446	TLPLTSALIDGSQST	20
485	DSPVLRLSNLDPGNY	20
500	SFRLTVTDSGDATNS	20
527	YPPVANAGPNHTITL	20
536	NHTITLPQNSITLNG	20
543	QNSITLNGNQSSDDH	20
557	HQIVLYEWSLGPGE	20
596	TFQLKVTDSRQQST	20
598	QLKVTDSRQQSTAV	20
614	TVIVQPENNRPPVAV	20
636	IFPVESATLDGSSSS	20
666	PSAVEMENIDKAIAT	20
668	AVEMENIDKAIATVT	20
671	MENIDKAIATVTGLQ	20
675	DKAIATVTGLQVGT	20
698	QQGLSSTSTLTAVK	20

TableXLVIII-V1-HLA-DR1-0401-15mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 15 amino acids, and the end position for each peptide is the start position plus fourteen.		
Pos	123456789012345	score
704	TSTLTAVVKENNSP	20
708	TVAVKKENNSPPRAR	20
726	RHVLVLPNNSITLDG	20
727	HVLVLPNNSITLDGS	20
752	YLWIRDGQSPAAGDV	20
764	GDVIDGSDHSVALQL	20
771	DHSVALQLTNLVEGV	20
782	VEGVYTFHLRVTDSD	20
787	TFHLRVTDSDQASDT	20
805	TVEVQDPKRKSGLVE	20
815	SGLVELTLQVGVGQL	20
823	QVGVGQLTEQRKDTL	20
835	DTLVRQLAVLLNVLD	20
838	VRQLAVLLNVLDSDI	20
841	LAVLLNVLDSDIKVQ	20
845	LVLDSDIKVQKIRA	20
860	HSDLSTVIVFYVQSR	20
865	TVIVFYVQSRPPFKV	20
877	FKVLKAAEVARNLHM	20
882	AAEVARNLHMRLSKE	20
890	HMRLSKEADFLFK	20
902	LFKVLRVDTAGCLLK	20
903	FKVLRVDTAGCLLKC	20
905	VLRVDTAGCLLKCSG	20
956	IFYVTVAFTLIVLT	20
958	YVTVAFTLIVLTGG	20
963	AFTLIVLTGGFTWLC	20
998	LDNMDEQERMELRPK	20
1024	SSLMVSESEFSDSDQD	20
1050	NPKVSMNGSIRNGAS	20
1052	KVSMNGSIRNGASFS	20
1	MAPPTGVLSSLLLLV	18
2	APPTGVLSSLLLLVT	18
21	ARKQCSEGRYSNAV	18
29	RTYSNAVISPNLETT	18
34	AVISPNLETTTRIMRV	18
35	VISPNETTRIMRVS	18
58	TAACCDLSSCDLAWW	18
130	WGDSPEDIRKDLPL	18

TableXLVIII-V1-HLA-DR1-0401-15mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 15 amino acids, and the end position for each peptide is the start position plus fourteen.		
Pos	123456789012345	score
146	KDWGLEEMSEYSDDY	18
169	QPSGKQEPGRSAEYT	18
188	LPGSEGA FNSSVGDS	18
208	ETQQDPELHYLNESA	18
225	PAPKLPERSVLLPLP	18
252	KASQLQEQQSSNSSGK	18
275	LPPASLELSSVTVEK	18
276	PPASLELSSVTVEKS	18
295	VTPGSTEHSIPTPPT	18
298	GSTEHSIPTPTSAA	18
306	TPPTSAAPESTPSE	18
322	PISPTTAPRTVKELT	18
328	APRTVKELTVSAGDN	18
358	VAPAPPVETTYNYEW	18
368	YNYEWNLISHPTDYQ	18
374	LISHPTDYQGEIKQG	18
379	TDYQGEIKQGHKQTL	18
389	HKQTLNLSQLSVGLY	18
403	YVFKVTVSSENAFGE	18
413	NAFGEFVNVTVKPA	18
431	NLPPVAVVSPQLQEL	18
438	VSPQLQELTLPLTSA	18
443	QELTLPLTSALIDGS	18
449	LTSALIDGSQSTDDT	18
455	DGSQSTDDTEIVSYH	18
478	IEEKTSDVSPVLRLS	18
482	TSVDSPVLRLSNLDP	18
505	VTDSGATNSTTAAL	18
514	STTAALIVNNAVDYP	18
535	PNHTITLPQNSITLN	18
549	NGNQSSDDHQIVLYE	18
550	GNQSSDDHQIVLYEW	18
570	SEGKHVVMQGVQTPY	18
588	SAMQEGDYTFQLKVT	18
597	FQLKVTDSRQQSTA	18
606	RQQSTAVTVIVQPE	18
639	VESATLDGSSSSDDH	18
645	DGSSSSDDHGIVFYH	18
691	FRLTVKDQQGLSSTS	18

TableXLVIII-V1-HLA-DR1-0401-15mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 15 amino acids, and the end position for each peptide is the start position plus fourteen.		
Pos	123456789012345	score
695	VKDQQGLSSTSTLTV	18
739	DGSRSTDDQRIVSYL	18
740	GSRSTDDQRIVSYLW	18
762	AAGDVIDGSDHSVAL	18
765	DVIDGSDHSVALQLT	18
769	GSDHSVALQLTNLVE	18
788	FHLRVTD SQGASDTD	18
813	RKSGLVELTLQVGVG	18
825	GVGQLTEQRKDTLVR	18
831	EQRKDTLVRQLAVLL	18
832	QRKDTLVRQLAVLLN	18
853	KVQKIRAHSDLSTVI	18
856	KIRAHSDLSTVIVFY	18
857	IRAHSDLSTVIVFYV	18
880	LKAAEVARNLHMRLS	18
957	FYVTVLAFTLIVLTG	18
996	TILDNMDEQERMELR	18
1009	LRPKYGIKHRSTEHN	18
1015	IKHRSTEHNSSLMVS	18
1034	DSDQDTIFSREKMER	18
1035	SDQDTIFSREKMERG	18
1053	VSMNGSIRNGASFYS	18
400	VGLYVFKVTVSSENA	17
594	DYTFQLKVTDSRQQ	17
785	VYTFHLRVTD SQGAS	17
69	LAWWFEGRCYLVSCLP	16
145	GKDWGLEEMSEYSDD	16
182	YTDWGLLPGSEGA FN	16
214	ELHYLNESASTPAPK	16
378	PTDYQGEIKQGHKQT	16
412	ENAFGEFVNVTVKP	16
465	IVSYHWEENGPFIE	16
498	NYSFRLTVTDSDGAT	16
559	IVLYEWSLPGGSEK	16
581	QTPYLHLSAMQEGDY	16
634	ELIFPVESATLDGSS	16
654	GIVFYHWEHVRGPSA	16
655	IVFYHWEHVRGPSAV	16
688	TYHFRITVKDQQGLS	16

TableXLVIII-V1-HLA-DR1-0401-15mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 15 amino acids, and the end position for each peptide is the start position plus fourteen.		
Pos	123456789012345	score
783	EGVYTFHLRVTD SQG	16
866	VIVFYVQSRPPFKVL	16
867	IVFYVQSRPPFKVLK	16
941	IQRYIWDGESNCEWS	16
954	WSIFYVTVLAFTLIV	16
961	VLAFTLIVLTGGFTW	16
970	TGGFTWLCICCKCRQ	16
972	GFTWLCICCKCRQKR	16
1030	ESEFSDSDQDTIFSRE	16
1038	DTIFSREKMERGNPK	16
475	GPFIEEKTSDVSPVL	15
690	HFRLTVKDQQGLSST	15
886	ARNLHMRLSKEKADF	15
1012	KYGIKHRSTEHNSSL	15
4	PTGVLSSLLLLVTIA	14
9	SSLLLLVTIAGCARK	14
10	SSLLLLVTIAGCARKQ	14
11	LLLLVTIAGCARKQC	14
14	LVTIAGCARKQCSEG	14
32	SNAVISPNETTRIM	14
37	SPNETTRIMRVSH	14
104	LRPVQRPAQLLDYGD	14
110	PAQLLDYGDMMMLNRG	14
111	AQLLDYGDMMMLNRGS	14
116	YGDMMMLNRGSPSGIW	14
118	DMMLNRGSPSGIWGD	14
134	PEDIRKDLPLFGKDW	14
138	RKDLPLFGKDWGLEE	14
141	LPFLGKDWGLEEMSE	14
185	WGLLPGSEGA FNSSV	14
196	NSSVGDS PAVPAETQ	14
235	LLPLPTTPSSGEVLE	14
265	GKEVLMPSHSLPPAS	14
266	KEVLMPSHSLPPASL	14
267	EVLMPSHSLPPASLE	14
284	SVTVEKSPVLTVTPG	14
318	PSELPISPTTAPRTV	14
320	ELPISPTTAPRTVKE	14
329	PRTVKELTVSAGDNL	14

TableXLVIII-V1-HLA-DR1-0401-15mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 15 amino acids, and the end position for each peptide is the start position plus fourteen.		
Pos	123456789012345	score
332	VKELTVSAGDNLIT	14
342	NLIITLPDNEVELKA	14
344	IITLPDNEVELKAFV	14
351	EVELKAFVAPAPPVE	14
361	APPVETTYNYEWNLI	14
382	QGEIKQGHKQTLNLS	14
392	TLNLSQLSVGLYVFK	14
395	LSQLSVGLYVFKVTV	14
397	QLSVGLYVFKVTVSS	14
401	GLYVFKVTVSSENAF	14
406	KVTVSSENAFGEFV	14
427	ARRVNLPPVAVVSPQ	14
429	RVNLPPVAVVSPQLQ	14
434	PVAVVSPQLQELTLP	14
450	TSALIDGSQSTDDTE	14
451	SALIDGSQSTDDTEI	14
462	DTEIVSYHWEEINGP	14
463	TEIVSYHWEEINGPF	14
470	WEEINGPFIEEKTSV	14
481	KTSVDSPVLRLSNLD	14
488	VLRLSNLDPGNYSFR	14
502	RLTVTDSGATNSTT	14
518	ALIVNNAVYPPVAN	14
522	NNAVDYPPVANAGPN	14
538	TITLPQNSITLNGNQ	14
545	SITLNGNQSSDDHQI	14
573	KHVVMQGVQTPYLHL	14
577	MQGVQTPYLHLSAMQ	14
587	LSAMQEGDYTFQLKV	14
609	STAVVTIVQPENNR	14
613	VTIVQPENNRPPVA	14
623	RPPVAVAGPDKELIF	14
625	PVAVAGPDKELIFPV	14
632	DKELIFPVESATLDG	14
641	SATLDGSSSSDDHGI	14
652	DHGIVFYHWEHVRGP	14
660	WEHVRGPSAVEMENI	14
678	IATVTGLQVGTYHFR	14
683	GLQVGTYHFRLTVKD	14

TableXLVIII-V1-HLA-DR1-0401-15mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 15 amino acids, and the end position for each peptide is the start position plus fourteen.		
Pos	123456789012345	score
692	RLTVKDQQGLSSTST	14
735	SITLDGSRSTDDQRI	14
747	QRIVSYLWIRDGQSP	14
763	AGDVIDGSDHSVALQ	14
775	ALQLTNLVEGVYTFH	14
803	TATVEVQDPKRKSG	14
814	KSGLVELTLQVGVGQ	14
817	LVELTLQVGVGQLTE	14
819	ELTLQVGVGQLTEQR	14
821	TLQVGVGQLTEQRKD	14
826	VGQLTEQRKDTLVRQ	14
834	KDTLVRQLAVLLNL	14
844	LLNVLDSDIKVQKIR	14
851	DIKVQKIRAHSDLST	14
854	VQKIRAHSDLSTVIV	14
863	LSTVIVFYVQSRPPF	14
864	STVIVFYVQSRPPFK	14
876	PFKVLKAAEVARNLH	14
912	GCLLKCSGHGHCDPL	14
928	KRCICSHLWMENLIQ	14
932	CSHLWMENLIQRYIW	14
942	QRYIWDGESNCEWSI	14
953	EWSIFYVTVLAFTLI	14
959	VTVLAFTLIVLTGGF	14
965	TLIVLTGGFTWLCIC	14
966	LIVLTGGFTWLCICC	14
973	FTWLCICCKRQKRT	14
975	WLCICCKRQKRTKI	14
1023	NSSLMVSESEFSDSQ	14
1043	REKMERGNPKVSMNG	14
1056	NGSIRNGASFSYCSK	14

TableXLVIII-V2-HLA-DR1-0401-15mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 5; each start position is specified, the length of peptide is 15 amino acids, and the end position for each peptide is the start position plus fourteen.		

Pos	123456789012345	score
11	MSEYADDYRELEKDL	22
15	ADDYRELEKDLLQPS	22
4	KDWGLEEMSEYADDY	18
3	GKDWGLEEMSEYADD	16
10	EMSEYADDYRELEKD	12
14	YADDYRELEKDLLQP	12

TableXLVIII-V3-HLA-DR1-0401-15mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 7; each start position is specified, the length of peptide is 15 amino acids, and the end position for each peptide is the start position plus fourteen.		
Pos	123456789012345	score
3	RLGWSPCCARKQCS	16
1	MTRLGWSPCCARKQ	14
6	WPSPCCARKQCSEGR	12

TableXLVIII-V5-HLA-DR1-0401-15mers-254P1D6B		
Each peptide is a portion of SEQ ID NO: 11; each start position is specified, the length of peptide is 15 amino acids, and the end position for each peptide is the start position plus fourteen.		
Pos	1 2 3 4 5 6 7 8 9 0 1 2 3 4 5	score
7	PEDIRKDLTFLGKDW	20
3	WGDSPEDIRKDLTFL	18
11	RKDLTFLGKDWGLEE	14
14	LTLGKDWGLEEMSE	14
4	GDSPEDIRKDLTFLG	12
8	EDIRKDLTFLGKDWG	12

TableXLIX-V1-HLA-DRB1-1101-15mers-254P162B		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 15 amino acids, and the end position for each peptide is the start position plus fourteen.		
Pos	123456789012345	score
668	AVEMENIDKAIATVT	27
42	TTRIMRVSHTFPVVD	26
138	RKDLPLGLGKDWGLEE	26
654	GIVFYHWEHVRGPSA	26
961	VLAFTLIVLTGGFTW	26
157	SDDYRELEKDLLQPS	25

TableXLIX-V1-HLA-DRB1-1101-15mers-254P162B		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 15 amino acids, and the end position for each peptide is the start position plus fourteen.		
Pos	123456789012345	score
113	LLDYGDMMMLNRGSPS	24
369	NYEWNLISHPTDYQG	24
49	SHTFPVVDCTAACCD	23
97	RSYLTFLVRPVQRPA	23
831	EQRKDTLVRQLAVLL	23
900	FLLFKVLRVDTAGCL	23
182	YTDWGLLPGSEGAFN	22
242	PSSGEVLEKEKASQL	22
416	GEGFVNVTVPARRV	22
524	AVDYPPVANAGPNHT	22
598	QLKVTSSRQSTAV	22
657	FYHWEHVRGPSAVEM	22
749	IVSYLWIRDGQSPAA	22
848	LDSDIKVQKIRAHSD	22
131	GDSPEDIRKDLPLFG	21
265	GKEVLMPSHSLPPAS	21
764	GDVIDGSDHSVALQL	21
887	RNLHMRLSKEKADFL	21
899	DFLLFKVLVRVDTAGC	21
8	LSSLLLLVTIAGCAR	20
101	TFVLRPVQRPAQLLD	20
115	DYGDMMMLNRGSPSGI	20
165	KDLLQPSGKQEPRGS	20
592	EGDYTFQLKVTSSR	20
688	TYHFRLTVKDQQGLS	20
783	EGVYTFHLRVTDSSQ	20
805	TVEVQPDPRKSGLVE	20
865	TVIVFYVQSRPPFKV	20
908	VDTAGCLLKCSGHGH	20
1040	IFSREKMERGNPKVS	20
1052	KVSMNGSIRNGASF	20
153	MSEYSDDYRELEKDL	19
279	SLELSSVTVEKSPVL	19
704	TSTLTVAVKKENNSP	19
747	QRIVSYLWIRDGQSP	19
814	KSGLVELTLQVGVGQ	19
866	VIVFYVQSRPPFKVL	19
68	DLAWWFEGRCYLWSC	18
99	YLTFVLRPVQRPAQL	18

TableXLIX-V1-HLA-DRB1-1101-15mers-254P162B		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 15 amino acids, and the end position for each peptide is the start position plus fourteen.		
Pos	123456789012345	score
179	SAEYTDWGLLPGSEG	18
192	EGAFNSSVGDSAPAV	18
212	DPELHYLNESASTPA	18
232	RSVLLPLPTTPSSGE	18
329	PRTVKELTVSAGDNL	18
378	PTDYQGEIKQGHKQT	18
400	VGLYVFKVTVSSENA	18
429	RVNLPPVAVVSPQLQ	18
485	DSPVLRLSNLDPGNY	18
594	DYTFQLKVTDSRQ	18
970	TGGFTWLCICCCRQ	18
992	KTKYTILDNMDEQER	18
1010	RPKYGIKHRSTEHS	18
1038	DTIFSREKMERGNPK	18
70	AWWFEGRCYLWSCPH	17
365	ETTYNYEWNLISHPT	17
417	EGFVNVTVPARRVN	17
610	TAVVTIVQPENNR	17
655	IVFYHWEHVRGPSAV	17
740	GSRSTDDQRIVSYLW	17
775	ALQLTNLVEGVYTFH	17
874	RPPFKVLKAAEVARN	17
972	GFTWLCICCCRQKR	17
39	NLETRIMRVSHPTF	16
214	ELHYLNESASTPAK	16
367	TYNYEWNLISHPTDY	16
465	IVSYHWEEINGPFIE	16
467	SYHWEEINGPFIEEK	16
481	KTSVDSPLRLSNLD	16
559	IVLYEWSLPGSGEGK	16
561	LYEWSLPGSGEGKHV	16
578	QGVQTPYLHLSAMQE	16
581	QTPYLHLSAMQEGDY	16
656	VFYHWEHVRGPSAVE	16
712	KKENNSPPRARAGGR	16
751	SYLWIRDGQSPAAGD	16
826	VGQLTEQRKDTLVRQ	16
864	STVIVFYVQSRPPFK	16
882	AAEVARNLHMRLSKE	16

TableXLIX-V1-HLA-DRB1-1101-15mers-254P162B		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 15 amino acids, and the end position for each peptide is the start position plus fourteen.		
Pos	123456789012345	score
896	EKADFLFKVLRVDT	16
955	SIFYVTVLAFTLIVL	16
956	IFYVTVLAFTLIVLT	16
983	RQKRTKIRKTKYTI	16
1008	ELRPKYGIKHRSTE	16
48	VSHTFPVVDCTAAC	15
100	LTFLVRPVQRPAQLL	15
294	TVTPGSTEHSIPTP	15
500	SFRLTVDSDGATNS	15
625	PVAVAGPDKELIFPV	15
873	SRPPFKVLKAAEVAR	15
879	VLKAAEVARNLHMRL	15
920	HGHCDPLTKRCICSH	15
935	LWMENLIQRYIWDGE	15
975	WLCICCCRQKRTKI	15
1009	LRPKYGIKHRSTEHN	15
1037	QDTIFSREKMERGNP	15
14	LVTIAGCARKQCSEG	14
15	VTIAGCARKQCSEGR	14
21	ARKQCSEGRYSNAV	14
76	RCYLVSCEPHKENCEP	14
77	CYLVSCEPHKENCEPK	14
83	PHKENCEPKMGPIR	14
84	HKENCEPKMGPIRS	14
87	NCEPKMGPIRSYLT	14
169	QPSGKQEPRGSAEY	14
244	SGEVLEKEKASQLQE	14
281	ELSSVTVEKSPVLT	14
292	VLTVTPGSTEHSIPT	14
351	EVELKAFVAPAPPVE	14
382	QGEIKQGHKQTLNLS	14
398	LSVGLYVFKVTVSSE	14
399	SVGLYVFKVTVSSEN	14
421	NVTVPARRVNLPPV	14
432	LPPVAVVSPQLQELT	14
446	TLPLTSALIDGSQST	14
482	TSVDSPLRLSNLDP	14
518	ALIVNNAVYPPVAN	14
543	QNSITLNGNQSSDDH	14

TableXLIX-V1-HLA-DRB1-1101-15mers-254P162B		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 15 amino acids, and the end position for each peptide is the start position plus fourteen.		
Pos	123456789012345	score
613	VTVIVQPENNRPPVA	14
678	IATVTGLQVGTYHFR	14
705	STLTVAVKKENNSPP	14
714	ENNSPPRARAGGRHV	14
732	PNNISITLDSRSTDD	14
823	QVGVGQLTEQRKDTL	14
838	VRQLAVLLNVLDSDI	14
842	AVLLNVLDSDIKVQK	14
845	LNVLDSDIKVQKIRA	14
850	SDIKVQKIRAHSDLS	14
883	AEVARNLHMRLSKEK	14
912	GCLLKCSGHGHCPL	14
914	LLKCSGHGHCPLTK	14
986	RTKIRKKTKYTILDN	14
998	LDNMDEQERMELRPK	14
1004	QERMELRPKYGIKHR	14
1014	GIKHRSTEHNSSLMV	14
5	TGVLSSLLLVTIAG	13
7	VLSSLLLVTIAGCA	13
10	SLLLLVTIAGCARKQ	13
90	PKKMGPISYLTFLV	13
96	IRSYLTFLVRPVQRP	13
114	LDYGDMMLNRGSPSG	13
134	PEDIRKDLPLFGKDW	13
226	APKLPERSVLLPLPT	13
228	KLPERSVLLPLPTTP	13
263	SSGKEVLMPSHSLPP	13
272	SHSLPPASLELSSVT	13
287	VEKSPVLTVPGST	13
337	VSAGDNLIITLPDNE	13

TableXLIX-V1-HLA-DRB1-1101-15mers-254P162B		
Each peptide is a portion of SEQ ID NO: 3; each start position is specified, the length of peptide is 15 amino acids, and the end position for each peptide is the start position plus fourteen.		
Pos	123456789012345	score
348	PDNEVELKAFVAPAP	13
390	KQTLNLSQLSVGLYV	13
392	TLNLSQLSVGLYVFK	13
401	GLYVFKVTVSSENAF	13
402	LYVFKVTVSSENAFG	13
439	SPQLQELTLPLTSAL	13
497	GNYSFRLTVTDSGGA	13
556	DHQIVLYEWSLGP GS	13
577	MQGVQTPYLHLSAMQ	13
593	GDYTFQLKVTDS SRQ	13
614	TVIVQPENNRPPVAV	13
633	KELIFPVESATLDGS	13
666	PSAVEMENIDKAIAT	13
706	TLTVAVKKENNSPPR	13
725	GRHVLVLPNNSITLD	13
784	GVYTFHLRVTD SQGA	13
787	TFHLRVTD SQGASDT	13
816	GLVELTLQVGVGQLT	13
835	DTLVRQLAVLLNVLD	13
934	HLWMENLIQRYWDG	13
953	EWSIFYVTVLAFTLI	13
954	WSIFYVTVLAFTLIV	13
960	TVLAFTLIVLTGGFT	13
963	AFTLIVLTGGFTWLC	13
1043	REKMERGNPKVSMNG	13

TableXLIX-V2-HLA-DRB1-1101-15mers-254P162B		
Each peptide is a portion of SEQ ID NO: 5; each start position is		

specified, the length of peptide is 15 amino acids, and the end position for each peptide is the start position plus fourteen.		
Pos	123456789012345	score
15	ADDYRELEKDLLQPS	25
11	MSEYADDYRELEKDL	19
5	DWGLEEMSEYADDYR	12

TableXLIX-V3-HLA-DRB1-1101-15mers-254P162B		
Each peptide is a portion of SEQ ID NO: 7; each start position is specified, the length of peptide is 15 amino acids, and the end position for each peptide is the start position plus fourteen.		
Pos	123456789012345	score
6	WPSPCCARKQCSEGR	14
1	MTRLGWSPSPCCARKQ	12
3	RLGWSPSPCCARKQCS	12
5	GWSPSPCCARKQCSEG	8
8	SPCCARKQCSEGRTY	6

TableXLIX-V5-HLA-DRB1-1101-15mers-254P162B		
Each peptide is a portion of SEQ ID NO: 11; each start position is specified, the length of peptide is 15 amino acids, and the end position for each peptide is the start position plus fourteen.		
Pos	1 2 3 4 5 6 7 8 9 0 1 2 3 4 5	score
11	RKDLTFLGKDWGLEE	28
4	GDSPEDIRKDLTFLG	15
7	PEDIRKDLTFLGKDW	13

**Table L: Protein Characteristics of 254P1D6B**

	Bioinformatic Program	URL	Outcome
ORF	ORF finder		3216 bp
Protein length			1072 aa
Transmembrane region	TM Pred	<a href="http://www.ch.embnet.org/">http://www.ch.embnet.org/</a>	TM Helix AA 954-981
	HMMTop	<a href="http://www.enzim.hu/hmmtop/">http://www.enzim.hu/hmmtop/</a>	TM Helix AA 956-980
	Sosui	<a href="http://www.genome.ad.jp/SOSui/">http://www.genome.ad.jp/SOSui/</a>	TM Helix AA 957-979
	TMHMM	<a href="http://www.cbs.dtu.dk/services/TMHMM">http://www.cbs.dtu.dk/services/TMHMM</a>	TM Helix AA 956-978
Signal Peptide	Signal P	<a href="http://www.cbs.dtu.dk/services/SignalP/">http://www.cbs.dtu.dk/services/SignalP/</a>	Yes signal peptide
pI	pI/MW tool	<a href="http://www.expasy.ch/tools/">http://www.expasy.ch/tools/</a>	pI 5.34
Molecular weight	pI/MW tool	<a href="http://www.expasy.ch/tools/">http://www.expasy.ch/tools/</a>	1.17
Localization	PSORT	<a href="http://psort.nibb.ac.jp/">http://psort.nibb.ac.jp/</a>	46% Plasma Membrane 10% endoplasmic reticulum 33.3% Golgi 33.3% Endoplasmic reticulum 22.2% Plasma Membrane 11.1% extracellular, including cell wall TYA transposon protein PKD
	PSORT II	<a href="http://psort.nibb.ac.jp/">http://psort.nibb.ac.jp/</a>	
Motifs	Blocks	<a href="http://www.blocks.fhcrc.org/">http://www.blocks.fhcrc.org/</a>	Purothionin signature
	Repeats	<a href="http://dove.embl-heidelberg.de/">http://dove.embl-heidelberg.de/</a>	No Repeats

**Table LI. Exon compositions of 254P1D6B**

Exon No.	Start position	End position	Length
1	1	406	406
2	407	566	160
3	567	1312	746
4	1313	1505	193
5	1506	1604	99
6	1605	1702	98
7	1703	1790	88
8	1791	1883	93
9	1884	2016	133
10	2017	2245	229
11	2246	2369	124
12	2370	2502	133
13	2503	2651	149
14	2652	2803	152
15	2804	2942	139
16	2943	3102	160
17	3103	3245	143
18	3246	3368	123
19	3369	3459	91
20	3460	3551	92
21	3552	6791	3240

**Table LII. Nucleotide sequence of transcript variant 254P1D6B v.3 (SEQ ID NO: 269)**

gctgccgcgg	gcgggtgggcg	gggatccccc	gggggtgcaa	ccttgctcca	cctgtgctgc	60
cctcggcggg	cctggctggc	cccgcgcaga	gcggcggcgg	cgctcgctgt	cactgccgga	120
ggtgagagcg	cagcagtagc	ttcagcctgt	cttgggcttg	gtccagattc	gctcctctgg	180
ggctacgtcc	cggggaagag	gaagcgagga	tttgctggg	gtggggctgt	acctcttaac	240
agcaggtgcg	cgcgcgaggg	tgtgaacgtg	tgtgtgtgtg	tgtgtctgtg	tgtgtgtgtg	300
taagacctgc	gatgacgacg	aggaggaaca	agtgggacgg	cgagtgatgc	tcagggccag	360
cagcaacgca	tggggcgagc	ttcagtgtcg	ccagcagtg	ccacaggtac	ggtatctact	420

tcccagagcg	cctggccgag	aaataggaaa	gagggcagcc	agtaggcagg	ccaataccca	480
acaaaagtag	aatcgagacg	ccctgagttc	agaagttctt	gaggccaaat	ctggctccta	540
aaaaacatca	aaggaagcct	gcaccaaact	ctctctcagg	ccgcctcaga	agcctgccat	600
caccctactgt	gtggtgcaca	atggcgcccc	ccacagggtg	gctctcttca	ttgctgctgc	660
tggtgacaat	tgcagtttgc	ttatggtgga	tgcactcatg	gcaaaaaaat	cactggtgag	720
catcatttaa	gaagaccat	gactagactg	ggctggccga	gccccatgtt	tgcccgtaag	780
cagtgcagcg	aggggaggac	atattccaat	gcagtcattt	cacctaacct	ggaaaccacc	840
agaatcatgc	gggtgtctca	caccttcctt	gtcgtagact	gcacggccgc	ttgctgtgac	900
ctgtccagct	gtgacctggc	ctggtggttc	gagggccgct	gctacctggt	gagctgcccc	960
cacaaagaga	actgtgagcc	caagaagatg	ggccccatca	ggtcttatct	cacttttgtg	1020
ctccggcctg	ttcagaggcc	tgcacagctg	ctggactatg	gggacatgat	gctgaacagg	1080
ggctccccct	cggggatctg	gggggactca	cctgaggata	tcagaaagga	cttgcccttt	1140
ctaggcaag	attggggcct	agaggagatg	tctgagtact	cagatgacta	ccgggagctg	1200
gagaaggacc	tcttgcaacc	cagtggcaac	caggagccca	gagggagtgc	cgagtacacg	1260
gactggggcc	tactgccggg	cagcgagggg	gccttcaact	cctctgttgg	agacagtcct	1320
gcggtgccag	cggagacgca	gcaggaccct	gagctccatt	acctgaatga	gtcggcttca	1380
acccctgccc	caaaactccc	tgagagaagt	gtgttgcttc	ccttgccgac	tactccatct	1440
tcaggagagg	tgttgagaa	agaaaaggct	tctcagctcc	aggaacaatc	cagcaacagc	1500
tctgaaaaag	aggttcta	gccttcccat	agtcttccct	cggcaagcct	ggagctcagc	1560
tcagtcaccg	tggagaaaag	cccagtgtct	acagtcaccc	cggggagtac	agagcacagc	1620
atcccaacac	ctcccactag	cgcagccccc	tctgagtcga	ccccatctga	gctaccata	1680
tctcctacca	ctgctccccg	gacagtga	gaacttacgg	tatcggtctg	agataacct	1740
attataactt	taccgacaa	tgaagttgaa	tgcaaggcct	ttgttgccgc	agcgccacct	1800
gtagaaacaa	cctacaacta	tgaatgga	ttaaataagc	acccacaga	ctaccaaggt	1860
gaaataaaac	aaggacacaa	gcaaactctt	aacctctctc	aattgtccgt	cggactttat	1920
gtcttcaaag	tcactgtttc	tagtga	gcctttggag	aaggatttgt	caatgtcact	1980
gttaagcctg	ccagaagagt	caacctgcca	cctgtagcag	ttgtttctcc	ccaactgcaa	2040
gagctcactt	tgctttgac	gtcagccctt	attgatggca	gccaaagtac	agatgatact	2100
gaaatagtga	gttatcattg	ggaagaaata	aacgggccc	tcatagaaga	gaagacttca	2160
gttgactctc	ccgtcttacg	cttgtctaac	cttgatcctg	gtaactatag	tttcaggttg	2220
actgttacag	actcggacgg	agccactaac	tctacaactg	cagcccta	agtgaacaat	2280
gctgtggact	accaccagt	tgcta	ggaccaa	acaccataac	tttgcccaa	2340
aactccatca	ctttgaatgg	aaaccagagc	agtgcagatc	accagattgt	cctctatgag	2400
tggtccctgg	gtcctggggg	tgagggcaaa	catgtggtca	tgcaaggag	acagacgcca	2460
taccttcatt	tatctgcaat	gcaggaagga	gattatacat	ttcagctgaa	ggtgacagat	2520
tcttcaaggc	aacagtctac	tgctgtggtg	actgtgattg	tcagccctga	aaacaataga	2580
cctccagtgg	ctgtggccgg	ccctgataaa	gagctgatct	tcccagtgga	aagtgtacc	2640
ctggatggg	gcagcagcag	cgatgaccac	ggcatgtctt	tctaccactg	ggagcacgtc	2700
agagggccca	gtgcagtggg	gatggaaaat	attgacaaag	caatagccac	tgtagctggt	2760
ctccaggtgg	ggacctacca	cttccgtttg	acagtgaag	accagcagg	actgagcagc	2820
acgtccaccc	tcactgtggc	tgtgaagaag	gaaaataata	gtcctcccag	agcccgggct	2880
gggtggcagac	atgttcttgt	gcttcccaat	aattccatta	ctttggatgg	ttcaaggctc	2940
actgatgacc	aaagaattgt	gtcctatctg	tggtccggg	atggccagag	tccagcagct	3000
ggagatgtca	tcgatggctc	tgaccacagt	gtggtctctg	agcttacgaa	tctggtggag	3060
ggggtgtaca	ctttccactt	gcgagtcacc	gacagtcagg	gggcctcgga	cacagacact	3120
gccactgtgg	aagtgcagcc	agaccctagg	aagagtggcc	tggtggagct	gaccctgcag	3180
gttggtgttg	ggcagctgac	agagcagcgg	aaggacaccc	ttgtgaggca	gctggctgtg	3240
ctgctgaacg	tgttgactc	ggacattaa	gtccagaaga	ttcgggcccc	ctcgatctc	3300
agcacctgta	ttgtgtttta	tgtacagagc	agggccgctt	tcaaggttct	caaagctgct	3360
gaagtggccc	gaaatctgca	catgcggctc	tcaaaggaga	aggctgactt	cttgcttttc	3420
aaggtcttga	gggttgatac	agcaggttgc	cttctgaagt	gttctggcca	tggtcactgc	3480
gacccctca	caaagcgctg	catttgtctt	cacttatgga	tggagaacct	tatacagcgt	3540
tatatctggg	atggagagag	caactgtgag	tggagtatat	tctatgtgac	agtgttggct	3600
tttactctta	ttgtgctaac	aggaggtttc	acttggtctt	gcatctgctg	ctgcaaaaga	3660
caaaaaagga	ctaaaatcag	gaaaaaaaca	aagtacacca	tcctggataa	catggatgaa	3720
caggaaagaa	tggaaactgag	gcccaaatat	ggtatcaagc	accgaagcac	agagcacac	3780
tccagcctga	tggtatccga	gtctgagttt	gacagtgacc	aggacacaa	cttcagccga	3840
gaaaagatgg	agagagggaa	tccaaagggt	tccatgaa	gttccatcag	aaatggagct	3900
tccttcagtt	attgtctaaa	ggacagataa	tggtcgagtt	cattgtaaag	tggaaggacc	3960
ccttgaatcc	aagaccagtc	agtgggagtt	acagcacaaa	accactctt	ttagaatagt	4020
tcattgacct	tcttccccag	tggttagat	gtgtatcccc	acgtactaaa	agaccggttt	4080
ttgaaggcac	aaaacaaaaa	ctttgtctct	ttaactgaga	tgcttgtaa	tagaaataaa	4140
ggctgggtaa	aactctaagg	tataacttta	aaagagttt	gagtttttgt	agctggcaca	4200
atctcatatt	aaagatgaac	aacgatttct	atctgtagaa	ccttagagaa	ggtgaatgaa	4260
acaaggtttt	aaaaagggat	gatttctgtc	ttagccgctg	tgattgcctc	taaggaacag	4320
cattctaaac	acggtttctc	ttgtaggacc	tgcagtcaga	tggtgtgta	tgtaaaata	4380
gcttgtctaa	gaggcacggg	ccatctgtgg	aggtacggag	tcttgcagtg	agcaagcttt	4440
ctgtgtgac	ggcaacactc	gcacagtgcc	aagccctcct	ggttttta	tctgtgctat	4500
gtcaatggca	gttttcatct	ctctcaagaa	agcagctgtt	ggccattcaa	gagctaagga	4560
agaatcgat	tctaaggact	gaggcaatag	aaaggggagg	aggagcttaa	tgccgtgcag	4620

Score = 781 bits (406), Expect = 0.0 Identities = 406/406 (100%) Strand = Plus / Plus

199

Query: 301 taagacctgcatgacgacgaggaggaacaagtgggacggcgagtgatgctcagggccag 360  
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
 Sbjct: 301 taagacctgcatgacgacgaggaggaacaagtgggacggcgagtgatgctcagggccag 360

Query: 361 cagcaacgcatggggcgagcttcagtgtcgccagcagtgaccacag 406  
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
 Sbjct: 361 cagcaacgcatggggcgagcttcagtgtcgccagcagtgaccacag 406

Score = .314 bits (163), Expect = 2e-81Identities = 165/166 (99%) Strand = Plus / Plus

Query: 405 agttcttgaggccaaatctggctcctaaaaaacatcaaaggaagcttgacccaaactctc 464  
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
 Sbjct: 514 agttcttgaggccaaatctggctcctaaaaaacatcaaaggaagcttgacccaaactctc 573

Query: 465 ttcagggccgcctcagaagcctgccatcacccactgtgtggtgcacaatggcgcccccca 524  
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
 Sbjct: 574 ttcagggccgcctcagaagcctgccatcacccactgtgtggtgcacaatggcgcccccca 633

Query: 525 caggtgtgctctcttcattgctgctgctggtgacaattgcaggttg 570  
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
 Sbjct: 634 caggtgtgctctcttcattgctgctgctggtgacaattgcaggttg 679

Score = 1.197e+04 bits (6225), Expect = 0.0Identities = 6225/6225 (100%) Strand = Plus / Plus

Query: 567 gttgtgcccgtgaagcagtgacgaggggaggacatattccaatgcagtcatttcaccta 626  
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
 Sbjct: 767 gttgtgcccgtgaagcagtgacgaggggaggacatattccaatgcagtcatttcaccta 826

Query: 627 acttggaaccaccagaatcatgcgggtgtctcacaccttcctgtcgtagactgcacgg 686  
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
 Sbjct: 827 acttggaaccaccagaatcatgcgggtgtctcacaccttcctgtcgtagactgcacgg 886

Query: 687 ccgcttgctgtgacctgtccagctgtgacctggcctggtggttcgagggcgctgtacc 746  
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
 Sbjct: 887 ccgcttgctgtgacctgtccagctgtgacctggcctggtggttcgagggcgctgtacc 946

Query: 747 tggtagctgccccacaaagagaactgtgagcccaagaagatgggccccatcaggtctt 806  
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
 Sbjct: 947 tggtagctgccccacaaagagaactgtgagcccaagaagatgggccccatcaggtctt 1006

Query: 807 atctcacttttgctccggcctgttcagaggcctgcacagctgctggactatggggaca 866  
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
 Sbjct: 1007 atctcacttttgctccggcctgttcagaggcctgcacagctgctggactatggggaca 1066

Query: 867 tgatgctgaacaggggctccccctcggggatctgggggactcacctgaggatatcagaa 926  
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
 Sbjct: 1067 tgatgctgaacaggggctccccctcggggatctgggggactcacctgaggatatcagaa 1126

Query: 927 aggacttgccctttctaggcaaaagattggggcctagaggagatgtctgagtactcagatg 986  
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
 Sbjct: 1127 aggacttgccctttctaggcaaaagattggggcctagaggagatgtctgagtactcagatg 1186

Query: 987 actaccgggagctggagaaggacctcttgcaaccagtggaagcaggagcccagaggga 1046  
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
 Sbjct: 1187 actaccgggagctggagaaggacctcttgcaaccagtggaagcaggagcccagaggga 1246

Query: 1047 gtgccgagtacacggactggggcctactgccgggcagcgagggggccttcaactcctctg 1106  
 ||||||||||||||||||||||||||||||||||||||||||||  
 Sbjct: 1247 gtgccgagtacacggactggggcctactgccgggcagcgagggggccttcaactcctctg 1306

Query: 1107 ttggagacagtcctgcggtgccagcggagacgcagcaggaccctgagctccattacctga 1166  
 ||||||||||||||||||||||||||||||||||||||||||||  
 Sbjct: 1307 ttggagacagtcctgcggtgccagcggagacgcagcaggaccctgagctccattacctga 1366

Query: 1167 atgagtcggcttcaaccctgccccaaaactccctgagagaagtgtgttgcttcccttgc 1226  
 ||||||||||||||||||||||||||||||||||||||||||||  
 Sbjct: 1367 atgagtcggcttcaaccctgccccaaaactccctgagagaagtgtgttgcttcccttgc 1426

Query: 1227 cgactactccatcttcaggagaggtgttgagaaaagaaaaggcttctcagctccaggaac 1286  
 ||||||||||||||||||||||||||||||||||||||||||||  
 Sbjct: 1427 cgactactccatcttcaggagaggtgttgagaaaagaaaaggcttctcagctccaggaac 1486

Query: 1287 aatccagcaacagctctggaaaagaggttctaatagccttcccatagtcttcctccggcaa 1346  
 ||||||||||||||||||||||||||||||||||||||||||||  
 Sbjct: 1487 aatccagcaacagctctggaaaagaggttctaatagccttcccatagtcttcctccggcaa 1546

Query: 1347 gcctggagctcagctcagtcaccgtggagaaaagcccagtgctcacagtcaccccgggga 1406  
 ||||||||||||||||||||||||||||||||||||||||||||  
 Sbjct: 1547 gcctggagctcagctcagtcaccgtggagaaaagcccagtgctcacagtcaccccgggga 1606

Query: 1407 gtacagagcacagcatcccaacacctcccactagcgcagccccctctgagtcaccccat 1466  
 ||||||||||||||||||||||||||||||||||||||||||||  
 Sbjct: 1607 gtacagagcacagcatcccaacacctcccactagcgcagccccctctgagtcaccccat 1666

Query: 1467 ctgagctacccatatctcctaccactgctcccaggacagtgaaagaacttacgggatcgg 1526  
 ||||||||||||||||||||||||||||||||||||||||||||  
 Sbjct: 1667 ctgagctacccatatctcctaccactgctcccaggacagtgaaagaacttacgggatcgg 1726

Query: 1527 ctggagataaacctaattataactttacccgacaatgaagttgaactgaaggcctttgttg 1586  
 ||||||||||||||||||||||||||||||||||||||||||||  
 Sbjct: 1727 ctggagataaacctaattataactttacccgacaatgaagttgaactgaaggcctttgttg 1786

Query: 1587 cgccagcgccacctgtagaaacaacctacaactatgaatggaatttaataagccacccca 1646  
 ||||||||||||||||||||||||||||||||||||||||||||  
 Sbjct: 1787 cgccagcgccacctgtagaaacaacctacaactatgaatggaatttaataagccacccca 1846

Query: 1647 cagactaccaaggtgaaataaaaacaaggacacaagcaaactcttaacctctctcaattgt 1706  
 ||||||||||||||||||||||||||||||||||||||||||||  
 Sbjct: 1847 cagactaccaaggtgaaataaaaacaaggacacaagcaaactcttaacctctctcaattgt 1906

Query: 1707 ccgtcggactttatgtcttcaaagtcaactgtttctagtgaaaacgcctttggagaaggat 1766  
 ||||||||||||||||||||||||||||||||||||||||||||  
 Sbjct: 1907 ccgtcggactttatgtcttcaaagtcaactgtttctagtgaaaacgcctttggagaaggat 1966

Query: 1767 ttgtcaatgtcactgttaagcctgccagaagagtcaacctgccacctgtagcagttgttt 1826  
 ||||||||||||||||||||||||||||||||||||||||||||  
 Sbjct: 1967 ttgtcaatgtcactgttaagcctgccagaagagtcaacctgccacctgtagcagttgttt 2026

Query: 1827 ctccccaaactgcaagagctcactttgcctttgacgtcagccctcattgatggcagccaaa 1886  
 ||||||||||||||||||||||||||||||||||||||||||||  
 Sbjct: 2027 ctccccaaactgcaagagctcactttgcctttgacgtcagccctcattgatggcagccaaa 2086

Query: 1887 gtacagatgatactgaaatagtgagttatcattgggaagaaataaacgggccccttcatag 1946  
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
 Sbjct: 2087 gtacagatgatactgaaatagtgagttatcattgggaagaaataaacgggccccttcatag 2146

Query: 1947 aagagaagacttcagttgactctcccgctcttacgcttgcttaaccttgatcctggtaact 2006  
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
 Sbjct: 2147 aagagaagacttcagttgactctcccgctcttacgcttgcttaaccttgatcctggtaact 2206

Query: 2007 atagtttcaggttgactgttacagactcggacggagccactaactctacaactgcagccc 2066  
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
 Sbjct: 2207 atagtttcaggttgactgttacagactcggacggagccactaactctacaactgcagccc 2266

Query: 2067 taatagtgaacaatgctgtggactacccaccagttgctaatagcaggaccaaatacacacca 2126  
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
 Sbjct: 2267 taatagtgaacaatgctgtggactacccaccagttgctaatagcaggaccaaatacacacca 2326

Query: 2127 taactttgccccaaaactccatcactttgaatggaaaccagagcagtgacgatcaccaga 2186  
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
 Sbjct: 2327 taactttgccccaaaactccatcactttgaatggaaaccagagcagtgacgatcaccaga 2386

Query: 2187 ttgtcctctatgagtggcctcctgggtcctgggagtgagggcaaacaatgtgggtcatgcagg 2246  
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
 Sbjct: 2387 ttgtcctctatgagtggcctcctgggtcctgggagtgagggcaaacaatgtgggtcatgcagg 2446

Query: 2247 gagtacagacgccataccttcatttatctgcaatgcaggaaggagattatacatttcagc 2306  
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
 Sbjct: 2447 gagtacagacgccataccttcatttatctgcaatgcaggaaggagattatacatttcagc 2506

Query: 2307 tgaaggtgacagattcttcaaggcaacagctctactgctgtgggtgactgtgattgtccagc 2366  
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
 Sbjct: 2507 tgaaggtgacagattcttcaaggcaacagctctactgctgtgggtgactgtgattgtccagc 2566

Query: 2367 ctgaaaacaatagacctccagtggtgtggccggccctgataaagagctgatcttccag 2426  
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
 Sbjct: 2567 ctgaaaacaatagacctccagtggtgtggccggccctgataaagagctgatcttccag 2626

Query: 2427 tggaaagtgtaccctggatgggagcagcagcagcgatgaccacggcattgtcttctacc 2486  
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
 Sbjct: 2627 tggaaagtgtaccctggatgggagcagcagcagcgatgaccacggcattgtcttctacc 2686

Query: 2487 actgggagcacgtcagaggccccagtgagtgagatggaaaaatattgacaaagcaatag 2546  
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
 Sbjct: 2687 actgggagcacgtcagaggccccagtgagtgagatggaaaaatattgacaaagcaatag 2746

Query: 2547 ccactgtgactgggtctccaggtggggacctaccacttccgtttgacagtgaagaccagc 2606  
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
 Sbjct: 2747 ccactgtgactgggtctccaggtggggacctaccacttccgtttgacagtgaagaccagc 2806

Query: 2607 agggactgagcagcacgtccaccctcactgtggctgtgaagaaggaaaaataatagtcctc 2666  
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
 Sbjct: 2807 agggactgagcagcacgtccaccctcactgtggctgtgaagaaggaaaaataatagtcctc 2866

Query: 2667 ccagagccccgggctgggtggcagacatgttcttgtgcttcccaataattccattactttgg 2726  
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
 Sbjct: 2867 ccagagccccgggctgggtggcagacatgttcttgtgcttcccaataattccattactttgg 2926

Query: 2727 atggttcaaggtctactgatgaccaaagaattgtgtcctatctgtggatccgggatggcc 2786  
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
 Sbjct: 2927 atggttcaaggtctactgatgaccaaagaattgtgtcctatctgtggatccgggatggcc 2986

Query: 2787 agagtccagcagctggagatgtcatcgatggctctgaccacagtgtggctctgcagctta 2846  
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
 Sbjct: 2987 agagtccagcagctggagatgtcatcgatggctctgaccacagtgtggctctgcagctta 3046

Query: 2847 cgaatctggtggaggggggtgtacactttccacttgcgagtcaccgacagtcagggggcct 2906  
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
 Sbjct: 3047 cgaatctggtggaggggggtgtacactttccacttgcgagtcaccgacagtcagggggcct 3106

Query: 2907 cggacacagacactgccactgtggaagtgcagccagaccctaggaagagtggcctggtgg 2966  
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
 Sbjct: 3107 cggacacagacactgccactgtggaagtgcagccagaccctaggaagagtggcctggtgg 3166

Query: 2967 agctgaccctgcaggttgggtgtgggcagctgacagagcagcggaaggacacccttgtga 3026  
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
 Sbjct: 3167 agctgaccctgcaggttgggtgtgggcagctgacagagcagcggaaggacacccttgtga 3226

Query: 3027 ggcagctggctgtgctgctgaacgtgctggactcggacattaaggtccagaagattcggg 3086  
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
 Sbjct: 3227 ggcagctggctgtgctgctgaacgtgctggactcggacattaaggtccagaagattcggg 3286

Query: 3087 cccactcggatctcagcaccgtgattgtgttttatgtacagagcaggccgcctttcaagg 3146  
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
 Sbjct: 3287 cccactcggatctcagcaccgtgattgtgttttatgtacagagcaggccgcctttcaagg 3346

Query: 3147 ttctcaaagctgctgaagtggcccgaaatctgcacatgcggctctcaaaggagaaggctg 3206  
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
 Sbjct: 3347 ttctcaaagctgctgaagtggcccgaaatctgcacatgcggctctcaaaggagaaggctg 3406

Query: 3207 acttcttgcttttcaaggctctgaggggtgatacagcaggttgccttctgaagtgttctg 3266  
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
 Sbjct: 3407 acttcttgcttttcaaggctctgaggggtgatacagcaggttgccttctgaagtgttctg 3466

Query: 3267 gccatggtcactgcgacccccctcaciaaagcgctgcatttgctctcacttatggatggaga 3326  
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
 Sbjct: 3467 gccatggtcactgcgacccccctcaciaaagcgctgcatttgctctcacttatggatggaga 3526

Query: 3327 accttatacagcggttatatctgggatggagagagcaactgtgagtggagtatattctatg 3386  
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
 Sbjct: 3527 accttatacagcggttatatctgggatggagagagcaactgtgagtggagtatattctatg 3586

Query: 3387 tgacagtgttggttttactcttattgtgctaacaggagggtttcacttggctttgcatct 3446  
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
 Sbjct: 3587 tgacagtgttggttttactcttattgtgctaacaggagggtttcacttggctttgcatct 3646

Query: 3447 gctgctgcaaaagacaaaaaaggactaaaatcaggaaaaaaacaaagtacaccatcctgg 3506  
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
 Sbjct: 3647 gctgctgcaaaagacaaaaaaggactaaaatcaggaaaaaaacaaagtacaccatcctgg 3706

Query: 3507 ataacatggatgaacaggaaagaatggaactgaggcccaaataatgggtatcaagcaccgaa 3566  
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
 Sbjct: 3707 ataacatggatgaacaggaaagaatggaactgaggcccaaataatgggtatcaagcaccgaa 3766

Query: 3567 gcacagagcacaactccagcctgatggatccgagctctgagtttgacagtgaccaggaca 3626  
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
 Sbjct: 3767 gcacagagcacaactccagcctgatggatccgagctctgagtttgacagtgaccaggaca 3826

Query: 3627 caatcttcagccgagaaaagatggagagaggggaatccaaagggttccatgaatgggtcca 3686  
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
 Sbjct: 3827 caatcttcagccgagaaaagatggagagaggggaatccaaagggttccatgaatgggtcca 3886

Query: 3687 tcagaaatggagcttccttcagttattgctcaaaggacagataatggcgagttcattgt 3746  
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
 Sbjct: 3887 tcagaaatggagcttccttcagttattgctcaaaggacagataatggcgagttcattgt 3946

Query: 3747 aaagtggaaggacccttgaatccaagaccagtcagtgagggttacagcacaaaaccac 3806  
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
 Sbjct: 3947 aaagtggaaggacccttgaatccaagaccagtcagtgagggttacagcacaaaaccac 4006

Query: 3807 tcttttagaatagttcattgaccttcttcccagtgagggttagatgtgtatccccacgtac 3866  
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
 Sbjct: 4007 tcttttagaatagttcattgaccttcttcccagtgagggttagatgtgtatccccacgtac 4066

Query: 3867 taaaagaccggtttttgaaggcacaaaacaaaactttgctcttttaactgagatgcttg 3926  
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
 Sbjct: 4067 taaaagaccggtttttgaaggcacaaaacaaaactttgctcttttaactgagatgcttg 4126

Query: 3927 ttaatagaaataaaggctgggtaaaactctaagggtatataacttaaagagttttgagttt 3986  
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
 Sbjct: 4127 ttaatagaaataaaggctgggtaaaactctaagggtatataacttaaagagttttgagttt 4186

Query: 3987 ttgtagctggcacatctcatattaaagatgaacaacgatttctatctgtagaaccttag 4046  
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
 Sbjct: 4187 ttgtagctggcacatctcatattaaagatgaacaacgatttctatctgtagaaccttag 4246

Query: 4047 agaaggtgaatgaaacaagggttttaaaaagggtgatttctgtcttagccgctgtgattg 4106  
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
 Sbjct: 4247 agaaggtgaatgaaacaagggttttaaaaagggtgatttctgtcttagccgctgtgattg 4306

Query: 4107 cctctaaggaacagcattctaaacacggtttctctttaggacctgcagtcagatggctg 4166  
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
 Sbjct: 4307 cctctaaggaacagcattctaaacacggtttctctttaggacctgcagtcagatggctg 4366

Query: 4167 tgtatgttaaaatagcttcttaagaggcacgggcatctgtggaggtacggagctcttg 4226  
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
 Sbjct: 4367 tgtatgttaaaatagcttcttaagaggcacgggcatctgtggaggtacggagctcttg 4426

Query: 4227 atgtagcaagctttctgtgctgacggcaacactcgacagtgccaagccctcctgggttt 4286  
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
 Sbjct: 4427 atgtagcaagctttctgtgctgacggcaacactcgacagtgccaagccctcctgggttt 4486

Query: 4287 taattctgtgctatgtcaatggcagttttcatctctctcaagaaagcagctgttggccat 4346  
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
 Sbjct: 4487 taattctgtgctatgtcaatggcagttttcatctctctcaagaaagcagctgttggccat 4546

Query: 4347 tcaagagctaaggaagaatcgatttctaaggactgaggcaatagaaagggaggaggagc 4406  
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
 Sbjct: 4547 tcaagagctaaggaagaatcgatttctaaggactgaggcaatagaaagggaggaggagc 4606

Query: 4407 ttaatgccgtgcaggttgaaggtagcattgtaacattatcttttctttctctaagaaaa 4466  
 ||||||||||||||||||||||||||||||||||||||||||||  
 Sbjct: 4607 ttaatgccgtgcaggttgaaggtagcattgtaacattatcttttctttctctaagaaaa 4666

Query: 4467 ctacactgactcctctcggtgttgttttagcagtatagttctctaataagtaaacggatcccc 4526  
 ||||||||||||||||||||||||||||||||||||||||||||  
 Sbjct: 4667 ctacactgactcctctcggtgttgttttagcagtatagttctctaataagtaaacggatcccc 4726

Query: 4527 agtttacattaaatgcaatagaagtgattaattcattaagcatttattatgttctgtagg 4586  
 ||||||||||||||||||||||||||||||||||||||||||||  
 Sbjct: 4727 agtttacattaaatgcaatagaagtgattaattcattaagcatttattatgttctgtagg 4786

Query: 4587 ctgtgcgttttgactgccatagatagggataacgactcagcaattgtgtatatattccaa 4646  
 ||||||||||||||||||||||||||||||||||||||||||||  
 Sbjct: 4787 ctgtgcgttttgactgccatagatagggataacgactcagcaattgtgtatatattccaa 4846

Query: 4647 aactctgaaatacagtcagtccttaacttggatggcggtggttatgatactctggtccccga 4706  
 ||||||||||||||||||||||||||||||||||||||||||||  
 Sbjct: 4847 aactctgaaatacagtcagtccttaacttggatggcggtggttatgatactctggtccccga 4906

Query: 4707 caggtactttccaaaataacttgacatagatgtattcacttcatatgtttaaaaatacat 4766  
 ||||||||||||||||||||||||||||||||||||||||||||  
 Sbjct: 4907 caggtactttccaaaataacttgacatagatgtattcacttcatatgtttaaaaatacat 4966

Query: 4767 ttaagtttttctaccgaataaatcttatttcaaacatgaaagacaattaaaacattccca 4826  
 ||||||||||||||||||||||||||||||||||||||||||||  
 Sbjct: 4967 ttaagtttttctaccgaataaatcttatttcaaacatgaaagacaattaaaacattccca 5026

Query: 4827 cccacaaagcagttactcccgagcaattaactggagttaattgtagcctgctacgttgact 4886  
 ||||||||||||||||||||||||||||||||||||||||||||  
 Sbjct: 5027 cccacaaagcagttactcccgagcaattaactggagttaattgtagcctgctacgttgact 5086

Query: 4887 gggttcagggtagttcccatccacccttggtcctgaggctgggtggccttggtgggtgcct 4946  
 ||||||||||||||||||||||||||||||||||||||||||||  
 Sbjct: 5087 gggttcagggtagttcccatccacccttggtcctgaggctgggtggccttggtgggtgcct 5146

Query: 4947 tggcattttttgtgggaagattagaatgagagatagaaccagtggttggtaccaagtgt 5006  
 ||||||||||||||||||||||||||||||||||||||||||||  
 Sbjct: 5147 tggcattttttgtgggaagattagaatgagagatagaaccagtggttggtaccaagtgt 5206

Query: 5007 gagcacacctaacaatatcctgttgacaaatgcttttttaacacatgggaaaactagga 5066  
 ||||||||||||||||||||||||||||||||||||||||||||  
 Sbjct: 5207 gagcacacctaacaatatcctgttgacaaatgcttttttaacacatgggaaaactagga 5266

Query: 5067 atgcattgctgatgaagaagcaaggattttaaacaccagggcaggagtgccagagaaaaat 5126  
 ||||||||||||||||||||||||||||||||||||||||||||  
 Sbjct: 5267 atgcattgctgatgaagaagcaaggattttaaacaccagggcaggagtgccagagaaaaat 5326

Query: 5127 gtttcccatgggttcttaaaaaaaattcagcttttaggtgcttttgtcatctcccgag 5186  
 ||||||||||||||||||||||||||||||||||||||||||||  
 Sbjct: 5327 gtttcccatgggttcttaaaaaaaattcagcttttaggtgcttttgtcatctcccgag 5386

Query: 5187 tattcatcctcatgggaccatcttatttttacttattgtaatttactggggaaaggcaga 5246  
 ||||||||||||||||||||||||||||||||||||||||||||  
 Sbjct: 5387 tattcatcctcatgggaccatcttatttttacttattgtaatttactggggaaaggcaga 5446

Query: 5247 actaaaaagtgtgtcatTTTTTTTTTaaaataattgctttgcttatgcctacactttctg 5306  
 |||||  
 Sbjct: 5447 actaaaaagtgtgtcatTTTTTTTTTaaaataattgctttgcttatgcctacactttctg 5506

Query: 5307 tataactagccaattcaatactgtctatagtgttagaaggaaaatgtgattTTTTTTTTT 5366  
 |||||  
 Sbjct: 5507 tataactagccaattcaatactgtctatagtgttagaaggaaaatgtgattTTTTTTTTT 5566

Query: 5367 taaccagtattgagcttcataagcctagaatctgccttatcaggtgaccaggggttatggt 5426  
 |||||  
 Sbjct: 5567 taaccagtattgagcttcataagcctagaatctgccttatcaggtgaccaggggttatggt 5626

Query: 5427 tgtttgcattgcaaatgtgaatttctggcataggggacagcagcccaaatgtaaagtcac 5486  
 |||||  
 Sbjct: 5627 tgtttgcattgcaaatgtgaatttctggcataggggacagcagcccaaatgtaaagtcac 5686

Query: 5487 gggcgtaatgaggaagaaggaggagtgaaacattaccgctttatgtacataacatatgcagt 5546  
 |||||  
 Sbjct: 5687 gggcgtaatgaggaagaaggaggagtgaaacattaccgctttatgtacataacatatgcagt 5746

Query: 5547 ttacatactcatttgatccttataatcaaccttgaaggaggagatactatcattcttatgt 5606  
 |||||  
 Sbjct: 5747 ttacatactcatttgatccttataatcaaccttgaaggaggagatactatcattcttatgt 5806

Query: 5607 tgcagatagccctctgaaggcccagagaggttaagtaacttcccagaggtcatggccaag 5666  
 |||||  
 Sbjct: 5807 tgcagatagccctctgaaggcccagagaggttaagtaacttcccagaggtcatggccaag 5866

Query: 5667 aagtagtggtccaagaactgaatgcaaatTTTTTaaactgtagagttctgctttccact 5726  
 |||||  
 Sbjct: 5867 aagtagtggtccaagaactgaatgcaaatTTTTTaaactgtagagttctgctttccact 5926

Query: 5727 aaacaaagaactcctgccttgatggatggagggcaaatcttggtggaacttttggggccac 5786  
 |||||  
 Sbjct: 5927 aaacaaagaactcctgccttgatggatggagggcaaatcttggtggaacttttggggccac 5986

Query: 5787 ctgaaagtctattcccaggactaagaggaatttcttttaatggatccagagagccaagg 5846  
 |||||  
 Sbjct: 5987 ctgaaagtctattcccaggactaagaggaatttcttttaatggatccagagagccaagg 6046

Query: 5847 tcagagggagagatggcctgcatagtctcctgtggatcacacccgggccacccctccctc 5906  
 |||||  
 Sbjct: 6047 tcagagggagagatggcctgcatagtctcctgtggatcacacccgggccacccctccctc 6106

Query: 5907 taggtttacagtggacttcttctgccccctcctcttttctgtccttgccatctcagcct 5966  
 |||||  
 Sbjct: 6107 taggtttacagtggacttcttctgccccctcctcttttctgtccttgccatctcagcct 6166

Query: 5967 ggcctctctgatccttccatcacagaaggatcttgaatctctgggaaatcaaacatcaca 6026  
 |||||  
 Sbjct: 6167 ggcctctctgatccttccatcacagaaggatcttgaatctctgggaaatcaaacatcaca 6226

Query: 6027 gtagtgatcagaaagtgagtcctgtcttgtcaccctatttctcatcagaacaaagcacga 6086  
 |||||  
 Sbjct: 6227 gtagtgatcagaaagtgagtcctgtcttgtcaccctatttctcatcagaacaaagcacga 6286

Query: 6087 gatggaatgaccaaccagcattcttcatggtggactgcttatcattgaggatctttggga 6146  
 |||  
 Sbjct: 6287 gatggaatgaccaaccagcattcttcatggtggactgcttatcattgaggatctttggga 6346

Query: 6147 gataaagcacgctaagagctctggacagagaaaaacaggccctagaatatgggagtgagg 6206  
 |||  
 Sbjct: 6347 gataaagcacgctaagagctctggacagagaaaaacaggccctagaatatgggagtgagg 6406

Query: 6207 gtttgtagggctcataggctaacaagcacttttagttgctggtttacattcaatgaaggag 6266  
 |||  
 Sbjct: 6407 gtttgtagggctcataggctaacaagcacttttagttgctggtttacattcaatgaaggag 6466

Query: 6267 gattcatacccatggcattacaaggctaagcatgtgtatgactaaggaactatctgaaa 6326  
 |||  
 Sbjct: 6467 gattcatacccatggcattacaaggctaagcatgtgtatgactaaggaactatctgaaa 6526

Query: 6327 acatgcagcaaggtaagaaaatgtaccactcaacaagccagtgatgccaccttttgtagc 6386  
 |||  
 Sbjct: 6527 acatgcagcaaggtaagaaaatgtaccactcaacaagccagtgatgccaccttttgtagc 6586

Query: 6387 cggggaggagagtgactaccattgtttttgtgtgacaaagctatcatggactatttta 6446  
 |||  
 Sbjct: 6587 cggggaggagagtgactaccattgtttttgtgtgacaaagctatcatggactatttta 6646

Query: 6447 tcttggttttattgcttaaaatatattttttccctatgtgttgacaaggattttctaa 6506  
 |||  
 Sbjct: 6647 tcttggttttattgcttaaaatatattttttccctatgtgttgacaaggattttctaa 6706

Query: 6507 tatcacactattaaatatatgcactaatctaaataaagggtgtctgtattttctgtaatgc 6566  
 |||  
 Sbjct: 6707 tatcacactattaaatatatgcactaatctaaataaagggtgtctgtattttctgtaatgc 6766

Query: 6567 ttatttttagggggaaattgttttctttatgcttcagggtagaggattcccttgagta 6626  
 |||  
 Sbjct: 6767 ttatttttagggggaaattgttttctttatgcttcagggtagaggattcccttgagta 6826

Query: 6627 taggtcagcaaaactctggcctgcagcctgtgtgtgcacgccccatgagccgaaaagtggg 6686  
 |||  
 Sbjct: 6827 taggtcagcaaaactctggcctgcagcctgtgtgtgcacgccccatgagccgaaaagtggg 6886

Query: 6687 tcttatgttttcaaagtgttaaaaaataaaaaaaatttgaaacatgtgaactatatga 6746  
 |||  
 Sbjct: 6887 tcttatgttttcaaagtgttaaaaaataaaaaaaatttgaaacatgtgaactatatga 6946

Query: 6747 cattcagatttgtgttcataaataaagtttttattggaacatatcc 6791  
 |||  
 Sbjct: 6947 cattcagatttgtgttcataaataaagtttttattggaacatatcc 6991

Table LIV . Peptide sequences of protein coded by 254P1D6B v.3 (SEQ ID NO: 272)

MTRLGWSPSPC	CARKQCSEGR	TYSNAVISP	LETTRIMRVS	HTFPVVDCTA	ACCDLSSCDL	60
AWWFEGRCYL	VSCPHKENCE	PKKMGPIRSY	LTFVLRPVQR	PAQLLDYGDM	MLNRGSPSGI	120
WGDSPEDIRK	DLPFLGKDWG	LEEMSEYSDD	YRELEKDLLQ	PSGKQEPGRS	AEYTDWGLLP	180
GSEGA FNSSV	GDSPAVPAET	QQDPELHYLN	ESASTPAPKL	PERSVLLPLP	TTPSSGEVLE	240
KEKASQLQEQ	SSNSSGKEVL	MPSHSLPPAS	LELSSVTVEK	SPVLTVTPGS	TEHSIPTPPT	300
SAAPSESTPS	ELPISPTTAP	RTVKELTVSA	GDNLIITLPD	NEVELKAFVA	PAPPVETTYN	360
YEWNLI SHPT	DYQGEIKQGH	KQTLNLSQLS	VGLYVFKVTV	SSENAFGEGF	VNVTVKPARR	420
VNLPPVAVVS	PQLQELTLPL	TSALIDGSQS	TDDTEIVSYH	WEEINGPFIE	EKTSVDSPLV	480

RLSNLDPGNY	SFRLTVTDS	GATNSTTAAL	IVNNAVDYPP	VANAGPNHTI	TLPQNSITLN	540
GNQSSDDHQI	VLYEWSLPG	SEGKHVVMQ	VQTPYLHLSA	MQEGDYTFQL	KVTDSSRQQS	600
TAVVTIVIQP	ENNRPPVAVA	GPDKELIFPV	ESATLDGSSS	SDDHGIVFYH	WEHVRGPSAV	660
EMENIDKAIA	TVTGLQVGTY	HFRLTVKDQ	GLSSTSTLTV	AVKKENNSPP	RARAGGRHVL	720
VLPNNSITLD	GSRSTDDQRI	VSYLWIRDG	SPAAGDVIDG	SDHSVALQLT	NLVEGVYTFH	780
LRVTDSQGAS	DTDATATVEVQ	PDPRKSGLVE	LTLQVGVGQL	TEQRKDTLVR	QLAVLLNVLD	840
SDIKVQKIRA	HSDLSTVIVF	YVQSRPPFKV	LKAAEVARNL	HMRLSKEKAD	FLLFKVLRVD	900
TAGCLLKCSG	HGHCDPLTKR	CICSHLWMEN	LIQRYIWDGE	SNCEWSIFYV	TVLAFTLIVL	960
TGGFTWLCIC	CCKRQKRTKI	RKKTKYTILD	NMDEQERMEL	RPKYGIKHRS	TEHNSSLMVS	1020
ESEFDSQDQT	IFSREKMERG	NPKVSMNGSI	RNGASFYSYCS	KDR		1063

Table LV. Amino acid sequence alignment of 254P1D6B v.1 (SEQ ID NO: 273)  
and 254P1D6B v.3 (SEQ ID NO: 274)

Score = 2124 bits (5503), Expect = 0.0Identities = 1053/1053 (100%), Positives = 1053/1053 (100%)

V.1: 20	CARKQCSEGR	TYSNAVISPN	LETTRIMRV	SHTFPVVDCTAACCDLSSCDLAWWF	EGRCYL 79						
V.3: 11	CARKQCSEGR	TYSNAVISPN	LETTRIMRV	SHTFPVVDCTAACCDLSSCDLAWWF	EGRCYL 70						
V.1: 80	VSCPHKENCEPK	KMGPIRSYLT	TFVLRPVQRP	AQLLDYGD	MMLNRGSPSGIWGDS	PEDIRK 139					
V.3: 71	VSCPHKENCEPK	KMGPIRSYLT	TFVLRPVQRP	AQLLDYGD	MMLNRGSPSGIWGDS	PEDIRK 130					
V.1: 140	DLPFLGKDWGLE	EMSEYSDDY	RELEKDLLQ	PSGKQEP	RGSAEYTDWGL	LPGSEGA	FNSSV 199				
V.3: 131	DLPFLGKDWGLE	EMSEYSDDY	RELEKDLLQ	PSGKQEP	RGSAEYTDWGL	LPGSEGA	FNSSV 190				
V.1: 200	GDSPAVPAETQ	QDPELHYL	NESASTPAP	KLPERSON	VLLPLPTTP	SSGEVLE	KEKASQ	LQEQ 259			
V.3: 191	GDSPAVPAETQ	QDPELHYL	NESASTPAP	KLPERSON	VLLPLPTTP	SSGEVLE	KEKASQ	LQEQ 250			
V.1: 260	SSNSSGKEVLM	PSHSLPPA	SLELSSVT	VEKSPVL	TVTPGST	EH	SIPTP	PTSAAPSE	STPS 319		
V.3: 251	SSNSSGKEVLM	PSHSLPPA	SLELSSVT	VEKSPVL	TVTPGST	EH	SIPTP	PTSAAPSE	STPS 310		
V.1: 320	ELPISPTTAP	R	TVKELTVS	SAGDNL	IITLPDNE	VELKAF	VAPAPP	VETTYN	YEWNLIS	SHPT 379	
V.3: 311	ELPISPTTAP	R	TVKELTVS	SAGDNL	IITLPDNE	VELKAF	VAPAPP	VETTYN	YEWNLIS	SHPT 370	
V.1: 380	DYQGEIKQGH	KQTLNLSQ	LSVGLYV	FKVTVS	SEN	AFGEGF	VNVTVK	PARRV	NLPPVA	VVS 439	
V.3: 371	DYQGEIKQGH	KQTLNLSQ	LSVGLYV	FKVTVS	SEN	AFGEGF	VNVTVK	PARRV	NLPPVA	VVS 430	
V.1: 440	PQLQELTLPL	T	SALIDGSQ	STDDTEI	VSYHWE	EINGPFI	E	EKTSVD	SPVLR	LSNLDP	GN 499
V.3: 431	PQLQELTLPL	T	SALIDGSQ	STDDTEI	VSYHWE	EINGPFI	E	EKTSVD	SPVLR	LSNLDP	GN 490
V.1: 500	SFRLTVTDS	GATNSTTA	ALIVNNA	VDYPPVA	NAGPNHT	ITL	PQNSIT	LN	GNQSSD	DHQI 559	
V.3: 491	SFRLTVTDS	GATNSTTA	ALIVNNA	VDYPPVA	NAGPNHT	ITL	PQNSIT	LN	GNQSSD	DHQI 550	
V.1: 560	VLYEWSLGP	GSEGHVVM	QGVQTPY	LHLSAMQ	EGDYTFQ	LKVTDSS	RQQSTAV	VTVIVQ	P 619		
V.3: 551	VLYEWSLGP	GSEGHVVM	QGVQTPY	LHLSAMQ	EGDYTFQ	LKVTDSS	RQQSTAV	VTVIVQ	P 610		
V.1: 620	ENNRPPVA	VAGPDKEL	IFPVESAT	LDGSSSSD	DHGIVFYH	WEHVRG	PSA	VEMENID	KAIA 679		
V.3: 611	ENNRPPVA	VAGPDKEL	IFPVESAT	LDGSSSSD	DHGIVFYH	WEHVRG	PSA	VEMENID	KAIA 670		
V.1: 680	TVTGLQVG	TYHFRLTV	KDQQLS	STSTLT	VAVKKEN	NSPPRAR	AGGRH	VLVLP	NN	SITLD 739	
V.3: 671	TVTGLQVG	TYHFRLTV	KDQQLS	STSTLT	VAVKKEN	NSPPRAR	AGGRH	VLVLP	NN	SITLD 730	
V.1: 740	GSRSTDDQ	RIVSYLW	IRDGQSPA	AGDVIDG	SDHSVALQ	LTNLVEG	VYTFH	LRVTDS	Q 799		
V.3: 731	GSRSTDDQ	RIVSYLW	IRDGQSPA	AGDVIDG	SDHSVALQ	LTNLVEG	VYTFH	LRVTDS	Q 790		
V.1: 800	DTDATATVE	VQPDPRK	SGLVELT	LQVGVGQ	LTEQRKDT	LV	ROLA	VLLNVLD	SDIKVQ	KIRA 859	
	DTDATATVE	VQPDPRK	SGLVELT	LQVGVGQ	LTEQRKDT	LV	ROLA	VLLNVLD	SDIKVQ	KIRA	

V.3: 791 DTDATVEVQPDPRKSGLVLTQVGVGQLTEQRKDTLVRQLAVLLNVLDSDIKVQKIRA 850  
 V.1: 860 HSDLSTVIVFYVQSRPPFKVLKAAEVARNLHMRLSKEKADFLLFKVLRVDTAGCLLKCSG 919  
 HSDLSTVIVFYVQSRPPFKVLKAAEVARNLHMRLSKEKADFLLFKVLRVDTAGCLLKCSG  
 V.3: 851 HSDLSTVIVFYVQSRPPFKVLKAAEVARNLHMRLSKEKADFLLFKVLRVDTAGCLLKCSG 910  
 V.1: 920 HGHCDPLTKRCICSHLWMENLIQRYIWDGESNCEWSIFYVTVLAFTLIVLTGGFTWLCIC 979  
 HGHCDPLTKRCICSHLWMENLIQRYIWDGESNCEWSIFYVTVLAFTLIVLTGGFTWLCIC  
 V.3: 911 HGHCDPLTKRCICSHLWMENLIQRYIWDGESNCEWSIFYVTVLAFTLIVLTGGFTWLCIC 970  
 V.1: 980 CCKRQKRTKIRKTKYTIIDNMDEQERMELRPKYGIKHRSTEHNSSLMVSESEFSDSDQDT 1039  
 CCKRQKRTKIRKTKYTIIDNMDEQERMELRPKYGIKHRSTEHNSSLMVSESEFSDSDQDT  
 V.3: 971 CCKRQKRTKIRKTKYTIIDNMDEQERMELRPKYGIKHRSTEHNSSLMVSESEFSDSDQDT 1030  
 V.1: 1040 IFSREKMERGNPKVSMNGSIRNGASFSYCSKDR 1072  
 IFSREKMERGNPKVSMNGSIRNGASFSYCSKDR  
 V.3: 1031 IFSREKMERGNPKVSMNGSIRNGASFSYCSKDR 1063